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Abstract 
 
 
Widespread antibiotic resistance among pathogenic bacteria and the low specificity of 
these drugs cause a pressing need for the development of novel antibiotics. Endolysins 
are proteins that are produced by bacteriophage infected cells and digest the bacterial 
cell wall for phage progeny release. These efficient enzymes are highly specific for 
the target bacteria without affecting other species. Development of resistance against 
endolysins is rare, because they evolved to target molecules that are essential for 
bacterial viability. Taken together, this makes them promising novel antibiotics.  
 
The development of recombinant endolysins as antibacterial agents requires an 
inexpensive and safe production platform. Microalgae emerged as an alternative 
expression platform in the last years. This study investigated therefore the production 
of endolysins in two distinct microalgal systems, the eukaryotic green microalga 
Chlamydomonas reinhardtii and the cyanobacterium Synechocystis sp. PCC 6803. C. 
reinhardtii is an attractive production platform for therapeutic proteins, due to the lack 
of endotoxins and infectious agents and its GRAS status (Generally Recognised as 
Safe). Synechocystis is a prokaryotic system and is natural transformable. Both offer 
established techniques for the expression of foreign genes and can be cultivated in full 
containment in simple photobioreactors.  
 
Transgenic lines of C. reinhardtii and Synechocystis expressing endolysins specific to 
the human pathogens Streptococcus pneumoniae and Staphylococcus aureus were 
created. The S. pneumoniae-specific endolysin Pal has been purified in an active form 
and its specificity and efficiency in killing the target bacterium demonstrated in vitro. 
Another endolysin specific to Propionibacterium acnes, a bacterium involved in the 
skin condition acne vulgaris, was synthesised in Synechocystis. The synthesis of the 
endolysins in the microalgae was analysed under the influence of different expression 
elements and at different growth stages, and the yields of recombinant protein were 
quantified to evaluate microalgae as a production platform for antibacterial and other 
protein therapeutics. 
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aadA aminoglycoside-3’’-adenyl-transferase gene 
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ATP adenosine triphosphate 
bp base pairs 
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BSAC British Society for Antimicrobial Chemotherapy 
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DNA deoxyribonucleic acid 
ECL enhance chemiluminescence 
e. g. exempli gratia  =  for example 
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g gram 
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GFP green fluorescent protein 
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mg milligram 
min minute 
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mRNA messenger RNA 
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PCR polymerase chain reaction 
PSI photosystem I 
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1 Introduction 
 
1.1 The need for new antibiotics 
 
After the discovery of penicillin in 1928 and the subsequent development of further 
antibiotics, these drugs became a potent and efficient weapon against infectious 
diseases. In 1967 the US Surgeon General William H. Stewart even declared that the 
war against infectious diseases was won, and this represented the general opinion of 
the medical community during this time (Spellberg et al. 2008; Fauci 2001). However, 
the increase of antibiotic resistance in the last decades has severely reduced the 
reliability of antibiotic treatments. In particular, the prevalence and range of multi-
drug resistant strains has increased alarmingly (Levy & Marshall 2004).  
 
The director of the Welcome Trust, Professor Jeremy Farrar, and the Chief Medical 
Officer for England, Professor Dame Sally Davies, warned in 2014 that antibiotic 
resistance has reached a tipping point at which it starts to become a threat also in 
Europe. The World Health Organization (WHO) had already made antimicrobial 
resistance the topic of World Health Day 2011, and released a global report on 
antimicrobial resistance in May 2014. The report stated that very high rates of 
antimicrobial resistance were observed in all WHO regions in bacterial pathogens 
such as Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus and 
Streptococcus pneumoniae. These bacteria cause common health-care associated and 
community-acquired infections such as urinary tract infections, wound infections, 
blood stream infections and pneumonia. The report warned that antimicrobial 
resistance is an “increasingly serious threat to global public health” and that there is a 
real risk of falling back into a pre-antibiotic era in the 21st century (WHO report 
2014).  
 
At the same time the development of new antibiotics has severely declined in the last 
few decades, mainly owing to the lower profitability of antibiotics compared to other 
drugs (Figure 1.1). Drug development generally requires very high costs, but 
antibiotics are short-course therapies, which make them less profitable than drugs for 
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chronic diseases (Spellberg et al. 2008). Furthermore, the risk of resistance 
development makes it important to limit the widespread use of newly-developed 
antibiotics to maintain their efficacy, which negatively affects the profits from that 
drug (Spellberg et al. 2008). The British Society for Antimicrobial Chemotherapy 
(BSAC) even established the global initiative Antibiotic Action, which seeks to 
inform and educate about the need for discovery, research and development of new 
antibiotics. The initiative is supported by several microbiological and medical 
societies, researchers, health professionals and politicians worldwide. In addition, the 
Infectious Disease Society of America (IDSA), which gives policy recommendations 
to the US government, has started the “10 x ’20 initiative”, which calls for the 
delivery of ten new antibiotics by the year 2020 to tackle the problem of antibiotic-
resistant infections that costs the US health care system between $21 and $34 billion 
and over 8 million additional hospital days per year (Wright 2012; Infectious Diseases 
Society of America 2011).  
 
 
 
 
 
 
 
 
Figure removed 
 
 
 
 
 
 
 
Figure 1.1: Dates of the discovery of distinct classes of antibacterial drugs and the “discovery 
void” in the last few decades 
The indicated dates represent the dates of the initial discovery or the patent. Reproduced from (WHO 
report 2014), originally from (Silver 2011).  
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Infectious diseases are the second-leading cause of death worldwide and also belong 
to the top causes of death in developed countries (WHO report 2004). Antibiotics are 
still the major weapons against severe infectious diseases and it is therefore very 
important to preserve the efficacy of the available antibiotics, but also to develop new 
antibiotics with different targets and new strategies to circumvent the resistance 
mechanisms of the microorganisms.  
 
 
1.1.1 Antibiotics and the development of antimicrobial resistance 
 
Antibiotics are substances that kill or prevent the growth of microorganisms. The term 
antibiotics can refer to substances that are produced by bacteria or fungi as a 
protection mechanism against other microorganisms, as well as to chemically 
modified semisynthetic antibiotics and synthetic antimicrobial drugs.  
 
Arsphenamine is often described as the first antibacterial agent. It was discovered in 
the laboratory of Paul Ehrlich in 1909 and was sold under the trade name Salvarsan as 
a treatment against Syphilis. In 1928, the first natural substance with an antibacterial 
effect was discovered by Alexander Fleming. This antibiotic is produced by the 
fungus Penicillium crysogenum and was called penicillin (Madigan 2009). The large-
scale production of penicillin G started in 1939, and the substance was first and very 
efficiently used for the treatment of staphylococcal and pneumococcal infections 
among soldiers before it became available for general use in 1945 (Madigan 2009). 
Alexander Fleming received the Nobel prize in 1945 for the discovery of penicillin, 
which revolutionised the treatment of infections (WHO report 2014). Shortly after 
1945, pharmaceutical companies began to search for other antibiotics and discovered 
a variety of structurally different antibiotics with different mechanisms of actions. 
Furthermore, researchers developed semisynthetic antibiotics with different spectra 
and efficiencies by chemical modification of natural antibiotics in the following 
decades. However, the discovery and development of new antibiotics has declined 
severely in the last decades, and the last truly new class was discovered in the 1980s 
(Figure 1.1).  
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Over 2 billion years ago, antibiotics developed as a defence mechanism of 
microorganisms against competitors. At the same time mechanisms to resist the 
antimicrobial substances also evolved in microorganisms to keep up in the battle of 
competing microorganisms (Spellberg 2008).  
 
Different mechanisms are known that cause resistance against antimicrobial agents. 
Some microorganisms, for example, are impermeable to certain antibiotics. Gram-
negative bacteria have an outer membrane around their cell wall, which makes them 
impermeable to penicillin G, but not tetracycline or streptomycin (Figure 1.2) 
(Madigan 2009). The organism can also lack the target of the antibiotic. Bacteria of 
the genus Mycoplama, for example, lack a cell wall and are therefore resistant against 
β-lactam antibiotics that inhibit cell wall synthesis (Madigan 2009). Another 
resistance mechanism involves the rapid transport of the antibiotic out of the cell by 
antibiotic-efflux pumps (Figure 1.2). One type of efflux pump can often confer 
resistance against several antibiotics. For example, bacteria with RND-type pumps are 
resistant against tetracyclines, chloramphenicol and the fluoroquinolones (Levy & 
Marshall 2004; Nikaido 1996). Other organisms are able to modify or degrade the 
antimicrobial substance. The β-lactamase enzymes cleave the β-lactam ring and in 
doing so, destroy penicillins and cephalosporins (Figure 1.2). Hundreds of different β-
lactamases have been discovered to-date (Levy & Marshall 2004). Other modifying 
enzymes can inactivate chloramphenicol and aminoglycosides by acetylation or 
phosphorylation of key chemical groups on the antibiotics. Furthermore, the 
modification of the target structure of the antibiotic or the affected metabolic pathway 
is also a common strategy to require resistance (Levy & Marshall 2004). The 
mechanism of action of penicillin and other β-lactam antibiotics is the inhibition of 
cell wall synthesis by binding to the enzyme that carries out the transpeptidation of 
two glycan linked peptide strands in the cell wall. This enzyme is therefore called 
penicillin-binding protein (PBP). Some bacteria exchanged the PBP for another, 
structurally different protein with greatly reduced affinity to β-lactam antibiotics 
(Antignac & Tomasz 2009). This exchange confers resistance against β-lactam 
antibiotics and combination drugs with β-lactamase inhibitors. Today, 15 classes of 
antibiotics are known that target different physiological and metabolic functions, but 
resistance mechanisms have developed against every class (Levy 2002).  
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Figure 1.2: Biological mechanisms of antibiotic resistance  
The main mechanisms conferring antimicrobial resistance shown in the figure are antibiotic-efflux 
pumps, enzymatic deactivation of the antibiotic and impermeability for the antibiotic. Reproduced from 
Levy & Marshall (2004). 
 
 
The genes for resistance are either encoded on the chromosome or on plasmids, and 
can spread by various mechanisms such as the exchange of plasmids, transfer via 
bacteriophages, the uptake of naked DNA and via transposons (Figure 1.3) (Levy & 
Marshall 2004). Microorganisms are able to duplicate the plasmids and to pass them 
to other closely or even distantly related organisms (a process termed conjugation). In 
this way resistance genes can be easily transferred and spread within the microbial 
population (Figure 1.3) (Madigan 2009). Chromosomal resistance genes can be 
released to the environment after cell lysis and some species can integrate these genes 
as free DNA in a process called transformation (Figure 1.3). Antimicrobial resistance 
genes are often located on transposons – mobile DNA elements that can change their 
position within the genome or from a plasmid to the genome (Levy & Marshall 2004). 
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Furthermore, integrons can be involved in the acquisition of resistance genes. 
Integrons are assembly platforms that integrate different genes by site-specific 
recombination under one promoter (Mazel 2006). A further propagation mechanism is 
the transfer of genes between different bacterial cells via virulent or temperate 
bacteriophage in a process called transduction. The continued exposure to 
antimicrobial drugs, kills the susceptible cells and selects for the resistant organisms, 
which then propagate in the population (Levy & Marshall 2004). 
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Figure 1.3: The genetics of antimicrobial resistance 
The figure shows the location of antimicrobial resistance genes and mechanisms by which resistance 
genes can spread to other bacterial cells. The genes can be transferred via the exchange of plasmids, 
bacteriophages, the uptake of naked DNA and transposons. Reproduced from Levy & Marshall (2004). 
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1.1.2 Limitations of conventional antibiotics 
 
Beside the increasing occurrence of resistance against conventional antibiotics, there 
are further limitations of these drugs. Most antibiotics have a broad-spectrum against a 
range of bacterial classes and therefore each treatment affects not only the pathogen, 
but also the beneficial and protective human bacterial flora. Not only does this 
increase the susceptibility to infections with pathogenic bacteria and fungi, but also 
can cause conditions such as obesity, type 1 diabetes, inflammatory bowel disease, 
allergies and asthma (Blaser 2011; Chen & Blaser 2007). Furthermore, reoccurring 
exposure to antibiotics results in the spread of antimicrobial resistance genes within 
the commensal bacterial flora, which functions as a reservoir for resistance genes and 
can pass the genes on to pathogenic bacteria (Schmelcher et al. 2012). It would be 
therefore highly desirable to develop narrow-spectrum antibiotics that specifically kill 
only the targeted pathogen, to reduce the collateral effects on the commensal bacterial 
flora and to decrease the spread of antimicrobial resistance genes (Blaser 2011).  
 
However, to-date the available diagnostic methods are still limited and the usage of 
broad-spectrum antibiotics is a convenient way to handle daily practices in doctors’ 
surgeries, since in most cases these drugs are effective even when the pathogen has 
not been identified. Nevertheless, the increasing occurrence of antibiotic-resistant 
bacteria makes it more and more important to accurately diagnose the pathogen and its 
susceptibility to different antibiotics. In the last few decades the number of available 
diagnostic methods has increased and the methods have greatly improved. However, 
further research needs to be done to develop accurate, but also rapid and practicable 
diagnostic methods. This is reflected by the choice of the Longitude Prize 2014, an 
inducement prize contest, in which the public voted for “antibiotics” as “the greatest 
challenge of recent times”. The committee set the challenge as “the creation of a cost-
effective, accurate, rapid and easy-to-use test for bacterial infections that will allow 
health professionals worldwide to administer the right antibiotic at the right time”. 
With the development of better diagnostic methods and a growing awareness of the 
importance of the human microbiome, the demand for narrow-spectrum antibiotics 
will most likely greatly increase. 
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Furthermore, not many conventional antibiotics are available that can eliminate 
bacteria in biofilms. Biofilms on the mucosal membranes in the nasopharynx are seen 
as a major reservoir for pathogenic bacteria (e.g S. pneumoniae and S. aureus) in the 
population and are often the starting point of infections. The diminution of this 
reservoir would most likely have a great impact on the incidence of S. pneumoniae 
and S. aureus infections (Loeffler et al. 2003). The available antibiotics that can target 
bacteria on the mucosal membrane – namely, mupirocin and polysporin – have been 
used prophylactically in hospitals, which helped to prevent the spread of methicillin-
resistant S. aureus (MRSA) strains in these facilities. However, strains with 
resistances to these antibiotics have appeared as well (Hudson 1994).  
 
Moreover, many conventional antibiotics have side effects, and there are restrictions 
on the use, especially for the treatment of children (Payne et al. 2007). There is 
therefore a great need to develop novel and also improved classes of antibiotics, not 
only for the treatment of infections with multi-resistant pathogens but for all 
infections. 
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1.2 Bacteriophage endolysins as potential new generation antibiotics 
 
1.2.1 Bacteriophages and phage therapy  
 
Bacteriophages are viruses that infect bacteria and are the most abundant entities on 
the planet. It is estimated that the number of bacteriophage particles amounts to 1031. 
The majority are tailed bacteriophages, which comprise of a tail and a head that 
encapsulates the DNA or RNA genome (Figure 1.4) (Elbreki et al. 2014). The nucleic 
acids can be single or double stranded, and some bacteriophages have a circular 
genome, while others carry a linear genome. The tail is involved in the attachment to 
the bacterial cell and the injection of the nucleic acids.  
 
 
 
 
 
Figure removed 
 
 
 
 
 
Figure 1.4: Electron micrograph of a Acinetobacter baumannii bacteriophage (A) and schematic 
representation of the structure of a tailed bacteriophage (B) 
Modified from Elbreki et al. (2014), 3D model in (B) modified from www.wikipedia.com. 
 
 
Felix d’Herelle characterised and named bacteriophages in 1917 and initiated 
experiments investigating the use of bacteriophages as treatments for bacterial 
infections (so-called ‘phage therapy’) in the early 1920s (Elbreki et al. 2014). Felix 
d’Herelle also participated in the establishment of the International Bacteriophage 
Institute in Tblisi, Georgia, which is also known as the Eliava Institute. This institute 
has performed extensive research into phage therapy since then and supplies countries 
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of the former Soviet Union with bacteriophage preparations for the treatment of 
bacterial infections. However, the production strongly declined after the break-up of 
the Soviet Union (O’Flaherty et al. 2009). In the 1930s, several companies in the US, 
France and Germany produced phage preparations as antimicrobials e.g. Eli Lilly 
(US). However, after the discovery and spread of antibiotics and only mixed success, 
phage therapy disappeared in Western countries in the 1940s (Elbreki et al. 2014).  
 
The increase in antibiotic-resistant strains and the enormous expansion in our 
understanding of phage biology has now caused a rediscovery of phage therapy in 
western countries. Several companies and research groups have started to investigate 
the potential of bacteriophages for the treatment of infectious diseases and other 
applications, such as their use as food preservatives (O’Flaherty et al. 2009). With the 
rediscovery of phage therapy, attention was also drawn to bacteriophage-encoded 
endolysins. These enzymes are used by most bacteriophages to digest the 
peptidoglycan of the bacterial cell wall for phage progeny release at the end of the 
lytic cycle, and have the potential to be used on their own as antibacterial agents 
(Schmelcher et al. 2012; Loessner 2005; Fischetti 2008).  
 
 
1.2.2 Endolysins play an important role in the lytic life cycle of 
bacteriophages 
 
Endolysins are bacteriophage-encoded enzymes that are produced in bacterial cells 
after they have been infected by a bacteriophage. These proteins are also known as 
bacteriophage lysozymes, lysins or muralytic/mureolytic enzymes (Loessner 2005).  
 
Bacteriophages have two types of life cycle. Virulent bacteriophages immediately 
enter the lytic life cycle (explained below), whereas the genome of temperate 
bacteriophages is first inserted into the host chromosome during the lysogenic cycle. 
The bacteriophage genome, often referred to as a prophage, is replicated together with 
the host chromosome during cell replication, and can remain silent for a long period of 
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time before environmental conditions prompt entry into the lytic cycle (O’Flaherty et 
al. 2009).  
 
To infect a bacterial cell, bacteriophages attach to the cell surface, often to receptors, 
and insert their genetic material into the cell. In the case of virulent bacteriophages the 
infection results immediately in the hijacking of the cell metabolism. The bacterial 
DNA and protein synthesis machinery changes to produce bacteriophage particles and 
the host genome is degraded (Figure 1.5) (O’Flaherty et al. 2009). At the same time, 
endolysins and another type of proteins, called holins, are produced and accumulate in 
the cytoplasm of the infected bacterium (Loessner 2005). The holin proteins help to 
tightly control the moment of the endolysin-mediated cells lysis. At the end of the 
lytic cycle and once a critical holin concentration has been reached, the hydrophobic 
proteins assemble into oligomers and insert into the cell membrane (Schmelcher et al. 
2012; Young et al. 2000). The insertion of the holin proteins results in the creation of 
pores, which allow the endolysin to pass across the cytoplasmic membrane and enter 
the peptidoglycan (Loessner 2005). Figure 1.6 shows the mechanism for the cell wall 
of Gram-negative bacteria (for the Gram-positive cell wall see figures 3.2 and 5.2). 
Subsequently, the endolysins cleave specific bonds of the peptidoglycan, which 
results in the disruption of the cell wall and the high internal pressure of 20 – 50 
atmospheres causes the osmotic lysis and the death of the bacterial cell (Schmelcher et 
al. 2012). The cell lysis results in the release of the phage progenies, which can now 
infect new bacterial cells (Figure 1.5).  
 
To-date, only a few exceptions have been described of endolysins that do not depend 
on a holin for release to the peptidoglycan. Two examples are an endolysin from a 
Oenococcus oeni bacteriophage and the Lactobacillus plantarum-specific 
bacteriophage Øg1e that are both attached to signal peptides and are exported by the 
host sec system (São-José et al. 2000; Kakikawa et al. 2002). 
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Figure 1.5: Bacteriophage lytic life cycle 
The infection starts with the attachment of the bacteriophage to the target bacterium (1). Subsequently, 
the phage DNA or RNA is injected into the cell (2). The degradation of the host DNA is initiated and 
the bacterial DNA and protein synthesis machinery changes to produce bacteriophage particles (3) and 
(4). The release of endolysins via pores formed by holins causes the lysis of the bacterial cell wall and 
releases hundreds of new bacteriophages to the environment (5). 
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Figure 1.6: Schematic representation of the bacterial cell wall of (Gram-negative bacteria) and 
the peptidoglycan (type A1γ) showing the bonds that are targeted by different endolysins 
The endolysins are produced in the cytoplasm of the bacterial cells that are infected by a bacteriophage. 
At the end of the lytic cycle, holin proteins are inserted into the cytoplasmic membrane, which results 
in pores (A). The endolysins can get through these pores to the cell wall, where the enzymes cleave 
specific bonds of the peptidoglycan (B). B shows the structure of type A1γ peptidoglycan, found for 
example in E. coli and Listeria. CCWP = carbohydrate cell wall polymer, LU = linkage unit, P = 
phosphate group, MurNAc = N-acetyl-muramic acid, GlcNAc = N-acetyl-glucosamine acid, Ala = 
alanine, Glu = glutamic acid, Lys = lysine, m-DAP = meso-diaminopimelic acid. Modified from 
Loessner (2005). 
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1.2.3 Endolysin structure & mode of action  
 
Bacteriophages are highly specific to a target bacterium. In addition their endolysins 
are usually only effective against the species of bacteria in which they are naturally 
produced, or in some cases, against other species within the same genus (Borysowski 
et al. 2006). 
 
Endolysins that are specific for Gram-positive bacteria usually have a modular 
organisation. Many of these endolysins have a two-domain structure with a N-
terminal catalytic domain and a C-terminal cell binding domain connected by a linker 
(Figure 1.8, Figure 1.7) (Fischetti 2005). However, there are also endolysins with 
different domain architectures. Many staphylococcal endolysins, for example, have 
two catalytic domains followed by one cell binding domain (Navarre et al. 1999; 
O’Flaherty et al. 2005). Alternatively, the cell binding domain can be located in the 
middle of the enzyme and surrounded by two catalytic domains, which is the case for 
the endolysin λSA2 that is specific to Streptococcus agalactiae (Figure 1.8) (Pritchard 
et al. 2004). Despite their modular structure, nearly all known endolysins specific to 
Gram-positive bacteria are single polypeptides encoded by one gene. The only 
exception here is PlyC, an endolysin of the group A Streptococcus bacteriophage C1, 
which is encoded by two different genes (Nelson et al. 2006).  
 
The cell binding domains of endolysins attach the enzyme tightly to its substrate after 
cell lysis. Endolysins are also able to enter and cleave the peptidoglycan of Gram-
positive bacteria from outside of the cell (i.e. ‘exolysins’). Therefore, the attachment 
prevents the endolysins from attacking surrounding cells of the target bacterium, 
which can still function as a host for the bacteriophage (Schmelcher et al. 2012). In 
contrast, the outer membrane of Gram-negative bacteria protects uninfected cells 
against lysis by endolysins from outside. Endolysins that are specific to Gram-
negative bacteria are therefore usually smaller single-domain proteins without a cell 
binding domain (Cheng et al. 1994).  
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Figure 1.7: Crystal structures of the S. pneumoniae-specific endolysin Cpl-1 (A), the Listeria 
monocytogenes-specific endolysin PlyPSA (B) and a general schematic representation of two 
domain endolysins (C) 
Reproduced from Hermoso et al. (2003) (A) and Korndörfer et al. (2006) (B).  
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Figure 1.8: Schematic representation showing the modular organisation of selected bacteriophage 
endolysins 
CBD = Cell binding domain, ChBD = Choline binding domain, Cpl-7 = Cpl-7-like bindng domain, 
SH3b = Bacterial Src homology 3 domain (cell wall binding domain). Reference: (1) Zimmer et al. 
(2003), (2) Loessner et al. (1995), (3) García (1990), (4) García (1990), (5) O’Flaherty et al. (2005), (6) 
Pritchard et al. (2004), (7) Pritchard et al. (2007), (8) Briers et al. (2007). Reproduced from Schmelcher 
et al. (2012). 
 
 
Furthermore, the cell wall binding domain is responsible to a large degree for the 
specificity of the endolysin for certain species or genera. The domain binds 
noncovalently to molecules in the cell envelope, which can be part of the 
peptidoglycan or other cell wall associated molecules. It has been shown that the 
LysM domain binds to the N-acetyl-glucosamine acid of the peptidoglycan 
(Visweswaran et al. 2011). The binding domains of several pneumococcal endolysins 
bind to the choline of the teichoic acids in the cell wall, whereas the Cpl-7 cell wall 
binding domain attaches to the Streptococcal cell wall in a mechanism independent of 
choline (Schmelcher et al. 2012). The SH3b binding domains can be found in a range 
of endolysins, including Staphylococcus-specific endolysins and lysostaphin, a 
bacteriocin that is produced by Staphylococcus simulans against S. aureus (Schindler 
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& Schuhardt 1964; Sass & Bierbaum 2006). It has been shown, for several endolysins, 
that the cell wall binding domain is required for full lytic activity (Sanz et al. 1992; 
Sass & Bierbaum 2006). The crystal structure of the S. pneumoniae-specific endolysin 
Cpl-1 suggests that the cell wall binding domain positions the catalytic domain in the 
right orientation towards the substrate, which might be the reason that the domain is 
required for full enzymatic activity in several endolysins (Hermoso et al. 2003; 
Schmelcher et al. 2012). In contrast, some endolysins remained fully active after the 
removal of the binding domain, or were even found to be more active (Cheng & 
Fischetti 2007; Low et al. 2005). These results and further studies encourage the 
engineering of tailor-made improved endolysins. Tailor-made endolysins have been 
created by removing the cell binding domains, combining domains from different 
endolysins or adding additional domains, as well as random and site-directed 
mutagenesis. Several studies found increased activities or extended lytic spectra for 
the new designed endolysins (Schmelcher et al. 2012). 
 
The catalytic domain is responsible for the enzymatic cleavage of the peptidoglycan 
and can be an N-acetyl-β-D-glucosaminidase or N-acetyl-β-D-muramidase 
(lysozymes), which both cleave one of the two glycosidic bonds of the carbohydrate 
strand. Other catalytic domains have endopeptidase activity and cleave a specific bond 
of the peptide chains. Furthermore, these domains can be N-acetylmuramoyl-L-
alanine amidases, which hydrolyse the amide bond between the sugar strand and the 
peptide chain (Figure 1.6 B) (Loessner 2005). Catalytic domains can also have an 
influence on the specificity of an endolysin. The peptidoglycan structures differ 
between both Gram-types, but also between different bacterial species. A pentaglycine 
bridge, for example, can be only found in Staphylococcus and very few other species. 
The absence or presence of the specific target bond contributes therefore to a 
limitation of the host range (Schmelcher et al. 2012). Furthermore, the catalytic 
domain contributes to the net charge of the endolysin, which can also have an 
influence on the host range (Low et al. 2011).  
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1.2.4 Bacteriophage endolysins as antimicrobial agents 
 
Endolysins have been studied by different research groups and it has been shown for 
several endolysins, that when applied externally to Gram-positive bacteria, these 
enzymes are able to lyse and kill cells of the target bacterium (Fenton et al. 2010; 
Borysowski et al. 2006). This has been shown for endolysins purified from 
bacteriophage-infected bacteria and for recombinant endolysins that were mainly 
synthesized using the expression platform Escherichia coli (Garcia et al. 1983c; 
Sheehan et al. 1997; Loessner 2005). It was believed that endolysins could not be used 
as a treatment against Gram-negative bacteria, since the outer membrane represents a 
barrier for the enzymes. However, a few studies demonstrated recently the successful 
application in vitro of endolysins against Gram-negative bacteria (Lai et al. 2011; 
Lukacik et al. 2012). 
 
Several promising pre-clinical trials have been performed with endolysins specific to 
different Gram-positive human pathogens. Table 1.1 gives an overview of the 
endolysins and the animal models of disease that have been used in in vivo studies. 
Overall, the studies found that the administration of the endolysin under study resulted 
also in vivo, in a significant decrease of the bacterial loads and therefore an increase of 
the survival rates of the infected animals. Moreover, numerous in vivo studies showed 
that endolysins can prevent the colonisation of the mucosal membrane by pathogens, 
which cannot be achieved by most conventional antibiotics (Loeffler et al. 2001; 
Loeffler et al. 2003; McCullers et al. 2007).  
 
Most endolysins have a high specificity for the cell wall of bacterial species in which 
they are naturally produced. Some endolysins are even effective only against certain 
serotypes or strains, whereas others lyse bacteria within the same genus (López et al. 
2004). In contrast to conventional antibiotics, which usually have a broad-spectrum, 
endolysins could be used to specifically eliminate the pathogen without harming the 
commensal bacterial flora. As already discussed in 1.1.2, the usage of narrow-
spectrum antibiotics for the treatment is highly desirable, but requires accurate and 
practicable diagnostic methods. With the development of better diagnostic methods, 
the demand for narrow-spectrum antibiotics will most likely greatly increase. 
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Table 1.1: A selection of endolysins investigated in in vivo studies 
Reproduced from www.phibiotics.org and Fenton et al. (2010) 
 
Endolysin Bacteriophage Target bacterium Catalytic activity Model systems (Mode of administration) Reference 
 
Cpl-1 
 
Cp-1 
 
Streptococcus 
pneumoniae  
 
1,4-N-
acetylmuramidase 
 
Murine model of pneumococcal bacteremia (intravenous) 
Murine model for acute otitis media (intranasal) 
Rat model of experimental endocarditis (intravenous) 
Infant-rat model of experimental pneumococcal meningitis 
(intracisternal, intraperitoneal)  
 
 
Loeffler et al. (2003) 
McCullers et al. (2007) 
Entenza et al. (2005) 
Grandgirard et al. (2008) 
Pal Dp-1 Streptococcus 
pneumoniae 
 
N-acetylmuramoyl-
alanine amidase 
Murine model of nasopharyngeal colonization (intranasal) 
Murine peritonitis-sepsis model (intraperitoneal) 
Loeffler et al. (2001) 
Jado et al. (2003) 
PlyGBS NCTC11261 Streptococcus agalactiae 
Streptococcus pyogenes 
 
1,4-N-
acetylmuramidase 
Murine model of vaginal and upper respiratory colonization 
(intranasal, intravaginal, oral) 
Cheng et al. (2005) 
PlyG Bacillus   
phage γ 
Bacillus anthracis 
Bacillus cereus 
 
N-acetylmuramoyl-
alanine amidase 
Murine model of Bacillus anthracis infection (intraperitoneal) Schuch et al. (2002) 
PlyBH 
 
Ames prophage 
 
Bacillus anthracis 
 
Amidase Murine model of peritonitis (intraperitoneal) Yoong et al. (2006) 
PlyC C1 Streptococcus pyogenes 
 
Amidase Murine model of oral colonization (oral) Nelson et al. (2001) 
MV-L ϕMR11 Staphylococcus aureus 
Staphylococcu simulans 
N-acetylmuramoyl-
alanine amidase 
Murine model of nasal colonization (intranasal) 
Murine model of MRSA bacteremia (intraperitoneal) 
Rashel et al. (2007) 
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1.2.4.1 Resistance to endolysins  
 
As discussed in 1.1.1, the number of multi-drug resistant bacteria has increased in 
recent decades and resistant strains have appeared against all classes of antibiotics that 
have been developed to-date. It is therefore desirable to develop novel classes of 
antibiotics, which are less susceptible to resistance development. As also mentioned in 
1.1.2 the use of narrow-spectrum antibiotics could decrease the spread of 
antimicrobial resistance genes within the bacterial community by preventing selective 
pressure on the whole commensal flora of a patient with every treatment. The high 
specificity of endolysins is therefore advantageous to decelerate the development and 
spread of antibiotic resistance.  
 
Since endolysins cleave the peptidoglycan from outside and do not need to get into the 
cell, several of the resistance mechanisms discussed in 1.1.1 cannot affect the activity 
of endolysins. Intracellular resistance mechanisms such as antibiotic-efflux pumps, 
cytoplasmic enzymes that degrade or modify antimicrobials, and the reduction of 
membrane permeability, can be therefore excluded (Schmelcher et al. 2012). 
However, resistance development due to target modification or the activity of 
extracellular enzymes is still conceivable.  
 
Bacteriophages and their endolysins evolved over billions of years in parallel with the 
target bacterium. To ensure the survival of the bacteriophage, this co-evolution 
required that endolysins target components in the cell wall that are essential for the 
viability of the bacterium. It is therefore believed that endolysins target highly 
immutable structures within bacteria and that the development of resistance against 
endolysin is a rare event (Schmelcher et al. 2012). 
 
A few studies have attempted to induce resistance against certain endolysins. Loeffler 
et al. (2001) showed that the repeated exposure of Streptococcus pneumoniae to low 
concentrations of the pneumococcal endolysin Pal (< 1 U) on agar plates (16 rounds) 
or increasing concentrations in liquid cultures did not cause the development of 
resistant strains (4.1.1). Another study exposed Bacillus cells to the mutagen methane-
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sulphonic acid ethyl ester to accelerate resistance development against the endolysin 
PlyG. The treatment did not result in any PlyG-resistant strains, whereas the same 
treatment resulted in a 1,000 – 10,000-fold increase in resistance against the 
antibiotics streptomycin and novobiocin (Schuch et al. 2002; Schmelcher et al. 2012).  
However, antimicrobial resistance has been observed against other peptidoglycan 
hydrolases, for example human lysozyme and lysostapin, which has a similar modular 
organisation and a high sequence similarity to several Staphylococcus endolysins 
(Schmelcher et al. 2012). Therefore, the development of resistance against endolysins 
cannot be entirely excluded. 
 
A strategy to decrease the risk of resistance development could be the administration 
of several endolysins in combination, or the combination of an endolysin with a 
conventional antibiotic. It has been shown that Cpl-1 has synergy with the antibiotics 
gentamicin and penicillin (Djurkovic et al. 2005). Furthermore, the endolysins Pal and 
Cpl-1 in combination were found to have a synergistic effect (4.1.1) (Jado et al. 2003). 
Synergy was also observed for the staphylococcal endolysin LysK in combination 
with lysostaphin (S. C. Becker et al. 2008). These results encourage the combinational 
use of endolysins and antibiotics to enhance on one hand the efficacy, and on the other 
hand to discourage the development of resistance.  
 
 
1.2.4.2 Safety & immunogenicity 
 
Despite the promise of endolysins, the application of whole enzymes as antibacterial 
agents to treat infections raises several concerns. The degradation of bacterial cells by 
endolysins releases cell debris such as peptidoglycan pieces, teichoic acids and 
liopteichoic acids, which can cause an inflammatory response, and even result in 
septic shock or organ failure. A study that investigated the inflammatory response 
after continuous intravenous application of Cpl-1 in rats observed indeed an increase 
of proinflammatory cytokines (Entenza et al. 2005). Vancomycin, which was used as 
a control in the study, also induced an inflammatory response, but levels were less 
pronounced. Furthermore, the study found that Cpl-1 eliminated S. pneumoniae cells 
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from the blood within 30 minutes, which was faster than vancomycin, and concluded 
that the findings support the use of Cpl-1 for intravenous treatment of infections, but 
that therapeutic concentrations and safety need to be further investigated. In contrast, 
a study by Witzenrath et al. treated mice intraperitoneally with Cpl-1 against a 
pneumococcal pneumonia infection and observed even lower levels of 
proinflammatory cytokines in Cpl-1-treated mice compared to untreated mice 
(Witzenrath et al. 2009).  
 
Another concern that needs to be addressed when proteins are administered is a 
potential immune response and the generation of deactivating antibodies. Several 
studies showed that the intravenous and intraperitoneal treatment with endolysins, for 
example Pal and Cpl-1, results in the production of antibodies against the endolysins 
(Jado et al. 2003; Loeffler et al. 2003). The hyperimmune serum of rabbits after 
immunisation with Cpl-1 was shown to marginally decrease the in vitro activity of 
Cpl-1. However, the previous immunisation of mice with Cpl-1 or Pal, did not affect 
the eradication of S. pneumoniae from infected mice by a second treatment with the 
endolysins in comparison to unimmunised mice (Jado et al. 2003; Loeffler et al. 
2003). The study by Jado et al. reported that no signs of anaphylaxis or adverse side 
effects were observed after treatment with Pal or Cpl-1. The first in vivo study that 
demonstrated the potential of an endolysin for the treatment of MRSA also found that 
the treatment with MV-L resulted in the production of antibodies. However, the 
antibodies did not decrease the bacteriolytic activity of MV-L and no harmful side 
effects were observed (Rashel et al. 2007).  
 
Nevertheless, non-native proteins get degraded by the host immune system. It has 
been shown that the half-life of Cpl-1 after intravenous administration in rats was 
approximately 20 minutes, which is similar to the administration of other non-native 
proteins (Loeffler et al. 2003). Since several studies achieved promising results in in 
vivo studies, it has been suggested that the enzymatic activity of endolysins is fast 
enough to outcompete the degradation by the immune response (Schmelcher et al. 
2012). An encouraging study by Resch et al. (2011) that created dimers of Cpl-1 via 
the introduction of cysteine residues for disulphide bridge formation demonstrated an 
enhanced enzymatic activity and a decelerated degradation in the plasma. 
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Nevertheless, endolysins could be good candidates for topical or mucosal membrane 
treatments, in which the enzymes are less affected by the clearance of the immune 
system and the risk of an inflammatory reaction is reduced.  
 
 
1.2.5 Further applications of endolysins 
 
Beside the use as novel antibiotics in human medicine, endolysins could be also used 
for different applications such as the control of bacterial contamination in food and 
feed, for the abolishment of bacterial pathogens on crop plants or the eradication of 
biofilms in food production (Schmelcher et al. 2012). Furthermore, applications in 
veterinary medicine, for example, the treatment of bovine mastitis have been 
suggested (Donovan et al. 2006).  
 
Taken together, endolysins are promising candidates for use as a novel and improved 
class of antibacterial agent, both in human medicine and also for use in other fields. 
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1.3 The target bacteria Streptococcus pneumoniae, Staphylococcus 
aureus and Propionibacterium acnes 
 
S. pneumoniae and S. aureus are major human pathogens that cause a range of serious 
infections and have a high proportion of antibiotic-resistant strains. Both species were 
listed in the WHO report about antibiotic resistance as “bacteria of international 
concern”, and are the only two Gram-positive bacteria on this list (WHO report 2014). 
The potential of endolysins as a treatment against S. pneumoniae and S. aureus has 
been demonstrated in vitro and in vivo (Witzenrath et al. 2009; Rashel et al. 2007). 
Skin infections caused by S. aureus and infections starting in the nasopharynx caused 
by both bacteria could be treated by topical or mucosal membrane treatments, which 
would reduce the risk of a rapid degradation of the endolysins and potential 
inflammatory reactions. S. pneumoniae and S. aureus were therefore chosen as target 
bacteria for this study that investigates the production of endolyins in microalgae. 
 
In addition, the production of an endolysin against Propionibacterium acnes in the 
cyanobacterium Synechocystis sp. PCC 6803 was investigated in this study. P. acnes 
has been associated with the skin condition acnes vulgaris and an endolysin effective 
against the bacterium could be therefore used in a topical treatment (Farrar & Ingham 
2004).  
 
 
1.3.1 Streptococcus pneumoniae 
 
S. pneumoniae is a Gram-positive, aerotolerant bacterium and is a major cause of 
pneumonia, bacterial meningitis and sepsis and is responsible for a high percentage of 
otitis media infections in children (Bogaert et al. 2004). It is considered one of the 
major human pathogens due to the morbidity and mortality it causes in young 
children, elderly people and patients with immunodeficiencies (Loeffler et al. 2001). 
Nearly one million children under the age of five years die every year from 
pneumonia and invasive diseases caused by S. pneumoniae, which is equivalent to 
11% of all deaths in this age group (O’Brien et al. 2009; WHO report 2014). S. 
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pneumoniae often colonizes asymptomatically the nasopharynx of healthy carriers, 
which is responsible for a majority of the transmission within the population (WHO 
report 2014).  
 
The number of antibiotic-resistant S. pneumoniae strains has increased in the last 
decades and is now a worldwide major public health concern (Adam 2002). S. 
pneumoniae shows high rates of reduced susceptibility to penicillins and macrolides 
(Figure 1.9 shows the data for the EU/EEA countries in 2012), as well as lower rates 
of resistance to fluoroquinolones (5.2% in the 2012 ECDC report) (ECDC - 
Surveillance report 2012). Penicillin resistance is caused by the acquisition of altered 
PBPs with reduced affinities for the binding to penicillins. The successive addition of 
mutation in the PBPs has resulted in increasing degrees of resistance (ECDC - 
Surveillance report 2012). Different degrees of antimicrobial resistance are defined by 
the minimal inhibitory concentration (MIC) of the antibiotic that is needed to inhibit 
the visible growth of the bacterium. The classification ranges from susceptible over 
non-susceptible and intermediate resistance to full resistance, but the definition of 
each class and the terminologies vary between studies (WHO report 2014). Macrolide 
resistance is either caused by a macrolide efflux system or a target modification of the 
23S subunit of the ribosome, which inhibits the binding of macrolides to the 23S 
subunit. Both mechanisms are caused by the acquisition of one gene, which results 
immediately in full resistance with high MIC values (ECDC - Surveillance report 
2012). Fluoroquinolones resistance is mediated by a mutation in the parC gene 
encoding a subunit of the topoisomerase IV, the target of the fluoroquinolones, or an 
efflux pump.  
 
Two vaccines against pneumococcal infections are available. The 23-valent vaccine 
consists of purified polysaccharides from 23 serotypes and covers theoretical 85 – 
90% of known S. pneumoniae strains. However, the vaccine is not effective in 
children under two years, which represent a major risk group, due to a lower immune 
response of young children (Bogaert et al. 2004). The conjugated vaccine comprises 
of seven to 11 pneumococcal polysaccharides bound to a diphtheria toxin, which 
causes an effective immune response in children under the age of two. The 
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disadvantage of this vaccine is that it covers only a part of the circulating S. 
pneumoniae serotypes (Bogaert et al. 2004). 
 
 
 
A 
Figure removed 
 
B 
Figure removed 
Figure 1.9: Antibiotic resistance of Streptococcus pneumoniae isolates in Europe 
Percentage (%) of invasive isolates that are non-susceptible or resistant to macrolides (A) or both to 
penicillins and macrolides (B) in the EU/EEA countries in 2012. Reproduced from ECDC - 
Surveillance report (2012) 
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1.3.2 Staphylococcus aureus 
 
Staphylococcus aureus is a Gram-positive, facultative anaerobic bacterium and 
member of the phylum Firmicutes. The bacterium colonises asymptomatically the skin 
and nasal cavity of approximately 30% of the population, but can also cause serious 
infections (ECDC - Surveillance report 2012). S. aureus is a common cause of a range 
of skin and soft-tissue infections and can also cause life-threatening diseases such as 
pneumonia, meningitis, endocarditis, toxic shock syndrome, food poisoning and 
sepsis. Furthermore, S. aureus is responsible for the majority of wound infections after 
surgeries (WHO report 2014). 
  
It is a prominent example of an organism that developed multi-drug resistance. 
Resistance of S. aureus against penicillin mediated by β-lactamases was already 
observed in the 1940s. Subsequently, β-lactamase stable drugs (e.g. methicillin) and 
β-lactamase inhibitors (e.g. clavulanic acid) were developed, but by the 1960s S. 
aureus had developed resistance against these drugs as well by acquisition of a gene 
that encodes a variant of the PBP with a low affinity of β-lactams, called PBP2a. 
These strains were therefore termed methicillin-resistant S. aureus (MRSA). By 2003, 
over 50% of S. aureus strains isolated in the United States were MRSA strains (Arias 
& Murray 2009). Subsequently, MRSA developed resistance against the glycopeptide 
antibiotic vancomycin, followed by resistance to many other antibiotics, including 
aminoglycosides, macrolides, fluoroquinolones, rifampicin and even newer antibiotics 
such as daptomycin and linezolid (Levy 2005). Figure 1.10 shows the prevalence of 
MRSA strains and strains resistant against rifampicin in the EU/EEA countries in 
2012 (ECDC - Surveillance report 2012). The resistance to rifampicin is mediated by 
a mutation in the rpoB gene, which results in a RNA polymerase with a decreased 
affinity for rifampicin (ECDC - Surveillance report 2012). 
 
Despite extensive research and numerous clinical trials with promising vaccine 
candidates, the creation of an vaccine against S. aureus has not been successful to-date 
(Fowler & Proctor 2014). 
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Figure 1.10: Antibiotic resistance of Staphylococcus aureus isolates in Europe 
Percentage (%) of invasive isolates that are resistant to methicillin and other β-lactam antibiotics 
(MRSA strains) (A) and to rifampicin (B) in the EU/EEA countries in 2012. Reproduced from ECDC - 
Surveillance report (2012). 
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1.3.3 Propionibacterium acnes 
 
Propionibacterium acnes is a Gram-positive, anaerobic bacterium of the phylum 
Actinobacteria, and it is a prevalent human skin commensal that colonises mainly 
areas that are rich in fatty acids such as the face, scalp and upper back.  
P. acnes is believed to play a role in the inflammatory stages of acne vulgaris. It has 
been shown that antibiotic treatments that reduced the number of P. acnes cells on the 
skin have a therapeutic effect on the severity of the acne condition (Farrar & Ingham 
2004). Furthermore, patients with acne vulgaris who did not respond to an antibiotic 
treatment were more likely to carry P. acnes strains, which were resistant to this 
antibiotic (Eady et al. 1989). One study found that P. acnes stimulates the release of 
the proinflammatory cytokines TNF-α, IL-1β and IL-8, which could play a role in the 
association of the bacterium with inflammatory acne. However, the exact mechanisms 
of this association and acne vulgaris are still unclear (Farrar & Ingham 2004).  
 
Acne vulgaris is a skin condition that affects about 80% of the population at some 
point in life, mainly in adolescence. It can be very painful, cause psychological 
problems and can result in lifelong scarring in severe cases (Farrar et al. 2007). 
Furthermore, P. acnes can cause eye lid infections and postoperative as well as 
device-related (e.g. joint prostheses) infections, especially in immunocompromised 
patients (Farrar et al. 2007). Acne vulgaris is treated with topical or oral antibiotics, 
but shows high levels of resistance against the prescribed antibiotics (Marinelli et al. 
2012).   Alternatively, chemical treatments with substances such as benzyl peroxide 
are used, which can have strong side effects.  
 
Especially, for the treatment of skin infections in the face and upper body the use of a 
narrow-spectrum antibiotic would be desirable to reduce the risk of opportunistic 
infections by fungi or bacteria. An endolysin against acne could not only be used in a 
pharmaceutical treatment, but also in a cosmetic product against mild acne, which 
would open up a much larger market. Products for the treatment of acne vulgaris, have 
a market that generates a revenue of nearly $3 billion annually. Furthermore, the 
application of an endolysin in a cosmetic product would significantly reduce the 
regulatory requirements and clinical-trials to bring the product to the market.  
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1.4 Microalgae as a production platform for recombinant 
therapeutic proteins 
 
The development of endolysins as antibacterial agents requires a suitable expression 
platform that can be used for efficient large-scale commercial production, but this 
platform also needs to fulfil all safety criteria for the production of therapeutic 
proteins.  
 
Antibiotics are traditionally low-priced and the production of small molecule drugs 
does not involve high costs. In contrast, the production cost for recombinant proteins 
is generally considerably higher (Dove 2002). It would be therefore desirable to use a 
system with low costs for the production of recombinant endolysins in order to 
compete with small molecule drugs. However, the successful development of an 
endolysin treatment that offers clear advantages over small molecule antibiotics, for 
example efficacy against pathogens with multi-drug resistances, advantageous 
narrow-spectrum properties or effectiveness against bacteria in biofilms, would justify 
a higher retail price and therefore higher production costs. In addition, a production 
system that offers itself clear advantages, other than low-cost production, would 
justify higher costs as well.  
 
In recent decades microalgae have started to get progressively more attention as 
production platforms for biological products. Primarily, the ability of photosynthetic 
organisms to utilise sunlight, inorganic nutrients and CO2 for the production of 
biological products makes these organisms appealing as the world becomes more and 
more aware of the problems related to increasing CO2 emission. Furthermore, the use 
of sustainable natural resources for production processes has become increasingly 
desirable.   
 
One of the primary focuses was to use algae for the production of biodiesel, since the 
production of biodiesel in higher plants reduces the availability of fertile land, which 
could be used for the production of food. However, despite extensive research 
endeavours and the successful production of different kinds of biofuels, to-date 
biodiesel production in microalgae is still not commercially viable in comparison to 
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petroleum derived fuels (Chisti 2013). However, with inevitably increasing prices for 
petroleum derived fuels and a successful reduction of the costs for production of 
biofuels from algae, this is likely to change. Nonetheless, the usage of microalgae for 
the production of other biological products, mainly high-value products, is starting to 
get more and more attention.  
 
Microalgae are believed to offer several advantages for the production of recombinant 
proteins. Some of these advantages are similar to the assets of transgenic plants as 
protein production platforms (Rasala et al. 2010). This includes simple and 
inexpensive nutrient requirements, which are believed to result in low costs for 
cultivation (Dove 2002; Specht et al. 2010; Rasala et al. 2010), and potentially in cost-
efficient recombinant protein production (Gimpel et al. 2014). As mentioned above, 
the ability of photosynthetic organisms to grow using light, inorganic substances and 
CO2, results not only in low nutrient requirements, but also has the potential to 
decrease the overall carbon footprint of recombinant protein production by consuming 
the CO2 that is produced during other steps of the production process. Furthermore, 
both microalgae and plant production systems can be easily and rapidly scaled up 
(Rasala et al. 2010).  
 
Several microalgae and plants are classified as GRAS organisms (Generally Regarded 
as Safe), which means these organisms are safe for human consumption. Furthermore, 
these microalgae and plants are free of endotoxins and viral or prion contaminants, 
which is important especially for the production of therapeutic proteins. Endotoxins 
are present in many bacteria, which makes it necessary to purify therapeutic proteins 
produced for example in the bacterium Escherichia coli. Viral and prion 
contaminations that can harm humans are often a concern when therapeutic proteins 
are produced in mammalian cell cultures (Specht et al. 2010). In addition, mammalian 
cell cultures are the most expensive production platform and are usually only used for 
complex mammalian proteins that cannot be produced in other systems. However, 
bacterial expression platforms with GRAS status do exist, such as lactic acid and 
coryneform bacteria, and the yields of recombinant proteins that can be achieved in 
these systems have increased in recent years (Ferrer-Miralles & Villaverde 2013; 
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Jørgensen et al. 2014). Nevertheless, bacterial systems can also have other drawbacks 
such as the aggregation of recombinant proteins and the formation of inclusion bodies.  
 
In addition, microalgae are believed to offer advantages over transgenic plants. 
Firstly, microalgae can be easily grown in full containment under sterile conditions in 
simple photobioreactors (PBRs) (Figure 1.11) (Specht et al. 2010; Rasala et al. 2010), 
which prevents the release of transgenes to the environment. In contrast, a major 
concern regarding the open and semi-enclosed cultivation (in green houses) of 
transgenic plants is the potential flow of transgenes to surrounding plants including 
food crops (Dove 2002). Furthermore, growth in PBRs reduces the risk of 
environmental contamination of the production system and therefore the 
contamination of the therapeutic protein. In contrast, the open and semi-enclosed 
cultivation of transgenic plants carries a high risk of infections with parasites and 
pathogens, which can result in the loss of the production crop (Specht et al. 2010). 
However, it should be mentioned that transgenic plants can be grown in bioreactors in 
closed containment as well. One option is the cultivation as plant cell suspension 
cultures, which also greatly reduces the risk of transgene flow to the environment and 
the contamination of the production platform. However, the disadvantages of this 
method are slower growth of the cultures and often lower yields of recombinant 
protein compared to the production in whole plants (Michoux et al. 2011). Another 
method is the cultivation of leaf tissues in temporary immersion bioreactors, which 
results in yields of recombinant proteins that are comparable to the production in 
whole plants (Michoux et al. 2011). However, these systems have not reach the same 
scale as PBRs for the cultivation of microalgae, especially in comparison to outdoor 
microalgae PBRs. An advantage of outdoor PBRs is that wasteland (such as deserts or 
salt land) can be used that is not fertile enough for the cultivation of crop plants.  
 
Moreover, the creation of transgenic plants requires in a lot of cases more time 
compared to transgenic microalgal strains. It takes between two and four weeks to 
create a transgenic microalgae, whereas the creation of a transgenic plant line can take 
months or even years (Specht et al. 2010).  
 
 
CHAPTER 1 - INTRODUCTION 
 
 53 
A 
 
B 
 
 
Figure 1.11: Photobioreactor systems that can be used for the contained cultivation of microalgae 
A shows an outdoor photobioreactor system located in the AlgaePARK in Wageningen, Netherlands. B 
shows an indoor photobioreactor system that comprises of 40 litre bags. This system is used by 
Supreme Biotechnologies Ltd, located in Nelson, New Zealand. 
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1.4.1 The definition of microalgae 
 
Microalgae are a diverse and polyphyletic group of microorganisms that are capable 
of performing oxygenic photosynthesis. Some definitions of microalgae are restricted 
to eukaryotic, photosynthetic microorganisms such as green algae (chlorophyta), red 
algae (rhodophyta), dinoflagellates (dinoflagellata) and diatoms (bacillariophyceae). 
However, in this study the term “microalgae” refers to eukaryotic as well as 
prokaryotic, photosynthetic microorganisms and includes cyanobacteria (traditionally 
called blue-green algae). Microalgae can be found in nearly all habitats from marine 
and freshwater environments to terrestrial habitats and these organisms contribute 
considerably to the overall carbon fixation on earth.  
 
In this study the chloroplast of the green microalga Chlamydomonas reinhardtii, an 
organism that has been used as a model organism for over 50 years, and the well-
studied cyanobacterium Synechocystis sp. PCC 6803 were used to investigate the 
potential of microalgae as production platforms for therapeutic recombinant 
endolysins. 
 
 
1.4.2 Chlamydomonas reinhardtii as a protein production platform 
 
C. reinhardtii offers all of the advantages stated above for the production of 
therapeutic proteins. The microalga is classified as a GRAS organism and can be 
grown in close containment. Furthermore, it has been shown that its cultivation can be 
easily scaled up (Gimpel et al. 2014; Chen & Johns 1996). Moreover, C. reinhardtii 
offers already established genetic and genomic tools and has been successfully used 
for the expression of a variety of recombinant proteins, including many therapeutic 
proteins (Almaraz-Delgado et al. 2014). 
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1.4.2.1 The green microalga Chlamydomonas reinhardtii  
 
C. reinhardtii is an unicellular, eukaryotic microalga that has a diameter of 
approximately 10 µm and can be found in freshwater and soil. The alga belongs to the 
chlorophyta or green algae, a group of micro- and macroalgae that all possess 
chlorophyll a and b, and produce starch as a storage compound. These are properties 
green algae share with higher plants. It is a member of the Chlamydomonadaceae, 
which is a family within the order Volvocales that comprises approximately 30 genera 
of microalgae with a cell wall and two to four flagella (Harris 2009).  
 
Figure 1.12 shows the structure of the C. reinhardtii cell, which carries two anterior 
flagella and possesses a relatively thick cell wall with several layers made of 
glycoproteins. However, several viable mutants have been isolated or created that lack 
an intact cell wall structure. The flagella are responsible for the motility of C. 
reinhardtii and play a role in the mating process. The cell contains multiple 
mitochondria, but only one cup-shaped chloroplast. The chloroplast occupies 
approximately two thirds of the cell; estimates range from 40 – 80% of the cell 
volume. A pyrenoid is located within the chloroplast and is responsible for carbon 
fixation. Furthermore, the C. reinhardtii cell carries an orange eyespot, which is able 
to sense light and enables the cell to orientate itself in the right position towards a 
light source via phototaxis (Harris 2009).  
 
C. reinhardtii has been used as a model organism to study a broad range of different 
fields including flagella function and assembly, photosynthesis, circadian rhythm, 
phototaxis and chloroplast biogenesis (Rochaix 1995). The nuclear genome of C. 
reinhardtii has a size of 120 Mb (mega base pairs) and was fully sequenced in 2007 
(Merchant et al. 2007). The nuclear genome comprises of 17 chromosomes carrying 
15,143 genes and has a relatively high guanine and cytosine (GC) content of 
approximately 64% (Merchant et al. 2007). The mitochondrial genome, which was 
sequenced already in 1993, has a size of 15.8 kb (Vahrenholz et al. 1993). The 
chloroplast carries between 80 and 100 copies of its genome, which is called the 
plastome. The plastome is circular and has a size of 203 kb and contains 99 genes. It 
was sequenced in 2002 by Maul et al. (2002) and has, in contrast to the nuclear 
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genome, a low GC content of 34%. The genes on the plastome encode ribosomal and 
transfer RNAs, an RNA polymerase, as well as ribosomal proteins. Furthermore, the 
plastome carries genes for core proteins of the photosynthetic apparatus (Maul et al. 
2002). The availability of all three C. reinhardtii genome sequences has greatly 
contributed to the advancement of our understanding of the organism, but also to the 
development and improvement of genetic tools for the genetic manipulation of the 
microalga. 
 
The replication of C. reinhardtii can happen either asexually or sexually. The 
vegetative cells are haploid, and divide usually by two (or three) rounds of binary 
fission before the lysis of the mother cell releases the daughter cells (Harris 2009). 
Vegetative cells are genetically fixed mating types, either mating type plus or mating 
type minus (mt+ / mt-) (Harris 2009). The entry into the sexual cycle is induced by 
nitrogen starvation or by other environmental stress conditions. The vegetative cells 
differentiate to gametes before two gametes with different mating types start pairing 
with their flagella before the cells fuse to a diploid cell, the zygote. The zygote 
develops into a dormant zygospore that is resistant to adverse environmental 
conditions. Under favorable conditions the zygote germinates and divides into four 
haploid daughter cells, which represent vegetative cells (Harris 2009). The daughter 
cells inherit the chloroplast genome from the mating type plus and the mitochondrial 
genome from the mating type minus gamete. The inheritance of the nuclear genome 
follows Mendel’s law of inheritance.  
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Figure 1.12: Schematic representation of the Chlamydomonas reinhardtii cell  
A shows the structure of the C. reinhardtii cell and was reproduced from Merchant et al. (2007).           
B shows an electron microscope image of C. reinhardtii cells and was reproduced from 
http://remf.dartmouth.edu/images/algaeSEM/source/1.html.  
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1.4.2.2 Genetic engineering of Chlamydomonas reinhardtii  
 
C. reinhardtii has been used extensively for research into genetic engineering in 
recent decades, and has resulted in the establishment of robust methods for the 
transformation of all three genomes of C. reinhardtii (Specht et al. 2010). The nuclear 
genome can be transformed with several DNA delivery methods such as microparticle 
bombardment (biolistics), agitation in the presence of glass beads (mainly using a cell 
wall less mutant), electroporation, as well as Agrobacterium transfection (Debuchy et 
al. 1989; Kindle 1990; Brown et al. 1991; Kumar et al. 2004). The chloroplast and 
mitochondrial genomes have been transformed using biolistics (Boynton et al. 1988; 
Randolph-Anderson et al. 1993). Furthermore, the chloroplast genome can be 
transformed by agitating of a cell wall less mutant in the presence of glass beads 
(2.3.8.2).  
 
The transformation of the nuclear genome has been successfully used for the 
expression of heterologous genes encoding, for example, the reporter protein GFP 
(Fuhrmann et al. 1999) and antibiotic resistance selectable markers such as the 
phleomycin resistance gene (ble) and the aminoglycoside 3’’-adenyl-transferase gene 
(aadA) (Franklin & Mayfield 2004). The expression from the nuclear genome offers 
the advantage that proteins can be directed to different compartments of the cell or 
secreted out of the cell using signal peptides, unlike proteins produced in the 
chloroplast (Franklin & Mayfield 2004). However, in this study the chloroplast was 
used for the production of the therapeutic endolysins for reasons discussed in the next 
section.  
 
The transformation of the chloroplast genome is performed with selectable markers 
that can be antibiotic resistance genes, such as aadA (spectinomycin/streptomycin 
resistance) or aphA6 (kanamycin resistance). Furthermore, the restoration of 
phototrophic growth in a mutant lacking a particular photosynthesis gene or the 
restoration of an arg9 mutant to arginine prototrophy can be used for selection (Purton 
et al. 2013). Chloroplast transformation vectors carry expression cassettes that are 
flanked by homologous sequences that target the insertion of the transgene to a 
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specific locus in the plastome (Purton et al. 2013). The transformation of C. 
reinhardtii and the system used in this study are further explained in 2.3.8.1.  
 
 
 
 
 
 
 
 
Figure removed 
 
 
 
 
 
 
Figure 1.13: Recombinant protein expression in different compartments of C. reinhardtii  
Recombinant proteins (depicted in the figure as blue and red monoclonal antibodies) can be either 
expressed from the nuclear genome or the plastome. After expression from the nuclear genome the 
proteins accumulate in the cytoplasm or can be directed using specific signal peptides to the 
chloroplast, endoplasmic reticulum (ER) or secreted to the periplasm and transported out of the cell. 
The expression from the plastome results in the accumulation of the proteins in the chloroplast stroma. 
There are no known mechanisms that transport proteins from the chloroplast to the cytoplasm. The 
inserted figures show examples of proteins that have been expressed in the different compartments. (a) 
shows gfp expression from the nuclear genome and (b) shows LuxCT accumulation in the chloroplast. 
Blue areas (plus the neighbouring white areas) indicate the cytoplasm and the green lines indicate the 
two membranes of the chloroplast surrounding the chloroplast stroma. The mitochondria are indicated 
by brown ovals. Reproduced from Franklin & Mayfield (2004). 
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1.4.2.3 The C. reinhardtii chloroplast as a protein synthesis factory 
 
There are several advantages of chloroplast expression over nuclear expression in C. 
reinhardtii. One major asset of chloroplast expression is that the levels of recombinant 
proteins that can be achieved in the organelle to-date are markedly higher compared to 
their expression from the nuclear genome (Potvin & Zhang 2010). This is most likely 
the result of silencing mechanisms in the nuclear genome (Specht et al. 2010). 
Another reason could be the polyploidy of the plastome, which provides a high copy 
number of the transgene and, therefore, most likely contributes to higher levels of 
gene expression.  
 
The integration of transgenes into the plastome occurs exclusively via homologous 
recombination, which allows the insertion site to be easily defined. Furthermore, it 
ensures that only one copy of the transgene is inserted. In contrast, in the nuclear 
genome transgenes are inserted into random locations and multiple insertions can 
occur. A defined insertion site prevents complications related to random insertion 
such as variable levels of expression or gene silencing through position effects. 
Furthermore, the plastome does not have any other regulatory mechanisms such as 
RNA interference, which can affect transgene expression and therefore reduce the 
production of a recombinant protein (Potvin & Zhang 2010). Moreover, the plastome 
can be transformed with several genes at the same time by inserting the transgenes in 
different locations. Alternatively, the plastome has the ability to express multiple 
genes from polycistrons, in which several genes are expressed using one promoter 
(Specht et al. 2010). Finally, as mentioned above, in C. reinhardtii the chloroplast 
genome is inherited from the m+ strain during the sexual cycle, which allows 
transgene containment by using mt- type strains for the creation of transgenic lines.  
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1.4.2.3.1 The chloroplast offers advantages for the production of bacteriophage 
endolysins 
 
The chloroplasts of green algae and higher plants originated from the endosymbiosis 
of a cyanobacterium by a heterotrophic, unicellular eukaryote at least 1.2 billion years 
ago, which is seen as the primary endosymbiotic event (Figure 1.14) (Parker et al. 
2008). The chloroplast possesses, therefore, many properties that reflect its 
prokaryotic origin, such as a eubacterial-type transcription and translation machinery 
with, for example, 70S ribosomes (Purton et al. 2013). Furthermore, all chloroplast 
proteases that have been identified to-date are homologues of prokaryotic proteases 
(Adam et al. 2006). The presence of several genes of chlamydial origin in the 
genomes of photosynthetic eukaryotes indicates an ancient endosymbiosis of a 
Chlamydiae cell by the ancestor of primary photosynthetic eukaryotes that happened 
before the primary endosymbiotic event (Becker et al. 2008). This event might have 
helped to establish the formation of plastids by providing genes that facilitated the 
communication between the cyanobacterial endosymbiont and the eukaryotic host cell 
(Huang & Gogarten 2007).  
 
These properties are most likely an advantage for the production of endolysins, which 
are naturally produced in bacteria and accumulate for a relatively long time inside the 
cell before their release to the peptidoglycan. It can therefore be assumed that these 
proteins are adapted to production by the prokaryotic transcription and translation 
machinery and that endolysins have a relatively high resistance against prokaryotic 
proteases. The chloroplast provides a prokaryotic environment, but at the same time 
lacks the target of the endolysins, the peptidoglycan. A study by Oey et al. (2009b) 
obtained results indicating that high levels of endolysin expression have a negative 
impact on bacterial expression systems (in this study Escherichia coli), which is 
potentially caused by interactions of the endolysins with the bacterial peptidoglycan, 
such as unspecific cleavage or binding. An expression system lacking peptidoglycan 
is therefore likely to present an advantage for the production of endolysins. It has been 
shown that the S. pneumoniae-specific endolysin PlyGBS can accumulate in the 
tobacco chloroplast to levels as high as 70% of total soluble protein, most likely as a 
result of low protein degradation (Oey et al. 2009a). Furthermore, the endolysins Pal 
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and Cpl-1 have been successfully produced in the tobacco chloroplast (Oey et al. 
2009b), and Cpl-1 has also been shown to accumulate in the chloroplast of C. 
reinhardtii (Taunt 2013). Another advantage is that post-translational modifications, 
such as glycosylation, do not occur in the chloroplast, which is a further characteristic 
that the chloroplast shares with bacterial systems (Specht et al. 2010).  
 
 
 
 
 
 
 
Figure removed 
 
 
 
 
 
 
 
 
Figure 1.14: Endosymbiosis theory 
The chloroplasts of green microalgae and higher plants originated from the endosymbiosis of a 
cyanobacterium by a heterotrophic, unicellular eukaryote, which is seen as the primary endosymbiotic 
event. Subsequently, further endosymbiotic events occurred, which resulted in plastids with multiple 
membranes as found in organisms such as dinoflagellates or apicomplexa. Reproduced from Parker et 
al. (2008). 
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1.4.2.3.2 The expression of therapeutic proteins in the C. reinhardtii chloroplast 
 
Chloroplast expression in C. reinhardtii has been used for the production of a whole 
range of therapeutic proteins, including antibodies, immunotoxins and (oral) vaccines 
(Almaraz-Delgado et al. 2014). Table 1.2 shows a selection of therapeutic proteins 
that have been successfully produced in the C. reinhardtii chloroplast.  
 
However, the recombinant protein yields that can be achieved in C. reinhardtii 
chloroplast are still lower compared to established production systems (TSP levels of 
more than 15% TSP are common in E. coli). Several studies have investigated factors 
that influence accumulation levels of recombinant proteins in the C. reinhardtii 
chloroplast. For example, it has been shown using the reporter protein GFP, that 
codon optimisation can result in an 80-fold increase in protein yields in the chloroplast 
(Franklin et al. 2002). Codon optimisation strategies are mainly based on the preferred 
(most common) codons for one amino acid in an organism, but can also take into 
account aspects such as preferred codon pairing. The codon usage table for the C. 
reinhardtii chloroplast by Nakamura et al. (2000) is shown and further discussed in 
chapter 6.  
 
To-date, only endogenous promoter/5´UTR elements have been shown to be effective 
for transgene expression in the chloroplast. The promoter/5´UTR elements that result 
in the highest expression levels are from the genes atpA, psaA and psbA (Bateman & 
Purton 2000; Rasala et al. 2011). However, high expression levels under the psbA 
promoter/5´UTR were only observed in a psbA deficient mutant. Though, it was 
possible to reintroduce the psbA gene under the control of a different promoter to 
restore photosynthesis, which resulted only in a marginal decrease of the expression 
levels of the transgene (Manuell et al. 2007). It has been shown that an authentic 
3’UTR is necessary for mRNA accumulation, since it stabilises the mRNA and plays 
a role in transcription termination and 3’ formation, but all 3’UTRs of endogenous 
chloroplast genes analysed so far, resulted in similar mRNA and protein levels for 
transgenes (Barnes et al. 2005). 
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Table 1.2:Overview of selected therapeutic proteins produced in the C. reinhardtii chloroplast 
Adapted from Specht et al. (2010) and Almaraz-Delgado et al. (2014), TSP = total soluble protein CTB = cholera toxin B subunit. 
Recombinant 
Protein 
Function Application Yield Reference 
     
HSV8-lsc Human antibody against glycoprotein D from Herpes simplex virus Therapeutic Not reported  Mayfield et al. (2003) 
CTB-VP1  Protein VP1 from foot and mouth disease virus fused to CTB Vaccine 3 - 4 % TSP Sun et al. (2003) 
hTRAIL Tumor necrosis factor-related apoptosis-inducing ligand Therapeutic 0.43% - 0.67 % TSP Yang et al. (2006) 
M-SAA Bovine mammary-associated serum amyloid Therapeutic 3 - 5 % TSP Manuell et al. (2007) 
CSFV-E2 Swine fever virus structural protein E2 Vaccine 1.5 - 2 % TSP He et al. (2007) 
hGAD65 Human glutamic acid decarboxylase Diagnostics and therapeutic 0.25 - 0.3 % TSP Wang et al. (2008) 
VP28 White spot syndrome virus protein 28 Vaccine 0.1 - 10.5 % TSP  Surzycki et al. (2009) 
CTB-D2 D2 fibronectin-binding domain of Staphylococcus aureus fused to CTB  Oral vaccine 0.7 % TSP Dreesen et al. (2010) 
 
VEGF  
14FN3 
 
 
Human vascular endothelial growth factor  
Domian 14 of human fibronectin 
Therapeutic 2 - 3 % TSP Rasala et al. (2010) 
Pfs25 and Pfs28 Plasmodium falciparum surface proteins Oral vaccine 0.5%, 0.2% TSP Gregory et al. (2012) 
αCD22PE40 Antibody against DC22 surface protein from B-cells fused to two 
domains of an exotoxin from Pseudomonas aeruginosa 
 
Immunotoxin 0.3 - 0.4 % TSP Tran et al. (2013) 
CtxB-Pfs25 Plasmodium falciparum surface protein 25 fused to CTB Oral vaccine 0.09% Gregory et al. (2013) 
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1.4.3 The potential of other eukaryotic microalgal species for the 
synthesis of recombinant proteins 
 
The transformation of several other eukaryotic microalgae species has been 
established in recent years. For example, nuclear transformation was achieved for a 
range of other green algae such as Dunaliella salina, Chlorella vulgaris, Chlorella 
sorokiniana, Haematoccus pluvialis and for diatoms such as Phaedactylum 
tricornutum or Cyclotella cryptica (Geng et al. 2003; Chow & Tung 1999; Dawson et 
al. 1997). Furthermore, chloroplast transformation has been successfully performed 
for the red alga Porphyridium sp. and the euglenoid Eugelena gracilis (Lapidot et al. 
2002; Doetsch et al. 2001). A comprehensive summary of algae species whose 
transformation was achieved until 2013, can be found in Vonlanthen (2013). The 
establishment of a robust transformation method is an important prerequisite for 
further investigations into the applicability of other microalgae as recombinant protein 
production platforms.  
 
Different microalgae species to C. reinhardtii might offer advantages for the 
production of certain proteins. Higher growth rates and maximal cell densities, which 
can be reached for example by Chlorella sorokiniana, would result in faster 
production or in higher protein yields per litre of medium. Marine species offer the 
advantage that salt water instead of fresh water can be used. However, this is mainly 
of interest for large scale production of lower value proteins. Furthermore, certain 
microalgae species produce secondary metabolites providing health benefits such as 
astaxanthin or carotenoids, which might be of interest for combinations with certain 
recombinant proteins. The transformation of H. pluvialis, for example, was 
established with the aim of producing vaccines for the use in aquaculture in the 
microalgae. The aim is to deliver the vaccine together with astaxanthin, which is 
required in the diet of pink-fleshed fish, using dried H. pluvialis cells (Gutiérrez et al. 
2012).  
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1.4.4 The cyanobacterium Synechocystis sp. PCC 6803 as a production 
platform for bacteriophage endolysins 
 
The primary focus of the study was the investigation of the suitability of the C. 
reinhardtii chloroplast as a production platform for bacteriophage endolysins. 
However, for reasons that are discussed in 6.1 the investigation was expanded to the 
cyanobacterium Synechocystis sp. PCC 6803, which is introduced below and in 6.1.  
 
 
1.4.4.1 An introduction to Synechocystis sp. PCC 6803 
 
Synechocystis sp. PCC 6803 is a Gram-negative, fresh-water cyanobacterium that was 
originally isolated from a lake in California in 1968 by R. Kunisawa. It possesses 
coccoid, non-filamentous cells with a size of 1.5 to 2 µm (Ikeuchi & Tabata 2001). 
Synechocystis can grow photoautotrophically as well as mixotrophically or 
heterotrophically (with five minutes of light activation per day) using glucose or 
organic acids as additional carbon sources. The cyanobacterium is also able to grow 
under anaerobic conditions in the presence of carbon sources (Vermaas 1996). The 
organism is mesophilic and basophilic and achieves optimal growth at temperatures of 
30°C to 34°C and at pH values between 8 and 10. The cell division of Synechocystis 
cells occurs by binary fission (Ikeuchi & Tabata 2001). Although cyanobacteria are 
classified as Gram-negative bacteria, they have a relatively thick peptidoglycan layer. 
Synechocystis cells are surrounded by a four layer cell envelope, which is composed 
of the cytoplasmic membrane, followed by the peptidoglycan cell wall and the outer 
membrane. The last layer is mostly formed by a S-layer or other carbohydrate 
structures (Liberton et al. 2006). 
 
The cyanobacterium is naturally transformable, since it is able to take up exogenous 
DNA (Vermaas 1998). Synechocystis carries a genome that is comprised of one 
circular chromosome and seven additional plasmids. The main chromosome has a size 
of 3.5 Mb, whereas the sizes of the plasmids vary between 2.3 and 120 kb (Kaneko et 
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al. 1996). Multiple copies (approximately ten) of the genome are present in each 
Synechocystis cell (Vermaas 1998). The genome of Synechocystis has been fully 
sequenced and has a GC content of 47.7% (Kaneko et al. 1996). Furthermore, the 
genome is well annotated and gene functions have been extensively studied. The 
annotated genome and information about gene functions and mutants are available in 
the databases CyanoBase and CyanoMutants1. 
 
Many tools for the genetic manipulation of Synechocystis have been established in the 
last few decades, including several different promoter systems, selectable markers and 
transformation vectors. The majority of promoters and expression elements that are 
used in Synechocystis are derived from strongly expressed endogenous genes 
encoding for proteins involved in photosynthesis and carbon fixation such as psbAII, 
psaA, psaD and rbcL (Peca et al. 2008; Dexter & Fu 2009). Nevertheless, a few 
foreign promoters have been shown to result in efficient expression as well, such as 
the inducible E. coli promoters trc10, trc20 and A1lacO-1 (Huang et al. 2010). The 
expression elements used in this study are described in 6.2.1.  
 
For the selection of Synechocystis transformants, antibiotic resistance genes are 
mainly used as selectable markers. Commonly used antibiotic resistance marker genes 
are nptI and nptII encoding for neomycin phosphotransferases conferring resistance 
against neomycin and kanamycin and the aadA gene, which confers resistances 
against streptomycin and spectinomycin (Koksharova & Wolk 2002; Vermaas 1998).  
 
 
 
 
 
 
  
                                                
1 CyanoBase: http://genome.microbedb.jp/cyanobase/  
CyanoMutants: http://www.kazusa.or.jp/cyano/mutants/  
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1.5 Summary, aims and objectives 
 
There is a pressing need for the development of new and improved classes of 
antibiotics to combat infections with multidrug resistant pathogens, and to minimise 
the spread of antibiotic resistance in the bacterial population. Furthermore, the 
development of narrow-spectrum antibiotics that do not harm the commensal 
microbial flora, and antibiotics that can target bacteria in biofilms is desirable. 
Bacteriophage endolysins are proposed as promising candidates for a novel class of 
antibiotics that potentially offer solutions for these problems. S. pneumoniae, S. 
aureus and P. acnes are examples of suitable target bacteria for a potential endolysin 
antibiotic treatment.  
Microalgae have emerged as novel production platforms for therapeutic proteins in the 
last few years. These organisms offer several advantages such as simple nutrient and 
cultivation requirements and growth in closed containment. Furthermore, several 
species have GRAS status and are free of endotoxins and viral or prion contaminants, 
which is especially desired for the production of therapeutic proteins.  
 
The aim of the research presented in this thesis was, therefore, to investigate the 
suitability of microalgae as production platforms for recombinant bacteriophage 
endolysins. With this aim, the following studies were performed: 
 
• Production of endolyins targeting the human pathogens S. pneumoniae and S. 
aureus in the chloroplast of Chlamydomonas reinhardtii, followed by an 
analysis of the stability and production yields of the proteins in the chloroplast 
 
• Demonstration of the antibacterial activity of the endolysins against the target 
bacteria and the development of purification strategies for the endolysins 
produced in C. reinhardtii 
 
• Production of endolysins, whose production in the C. reinhardtii chloroplast 
has been proven to be difficult, in the cyanobacterium Synechocystis sp. PCC 
6803, followed by a demonstration of the antibacterial activity  
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2 Materials and methods 
 
2.1 Microalgal and bacterial strains  
 
2.1.1 Chlamydomonas reinhardtii strains 
 
Table 2.1: Chlamydomonas reinhardtii strains used or created in this study 
 
Strain Genotype/phenotype Reference 
 
TN72 
 
mt+, CW15.3A (cell-wall deficient), psbH partly 
deleted by aadA cassette, PSII-deficient mutant, 
spectinomycin resistant 
 
 
Ninlayarn (2012) 
TN72_control TN72 transformed with the empty pASapI vector, 
carrying atpA promoter, psbH rescued 
 
Ninlayarn (2012) 
TN72_pal-HA TN72 carrying pal with HA-tag sequence under atpA 
promoter, psbH rescued 
 
This study 
TN72_ϕ11-HA TN72 carrying ϕ11 with HA-tag sequence under atpA 
promoter, psbH rescued 
 
This study 
TN72_pal-HA-His TN72 carrying pal with HA- and His-tag sequence 
under atpA promoter, psbH rescued 
 
This study, 
by N. Hiegle 
TN72_ϕ11-HA-His TN72 carrying ϕ11 with HA- and His-tag sequence 
under atpA promoter, psbH rescued 
 
This study, 
by N. Hiegle 
TN72_SR_control 
 
TN72 transformed with the empty pSRSapI vector, 
carrying psaA exon 1 promoter, psbH rescued 
 
R. Young, 
unpublished 
TN72_SR_pal-HA 
 
TN72 carrying pal with HA-tag sequence under psaA 
exon 1 promoter, psbH rescued 
 
This study 
TN72_SR_pal-x 
 
TN72 carrying pal without a sequence for a tag under 
psaA exon 1 promoter, psbH rescued 
 
This study 
TN72_SR_cpl-1-HA 
 
TN72 carrying cpl-1 with HA-tag sequence under 
psaA exon 1 promoter, psbH rescued 
 
Taunt (2013) 
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2.1.2 Bacterial strains 
 
2.1.2.1 Synechocystis sp. PCC 6803 strains 
 
Table 2.2: Synechocystis sp. PCC 6803 strains used or created in this study 
 
Strain Genotype/phenotype Reference 
 
Synechocystis sp. PCC 6803  
 
 
Wild type, large, glucose-tolerant 
 
Williams (1988) 
 
Syn6803_nrsB_pal-HA Carrying pal with HA-tag sequence under nrsBRS 
promoter system, kanamycin resistant 
 
This study 
Syn6803_nrsB_ϕ11-HA Carrying ϕ11 with HA-tag sequence under psbAII 
promoter, kanamycin resistant 
 
This study 
Syn6803_AII_ϕ11-HA Carrying ϕ11 with HA-tag sequence under 
nrsBRS promoter system, kanamycin resistant 
 
This study 
Syn6803_nrsB_gp201 Carrying gp201 with HA-tag sequence under 
nrsBRS promoter system, kanamycin resistant 
 
This study 
Syn6803_AII_gp201-HA Carrying gp201 with HA-tag sequence under 
psbAII promoter, kanamycin resistant 
 
This study 
Syn6803_nrsB_gp202-HA Carrying gp202 with HA-tag sequence under 
nrsBRS promoter system, kanamycin resistant 
 
This study 
 
 
2.1.3 Escherichia coli strains 
 
Table 2.3: E. coli strains used for cloning or the expression of endolysin genes 
 
Strain Genotype/phenotype Reference 
 
DH5α 
 
fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80 Δ(lacZ)M15 
gyrA96 recA1 relA1 endA1 thi-1 hsdR17 
 
 
Hanahan 
(1983) 
DH5α_pal-HA Carrying pASApI containing pal with HA-tag sequence under 
atpA promoter 
 
This study  
DH5α_ϕ11-HA Carrying pASApI containing pal with HA-tag sequence under 
atpA promoter 
This study 
 
DH5α_control 
 
Carrying pASApI without gene of interest under atpA promoter 
 
 
This study 
  CHAPTER 2 – MATERIALS & METHODS 
 
 72 
2.1.3.1 Target bacteria 
 
Table 2.4: Target bacteria used for antibacterial activity studies 
Species and strain Genotype/phenotype Reference 
 
Streptococcus pneumoniae 
  
16 NP3 Serotype 19F, reference strain, penicillin 
resistant 
 
Royal Free Hospital 
H08212 0259 Serotype 6A, clinical isolate Royal Free Hospital  
 
H08052 0052 Serotype 6B, clinical isolate Royal Free Hospital  
 
H05252 0075 Serotype 6B, clinical isolate Royal Free Hospital  
 
H08432 0293 Serotype 27, clinical isolate Royal Free Hospital  
 
35 NP1 Serotype 6B, clinical isolate, 
intermediate resistance against penicillin 
(Minimal inhibitory concentration 
(MIC): 0.125 µg/ml) and co-trimoxazole 
(MIC: 6 µg/ml) 
 
Royal Free Hospital 
 
Streptococcus pyogenes   
 
ATCC 19615 
 
Streptococcus group A Royal Free Hospital 
 
Staphylococcus aureus  
 
  
ATCC 28213  
 
Reference strain Royal Free Hospital 
ATCC 43300  
 
Clinical isolate, methicillin resistant 
strain (MRSA), resistant to methicillin, 
resistant to oxacillin 
 
Royal Free Hospital 
ATCC 25923  
 
Clinical isolate, methicillin sensitive 
strain (MSSA) 
 
Royal Free Hospital 
 
Propionibacterium acnes 
 
ATCC 6919 
 
 
 
DSM number: 1897, type strain, other 
collection numbers: NCTC 737 
 
 
 
 
DSMZ - German Collection 
of Microorganisms and Cell 
Cultures 
 
 
Agrobacterium tumefaciens 
  
Obtained from T. Barbi 
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2.2 Plasmids 
 
Table 2.5: Plasmids used in this study 
 
Plasmid Characterisation Reference 
 
pASapI 
 
Carries an expression cassette with atpA 
promoter/5’UTR and rbcL 3’UTR, the C. reinhardtii 
psbH gene as selectable marker together with regions 
upstream and downstream of psbH for homologous 
recombination 
 
 
Ninlayarn (2012) 
pASapI_control pASapI carrying an empty expression cassette 
 
Ninlayarn (2012) 
pASapI_pal-HA pASapI carrying pal with HA-tag sequence  
 
This study 
pASapI_ϕ11-HA pASapI carrying ϕ11 with HA-tag sequence  
 
This study 
pASapI_pal-HA-His pASapI carrying pal with HA- and His-tag sequence 
in expression cassette 
 
This study, 
by N. Hiegle 
pASapI_ϕ11-HA-His pASapI carrying ϕ11 with HA- and His-tag sequence 
in expression cassette 
 
This study, 
by N. Hiegle 
pSRSapI Carries an expression cassette with psaA exon1 
promoter/5’UTR and rbcL 3’UTR, the C. reinhardtii 
psbH gene as selectable marker together with regions 
upstream and downstream of psbH for homologous 
recombination 
 
Young & Purton 
(2014) 
pSRSapI_control 
 
 
pSRSapI carrying an empty expression cassette 
 
 
Young & Purton 
(2014) 
pSRSapI_pal-HA 
 
pSRSapI carrying pal with HA-tag sequence under 
psaA exon 1 promoter, psbH rescued 
 
This study 
pSRSapI_ pal-x 
 
pSRSapI carrying pal without a sequence for a tag 
under psaA exon 1 promoter, psbH rescued 
 
This study 
pSRSapI_cpl-1-HA 
 
pSRSapI carrying cpl-1 with HA-tag sequence under 
psaA exon 1 promoter, psbH rescued 
 
Taunt (2013) 
pLAH.AII Carries an expression cassette with the Synechocystis 
sp. PCC 6803 psbAII promoter/5’UTR, upstream and 
downstream regions of psbAII for homologous 
recombination and Tn903 kanamycin resistance 
cassette for selection 
 
Al’Haj (2014) 
pLAH.nrsB Carries an expression cassette with Synechocystis sp. 
PCC 6803 nrsB promoter/5’UTR and nrsRS 
regulatory elements, upstream and downstream 
regions of psbAII for homologous recombination and 
Tn903 kanamycin resistance cassette for selection 
 
Al’Haj (2014) 
pLAH.AII_ϕ11-HA pLAH.AII carrying ϕ11 with HA-tag sequence  
 
This study 
  CHAPTER 2 – MATERIALS & METHODS 
 
 74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plasmid Characterisation Reference 
 
pLAH.AII_gp201-HA 
 
 
pLAH.AII carrying gp201 with HA-tag sequence  
 
This study 
pLAH.nrsB_pal-HA 
 
pLAH.nrsB carrying pal with HA-tag sequence This study 
pLAH.nrsB_ϕ11-HA 
 
pLAH.nrsB carrying ϕ11 with HA-tag sequence This study 
pLAH.nrsB_gp201-HA 
 
pLAH.nrsB carrying gp201 with HA-tag sequence This study  
pLAH.nrsB_gp202-HA 
 
pLAH.nrsB carrying gp202 with HA-tag sequence This study 
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2.3 Media and culture conditions 
 
2.3.1 Media for the cultivation of C. reinhardtii  
 
2.3.1.1 Gorman-Levine Tris-acetate phosphate (TAP) medium                  
(Harris 1989, modified) 
 
NH4Cl 0.4 g/L 
MgSO4 • 7H2O 0.1 g/L 
CaCl2 • 2H2O 0.05 g/L 
K2HPO4 0.108 g/L 
KH2PO4 0.056 g/L 
Tris  2.42 g/L 
Glacial acetic acid 1 ml/L 
Trace element stock solution 1  ml/L 
 
The pH was adjusted to 7.0. Solid medium was prepared by the addition of 2% (w/v) 
Bacto agar. 
 
 
2.3.1.2 Sueoka high-salt (HSM) medium (Harris 1989, modified) 
 
NH4Cl 0.4 g/L 
MgSO4 • 7H2O 0.1 g/L 
CaCl2 • 2H2O 0.05 g/L 
K2HPO4 0.717 g/L 
KH2PO4 0.363 g/L 
Trace element stock solution 1  ml/L 
 
The pH was adjusted to 6.9. Solid medium was prepared by the addition of 2% (w/v) 
Bacto agar. 
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2.3.2 Trace element stock solution 
 
H3BO4 11.4 g/L 
ZnSO4 • 7H2O 22 g/L 
MnCl2 • 4H2O 5.06 g/L 
FeSO4 • 7H2O 4.99 g/L 
CoCl2 • 6H2O 1.61 g/L 
CuSO4 • 4H2O 1.57 g/L 
(NH4)6Mo7O24 • 4H2O 1.1 g/L 
 
The trace elements were dissolved in 550ml ddH2O in the order indicated above, then 
heated to 100°C. Subsequently, 50 g EDTA•Na2 was dissolved in 250 ml H2O by 
heating and added to the above solution. The mixture was reheated to 100°C, cooled 
to 80 - 90°C and adjusted to pH 6.5 - 6.8 with 20% KOH and adjusted to one litre. 
The stock was incubated at room temperature for two weeks and allowed to form a 
rust coloured precipitate and filtered through three layers Whatman No. 1 paper under 
suction until the solution was clear. 
 
 
 
 
 
2.3.3 Media for the cultivation of Synechocystis sp. PCC 6803 
 
2.3.3.1 BG11 (Blue Green Medium) (Castenholz 1988) 
 
Ingredients for 1 L of 1x BG11 
100x BG11 10 ml 
Trace elements 1 ml 
Iron stock 1 ml 
Autoclave and allow to cool then add   
Phosphate stock 1 ml 
Na2CO3 stock 1 ml 
NaHCO3 stock 10 ml 
TES buffer (pH 8.2) 10 ml 
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Table 2.6: Stock solutions for BG11 medium 
 
 
 
Solid media BG11 medium was prepared by mixing 2x concentrated BG11 including 
3 g of sodium thiosulphate with an equal volume of Difco Bacto-agar (3% w/v in 
distilled water) after both solutions had been autoclaved separately to reach a final 
concentration of 1x BG11 and 1.5% agar. 
100x BG11 g/L 
NaNO3 149.6 
MgSO4 • 7H2O 7.49 
CaCl2 3.60 
Citric acid 0.60 
Na2EDTA 1.12 ml 0.25M solution, pH 8.0 
  
Trace elements g/100ml 
H3BO3 0.286 
MnCl2 • 4H2O 0.181 
ZnSO4 • 7H2O 0.022 
Na2MoO4 • 2H2O 0.039 
CuSO4 • 5H2O 0.008 
  
Iron stock g/100ml 
Ferric citrate 0.6 
Or ferric ammonium citrate 1.11 
  
Stock solutions g/100ml 
K2HPO4 3.05 
Na2CO3 2.0 
NaHCO3 8.401 
TES buffer (NaOH to pH 8.2) 22.9 
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2.3.4 Medium for the cultivation of Escherichia coli  
 
2.3.4.1 Lysogenic broth (LB) medium (Bertani 1951) 
 
Bacto-tryptone 10.0 g/L 
Yeast extract 5.0 g/L 
Sodium chloride 10.0 g/L 
 
Solid medium was prepared by the addition of 1.5% agar. 
 
 
2.3.5 Media for the cultivation of the target bacteria  
 
2.3.5.1 Trypticase soy yeast extract medium (DSMZ medium 92) 
 
Trypticase soy broth 30.0 g/L 
Yeast extract 3.0 g/L 
 
The pH was adjusted to 7.0 – 7.2. Solid medium was prepared by the addition of 1.5% 
agar. 
 
 
2.3.5.2 Skimmed milk tryptone glycerol glucose (STGG) medium            
(O’Brien et al. 2001) 
 
Skimmed milk powder 20 g/L 
Tryptone soy broth 30 g/L 
Glucose 5 g/L 
Glycerol 100 ml/L 
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2.3.5.3 Brain heart infusion medium 
 
Brain heart infusion (SIGMA) 17.5 g/L 
NaCl 5 g/L 
Na2HPO4 2.5 g/L 
Glucose 2 g/L 
Peptone 10 g/L 
 
Solid medium was prepared by the addition of 1.5% agar prior autoclaving. 
 
 
2.3.6 Antibiotics 
 
Antibiotic Stock solution Final concentration 
Ampicillin 100 mg/ml in H2O 100 µg/ml 
Kanamycin 100 mg/ml in H2O 50 µg/ml 
Spectinomycin 100 mg/ml in H2O 50 µg/ml 
Chloramphenicol 100 mg/ml in EtOH 500 µg/ml 
 
 
2.3.7 Culture conditions  
 
2.3.7.1 Chlamydomonas reinhardtii 
 
The C. reinhardtii strains used in this work are listed in Table 2.1. The strains were 
maintained on Gorman-Levine Tris-acetate phosphate (TAP) agar plates. For culture 
growth the plates were incubated at 20ºC and at a light intensity of 48 - 50 µmol/m2/s 
using Gro-lux or Luxline plus fluorescent tubes (Osram Sylvania). Subsequently, the 
plates were stored under dim light (5 - 10 µmol/m2/s) at 20ºC. The C. reinhardtii 
strains were transferred to fresh plates every six to eight weeks (Harris 1989).  
 
Small liquid cultures (up to 50 ml) and pre-cultures were inoculated with a loop full of 
cells from plates, which had been freshly restreaked a few days before. The cultures 
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were grown in Erlenmeyer flasks (liquid medium to air ratio 1:5 or 1:4) in an 
illuminated incubator with a light intensity of 100 – 200 µmol/m2/s, at 120 rpm 
shaking and at a temperature of 25ºC. Larger cultures (100 – 1,000 ml) were 
inoculated from liquid mid-log phase pre-cultures with a 1% inoculum and grown 
under the same conditions. In larger scale C. reinhardtii was grown in the photo 
bioreactor system of Supreme Biotech Ltd. in 30 - 40 litre bags under constant 
bubbling with air at 25ºC. 
 
 
2.3.7.2 Synechocystis sp. PCC 6803 
 
The Synechocystis sp. PCC 6803 strains are listed in Table 2.1. The strains were 
maintained on BG11 agar plates. Cultures on solid medium were grown in an 
illuminated incubator with a light intensity of 30 - 50 µmol/m2/s at 30ºC and 
subsequently stored under dim light (5 - 10 µmol/m2/s) at 20ºC. The Synechocystis 
strains were transferred to fresh plates every three to four weeks.  
Liquid BG11 cultures were grown in Erlenmeyer flasks (liquid medium to air ratio 1:5 
or 1:4) in an illuminated incubator with a light intensity of 100 – 200 µmol/m2/s, at 
120 rpm shaking and at a temperature of 25ºC. Small flasks and pre-cultures were 
inoculated with a loop full of cells from agar plates, whereas larger cultures of more 
than 50 ml were inoculated from a pre-culture with a 1% inoculum.  
 
 
2.3.7.3 Escherichia coli 
 
E. coli cultures were grown on LB agar plates or in LB liquid medium under constant 
shaking at 37ºC. If necessary the appropriate antibiotics were added in the 
concentrations stated in 2.3.6. For long-term storage, E. coli strains were stored as 
25% (v/v) glycerol stocks. This was achieved by mixing equal volumes of grown 
bacterial cultures with 50% (v/v) sterile glycerol. The aliquots were snap frozen in 
liquid nitrogen and stored at -80°C.  
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2.3.7.4 Streptococcus pneumoniae and Streptococcus pyogenes 
 
S. pneumoniae and S. pyogenes were grown on Columbia blood agar plates (SIGMA) 
overnight at 35 ºC under anaerobic or aerobic conditions, respectively. Alternatively, 
liquid cultures were grown in trypticase soy broth overnight at 35ºC without shaking. 
Anaerobic conditions were generated using Oxoid AGS CO2Gen Compact gas packs 
and an anaerobic jar from Oxoid. For long-term storage of S. pneumoniae, cells were 
grown in STGG medium, snap frozen in liquid nitrogen and stored at -80°C (O’Brien 
et al. 2001). For long-term storage of S. pyogenes, glycerol stocks were prepared as 
described in 2.3.7.3.   
 
 
2.3.7.5 Staphylococcus aureus 
 
S. aureus was grown on Columbia blood agar plates overnight at 35 ºC. Liquid 
cultures were grown in ISO-Sensitest broth from Oxoid overnight at 35ºC with or 
without shaking. For long-term storage of S. aureus, glycerol stocks were prepared as 
described in 2.3.7.3.   
 
 
2.3.7.6 Propionibacterium acnes 
 
P. acnes was grown in liquid brain heart infusion medium at 30°C for five to seven 
days under anaerobic conditions. Alternatively, P. acnes was cultured on Columbia 
blood agar plates or brain heart infusion medium agar plates at 30 ºC under anaerobic 
conditions. For long-term storage of P. acnes, glycerol stocks were prepared as 
described in 2.3.7.3.   
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2.3.8  Growth measurements 
 
2.3.8.1 Chlamydomonas reinhardtii and Synechocystis sp. PCC 6803 
 
Growth of C. reinhardtii and Synechocystis was measured by recording the optical 
density at 750 nm with a Unicam UV/Vis Spectrometer (Thermo Electron 
Corporation, USA). Samples with an OD750nm over 0.8 were diluted with the adequate 
medium. Alternatively, growth of C. reinhardtii was determined by counting cells 
with a haemocytometer. Therefore 10 µl of iodine tincture (19.7 mM iodine in 95 % 
(v/v) ethanol) was added to 1 ml of cell culture before the measurement to inhibit cell 
motility.  
 
Furthermore the biomass of C. reinhardtii was analysed at several growth stages. 
Therefore 50 ml samples were taken and the cells were harvested by centrifugation at 
5,000 x g. Subsequently, the cell pellet was washed one time with distilled H2O. The 
cells were transferred to pre-weighed Eppendorf tubes and freeze-dried until the 
weight was constant. The dry weight in g/L of culture volume was calculated.  
 
 
2.3.8.2 Heterotrophic bacteria  
 
The growth of bacterial cultures was measured by recording the optical density at 600 
nm with a Unicam UV/Vis Spectrometer (Thermo Electron Corporation, USA). 
Samples with an OD600nm over 1.0 were diluted with the adequate medium. 
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2.4 Molecular genetic methods 
 
2.4.1 Polymerase chain reaction (PCR) 
 
In vitro gene amplification was carried out by the polymerase chain reaction (Mullis et 
al. 1992) using the Phusion polymerase (Fermentas or Thermo Scientific). The 
components and protocol of a 50 µl PCR reaction are listed in Table 2.7. 
 
Table 2.7: Components and protocol used for PCR reactions 
 
 
2.4.1.1 Oligonucleotide primers 
 
The primers used for polymerase chain reactions in this study are shown in Table 2.8. 
All primers were synthesised by Eurofins MWG (Ebersberg, Germany).  
 
 
Components Concentration 
HF buffer 1  x 
Template DNA 50 - 100 ng 
Primers 10  pmol each 
dNTPs 1  mM (250 µM each) 
Phusion polymerase 0.6  U 
ddH2O Add to a final volume of 50 µl 
  
Step Temperature Time 
Initial denaturation 98ºC 2 min 
 Denaturation 98ºC 10 sec 
25 – 30 x Annealing Tm + 3ºC of the lower primer Tm    30 sec 
 Elongation 72ºC ≈ 1 min/kb 
Final elongation 72ºC 10 min 
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Table 2.8: Oligonucleotide primers used in this study 
Primer name Sequence (5’ to 3’) Function 
FLANK1 GTCATTGCGAAAATACTG PCR screening for 
successful 
transformation of C. 
reinhardtii with the 
vectors pASapI (A) 
or pSRSapI (B) 
rbcL.Fn CGGATGTAACTCAATCGGTAG 
rbcL.R CAAACTTCACATGCAGCA 
atpA.R (A) ACGTCCACAGGCGTCGT 
RYpsa.R (B) GGATTTCTCCTTATAATAAC 
rbcL.R CAAACTTCACATGCAGCA Sequencing of 
pASapI (A) and 
pSRSapI (B) inserts 
atpA.F (A) CAAGTGATCTTACCACTCAC 
psa.F (B) GTTCACGCGTAAGCTTTCTTAATTCAACATTT 
Pal.F ATCTGCTCTTCTATGGGTGTTGATATTG 
Attachment of a His-
tag to pal and ϕ11 
ϕ11.F ACGTGCTCTTCTATGCAAGCTAAATTAAC 
Histag.R 
TGTTGCATGCTTATTAATGATGATGATGATGAT
GAGCGTAATCTGGAAC 
HAremoval.R 
ATGCATGCTTAAACTTTAGATGTAATTAAACC
ATCAGGTTC 
Removal of the HA-
tag together with 
Pal.Fw 
psbAII.F (A) CCCAGAACTATGGTAAAGGCG PCR screening and 
sequencing for the 
insertion of the GOI 
into pLAH.AII (A) 
and  pLAH.nrsB  (B) 
psbAII.R GGTCTGCCTCGTGAAGAAGGTGTT 
nrsBseq.F (B) CCGTCTCATCTTCCACCAGC 
Syn6803ϕ11.F 
AGCGATTAATGCAAGCTAAATTAACAAAAAAC
GAATTTATTG 
Insertion of ϕ11 into 
the vectors   
pLAH.AII and 
pLAH.nrsB 
Syn6803ϕ11.R 
TGATGGATCCTTATTAAGCGTAGTCTGGAACA
TCG 
Syn6803pal.F ATGCCATATGGGTGTTGATATTGAAAAAGGTG Insertion of pal into 
the vectors   
pLAH.AII and 
pLAH.nrsB 
Syn6803pal.R 
TGATGGATCCTTATTAAGCGTAATCTGGAACA
TCG 
Syn6803gp20.F GCATATTAATGGTTCGTTATATTCCAGCTGC 
Insertion of gp20 into 
the vectors   
pLAH.AII and 
pLAH.nrsB 
Syn6803gp201.R 
GCATGGATCCTTATTAAGCATAGTCAGGTACA
TCATA 
Syn6803gp202.R 
GCATGGATCCTTATTAAGCGTAATCTGGAACA
TCG 
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2.4.2 Agarose gel electrophoresis 
 
DNA fragments were separated on 1% (w/v) agarose gels made with 1x TAE buffer 
(40 mM Tris, 1 mM sodium EDTA, 17.5 mM glacial acetic) and 1 µg/ml ethidium 
bromide. The samples were mixed with 6x DNA Loading Dye (Fermentas) before 
loading onto the gel that had been submerged in 1x TAE buffer in an electrophoresis 
tank. The electrophoresis was performed at 85 V for 30 to 120 min. Subsequently, the 
DNA fragments were visualized using a UV transilluminator (UVP Gel 
Documentation System). The O'GeneRuler™ 1 kb Plus DNA Ladder (Fermentas) was 
used to estimate the size of the DNA fragments.   
 
 
2.4.3 Plasmid isolation  
 
Plasmid isolation was performed with the GENEJet Plasmid Miniprep Kit from 
Fermentas or the QIAprep Spin Midiprep Kit from Qiagen according to the 
manufacturer’s instructions for lower quantities of a plasmid (up to 20 µg). For the 
isolation of larger quantities (up to 200 µg) of plasmids the commercial QIAfilter 
Plasmid Midi Kit (Qiagen) was used according to the manufacturer’s instructions. 
 
 
2.4.4 DNA purification and gel extraction 
 
PCR products were purified using the QIAquick PCR purification Kit from Qiagen 
(Hilden, Germany) and Gel extraction of DNA bands was performed using the 
QIAquick Gel Extraction Kit from Qiagen. 
 
 
2.4.5 Restriction enzyme digests, dephosphorylation and ligations 
 
Restriction enzyme digests were performed using restriction endonuclease enzymes 
according to the manufacturer’s instructions from New England Biolabs (NEB) and 
Fermentas (Thermo Scientific), respectively. Ligations were performed using T4 
DNA ligase from NEB with 3 to 5 times more insert than vector according to the 
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manufacturer’s instructions. To avoid relegation of digested vectors in some cases the 
5’ phosphate was removed after the digest using Antarctic phosphatase (NEB) 
according to the manufacturer’s instructions. 
 
 
2.4.6 DNA sequencing 
 
DNA sequencing of plasmids and PCR products was performed using the Scientific 
Support Services of The Wolfson Institute for Biomedical Research, University 
College London. The sequencing results were aligned and analysed using MacVector 
12.6.0.  
 
 
2.4.7 Preparing competent E. coli cells 
 
LB medium (10 ml) was inoculated with a single E. coli colony from an overnight 
culture on solid LB medium and grown under constant shaking at 37ºC overnight. 
Fresh LB medium (100 ml) was inoculated with 1% of the overnight culture and 
grown for 2.5 h under constant shaking at 37ºC to an OD600nm of 0.3 to 0.6. The cells 
were pelleted in precooled tubes by centrifugation at 3,000 x g for 5 minutes. 
Subsequently, each cell pellet derived from 25 ml culture was resuspended in 10 ml of 
50 mM CaCl2 and incubated for 30 minutes on ice. Cell were pelleted by 
centrifugation as described above and resuspended in 1.5 ml of fresh 50 mM CaCl2. 
Sterile glycerol was added to a final concentration of 15% before the competent cells 
were aliquoted and frozen at -80ºC. 
 
 
2.4.8 Transformation of competent E. coli cells by heat-shock 
 
An aliquot with 100 µl of competent E. coli cells were thawed and 1 µl of a plasmid 
preparation or 20 µl of a ligation product was added to the cells. The mixture was 
incubated for 30 minutes on ice before exposure to 42ºC for one minute. The 
transformed cells were added to 1 ml of LB medium and incubated at 37ºC for 1 h 
under continuous shaking. After incubation different volumes were platted on LB 
plates containing the appropriate antibiotic.  
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2.4.9 Transformation of the C. reinhardtii chloroplast 
 
2.4.9.1 The transformation system 
 
The vectors pASapI (Economou et al. 2014) and pSRSapI (Young & Purton 2014) 
carry the photosystem II gene psbH, whereas in the recipient strain TN72 of the 
chloroplast transformation psbH is partly replaced by an aadA cassette (Figure 2.1). 
Since psbH is essential for phototrophic growth, only cells of the recipient strain that 
restore psbH through homologous recombination with the DNA on the vector are able 
to grow phototrophically. Successful transformants can be therefore selected for 
restoration of phototrophic growth on minimal medium.  
 
 
 
 
Figure 2.1: Chloroplast transformation system with the vectors pASapI and pSRSapI and the 
recipient strains TN72.  
Homologous recombination (grey crosses) between chloroplast sequences (thick black lines) on the 
vectors and the plastome of the recipient strain (TN72) allows the restoration of psbH, which is 
necessary for phototrophic growth, combined with the introduction of the expression cassette including 
the gene of interest (GOI). Endogenous chloroplast genes are indicated in green, 
promoter/5’untranslated regions in blue and the GOI in yellow 
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The insertion site (SapI – SphI) for the gene of interest (GOI) on pASapI and pSRSapI 
is located directly downstream of psbH and therefore restoration of psbH by 
homologous recombination results also in the transfer of the GOI into a neutral region 
downstream of psbH. Furthermore, the insertion site is flanked by an expression 
cassette consisting of the promoter/5’untranslated region (UTR) of the endogenous 
chloroplast gene atpA in pASapI and psaA exon 1 in pSRSapI. Both vectors carry the 
3’UTR of the chloroplast rbcL gene for the expression of the GOI (Figure 2.1). 
 
 
2.4.9.2 Transformation of the C. reinhardtii chloroplast by agitation in the 
presence of glass beads 
 
A liquid culture of the C. reinhardtii recipient strain TN72 was grown to mid-log 
phase (1 – 2 x 106 cells/ml) in TAP medium under continuous illumination. Cells were 
pelleted by centrifugation at 8,000 x g for eight minutes and the pellet was 
resuspended in fresh TAP medium to a concentration of 2 x 108 cells/ml. Sterile test 
tubes containing about 0.3 g of 0.4 mm diameter glass beads were filled with 300 µl 
of the previously prepared cell suspension and 2 – 20 µg of plasmid DNA. The test 
tubes were vortexed for 15 sec each using a Vortex genie-2 (Scientific industries). 
Top agar (TAP or HSM + 0.5% agar) was melted and cooled down to 42ºC before 3.5 
ml of the agar were added to the test tubes. Cell suspension and top agar were mixed 
and instantly platted onto HSM plates. The plates were left for 1 h in the dark and 12 h 
in dim light before they were placed in bright light. Transformant colonies appeared 2 
– 4 weeks later.  
 
 
2.4.9.3 Isolation of DNA from C. reinhardtii 
 
To confirm that the gene of interest had been correctly inserted into the C. reinhardtii 
plastome or to sequence the transgenic lines, DNA was extracted by resuspending a 
loop full of cells from an agar plate in 20 µl of sterile ddH2O, followed by the addition 
of 20 µl ethanol (100%) and 200 µl of chelex (5%, w/v). The mixture was incubated at 
98ºC for 10 minutes and centrifuged at 21,000 x g for 10 minutes at room 
temperature. Subsequently, 2 µl of the supernatants were used in 50 µl PCR reactions.  
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2.4.10 Transformation of Synechocystis sp. PCC 6803 
 
The transformation method used was adapted from (Williams 1988) by (Al-Haj 2014). 
Liquid BG11 medium (50 ml) was inoculated with a loopful of Synechocystis cells 
from a freshly restreaked plate and allowed to grow in an illuminated shaking 
incubator at 25ºC and a light intensity of 50 - 100 µmol/m2/s for four days. The 
cultures were grown to an OD750nm of 0.4 – 0.8 and the concentration (cells/ml) was 
calculated by multiplying the OD750nm value obtained by 1.15 x 108 (Bishop 2002). 
Subsequently, the culture was harvested by centrifugation at 3,000 x g for 10 minutes 
and washed in 2 ml of fresh BG11 medium and spun down a second time. The cell 
pellet was resuspended in BG11 medium to a final concentration of 4 x 108 cells/ml. 
In duplicates, 1-5 µg of the vector DNA was added to 200 µl of the cell suspension 
and incubated at 30ºC for 4-6 hours. The cells were spread onto BG11 plates, allowed 
to dry, and then incubated for 2-3 days to allow expression of the introduced 
resistance marker. Subsequently, the plates were overlaid with 3 ml of 0.6% (w/v) 
agar containing kanamycin to give a final concentration of 200 µg/ml in the plates. 
The plates were incubated for approximately two weeks in a light intensity of ~40 
µmol/ m2/s at 30ºC and were then examined for the presence of putative transformant 
colonies. The colonies were restreaked three times to reached homoplasmicity before 
the insertion of the GOI was analysed by PCR. 
 
 
2.4.10.1 Isolation of DNA from Synechocystis sp. PCC 6803 
 
To confirm that the gene of interest had been inserted into Synechocystis sp. PCC 
6803 or to sequence the transgenic lines, DNA was extracted using the chelex-based 
method adapted from (Werner & Mergenhagen 1998). A loop full of cells from an 
agar plate was resuspended in 20 µl of sterile ddH2O, followed by the addition of 20 
µl ethanol (100%) and 200 µl of chelex (5%, w/v). The mixture was incubated at 98ºC 
for five minutes and centrifuged at 21,000 x g for two minutes at room temperature. 
Subsequently, 2 µl of the supernatants were used in 50 µl PCR reactions.  
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2.4.11 Bioinformatics 
 
For the alignments of DNA and protein sequences, virtual restriction enzyme digests, 
reverse complementation of DNA sequences and translation of DNA sequences the 
software MacVector 12.6.0 was used. Furthermore, the following free online 
molecular analysis tools and databases were used in this study.  
 
 
Table 2.9: Databases and websites used in this study 
 
Protein and DNA sequence databases 
UniProtKB/Swiss-Prot http://www.uniprot.org 
NCBI http://www.ncbi.nlm.nih.gov 
C. reinhardtii chloroplast genome http://www.chlamy.org/chloro/default.html 
  
Bioinformatics tools 
Reverse complementation http://www.bioinformatics.org/sms/rev_comp.html 
Primer design http://www.bioinformatics.org/sms2/ 
Restriction digest http://tools.neb.com/NEBcutter2/ 
Conversion tool http://www.attotron.com/cybertory/analysis/trans.htm 
Sequence alignment http://www.ebi.ac.uk/Tools/msa/clustalw2/ 
Protein and nucleotide BLAST http://blast.ncbi.nlm.nih.gov/Blast.cgi 
  
Endolysin database  
phiBIOTICS http://www.phibiotics.org 
  
Codon usage database  
Nakamura et al. 2000 http://www.kazusa.or.jp/codon/ 
  
Culture conditions of microorganisms 
DSMZ http://www.dsmz.de 
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2.5 Protein analysis 
 
2.5.1 Protein concentration assay 
 
Protein concentrations were determined with the Bio-Rad protein assay, based on the 
method of Bradford, using the microassay procedure for 96-well microtitre plates. The 
standards (25, 50, 100, 200, 300, 400, 500 µg/ml) and samples were measured in 
triplicates. The assay was performed by mixing 160 µl of each standard or sample 
with 40 µl of Bio-Rad protein assay dye reagent concentrate, followed by incubation 
at room temperature for 10 minutes. Subsequently, the absorbance was measured at 
595 nm.  
 
 
 
 
Figure 2.2: BSA standard curve for Bio-Rad protein assay 
Calibration curve for the Bradford assay created using bovine serum albumin (BSA) at concentrations 
ranging from 25-500 µg/ml assayed at 595 nm. The error bars show ± one standard deviation (n = 3). 
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2.5.2 Sodium dodecyl sulphate polyacrylamide gels (SDS-PAGE) 
 
SDS-PAGE was carried out using a Protein gel tank system from Biorad holding 80 x 
83 x 1 mm gels with 10 wells. The gels were prepared based on the Laemmli gel 
recipe (Laemmli 1970) stated in table 2.10 with a lower 15% resolving gel and an 
upper 3.75% stacking gel. Samples were prepared in Solution A or by the addition of 
4x protein gel sample loading buffer (Table 2.10), boiled at 99ºC for three minutes 
and centrifuged at 21,000 x g for 20 minutes before they were loaded onto the gel. 
The gels were run in reservoir buffer at 120V for 120 minutes. To visualize all 
proteins in the gel or to check if the western blotting was successful the gel was 
stained with Coomassie staining solution (Table 2.12) for one hour at room 
temperature and destained in destaining solution for at least two hours. Subsequently, 
the gel was scanned using the Odyssey® imaging system from LI-COR. 
 
 
Table 2.10: Buffers and solutions used for SDS-PAGE performance 
Protein gel sample loading buffer (4x)   
Tris-HCl pH 6.8 50 mM 
SDS 2 % 
Glycerol 10 % 
β-Mercaptoethanol 1 % 
EDTA (Ethylenediaminetetraacetic acid) 12.5 mM 
Bromophenol blue 0.02 % 
   
Solution A   
Tris-HCl pH 8.3 0.8 M 
Sorbitol 0.2 M 
β-Mercaptoethanol 1 % 
SDS 1 % 
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Table 2.11: Laemmli gel recipe, buffers and solutions used during SDS-PAGE performance 
 
 
 
 
 
15% Resolving gel (40 ml) Volume in 40 ml 
 
Acrylamide/bisacrylamide (Sigma) 
40% stock, acrylamide:bisacrylamide = 37:1 
 
 
15  
 
ml 
Resolving buffer (8x stock) 
0.25M Tris, 1.92M glycine, 1% SDS, pH8.3 
 
5  ml 
10% SDS 0.4  ml 
Distilled H2O 18  ml 
10% ammonium persulphate (AMPS) 1.5  ml 
Tetramethylethylenediamine (TEMED) 15  µl 
   
3.75% Stacking gel (20 ml) Volume in 20 ml 
Acrylamide/bisacrylamide (Sigma) 
40% stock, acrylamide:bisacrylamide = 37:1 1.88  ml 
Stacking buffer (4x stock) 
0.5M Tris-HCl (pH 6.8) 5  ml 
10% SDS 0.2  ml 
Distilled H2O 12  ml 
10% ammonium persulphate (AMPS) 1.5  ml 
Tetramethylethylenediamine (TEMED) 15  µl 
   
Reservoir buffer (10 x)  
Tris 0.25  M 
Glycine 1.92 M 
SDS 1 % 
The pH was adjusted to 8.3.   
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Table 2.12: Coomassie staining and destaining solutions 
 
 
2.5.3 Western blot analysis (semi-dry) 
 
After electrophoresis, the gel was soaked in Towbin buffer together with 8 pieces of 
3MM Whatman paper and an AmershamTM HybondTM-ECL nitrocellulose membrane 
(GE Healthcare), all of the same size as the gel, for about 20 minutes. For the transfer 
a sandwich was assembled in the following order from the anode side: 4 pieces of 
3MM Whatman paper, the nitrocellulose membrane, the gel, and another 4 pieces of 
Whatman paper on top. The transfer was performed at a voltage of 20 V for 
approximately one hour using a Trans-Blot SD semi-dry electrophoretic transfer cell 
from Biorad.  
 
 
2.5.3.1 Immuno-detection 
 
The membrane was subsequently blocked in blocking buffer under gently shaking at 
room temperature for one hour or at 4ºC overnight. After a quick rinse with TBS-T, 
the membrane was incubated with the primary antibody (all antibodies are stated in 
Table 2.15) in blocking buffer at room temperature for 1 – 3 hours under gently 
shaking. Afterwards the membrane was quickly rinsed and then washed for 5 – 10 
Coomassie Blue R staining solution   
Coomassie Brilliant Blue R  3 mM 
Methanol 50 % (v/v) 
Acetic acid 10 % (v/v) 
   
Destaining solution   
Methanol 40 % (v/v) 
Acetic acid 10 % (v/v) 
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minutes under vigorous shaking with TBS-T. The washes were repeated three times, 
before the secondary antibody in blocking buffer was applied for one hour, followed 
by three more washes. In experiments where horseradish peroxidase-linked secondary 
(ECL) antibodies were used, the membrane was first incubated with SuperSignal® 
West Pico Chemiluminescence Substrate (Thermo Scientific) for five minutes at room 
temperature. Subsequently, the membrane was exposed to a sheet of Hyperfilm ECL 
(GE Healthcare) in the dark room. The film was developed using a Xograph automatic 
film developer. The exposure time varied between 10 seconds and 20 minutes 
depending on the strength of the signal.  
 
For quantitative western blot analysis IRDye® secondary antibodies (DylightTM 800) 
were used and the infrared fluorescence signal (IR signal) was excited at 785 nm and 
detected using the Odyssey® Infrared Imaging system (Li-COR Biosciences). 
 
 
Table 2.13: Buffers and solutions used in western blot analysis 
Towbin buffer   
Tris  25 mM 
Glycine 192 mM 
Methanol 20 % (v/v) 
   
TBS-T   
TBS buffer   
Tris base 20 mM 
NaCl 137 mM 
HCl pH 7.4 1 M 
Tween-20 0.1 % 
   
Blocking buffer   
TBS-T    
Skimmed milk 0.5 - 5 % 
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2.5.3.2 Quantification of western blot analysis  
 
The infrared fluorescent signals of the bands in the western blot analysis measured 
using the Odyssey® Infrared Imaging system were analysed using the Image Studio 
Software 3.1.4 from LI-COR Biosciences for most analysis. For a few earlier analysis 
shown in this study the Odyssey® Infrared Imaging system application software 3.0 
was used. Both programs express the signal in different value dimensions. The newer 
software expresses the signal in values of several millions, whereas the older software 
states values between 0.01 and 200.   
 
To quantify the signal using the Image Studio Software, rectangles were drawn around 
each band to define the area for quantification. The program automatically subtracts a 
background value from the signal, which is determined as the median of the signal 
measured in an area of 2 pixels above and below the rectangle. LI-COR states that its 
system can be used to directly detect the amount of antigen in western blot analysis 
over a wide range of quantities (www.licor.com). The determination of the linear 
range for HA-tagged proteins in crude extracts is described in 3.2.4.  
 
The Odyssey® Infrared Imaging system and the Image Studio Software can be 
therefore used to compare the amount of the protein of interest between samples of 
one performance. Quantifications were always performed with samples on the same 
gel and membrane, since gel to gel (and membrane to membrane) differences in the IR 
fluorescence signal can occur (Thomson et al. 2011). When more than nine samples 
were compared, which exceeded the capacity of one gel, the gels were run in parallel 
and were blotted at the same time onto nitrocellulose membranes. All further steps 
were performed under the same conditions and the membranes were scanned in the 
Odyssey® system at the same time, which greatly minimised variations between 
samples on different gels. In figures that show comparisons between samples from 
different gels and membranes, the borders of the membranes are indicated by black 
boxes.   
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2.5.4 Protein microarray 
 
Western blot analysis of Pal with anti-HA antibodies resulted in clean blots with a 
single band at the size of Pal, which enabled immuno-detection using protein 
microarrays without separation on a SDS-PAGE. Chlorophyll causes a strong 
background when the Odyssey® Infrared Imaging system is used for detection.  
Protein microarrays were therefore only performed with samples that contained hardly 
any chlorophyll (after ultracentrifugation). The advantage is that a higher number of 
samples can be analysed in a single experiment compared to a western blot analysis. 
 
For the performance of protein microarrays, 2 µl of the samples (ultracentrifugation 
supernatant, elutions and washes) were directly spotted onto a nitrocellulose 
membrane. The membrane was allowed to dry for 30 minutes before blocking at 4ºC 
overnight. Subsequently, the nitrocellulose membrane was treated as described in 
2.5.3.1. The detection and quantification of the spots was in all cases performed using 
the Odyssey® Infrared Imaging system (Li-COR Biosciences). The IR signal was 
analysed using the Image Studio Software version 3.1.4 from LI-COR Biosciences as 
described in 2.5.3.2. 
 
 
2.5.5 Enzyme-linked immunosorbent assay (ELISA)  
 
For the performance of ELISA assays, a 96-well microtitre plate was coated with 50 
µl of sample or serial dilutions of the sample and incubated at 37ºC for two hours or at 
4ºC overnight. Afterwards the plate was washed three times with distilled H2O 
containing 0.1 % (w/v) Tween 20. The wells were blocked with 350 µl of ELISA 
blocking buffer for 1.5 hours at 37ºC or at 4ºC overnight, followed by three washes 
with distilled H2O. Subsequently, the wells were filled with 50 µl of the primary 
antibody (Table 2.15) in blocking buffer and incubated for two to three hours at 37ºC, 
followed by three washes with distilled H2O containing 0.1 % Tween 20. The 
secondary antibody (ECL anti-rabbit) was applied in blocking buffer (50 µl in each 
well) for two hours at 37ºC. After the incubation the wells were washed with distilled 
H2O containing 0.1 % Tween 20. To develop the reaction 100 µl of development 
  CHAPTER 2 – MATERIALS & METHODS 
 
 98 
solution were filled in each well and the plate was incubated at room temperature until 
a stable blue colour appeared. The reaction was stopped by the addition of 50 µl 0.5 M 
H2SO4 in each well. Subsequently, the absorbance was measured at 450 nm. 
 
 
Table 2.14: Buffers and solutions used in ELISA analyses 
 
 
PBS-T   
PBS buffer   
KCl 2.7 mM 
NaCl 137 mM 
Na2HPO4 • 2H2O 10 mM 
KH2PO4 2 mM 
Tween-20 0.1 % 
   
ELISA blocking buffer   
PBS    
BSA 2.5 % 
   
Development solution (10 ml)   
H2O 5 ml 
0.2 M Na2HPO4 2.5  ml 
0.1 M citric acid 2.5  ml 
Tetramethylbenzidine 1 tablet 
H2O2 (added just before loading) 10 µl 
   
Stopping solution   
H2SO4 0.5 M 
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2.5.6 Antibodies 
 
2.5.6.1 Custom made anti-Pal antibodies 
 
To be able to detect untagged Pal, the company Eurogentec (Belgium) was 
commissioned to raise Pal-specific antibodies from synthetic peptides in rabbits. First, 
two peptide sequences of 17 amino acids with a predicted high immunogenicity were 
chosen within the Pal sequence (Figure 2.3). Subsequently, the peptides were 
synthesised and attached to keyhole limpet hemocyanin (KLH) carrier protein. Two 
rabbits were injected four times with the peptides in intervals of three to seven days. 
Preimmune bleeds, medium bleeds and final bleeds were taken. The final bleed was 
confirmed to contain antibodies against Pal and used for western blot analyses.  
 
 
 
 
Figure 2.3: Protein sequence of Pal with the peptide sequences used to raise custom made anti-
Pal antibodies 
The two peptide sequences highlighted in red and blue with a predicted high immunogenicity were 
chosen to raise custom made antibodies in rabbits by the company Eurogentec (Belgium). A cysteine 
was added to the N-terminus of peptide 2 to target the coupling site on the keyhole limpet hemocyanin 
(KLH) carrier protein. 
 
 
 
 
 
MGVDIEKGVAWMQARKGRVSYSMDFRDGPDSYDCSSSMYYALRSAGASSAG
WAVNTEYMHAWLIENGYELISENAPWDAKRGDIFIWGRKGASAGAGGHTGM
FIDSDNIIHCNYAYDGISVNDHDERWYYAGQPYYYVYRLTNANAQPAEKKL
GWQKDATGFWYARANGTYPKDEFEYIEENKSWFYFDDQGYMLAEKWLKHTD
GNWYWFDRDGYMATSWKRIGESWYYFNRDGSMVTGWIKYYDNWYYCDATNG
DMKSNAFIRYNDGWYLLLPDGRLADKPQFTVEPDGLITAKV!
!
Peptide 1: C+ LADKPQFTVEPDGLIT !
Peptide 2: SMDFRDGPDSYDCSSS!
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2.5.6.2 Antibodies used in this study  
 
 
Table 2.15: Antibodies used in this study 
 
 
 
 
 
 
 
 
  
Antibodies Source Dilution 
Primary antibodies   
Anti-HA (polyclonal, produced in rabbit) Sigma-Aldrich 1:2,000 (Western blot) 
1:750 (ELISA) 
 
Anti-Pal (polyclonal, produced in rabbit) Eurogentec 1:2,000 (Western blot) 
1: 100 to 1:12,500 (ELISA) 
 
Anti-D1 (polyclonal, produced in rabbit) Gift from P. Nixon, 
Imperial College 
London, UK 
 
1:2,000 (Western blot) 
Anti-rbcL (polyclonal, produced in rabbit) 
 
Gift from J. Gray, 
University of 
Cambridge, UK 
1:20,000 (Western blot) 
 
   
Secondary antibodies   
ECL anti-rabbit IgG, horseradish 
peroxidase-linked species-specific whole 
antibody (from donkey) 
GE Healthcare 1:10,000 (Western) 
1:1,000 (Anti-HA ELISA) 
1:5,000 (Anti-Pal ELISA) 
Anti-rabbit IgG (H&L), DylightTM 800 
conjugated (from goat) 
Thermo Scientific 
 
1:20,000 
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2.6 Protein purification methods 
 
2.6.1 Preparation of crude extract and soluble protein extract 
 
C. reinhardtii cultures were grown to an OD750nm of 2 to 3 and harvested by 
centrifugation at 8,000 x g for 10 minutes or using a cream separator (Motor Sich, 
Ukraine) (for 30 litre cultures). The cell pellet was resuspended in 20 mM NaPi-buffer 
(NaH2PO4, the pH was adjusted to 6.9 with NaOH) to a concentration of 100 times the 
culture volume. In some cases protease inhibitor (Roche cOmplete, EDTA-free) was 
added to the cell suspension. Subsequently, the cells were broken by three cycles of 
freezing in liquid nitrogen and thawing at 37ºC, followed by vortexing for 10 seconds. 
The broken cell suspension was centrifuged at 21,000 x g for five minutes (or 3,000 x 
g for 20 minutes for volumes above 2 ml) and the supernatant was recovered and is 
referred to as crude extract in this study. To remove further cell debris, membranes 
and non-soluble proteins and gain a soluble protein extract the crude extract was 
centrifuged at 100,000 x g for one hour in an ultracentrifuge. 
 
 
2.6.2 Ammonium sulphate precipitation 
 
The samples (soluble protein extract or combined DEAE cellulose elution fractions) 
were stirred on ice and grounded ammonium sulphate was slowly added to it until the 
desired percentage of ammonium sulphate saturation was reached. The stirring was 
continued for 30 minutes before the solution was centrifuged at 3,000 x g for 30 
minutes. The pellet was resuspended in a smaller volume of 20 mM NaPi-buffer and 
used for further analyses. The supernatant was treated stepwise with higher 
concentrations of ammonium sulphate in the same way as described above. 
 
 
2.6.3 Purification with anti-HA (influenza haemagglutinin peptide) resin 
 
HA resin (100 – 200 µl) was incubated with 500 – 800 µl of the sample for 4 to 18 h 
at 4ºC on a rotating incubator. The tube was gently centrifuged 3 times to allow the 
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resin to settle down before the flow through of the sample was removed. 
Subsequently, the resin was washed five times with 1 ml NaPi-buffer. The HA tagged 
protein was eluted from the resin by incubation with 300 – 500 µl 0.1 M Glycine-HCl 
buffer (pH 2.5) for two minutes and immediately neutralized with 1 M Tris-HCl 
buffer (pH 8.0). Alternatively, the resin was eluted by incubation with 100 µg/ml HA 
peptide for 10 minutes.    
 
 
2.6.4 Purification with diethylethanolamine (DEAE) cellulose  
 
The purification of Pal with DEAE cellulose was for a first test performed in 
Eppendorf tubes with 100 to 300 µl of resin and subsequently in columns with 10 – 50 
ml resin. In Eppendorf tubes the resin was incubated with the sample for one to two 
hours at room temperature on a rotating incubator and then washed with 1 ml each of 
wash buffer 1, 2 and 3. Pal was eluted with 100 – 300 µl of choline containing elution 
buffer.  
When columns were used, the samples (soluble protein extracts of TN72_SR_pal-HA 
or TN72_SR_cpl-1-HA) were applied to the column using a peristaltic pump with a 
flow rate of 2 ml/min and the application of the sample was repeated two to three 
times. The resin was washed with six column volumes of wash buffer 1, eight 
volumes of wash buffer 2 and four volumes of wash buffer 3. Pal and Cpl-1 were 
eluted with two column volumes of elution buffer and 1 – 1.5 ml fractions of the 
elution were collected. The amount of Pal or Cpl-1 in the wash and elution fractions 
was analysed in a protein microarray as described in 2.5.4. Subsequently, the elution 
fractions with the highest amount of Pal or Cpl-1 were combined and dialysed using 
Slide-A-Lyzer G2 dialysis cassettes (Thermo Scientific) with a MWCO of 20,000. 
The combined and dialysed elution was concentrated using either Vivaspin 6 
centrifugal concentrators (Sartorius Stedim Biotech) with a MWCO of 30,000 or by 
ammonium sulphate precipitation (2.6.2). 
 
 
 
 
  CHAPTER 2 – MATERIALS & METHODS 
 
 103 
Table 2.16: Buffers and solutions used for the purification of Pal and Cpl-1 with DEAE cellulose 
 
 
 
 
 
 
 
 
 
 
 
 
Wash buffer 1   
NaPi-buffer (pH 6.9) 20 mM 
   
Wash buffer 2   
NaPi-buffer (pH 6.9) 20 mM 
NaCl 1.5 M 
   
Wash buffer 3   
NaPi-buffer (pH 6.9) 20 mM 
NaCl 0.1 M 
   
Elution buffer   
NaPi-buffer (pH 6.9) 20 mM 
NaCl 0.1 M 
Choline 6.5 % (w/v) 
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2.7 Antibacterial activity assays 
 
2.7.1 Spot tests 
 
A liquid culture of the target bacterium was grown overnight and 200 µl of the culture 
were spread onto Columbia blood agar plates or other appropriate nutrient agar plates. 
Subsequently, the plates were dried for five to ten minutes before 20 - 50 µl of each 
sample (C. reinhardtii crude extracts containing an endolysin and control extracts) 
were spotted onto the plates. The plates were incubated overnight regarding to the 
growth conditions of the target bacterium and inspected for inhibition zones on the 
next morning. 
 
 
2.7.2 Counting colony forming units (cfu) 
 
Cells from a liquid culture of the target bacterium were mixed with endolysin 
containing samples and control samples (crude extracts or purified endolysins) and 
incubated for 10 to 60 minutes. Subsequently, the mixture was diluted in serial 10 fold 
dilution steps before 20 µl of the dilutions were spotted on appropriate nutrient agar 
plates and incubated overnight regarding to the growth conditions of the target 
bacterium. On the next morning the colonies in each spot were counted and the colony 
forming units per ml of cell suspension were calculated. Furthermore, the differences 
in cfu between the endolysin treated and the control samples were calculated.  
 
Alternatively, samples that had been first analysed in a TRA to follow the lysis of the 
target bacterium were used for the cfu assay. As soon as the decrease in OD750nm in 
the presence of the endolysin had plateaued in the TRA, the mixtures of bacterial 
suspension and endolysin containing sample as well as the control assays were diluted 
and spotted on the agar plates as described above.  
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2.7.3 Turbidity reduction assays (TRAs) 
 
A culture of the target bacterium of interest was grown according to the growth 
conditions described in 2.3. S. pneumoniae cultures were grown overnight, 
subcultured the next morning and grown for another six hours to ensure that the 
culture had not reached the stationary phase before the start of the assay. 
Subsequently, the cultures were harvested and the cells were resuspended in 20 mM 
NaPi-buffer. The TRAs were first performed in 1 ml cuvettes and the OD was 
measured at 600 nm manually over a times course. Subsequently, the TRAs were 
performed in 96-well microtitre plates with a final assay volume of 200 µl. An ELx 
808 microplate reader (BIO-TEK INSTRUMENTS INC.) was used to measure the 
OD at 595 nm automatically every two minutes over times courses of 60 to 500 
minutes at 37ºC. The start OD595 or 600 nm values of the bacterial suspensions were 0.1 
to 1.0 depending on the assay. The assays were started by the addition of the 
endolysin containing samples and corresponding control samples. Most TRAs were 
performed by adding 20 µl of the endolysin or control preparation to 180 µl of 
suspension of the target bacterium.  
 
 
2.7.3.1 Endolysin preparations used in the TRAs 
 
C. reinhardtii samples containing endolysins used in the TRAs were prepared as 
described in 2.6.1 or 2.6.4. Synechocystis-produced endolysin samples were prepared 
by breaking Synechocystis cells by vortexing in the presence of glass beads (212 - 300 
µm) for two minutes followed by two minutes on ice for five cycles. Subsequently, 
the supernatant was separated from the cell debris by centrifugation (21,000 x g for 
five minutes) and used in the TRAs. 
 
E. coli-produced endolysin samples were prepared by breaking the cells with a French 
Pressure cell press at 10,000 psi for two cycles. The cell debris was pelleted by 
centrifugation at 5,000 x g for 20 minutes or 21,000 x g for five minutes. The 
supernatant was used in the TRAs. 
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3 Synthesis of the Streptococcus pneumoniae specific 
endolysin Pal in the chloroplast of C. reinhardtii   
 
3.1 Introduction 
 
3.1.1 The S. pneumoniae specific endolysin Pal  
 
Pal is an endolysin encoded by the lytic bacteriophage Dp-1 of S. pneumoniae. Dp-1 
is part of the Siphoviridae, a family of DNA viruses with a non-enveloped head and a 
flexible and non-contractile tail and has a genome that consists of a 57 kb double-
stranded DNA (López et al. 1992). Dp-1 was the first described bacteriophage of S. 
pneumoniae (López et al. 1977) and Pal was the first pneumococcal phage-encoded 
endolysin to be purified and described (Garcia et al. 1983a). Pal was named in this 
study and stands for “phage-associated lytic activity” (Garcia et al. 1983a). Garcia et 
al. also biochemically characterized it as an amidase that requires choline for full 
biochemical activity (Garcia et al. 1983a; Garcia et al. 1983b). Sheehan et al. (1997) 
localized and characterized the gene coding for Pal and were the first to express it in 
Escherichia coli.  
 
Pal has a two-domain structure with an N-terminal catalytic domain that exhibits N-
acetyl-muramoyl-L-alanine amidase activity and has a high similarity (41.9% identity) 
to the N-terminal region of a protein (orf259) from the lactococcal bacteriophage 
BK5-T (Sheehan et al. 1997) (Figure 3.1). It cleaves the peptidoglycan of the S. 
pneumoniae cell wall between the L-alanine of the peptide chain and the N-acetyl-
muramic acid of the sugar strand (Figure 3.2). The C-terminal binding domain binds 
specifically to choline in the teichoic acids of the cell wall and consists of six repeats 
of about 20 amino acids and a short C-terminal tail. This domain shows a high 
similarity to the choline-binding domains of several pneumococcal and clostridial 
proteins, and the highest similarity to the choline-binding domain of the major 
autolysin of S. pneumoniae LytA (64.6% identity, S. pneumoniae wild-type strain R6) 
(Figure 3.1). Sheehan et al. (1997) describe Pal therefore as the first example of a 
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natural chimeric enzyme of intergeneric origin and see it as a well-characterised 
support for the theory of the modular evolution of proteins. 
 
Sheehan et al. presume that the open reading frame (ORF) just upstream of the pal 
gene on the Dp-1 genome, which shares a stop and start codon with pal (TAATG) 
encodes for the holin protein of the lytic system. This orf encodes a protein with two 
predicted membrane-spanning helical domains and a highly charged C-terminal tail, 
which resembles the protein structure of the Ejh holin of the pneumococcal phage    
EJ-1 (Díaz et al. 1996).  
 
Pal requires choline-containing cell walls or in vitro incubation in the presence of free 
choline to become fully active and is for example unable to degrade cell walls, in 
which choline has been replaced by ethanolamine (Garcia et al. 1983a; Sheehan et al. 
1997). Choline binding strongly stabilises the cell wall binding domain and causes a 
conformational change that transmits the stabilisation to the catalytic domain. This 
“conversion” is most likely responsible for the full activation of Pal by choline 
binding (Varea et al. 2004). The two domains of Pal interact as cooperative, 
interdependent units and their denaturation happens as a single process. Varea et al. 
predicts two to three choline binding sites per Pal monomer, which are located at the 
interface of two consecutive repeats of the cell wall binding domain. The activity of 
Pal is inhibited by higher concentrations of free choline and has an IC50 (50% 
inhibitory concentration) of 2 mM choline.  
 
Furthermore, Varea et al. (2004) predicted the secondary structure of Pal using 
spectroscopic techniques and prediction methods. The catalytic domain is predicted to 
have a αβα2β6 structure, in which the single elements are connected by long loops. 
The six repeats of the cell wall binding domain are predicted to contain each one β–
hairpin followed by a coiled region.  
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Figure 3.1: Modular organisation of the endolysin Pal 
Pal consist of a N-terminal catalytic domain with N-acetyl-muramoyl-L-alanine amidase activity, 
which has a high sequence similarity to the lactococcal BK5-T open reading frame 259, and a C-
terminal cell wall binding domain, which has a high similarity to the one of the major autolysin of S. 
pneumoniae LytA. The cell wall binding domain consists of six repeats and binds to choline of the 
teichoic acids of the pneumococcal cell wall. 
 
 
 
 
 
Figure removed 
 
 
 
 
 
 
 
Figure 3.2: Cleaving site of the S. pneumoniae specific endolysin Pal 
The endolysin Pal is produced in the cytoplasm of S. pneumoniae cells infected with the bacteriophage 
Dp-1. At the end of the lytic cycle holin proteins are inserted into the cytoplasmic membrane, which 
results in pores (A). Pal can get through these pores to the cell wall, where it cleaves the peptidoglycan 
between the L-alanine of the peptide chain and the N-acetyl-muramic acid of the sugar strand (B). B 
shows streptococcal peptidoglycan (type A3α). CCWP = carbohydrate cell wall polymer, LU = linkage 
unit, P = phosphate group, MurNAc = N-acetyl-muramic acid, GlcNAc = N-acetyl-glucosamine acid, 
Ala = alanine, Glu = glutamic acid, Lys = lysine. Modified from Loessner (2005). 
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Besides expression in E. coli, Pal has been successfully expressed in active from in 
tobacco (Nicotiana tabacum cv. Petite Havana) chloroplasts, where it accumulated to 
up to 30% of the plants total soluble protein (Oey et al. 2009b). Oey et al. reported 
that cloning of Pal into their standard tobacco chloroplast expression vector in 
Escherichia coli was unsuccessful. They speculated that this was due to toxicity of Pal 
for E. coli. The same results were reported for the S. pneumoniae specific endolysin 
Cpl-1. Therefore a toxin shuttle vector was created in this study, which is based on 
premature transcription termination in E. coli using transcriptional terminator 
sequences that are specific for bacteria. This vector showed strongly decreased 
expression of the fluorescent protein GFP in E. coli and made it possible to clone pal 
and cpl-1 into the expression system using E. coli. Whereas a ligation experiment with 
equal amounts of pal and gfp genes into the standard expression vector resulted in 
100% gfp clones, the same ligation into the toxin shuttle vector resulted in similar 
amounts of pal and gfp clones (55% to 45%). Oey et al. (2009b) concluded therefore 
that their chloroplast vectors reached accumulation levels of Pal and Cpl-1, which 
became toxic to E. coli. At the same time, this study did not observe any effect of Pal 
or Cpl-1 against E. coli when the enzymes where applied from outside in turbidity 
reduction assays. Furthermore, this study describes a high stability of Pal and Cpl-1 in 
the tobacco chloroplast, since no decline of Pal and Cpl-1 accumulation was observed 
in older leaves despite that the protein biosynthesis decreases with leaf age (Oey et al. 
2009b). Furthermore, Pal accumulated a high level of 30% of total soluble protein. 
Oey et al. (2009b) presumed that this was due to a high resistance of Pal and Cpl-1 
(which are naturally produced and accumulate in bacteria) against prokaryotic-type 
proteases in the chloroplast. Oey et al. described also a very high stability of PlyGBS, 
a group B streptococcus specific endolysin, which accumulated to even 70% of total 
soluble protein in tobacco chloroplasts (Oey et al. 2009a).  
 
Oey et al. (2009a,b) concluded therefore that chloroplasts are ideal expression 
platforms for endolysin-type antibiotics due to their prokaryotic origin and therefore 
prokaryotic-type proteases combined with the absence of the endolysin substrate 
peptidoglycan.  
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3.1.2 Aims and objectives 
 
The aim of the experiments presented in this chapter was the expression of the 
endolysin Pal, a promising candidate as a novel protein antibiotic against 
Streptococcus pneumoniae, in the C. reinhardtii chloroplast, followed by an analysis 
of the accumulation and stability of the recombinant protein in the chloroplast. 
Subsequently, the maximal yields of Pal produced in C. reinhardtii were quantified to 
be able to examine the suitability of C. reinhardtii as a novel expression platform for 
Pal and other antimicrobial proteins in comparison to other protein production 
platforms such as bacteria or the tobacco chloroplast. 
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3.2 Results and Discussion 
 
3.2.1 Creation of transgenic lines of C. reinhardtii carrying the pal gene in 
the plastome 
 
Three different transgenic lines of C. reinhardtii carrying a synthetic pal gene in their 
plastome (together with corresponding control strains) were created to study the 
synthesis of the Pal protein in the algal chloroplast. The lines differ in regard to the 
promoters/5’untranslated regions (UTR’s) used for the expression of pal and the 
presence of an epitope tag (Figure 3.1).  
 
 
 
 
Figure 3.3: Pal expressing strains of C. reinhardtii TN72 created in this study and the 
corresponding control strains 
The diagram shows the differences in the expression elements and tags of the three C. reinhardtii TN72 
strains, which were created to study the expression of Pal in the C. reinhardtii chloroplast and the two 
corresponding control strains. Endogenous chloroplast genes are indicated in green, expression 
elements in blue, the gene of interests in yellow and the HA-tag in orange. 
 
  
psbH 5’atpA pal TN72_pal-HA HA 
TN72_SR_pal-HA 
TN72_SR_pal-x 
3’rbcL 
psbH 5’psaA 1 pal HA 3’rbcL 
psbH 5’psaA 1 pal 3’rbcL 
psbH 5’psaA 1 3’rbcL 
psbH 3’rbcL 5’atpA 
TN72_SR_control 
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All lines were created using a C. reinhardtii chloroplast transformation system that 
consists of the cell wall-less recipient strain TN72 and the expression vectors pASapI 
or pSRSapI. This transformation system uses the photosystem II gene psbH as a 
selectable marker and inserts the gene of interest (GOI) in a neutral region 
downstream of psbH. Successful transformants are selected for restoration of 
phototrophic growth on minimal medium. For a detailed description of the 
transformation system see materials and methods 2.3.8.  
 
 
3.2.1.1 Design and codon-optimisation of the synthetic pal gene 
 
The sequence of the Pal protein was taken from the database UniProtKB/Swiss-Prot 
(Entry: O03979; Entry name: ALYS_BPDP1; Gene name: PAL; Protein name: Lysin, 
EC=3.5.1.28; Organism: Pneumococcus bacteriophage Dp-1 (Taxonomic identifier: 
59241)). Pal is comprised of 296 amino acids and has a mass of 34,453 Da. The 
corresponding gene was codon-optimised for the C. reinhardtii chloroplast to a Codon 
Adaption Index (CAI) of 0.8 with respect to the codon usage table from Nakamura et 
al. (2000) (http://www.kazusa.or.jp/codon) and synthesised by GENEART 
(Regensburg, Germany) with the addition of a 5’ SapI and a 3’SphI restriction sites 
for subsequent cloning and a C-terminal human influenza haemagglutinin (HA) 
epitope tag for detection. The codon-optimised DNA sequence of the pal gene is 
attached in the appendix. The created pal gene has a length of 888 bp and including 
the HA-tag coding sequence and two stop codons (TAA) a length of 921 bp. The HA-
tagged Pal protein has a molecular mass of 35.6 kDa. 
 
 
3.2.1.2 Promoters and 5’/3’ untranslated regions used for the expression of pal  
 
Previous studies had shown that the promoters/5’UTRs from the highly expressed 
endogenous chloroplast genes atpA and psaA exon 1 result in the highest levels for 
recombinant proteins in the C. reinhardtii chloroplast (Purton et al. 2013; Michelet et 
al. 2011). The expression of pal was therefore analysed under the control of these two 
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promoters/5’UTRs. The atpA gene encodes for the α subunit of the chloroplast ATP 
synthase complex CF1/CF0 in green algae, including C. reinhardtii and higher plants 
(Leu et al. 1992). The psaA gene encodes a subunit of photosystem I and is split into 
three exons that are located apart from each other on the C. reinhardtii plastome. It 
has been shown that an authentic 3’UTR is necessary for mRNA accumulation, since 
it stabilises the mRNA and plays a role in transcription termination and 3’ formation, 
but all 3’UTRs of endogenous chloroplast genes analysed so far resulted in similar 
mRNA and protein levels for transgenes (Barnes et al. 2005). The 3’UTR of the rbcL 
gene has been successfully used in several previous studies and was therefore chosen 
for the expression of pal in this study (Barnes et al. 2005; Rasala et al. 2011). The 
rbcL gene encodes the large subunit of the very abundant enzyme Ribulose-1,5-
bisphosphate carboxylase/oxygenase (Rubisco).  
 
 
3.2.1.3 Creation of the transgenic lines 
3.2.1.3.1 TN72_ pal-HA 
 
In the transgenic line TN72_pal-HA the expression of pal is under the control of the 
atpA promoter and 5’UTR, and the rbcL terminator and 3’UTR. The pal gene contains 
the coding sequence for a C-terminal HA-tag (Figure 3.3). For the creation of 
TN72_pal-HA the expression vector pASapI was used (Table 2.5) (Economou et al. 
2014). The pal gene was cloned from the GENEART vector pMK_pal-HA into 
pASapI using the SapI and SphI restriction sites. The successful cloning of pal into 
pASapI was confirmed by sequencing. The resulting plasmid pASapI_pal-HA was 
transformed into C. reinhardtii TN72 using the glass bead method. The obtained 
colonies were restreaked three times to achieve homoplasmicity. Insertion of pal into 
the correct location in the chloroplast genome and homoplasmicity were confirmed by 
PCR with the primers FLANK1, atpA.R and rbcL.Fn (Figure 3.4) and by sequencing 
between the primers atpA.F and rbcL.R. Of six transformants analysed by PCR, four 
contained the expression cassette with pal in the correct location. The analysed 
transformants reached homoplasmicity before the second round of restreaking (Figure 
3.4).  
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3.2.1.3.2 TN72_SR_pal-HA 
 
TN72_SR_pal-HA uses the psaA exon 1 promoter/5’UTR and the rbcL terminator and 
3’UTR to drive the expression of pal. The pal gene contains the coding sequence for a 
C-terminal HA-tag (Figure 3.3). The vector pSRSapI was used for the creation of 
TN72_SR_pal-HA (Young & Purton 2014). The cloning was carried out as described 
for TN72_pal-HA. The correct insertion of pal into the chloroplast genome and 
homoplasmicity was confirmed by PCR with the primers FLANK1, RYpsa.R and 
rbcL.Fn (Figure 3.4, Figure 3.5) and sequencing. The PCR screening showed that all 
five analysed colonies had been successfully transformed and had reached 
homoplasmicity (Figure 3.5).  
 
 
3.2.1.3.3 TN72_SR_pal-x 
 
TN72_SR_pal-x uses the same expression cassette as TN72_SR_pal-HA, but it carries 
an untagged pal gene (Figure 3.3). The pal gene was amplified without the HA-tag 
sequence in a PCR with the primers Pal.Fw and HAremoval.Re. Afterwards, the PCR 
product was cloned into pJet, followed by digestion with SphI and SapI and cloning 
into pSRSapI. Subsequently, the construct was transformed into C. reinhardtii TN72 
and the correct insertion was confirmed as describe for TN72_SR_pal-HA (Figure 3.4, 
Figure 3.5). The PCR screening showed that all eight analysed colonies had been 
successfully transformed and had reached homoplasmicity (Three out of eight are 
shown in Figure 3.5).  
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Figure 3.4: PCR screening for the successful transformation of the C. reinhardtii TN72 
chloroplast 
Schematic diagram showing the binding sites of the sets of primers and the expected fragment sizes for 
the recipient strain TN72 and successful TN72_pal-HA and TN72_SR_pal-HA/x transformants (A). 
PCR screening for putative transformants with TN72 as control (B). The primer FLANK1 binds to the 
plastome outside of the insertion area. RbcL.Fn binds within the aadA cassette of the untransformed 
recipient strain TN72 and results together with FLANK1 in a product of 0.85 kb. The third primers 
(atpA.R and RYpsa.R) bind to the promoters of the expression cassettes and result together with 
FLANK1 in a product of 1.2 kb for the atpA promoter and 1.14kb for the psaA exon 1 promotor. 
Homoplasmic transformants show only a band at 1.2 or 1.14 kb, respectively. Heteroplasmic 
transformants show additionally a 0.85kb band. (A) Grey arrows = primers, blue boxes = expression 
elements, green boxes = plastome genes. (B) 1, 2 = Transformant 1, 2; R2/3 = Second/third restreak.  
 
Recipient strain TN72  
TN72_pal-HA transformant 
850 bp 
1200 bp 
FLANK1  FLANK1  
psbH 
psbH 
pal HA 3’rbcL 
psbH 
5’psaA 1 pal-HA/x 3’rbcL 
5’atpA 
5’atpA aadA 3’rbcL 
FLANK1  
FLANK1  
rbcL.Fn 
rbcL.Fn 
atpA.R 
FLANK1  atpA.R 
RYpsa.R 
TN72_SR_pal-HA/x transformant 
1140 bp 
FLANK1  RYpsa.R 
A 
3 
 
2.5 
 
2 
 
 
1.5 
 
1.2 
 
1 
0.9 
0.8 
0.7 
0.6 
0.5 
 
kb 
TN72 
1 
WT 
2 
R2 R3 
C. reinhardtii TN72_pal-HA 
transformants 
! 1.2 kb 
! 0.85 kb 
! 1 kb 
R2 R3 
B 
3 
 
2.5 
 
2 
 
 
1.5 
 
1.2 
 
1 
0.9 
0.8 
0.7 
0.6 
0.5 
 
kb 
TN72 
1 
WT 
2 
R2 R3 
C. reinha dtii TN72_pal-HA 
transformants 
! 1.2 kb 
! 0.85 kb 
! 1 kb
2 3 
B 
CHAPTER 3  
  
 117 
 
Figure 3.5: PCR screening for the successful transformation of the C. reinhardtii TN72 
chloroplast with pASRSapI_pal-HA and pASRSapI_pal-x 
In the PCR screening for putative TN72_SR_pal-HA and TN72_SR_pal-x transformants the primers 
FLANK1, rbcL.Fn and RYpsa.R were used. For binding regions of the primers see Figure 3.4. The 
primer FLANK1 binds to the plastome outside of the insertion area. RbcL.Fn binds within the aadA 
cassette of the untransformed recipient strain TN72 and results together with FLANK1 in a product of 
0.85 kb. The third primer RYpsa.R binds to the promoter of the expression cassettes and result together 
with FLANK1 in a product of 1.14kb. Homoplasmic transformants show only a band at 1.2 or 1.14 kb, 
respectively. Heteroplasmic transformants show additionally a 0.85kb band. TN72 = Recipient strain; 
1, 2, 3, 4, 5 = Transformant number 1, 2, 3, 4, 5; Expected band sizes are as follows: TN72 = 0.85 kb; 
Homoplasmic transformant = 1.14 kb; Heteroplasmic transformant: 0.85 kb and 1.14 kb. 
 
 
3.2.1.3.4 Control strains 
 
The corresponding control strains were created in previous studies by transformation 
of the recipient strain with the corresponding transformation vector carrying an empty 
expression cassette to ensure the same genetic background. TN72_control was 
transformed with pASapI and carries an empty expression cassette with the atpA 
promoter (Ninlayarn 2012). Similarly, TN72_SR_control was transformed with 
pSRSapI and carries the psaA exon 1 promoter, but no gene of interest (Young & 
Purton 2014) (Figure 3.3).  
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3.2.2 Expression of pal in the C. reinhardtii chloroplast 
3.2.2.1 Confirmation of pal expression using anti-HA antibodies 
 
Pal was synthesised with the addition of a C-terminal HA-tag to enable the detection 
of the Pal protein using commercially available anti-HA antibodies, since previous 
studies had shown that stable transformants of C. reinhardtii can occasionally fail to 
produce detectable levels of recombinant protein (Taunt 2013) (Rasala et al. 2010). 
The transformant lines obtained were therefore analysed for the presence of the Pal 
protein by western blot analysis using antibodies against the HA-tag and in 
combination with IRDye® secondary antibodies and the Odyssey® Infrared (IR) 
Imaging System. Alternatively, horseradish peroxidase-linked secondary (ECL) 
antibodies were used and the resulting chemiluminescence was detected with 
photographic film.  
 
Both detection systems confirmed the successful accumulation of Pal in the 
chloroplast of C. reinhardtii TN72_pal-HA and TN72_SR_pal-HA. Pal with the 
addition of the HA-tag (MW = 1.1 kDa) has a molecular weight of approximately 35.6 
kDa and the observed band runs as expected slightly above the 35 kDa marker of the 
protein ladder (Figure 3.6, for TN72_pal-HA see Figure 3.10). The western blot 
analyses did not show any additional bands for TN72_pal-HA or TN72_SR_pal-HA 
that were not present in the control suggesting that no detectable levels of N-terminal 
degradation products are formed in the C. reinhardtii chloroplast (Figure 3.6). 
Transgenic lines that are created via the introduction of genes into the chloroplast 
genome by homologous recombination are genetically identical and are expected to 
show identical expression levels for recombinant proteins. This is further analysed in 
5.2.2.1. For that reason one representative transformant of each strain was chosen for 
further experiments.  
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Figure 3.6: Western blot analysis of whole cell extracts of TN72_SR_pal-HA transformants 
showing the presence of HA-tagged Pal protein 
The western blot was performed with whole cell extract (= suspension of whole cells that were broken 
by the addition of SDS (2% w/v) and boiling) and anti-HA antibodies, IRDye® secondary antibodies 
and the Odyssey® Infrared Imaging System for detection. TN72_SR_control was used as a negative 
control. The expected band size is 35.6 kDa. Protein sizes were determined using the PageRulerTM 
Prestained Protein ladder (Thermo Scientific).  
 
 
3.2.2.2 Detection of Pal using custom made anti-Pal antibodies 
 
Specific antibodies for the detection of Pal were not readily available. Since the 
success rate for the synthesis of recombinant proteins in the C. reinhardtii chloroplast 
to detectable levels is only around 50% to 70% (Rasala et al. 2010) (Rasala & 
Mayfield 2011), Pal was first attached with a HA-tag for an easy and inexpensive 
detection. Nevertheless, the addition of tags can affect the biological activity of 
proteins, and furthermore most tags are immunogenic, which is not desirable for 
human or veterinary therapeutics (Terpe 2003). Thus, it was of interest to remove the 
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Pal had been confirmed with anti-HA antibodies. To be able to detect untagged Pal, 
the company Eurogentec (Belgium) was commissioned to raise Pal-specific antibodies 
from synthetic peptides in rabbits. Specific antibodies could be also used for sandwich 
ELISAs and highly specific purifications. Furthermore, they would enable the 
detection of N-terminal and mid-protein degradation products of Pal, which would not 
be detected with anti-HA antibodies owing to the lost of the HA-tag. 
 
To check that antibodies had been successfully raised in the final bleed serum of the 
rabbits, an Enzyme-Linked Immunosorbent Assay (ELISA) with a series of 
concentrations of the peptide (15 ng, 7.5 ng, 3.75 ng) and a series of dilutions of the 
final bleed serum (1:100, 1:500, 1:2,500, 1:12,500, 1:62,500) from the rabbits was 
performed.  
 
 
 
 
Figure 3.7: Enzyme-Linked Immunosorbent Assay (ELISA) to test the custom made anti-Pal 
antibodies against the peptides used to raise them 
Eurogentec (Belgium) injected two rabbits (554 and 555) with two peptides from the sequence of Pal to 
raise custom made antibodies against Pal. An ELISA was performed with a series of dilutions of the 
final bleed from the two rabbits (1:100, 1:500, 1:2500, 1:12500, 1:62500) and the peptides in 
concentrations of 3.75, 7.5 and 15 ng. Horseradish peroxidase-linked secondary (ECL) antibodies were 
used for the assay and the ELISA signal was detected at 450 nm. The error bars show the standard error 
of triplicates. 
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The final bleed serum could be used to detect both peptides down to a dilution of 
1:2,500 for all peptide concentrations tested proving that the antibodies had been 
successfully raised against both peptides. Peptide 1 could be detected down to a 
dilution of the serum of 1:12,500 and resulted in a stronger ELISA signal than peptide 
2 at all dilutions. The sera from both rabbits showed similar results for peptide 1, but 
the serum of rabbit 555 showed a lower signal for peptide 2 than the serum of rabbit 
554 at all dilutions (Figure 3.7). The serum of rabbit 554 was therefore chosen for 
further experiments. 
 
Subsequently, a western blot analysis with the final bleed serum of rabbit 554 was 
performed to check whether the antibodies are able to detect full-length Pal in broken 
cell extract and to analyse the synthesis of untagged Pal in TN72_SR_pal-x. The final 
bleed serum was tested in three different dilutions (1:500, 1:1000, 1:2000) in western 
blots with horseradish peroxidase-linked secondary (ECL) antibodies for the detection 
of HA-tagged and untagged Pal in broken cell extract of TN72_SR_pal-HA and 
TN72_SR_pal-x, respectively. Incubation with all three dilutions of the final bleed 
serum resulted for both strains in bands around 35 kDa, which were not present in the 
negative control with TN72_SR_control proving that the custom made antibodies are 
able to detect full-length Pal. A dilution of 1:2000 resulted in the clearest western blot 
picture (Figure 3.8). Furthermore, the western blot analyses confirmed the production 
of untagged Pal in TN72_SR_pal-x. The bands for HA-tagged Pal and untagged Pal 
showed similar intensities at the same cell concentration in two performances of the 
western blot analyses indicating that both are expressed to similar levels and that the 
HA-tag does not interfere with the stability of Pal in the C. reinhardtii chloroplast.  
The western blot analyses did not show any other bands in the lanes with samples of 
TN72_SR_pal-HA and TN72_SR_pal-x, which were not present in the lane of the 
negative control indicating that no degradation products of Pal are produced to 
detectable levels in the C. reinhardtii chloroplast (Figure 3.8).  
 
However, the custom made anti-Pal antibodies showed a lower sensitivity than anti-
HA antibodies in western blot analyses. The analyses of the yields of Pal synthesis in 
the C. reinhardtii chloroplast, which are discussed in the following sections, were 
therefore performed with TN72_(SR)_pal-HA and anti-HA antibodies.  
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Figure 3.8: Western blot analysis with custom made anti-Pal antibodies showing the presence of 
untagged Pal and HA-tagged Pal in cell extracts 
The western blot analysis was performed with whole cell extract of TN72_SR_pal-x, TN72_SR_pal-
HA and TN72_SR_control, custom made anti-Pal antibodies raised by the company Eurogentec 
(Belgium) and horseradish peroxidase-linked secondary (ECL) antibodies. The resulting 
chemiluminescence was detected with photographic film. The expected band size for untagged Pal is 
34.5 kDa and for HA-tagged Pal is 36.5 kDa. Protein size was determined using the PageRulerTM 
Prestained Protein ladder (Thermo Scientific). 
 
 
3.2.2.3 Expression of pal in Escherichia coli DH5α  
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of recombinant proteins. Therefore, it was of interest to compare the expression of pal 
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of the gene of interest in Escherichia coli DH5α although the GOIs are codon-
optimised for the C. reinhardtii chloroplast and the expression cassettes carry C. 
reinhardtii promoters and UTRs (Szaub 2012; Taunt 2013). This allows an easy, even 
though preliminary qualitative analysis of the expression of the GOIs in E. coli using 
the C. reinhardtii vectors. A quantitative comparison is not possible since neither the 
expression vectors nor the E. coli strain is optimised for recombinant protein 
expression. It can be assumed that the observed expression in this system is 
significantly lower than in an optimised E. coli expression system.  
 
The construct pASapI_pal-HA was transformed into E. coli and a western blot 
analysis with anti-HA antibodies was performed on crude cell extracts. It was possible 
to detect a faint band close to 35 kDa that was not present in the negative control 
proving the successful synthesis of Pal in E. coli DH5α (Figure 3.9). Additionally, the 
blot showed multiple stronger bands of lower molecular weight in the sample of 
DH5α_pal-HA, which did not occur in the negative control with DH5α_control 
(Figure 3.9).  
 
These bands could be N-terminal degradation products of Pal or the result of cryptic 
ribosome binding sites within the pal gene. A comparison of the estimated sizes of the 
smaller fragments with the Pal sequence showed that the majority of the five 
fragments do not end within the proximity of a methionine residue, which could have 
been coded by an additional AUG start codon. This indicates that the Pal fragments of 
lower molecular weight are most likely not the result of internal translation initiation 
regions, but rather degradation products generated by site-specific cleavage by E. coli 
proteases. An E. coli strain optimised for recombinant protein synthesis, for example a 
strain deficient for certain proteases, might therefore show a different pattern. On the 
other hand, it is conceivable that the accelerated degradation of Pal is due to toxicity 
of full-length Pal against E. coli as observed in Oey et al. (2009b). Nevertheless, this 
experiment indicates a faster degradation of Pal and suggests lower levels of full-
length Pal protein compared to degradation products in E. coli DH5α. Overall, the 
results of the last sections suggest that Pal has a higher stability in the C. reinhardtii 
chloroplast compared to E. coli DH5α, which would exhibit an advantage of the C. 
reinhardtii chloroplast as an expression platform over E. coli DH5α.  
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Figure 3.9: Western blot analysis with crude extracts of Escherichia coli DH5α_pal-HA 
transformants for the presence of HA-tagged Pal protein 
The western blot was performed with anti-HA antibodies and IRDye® secondary antibodies and the 
Odyssey® Infrared Imaging System for detection. The expected band size is 35.6 kDa. Protein size was 
determined using the PageRulerTM Prestained Protein ladder (Thermo Scientific). 
 
 
3.2.2.4 Comparison of pal expression when under the control of the 
promoter/5’UTR from either atpA or psaA exon 1  
 
Two strains of C. reinhardtii TN72 expressing Pal, which use different 
promoters/5’UTRs elements were created in this study, to compare the expression 
levels of pal under the control of the two endogenous elements that had shown the 
highest recombinant protein yields in previous studies with the aim to maximise the 
production of Pal. In TN72_pal-HA the expression of pal is under the control of the 
atpA promoter/5’UTR, whereas TN72_SR_pal-HA uses the psaA exon 1 
promoter/5’UTR (3.2.1.2).  
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Cultures of TN72_SR_pal-HA and TN72_pal-HA were grown in duplicate under the 
same conditions and samples were taken at multiple time points during growth to 
account for variations of protein levels at different growth stages. The samples were 
concentrated five times compared to the culture volume meaning they were 
normalised for the amount of Pal per culture volume. Subsequently, they were 
analysed in a western blot analysis with anti-HA antibodies and the Odyssey® 
Infrared Imaging System for the quantification of Pal. The western blot analysis for 
both strains is shown in figure 3.10 A. The graph in figure 3.10 and Table 3.1 show 
the average IR fluorescence of the duplicates measured by the Odyssey® Infrared 
Imaging System. The IR fluorescence values were divided by the OD750nm of the 
cultures at the time of sampling to account for small variations in growth.  
 
The amount of Pal in cells of TN72_pal-HA accounted at all growth stages for 8 - 
31% of the amount measured in TN72_SR_pal-HA. This shows that the amount of Pal 
is between three to ten times higher (depending on the growth stage) when produced 
under the control of the psaA exon 1 promoter/5’UTR compared to the atpA 
promoter/5’UTR. The strain TN72_SR_pal-HA was therefore chosen for further 
investigations.  
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Table 3.1: Comparison of the amount of Pal produced under the control of the atpA and psaA 
exon 1 promoter/5’UTR 
Cultures of TN72_SR_pal-HA and TN72_pal-HA were grown in duplicate under the same conditions 
and samples were taken at multiple time points during growth, harvested by centrifugation, concentrated 
five times in Na-Pi-buffer and 20 µl of the suspension were analysed in a western blot with anti-HA 
antibodies, IRDye® secondary antibodies and the Odyssey® Infrared Imaging System for detection and 
quantification. The IR fluorescence signals were divided by the optical density (750 nm) of the culture 
at the time of sampling and the percentage of Pal in TN72_pal-HA compared to TN72_SR_pal-HA was 
calculated for each growth stage. The standard deviation (±) is stated (n = 2). 
 
Time 
(h) 
Signal (IR fluorescence) / OD750nm Amount of Pal produced using the 
atpA compared to the psaA1 
promoter/5’UTR  (%) 
TN72_SR_pal-HA 
psaA1 promoter/5’UTR 
TN72_pal-HA 
atpA promoter/5’UTR 
25 71 242 ± 30 188 16 190 ± 13 616 23 
39.5 179 747 ± 83 567 22 145 ± 3 459 12 
44 213 758 ± 22 302 23 135 ± 2 204 11 
48 156 675 ± 60 774 26 160 ± 11 211 17 
66 259 163 ± 160771 22 027 ± 1 026 8 
72 81 344 ± 39 030 26 270 ± 12 321 32 
89 110 020 ±33 747 22 455 ± 2 011 20 
112 94 404 ± 15 524 29 654 ± 6 999 31 
137 60 840 9 195 15 
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Figure 3.10:  Comparison of the amount of Pal produced under the control of the atpA and psaA exon 1 promoter/5’UTR elements 
Cultures of TN72_SR_pal-HA and TN72_pal-HA were grown in duplicate under standard conditions and samples were taken at multiple time points during growth, 
concentrated five times in Na-Pi-buffer and 20 µl were analysed in a western blot analysis with anti-HA antibodies, IRDye® secondary antibodies and the Odyssey® Infrared 
Imaging System for detection (A) and quantification. The IR fluorescence signals were divided by the optical density (750 nm) of the culture at the time of sampling and are 
shown in (B). The black frames indicate which samples were analysed on the same gel and membrane. The error bars show ± one standard deviation (n = 2). 
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3.2.3 Analysis of Pal accumulation and stability in the chloroplast  
 
In section 3.2.2 the expression of pal was demonstrated using two different antibodies 
and it was shown that the expression of the gene is higher when driven by the psaA 
exon 1 promoter/5’UTR element than that from atpA. Subsequently it was of interest 
to analyse the accumulation and stability of Pal during the growth of C. reinhardtii 
with the aim to further maximise the yield of the endolysin. 
 
C. reinhardtii is able to grow photoautotrophically, heterotrophically with acetate or 
mixotrophically. The highest growth rates and cell densities are reached during 
mixotrophic growth in liquid media with acetate, equal light exposure of all cells (200 
- 400 µmol/m2/s) and continuous shaking or bubbling for aeration of the culture and 
(Harris 2009). A recent study that analysed the steady-state level of the reporter 
protein VFP and the endolysin Cpl-1 in C. reinhardtii TN72 during growth under 
different conditions showed that growth in Tris-acetate phosphate (TAP) medium 
with continuous light of 200 µmol/m2/s results in the highest yield of recombinant 
protein per culture volume (Braun Galleani 2014). The study revealed that the highest 
protein yield for VFP is achieved during growth at 30ºC, and for Cpl-1 at 25ºC. A 
second study confirmed higher yields of recombinant protein at 25ºC than at 30ºC for 
the endolysins Pal and Cpl-1 (Young, unpublished). These conditions (TAP medium, 
25ºC, 200 µmol/m2/s, continuous shaking) were therefore chosen to analyse the 
amount of Pal in C. reinhardtii and defined as standard conditions.  
 
 
3.2.3.1 The production of Pal in the chloroplast does not interfere with the 
growth of C. reinhardtii 
 
The synthesis of a recombinant protein is a metabolic burden for a cell, since it uses 
amino acids and metabolic energy for the production of a protein that is not of any 
use to the organism. The antimicrobial effect of the endolysin Pal relies upon the 
cleavage of the peptidoglycan in the streptococcal cell wall, and despite C. reinhardtii 
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not containing any peptidoglycan, it was nevertheless important to ensure that Pal 
does not have any toxic effect on the alga. It was therefore analysed if the production 
of Pal has a negative impact on the growth of C. reinhardtii. 
 
TN72_SR_pal-HA and TN72_SR_control were grown under standard conditions in 
the Algem photobioreactor (Algenuity, Stewartby (UK)). The OD750nm was 
automatically recorded every 0.5 h and the biomass (cell dry weight) was determined 
at four time points during growth. In the shown experiments TN72_SR_pal-HA was, 
in fact, found to grow slightly faster than TN72_SR_control and reached a slightly 
higher biomass (TN72_SR_pal-HA: 0.79 ± 0.00 g dry weight / litre culture volume, 
TN72_SR_control: 0.72 ± 0.01 g dry weight / litre culture volume) showing that Pal 
does not appear to have a negative effect on the growth of C. reinhardtii. No negative 
impact on the growth rate or the final OD750nm was observed at any other time when 
both strains were cultured in parallel.  
 
 
 
Table 3.2: Final biomass of C. reinhardtii TN72_SR_pal-HA and TN72_SR_control 
TN72_SR_pal-HA and TN72_SR_control were grown under continuous shaking at 120 rpm, 25ºC and 
with a light intensity of 200 µmol/m2/s in Gorman-Levine Tris-acetate phosphate (TAP) medium in the 
Algem photobioreactor (Algenuity, Stewartby (UK)) and the biomass (cell dry weight) was determined 
at four time points during growth. The standard deviation (±) is stated. 
 
 TN72_SR_pal-HA TN72_SR_control 
 
Maximal biomass 
(g dry weight/L) 
 
 
0.79 ± 0.00 
(n = 2) 
 
 
0.72 ± 0.01 
(n = 2) 
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Figure 3.11: Growth of C. reinhardtii TN72_SR_pal-HA compared to TN72_SR_control 
TN72_SR_pal-HA and TN72_SR_control were grown under continuous shaking at 120 rpm, 25ºC and 
with a light intensity of 200 µmol/m2/s in Gorman-Levine Tris-acetate phosphate (TAP) medium in the 
Algem photobioreactor (Algenuity, Stewartby (UK)). The OD750nm was automatically recorded every 
0.5 h and the biomass (cell dry weight) was determined at four time points during growth. The error 
bars show ± one standard deviation for the optical density measurements (n = 4) and the dry weight 
measurements (n = 2).   
 
 
3.2.3.2 Yield of Pal at different growth stages 
 
The yield of recombinant Pal protein in cells of TN72_SR_pal-HA was determined at 
different growth stages to analyse its expression and stability in the chloroplast. 
Furthermore, it was highly desirable to determine the growth stage that yields the 
highest amount of Pal for the quantification of the maximal yield and for further 
experiments with Pal. 
 
In these analyses TN72_SR_pal-HA was grown under standard conditions, the 
culture growth was recorded by measuring the OD750nm and samples were taken at 
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multiple time points during growth. Subsequently, the samples were analysed and 
quantified in a western blot analysis with anti-HA antibodies and the Odyssey® 
Infrared Imaging System. To understand the synthesis and stability of Pal in the 
chloroplast it was of interest to analyse the yield of Pal per batch of cells.  
 
To obtain the same cell density in every sample, the cells were harvested and pelleted 
and then resuspended in a volume depending upon the OD750nm of the culture at the 
time of sampling (Figure 3.10). These experiments showed an initial increase in the 
amount of Pal per cell from the lag phase to the logarithmic phase. During the 
logarithmic phase the amount of Pal per cell stayed approximately the same and 
decreased from the logarithmic to the stationary phase by about 60% (Figure 3.10, 
Figure 3.12 (light blue bars)). This shows that the amount of Pal per cell is highest 
during the logarithmic phase of growth and indicates that Pal synthesis, degradation 
and the dilution of the Pal concentration during cell division is at an approximate 
equilibrium in the logarithmic phase. Furthermore the results indicate that the 
synthesis decreases and the degradation of Pal increases under these conditions 
towards the end of the logarithmic phase and the beginning of the stationary phase, 
respectively.  
 
In order to determine the growth stage that provides the highest yield of Pal per 
culture volume, all samples were resuspended in the same volume after harvesting 
(Figure 3.13). The previously described results already suggest that the highest level 
of Pal protein per culture volume could be obtained at the end of the logarithmic 
phase before the amount of Pal per cell drops and when the culture has reached a high 
cell density. The second experiment confirmed this suggestion since it showed the 
lowest levels of Pal during the beginning of the logarithmic phase, the highest signal 
at the end of the logarithmic phase and a decrease by about 40% from the logarithmic 
to the stationary phase (Figure 3.13 (light blue bars in B)).  
 
Both experiments indicate that the highest level of Pal per culture volume is obtained 
after about 60 h (2.5 days) of growth, an OD750nm of 2.8 to 3.8. The maximal OD750nm 
is influenced by the quality of the light penetration. C. reinhardtii stops logarithmic 
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growth under the investigated conditions (in 25 ml to 500 ml flasks) at an OD750nm of 
3 to 4, but can continues growing at a slower rate to an OD750nm of up to 5. The C. 
reinhardtii chloroplast contains several energy-dependent proteases and it has been 
shown that decreased stromal ATP levels induced by uncouplers (e.g. CCCP) or 
incubation in the dark slow down the degradation of the chloroplast protein D1 
(Preiss et al. 2001). Furthermore, UV light can have a negative impact on proteins 
(Teresa et al. 2012). The yield of Pal was therefore additionally investigated in 
cultures that were transferred to the dark, at the beginning of the stationary phase. 
These cultures maintained similar levels of Pal per cell in the stationary phase as seen 
in the logarithmic phase, unlike the culture maintained in the light. This observation 
indicates that the degradation of Pal is slowed down in the dark (Figure 3.12 (dark 
blue bars in B)).  
 
Growing C. reinhardtii completely heterotrophically in the dark would make it 
possible to use already established fermenter-based culture systems for its cultivation, 
as used for heterotrophic growth of industrially important bacteria and yeast. 
Therefore it was of interest to compare the production of Pal under heterotrophic and 
mixotrophic conditions. The maximal OD750nm of C. reinhardtii cultures grown 
entirely heterotrophically in the dark (with 17.4 mM acetate) was found to be 
approximately three times lower than of mixotrophically grown cultures 
(Heterotrophic: OD750nm ≈1.7, Mixotrophic: OD750nm ≈5), which results in about 40 – 
70% (depending on the growth stage) lower yields of Pal per culture volume in 
heterotrophic compared to mixotrophic cultures, despite the reduced degradation in 
the dark (Figure 3.13).  
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Figure 3.12: Yield of Pal synthesis at different growth stages and the influence of darkness on the protein stability during stationary phase 
Cultures of TN72_SR_pal-HA were grown under standard conditions and samples were taken at multiple time points during growth. After harvesting the samples were 
normalised to the OD750nm at the time of sampling. The samples were analysed in western blot analyses with anti-HA antibodies, IRDye® secondary antibodies and the Odyssey® 
Infrared Imaging System for detection and quantification. All cultures were grown in the light (200 µmol/m2/s) at the beginning of the experiment. Then one half was moved to 
the dark after 58 h (dark blue) and the other half remained in the light (light blue). A shows one of the western blot pictures, B the averages of the Odyssey IR fluorescence 
signals and C the growth of the cultures. The black frames in A indicate separate gels and membranes in the western blot. The error bars in B show ± one standard deviation (n = 
2). 
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Figure 3.13: Yield of Pal synthesis per culture volume at different growth stages during mixotrophic and heterotrophic growth 
Cultures of TN72_SR_pal-HA were grown with acetate under mixotrophic conditions in the light (light blue) and heterotrophic conditions in the dark (dark blue). Samples were 
taken at multiple time points during growth, after harvest all samples were resuspended in an equal volume (a five times concentration of the culture volume). The samples were 
analysed in western blot analyses with anti-HA antibodies, IRDye® secondary antibodies and the Odyssey® Infrared Imaging System. A shows one of the western blot pictures, B 
shows the average of the Odyssey IR fluorescence signals and C the growth curves of the cultures The black frames in A indicate separate gels and membranes in the western 
blot. The error bars in B show ± one standard deviation (n = 4, two cultures, each analysed in duplicates), the error bars in C show the standard deviation between the two 
cultures (n = 2). L = Culture grown mixotrophic in the light, D = Culture grown heterotrophically in the dark.  
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Several previous studies have investigated whether higher acetate concentrations 
increase the cell density in the dark, but found that higher concentrations (above 15 or 
20 mM, respectively) inhibit the growth of C. reinhardtii (Sager & Granick 1953; 
Chen & Johns 1994). Sager & Granick showed that by adding more acetate once 
growth has ceased, another doubling of the cell density is possible. This study also 
investigated whether other carbon sources can be used for heterotrophic cultivation of 
C. reinhardtii. They tested 32 different carbon sources (including glucose, galactose, 
sucrose, lactose, maltose, mannose, ribose, starch, glycerol, citrate, fumarate and 
succinate), but found that none of them supports the growth of C. reinhardtii in the 
dark (Sager & Granick 1953). It is therefore difficult to increase the maximal cell 
densities of C. reinhardtii grown in batch cultures in the dark.  
 
 
3.2.3.3 Stability of Pal in the light and the dark following inhibition of the 
protein synthesis in the chloroplast using chloramphenicol  
 
The experiment described in 3.2.3.2 indicates that the synthesis and degradation of 
Pal is at an approximate steady state during the logarithmic phase and that the yield 
of Pal decreases towards the stationary phase in the light. Furthermore the results 
suggest that incubation in the dark slows protein degradation in the stationary phase. 
Nevertheless, the findings allow only limited conclusions to be drawn concerning the 
stability of Pal in the chloroplast. To analyse the stability and the degradation of Pal 
in the chloroplast more closely, protein synthesis in the organelle was specifically 
blocked by the 70S ribosome inhibitor, chloramphenicol (Hoobert & Blobel 1969). 
The yield of Pal was then determined over a time course after inhibition in both the 
light and in the dark.  
 
Cultures of TN72_SR_pal-HA were grown until an OD750nm of 1.0 and split equally 
into eight flasks. Four flasks were treated with 500 µg/ml of chloramphenicol 
(dissolved in ethanol) while the other four were supplemented with the same volume 
of the solvent ethanol, as a control. A concentration of 500 µg/ml chloramphenicol 
was chosen, because it showed an impact on culture growth and the greenness of the 
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culture in the first performance of the experiment (unlike 200 µg/ml) indicating that 
the concentration is sufficient to inhibit protein synthesis in the chloroplast. After 
addition of chloramphenicol, samples were taken at different time points over a 
period of 122 h. The samples were then normalised to the same cell density and 
analysed in a western blot analysis with anti-HA antibodies. The Odyssey® Infrared 
Imaging System was used for the quantification of Pal.  
 
As shown in figure 3.14, the amount of Pal per cell in the light-grown cultures 
decreased stepwise during the time course in the chloramphenicol-treated and the 
control cultures, but was at most time points lower in the chloramphenicol-treated 
cultures compared to the controls. Nevertheless, Pal was still detectable 122 h after 
the inhibition of the protein synthesis by chloramphenicol. In the dark the amount of 
Pal per cell did not decrease stepwise during the first 71 h (the data indicated a 
decrease at 25 h, but this was followed by a subsequent increase) and only decreased 
in the death phase of the culture (after 122 h). The amount of Pal was also in the dark 
in the chloramphenicol-treated cultures at most time points lower than in the control 
cultures, which were still able to synthesise proteins in the chlroroplast. Nevertheless, 
Pal was still detectable 122 h after the chloramphenicol inhibition of protein 
synthesis, and the amount was similar in both the treated and non-treated cultures. 
 
The samples of the experiment performed in the light were additionally analysed with 
an anti-D1 antibody as a control. The D1 protein is encoded in the chloroplast and is 
part of photosystem II. Only 3 h after the addition of chloramphenicol, the amount of 
D1 protein was lower in the treated cultures compared to the control cultures and had 
decreased to non-detectable levels after 6.5 h. Furthermore the chloramphenicol 
treatment had a strong impact on the growth of the cultures in the light, but not in the 
dark. The proteins in the chloroplast are mainly involved in photosynthesis and 
therefore do not play a major role during growth in the dark. Taken together, these 
data, indicate that the concentration of chloramphenicol (500 µg/ml) was sufficient to 
inhibit the protein synthesis in the chloroplast and shows that the degradation of the 
endogenous chloroplast protein D1 is a lot faster than the degradation of Pal in the C. 
reinhardtii chloroplast. A recent study that investigated the stability of recombinant 
human growth hormone produced in the C. reinhardtii chloroplast showed that only 6 
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h after the start of the experiment the levels of recombinant human growth hormone 
were lower in the chloramphenicol treated samples compared to the control samples 
and that the levels were strongly reduced 24 h after inhibition by chloramphenicol 
(Waterhouse, unpublished).  
 
Overall the experiments indicate that Pal exists as a stable protein in the C. 
reinhardtii chloroplast and that it is able to withstand the degradation processes in the 
chloroplast of C. reinhardtii for at least 122 h, unlike D1 or the human growth 
hormone. Additionally, it supports the theory of Oey et al. (2009a,b) that endolysins 
show a very high stability in chloroplasts due to eubacterial-type proteases and the 
resistance of endolysins against the proteases of their host bacteria. Furthermore the 
experiment confirms the results of section 3.2.3.2, which suggested that the 
degradation of Pal is slowed down during incubation in the dark.  
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Figure 3.14: Stability of Pal after inhibition of the protein synthesis in the chloroplast by chloramphenicol in the light and the dark 
Cultures of TN72_SR_pal-HA were grown under standard conditions to an OD750nm of 1 and then split between eight flasks. One half was treated with 500 µg/ml of 
chloramphenicol and the other half was supplemented with an equal volume of the solvent ethanol as a control, one half was placed in the dark and one half in the light, 
samples were taken over a time course of 122h, normalised to the same cell density and analysed in a western blot analysis with anti-HA or anti-D1 antibodies, IRDye® 
secondary antibodies and the Odyssey® Infrared Imaging System. The black frames in A indicate separate gels and membranes in the western blot. A shows one set of the 
western blot pictures, B the average of the Odyssey IR fluorescence signals, C the growth of the cultures The error bars in B and C show ± one standard deviation (n = 2). 
The expected band size for Pal is 35.6 kDa and for D1 32kDa. CA = chloramphenicol treated cultures, C = control cultures.  
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3.2.4 Quantification of Pal produced in the C. reinhardtii chloroplast 
 
In order to evaluate the potential of the C. reinhardtii chloroplast as an alternative 
expression platform to other established platforms, it was important to determine the 
yields of recombinant Pal protein.  
 
Western blot analyses with infrared fluorescence secondary antibodies, the Odyssey® 
Infrared Imaging System and HA-tagged standard proteins were used for the 
quantification. The Odyssey® system measures the infrared (IR) fluorescence signal 
of a fluorophore bound to the IRDye® secondary antibody. A laser excites the 
fluorophore during measurement and the fluorescence is measured over a time 
course. The corresponding software quantifies the total fluorescence signal and 
subtracts the background in an area of 2 pixels above and under (or alternatively right 
and left of) the band from the signal value. LI-COR states that its system can be used 
to directly detect the amount of antigen in western blot analysis over a wide range of 
quantities (www.licor.com). Several studies have used infrared fluorescence 
antibodies and the Odyssey® system for protein quantification in cell extracts (Wang 
et al. 2007; Thomson et al. 2011).  
 
 
3.2.4.1 Evaluation of purified CARHSP1 as a standard for the quantification of 
Pal in whole cell extracts 
 
In order to quantify the HA-tagged Pal, it was first necessary to obtain a purified HA-
tagged protein of known quantity. A tagged recombinant human CARHSP1 (calcium-
regulated heat stable) protein with a known concentration was therefore purchased 
from Abcam. 
 
The quantifications were performed with suspensions of whole cells that had been 
broken by the addition of 2% SDS and boiling (= whole cell extracts) to ensure that 
the total cellular amount of Pal protein was released for measurement. Firstly, it was 
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important to determine a linear range for Pal in whole cell extracts and to establish 
whether the purified standard protein could be used to quantify the concentration of 
another protein in whole cell extracts. For this purpose cultures of C. reinhardtii 
TN72_SR_pal-HA were grown under standard conditions to an OD750nm of 2, 
harvested and diluted/concentrated to 0.25x, 0.5x, 1x, 2.5x, 5x, 10x, 20x and 50x of 
the culture volume. Subsequently, the cells were broken and analysed in western blot 
analyses with anti-HA antibodies. These western blot analyses revealed that the IR 
fluorescence signal of HA-tagged Pal shows a linear correlation for whole cell 
extracts with concentrations ranging from 0.25x to 5x of the culture volume (Figure 
3.15).  
 
Following this step, the samples were analysed together with different quantities of 
the HA-tagged standard protein CARHSP1 on the same gel and membrane in western 
blot analyses with anti-HA antibodies. Observations during this study and that by 
Thomson et al. (2011) suggest that quantitative comparison of samples should ideally 
be done between samples on the same gel and membrane, since gel-to-gel (and 
membrane-to-membrane) differences in the IR fluorescence signal can occur. The 
CARHSP1 quantities were plotted against the corresponding IR fluorescence signals 
and the resulting equations were used to calculate the quantities of Pal (Figure 3.15). 
The three to four dilutions of the whole cell extracts that revealed the best standard 
curve were chosen on each membrane for the calculations. The lower molecular 
weight of Pal compared to CARHSP1 was taken into account for the quantification. 
 
Furthermore, it was considered whether the IR fluorescence signal of a purified 
protein (here CARHSP1) could be directly compared to the signal of a protein in cell 
extract, since the extract contains a lot of other proteins and cell debris that can bind 
to the nitrocellulose membrane and might reduce the binding capacity of the 
membrane for the protein of interest. Therefore, the quantification was performed 
with both pure CARSHP1 and with CARSHP1 that was added to the extract from 
TN72_SR_control with a concentration of 5x the culture volume to mimic the 
conditions in the most concentrated extract used in this experiment.  
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The results obtained for the quantification of Pal with pure CARSHP1 and CARSHP1 
mixed with the cell extract were within the same range and with overlapping standard 
deviations (Pure CARSHP1: 5.0 ± 0.9 mg / L culture volume, CARSHP1 plus cell 
extract: 6.1 ± 1.8 mg / L culture volume) (Table 3.3, Table 3.4). These results indicate 
therefore that other proteins and cell debris in the extract do not saturate the binding 
capacity of the nitrocellulose membrane and that the IR fluorescence signal of a 
purified protein can be compared to the signal of a protein in a whole cell extract.  
 
 
Table 3.3: Comparison of the quantification of Pal in whole cell extract with pure CARHSP1 and 
CARHSP1 plus TN72_SR_control extract as standards  
Cultures of TN72_SR_pal-HA were grown under standard conditions to an OD750nm of 2 and the cells 
were broken by the addition of SDS and boiling. Dilution series of TN72_SR_pal-HA whole cell 
extract and of pure CARHSP1 or CARHSP1 mixed with TN72_SR_control whole cell extract were 
analysed on the same gel and membrane in western blot analyses with anti-HA antibodies and IRDye® 
secondary antibodies. Standard curves of CARHSP1 quantities against the IR fluorescence signal of the 
Odyssey® Infrared Imaging System were used for the quantification of Pal, taking the lower molecular 
weight of Pal into account (see figure 3.15). The dilutions of the whole cell extracts with Pal on each 
membrane that revealed the best standard curve were chosen for the calculations. The standard 
deviations (±) are stated (n = x). 
 
 
 Membrane 
Pal (mg) / L culture 
volume Average 
Pure CARSHP1 standard 
1 
5.8 ± 0.5 
(n = 3) 
5.0 ± 0.9 
(n = 3) 
2 
4.0 ± 0.8 
(n = 4) 
3 
5.1 
(n = 1) 
CARSHP1 standard added to 
TN72_control whole cell extract 
(5x culture volume) 
1 
7.3 ± 2.4 
(n = 3) 6.1 ± 1.8 
(n = 2) 
2 
4.8 ± 1.0 
(n = 4) 
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Figure 3.15: Western blot analysis with whole cell extracts of TN72_SR_pal-HA and the pure HA-
tagged standard protein CARHSP1 for the quantification Pal 
Different quantities of CARHSP1 and different dilutions of whole cell extracts of C. reinhardtii 
TN72_SR_pal-HA were analysed on the same gel and membrane in western blot analyses with anti-HA 
antibodies and IRDye® secondary antibodies (A). Standard curves of the CARHSP1 quantities against 
the IR fluorescence signal of the Odyssey® Infrared Imaging System were used for the quantification of 
Pal, taking the lower molecular weight of Pal into account (B).  
 
 
3.2.4.2 Quantification of Pal using CARHSP1 and a multiple tag fusion protein 
as standards 
 
In section 3.2.4.1 it was established that the IR fluorescence signal of a purified 
protein could be used to quantify a protein in a whole cell extract. However, a 
complication of the commercial standard, CARHSP1 was that it contained two 
degradation products of ~36 kDa in addition to the full-length protein of 44 kDa. 
Furthermore, the intensity of the degradation products increased over time, even 
when stored at -80ºC. The sum of the IR fluorescence signals of all three bands was 
used for the quantification of Pal, since it was assumed that they all originated from 
full-length CARHSP1. Nevertheless, the appearance of degradation products 
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decreased the reliability of this protein as a standard. Therefore, a second standard, a 
commercial available multiple tag fusion protein (antibodies-online.com GmbH, 
Germany), was used to confirm the results obtained with CARHSP1. This was also 
done, because it is conceivable that two different proteins show a variable behaviour 
during western blot analyses (e.g. differences in the transfer properties to the 
nitrocellulose membrane, access and binding of antibodies to the protein) and that it 
might therefore be difficult to compare the IR fluorescence signals of two different 
proteins directly.  
 
Quantification was performed using two cultures: a culture in the mid-logarithmic 
phase with an OD750nm of 2, to ensure that the Pal yields per cell (per cell dry weight) 
are at the highest level, and with a culture at the end of the logarithmic phase at an 
OD750nm of 3.8. At this stage the highest yields per culture volume can be gained. 
Samples of the cultures were analysed in two different concentrations together with a 
dilution series of CARHSP1 or the multiple tag fusion protein. The yields were 
quantified as described in 3.2.4.1 (Figure 3.16). The quantification with the two 
different standard proteins gave results for both cultures with no significant 
difference (OD750nm of 2: p = 0.22443, OD750nm of 3.8: p = 0.7273) and 
overlapping standard deviations (Table 3.4). This suggests that any protein specific 
behaviour in western blot analyses plays a minor role. Furthermore, the results using 
the multiple tag fusion protein confirmed the results of the quantification with 
CARHSP1 (Table 3.3, Table 3.4). 
 
Besides quantifying the maximal amount of Pal per culture volume, it was also of 
interest to determine the yield of Pal per gram of cell dry weight. For that reason, the 
cultures used for the quantifications were freeze-dried and then used to determine the 
amount of Pal per cell dry weight. Overall the performed quantifications suggested 
that the maximal yield of recombinant Pal produced in the chloroplast of C. 
reinhardtii during mixotrophic growth and the conditions used in this study is about 
10 mg per litre of culture volume. Furthermore, the quantification indicated that Pal 
accounts for about 13 mg per g of cell dry weight in the logarithmic phase (Table 
3.4).  
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A yield of 13 mg recombinant Pal per g of cell dry weight is comparable to a recent 
study that produced bovine Milk Amyloid A (MAA) in the C. reinhardtii chloroplast 
at pilot greenhouse scale and achieved recombinant protein yields of 12 mg per g of 
cell dry weight (Gimpel et al. 2014). Furthermore, the results of these quantifications 
suggest that the yield of Pal is higher than yields that were achieved for the S. aureus 
vaccine candidate CTB-D2 (Table 1.2, 1.4.2.3.2), which accumulated to 1.6 mg per g 
of cell dry weight in the C. reinhardtii chloroplast (Dreesen et al. 2010).  
 
Most studies quantify the recombinant proteins produced in the C. reinhardtii 
chloroplast as percentage of total soluble protein (TSP) (Table 1.2, 1.4.2.3.2). 
Dreesen et al. (2010) state that TSP accounts for 23% of the total dry weight of 
lyophylized algae. Using this numbers, Pal would account for approximately 5% of 
TSP, a yield that has otherwise only been reached by a very few recombinant 
proteins. An example of such a protein is M-SAA (bovine mammary-associated 
serum amyloid), produced C. reinhardtii strain that was created by replacement of the 
endogenous psbA gene with a psbA-m-saa gene (Manuell et al. 2007).  
 
However, a protein that accumulates to 5% TSP should be clearly visible and stand 
out when cell extract of the strain is analysed on a Coomassie stained SDS-PAGE 
gel. Manuell et al. (2007) show a Coomassie stained SDS-PAGE with C. reinhardtii 
cell extract, in which M-SAA is clearly visible despite all other protein bands. 
However, Pal is hardly visible when cell extract of C. reinhardtii TN72_SR_pal-HA 
is analysed on a SDS-PAGE gel as shown in figure 4.16 and figure 4.21. One 
explanation for this could be that Pal does not retain the Coomassie stain as well as 
other proteins e.g. M-SAA. However, another explanation could be that the 
quantification with CARSPH1 and the multiple tag protein overestimate the amount 
of Pal. This could be caused by differences in the transfer behaviour of Pal to the 
nitrocellulose membrane or differences in the accessibility of Pal for the anti-HA 
antibodies in comparison to the two standard proteins. Nevertheless, the 
quantification should therefore be repeated with purified Pal as a standard to assure 
the result of the described quantification. 
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Table 3.4: Quantification of Pal at two different growth stages using CARHSP1 and a multiple 
tag fusion protein as standards 
Cultures of TN72_SR_pal-HA were grown under standard conditions to an OD750nm of 2 and 3.8; the 
cells were broken by the addition of SDS (2% w/v) and boiling. Dilution series of CARHSP1 or the 
multiple tag fusion protein were analysed together with two dilutions of TN72_SR_pal-HA whole cell 
extract on the same gel and membrane in western blot analyses with anti-HA antibodies and IRDye® 
secondary antibodies. Standard curves of quantities of the standard protein against the IR fluorescence 
signal of the Odyssey® Infrared Imaging System were used for the quantification of Pal, taking the 
lower molecular weight of Pal into account (see figure 3.15). The percentage of total soluble protein 
was determined with C. reinhardtii soluble protein extract gained after centrifugation at 13,000 x g for 
15 min. The standard deviations (±) are stated (n = x). 
 
Standard protein 
OD750nm of 
culture 
Pal (mg) / L culture 
volume 
Pal (mg) / g of cell dry 
weight 
CARSHP1 as 
standard 
2 
6.5 ± 0.8 
(n = 4) 
12.6 ± 0.7 
3.8 9.6 ± 1.6 
 (n = 4) 
NA 
Multiple tag 
fusion protein as 
standard 
2 7.2 ± 0.8 
(n = 4) 
14.0 ± 0.7 
3.8 
10.6 ± 5.0 
(n = 4) 
NA 
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Figure 3.16: Quantification of Pal in whole cell extracts of TN72_SR_pal-HA using purified CARHSP1 (A, B) and multiple tag fusion protein (C, D) and the 
Odyssey® Infrared Imaging system 
Cultures of TN72_SR_pal-HA were grown under standard conditions to an OD750nm of 2 and 3.8; the cells were broken by the addition of SDS (2% w/v) and boiling. Dilution 
series of CARHSP1 or the multiple tag fusion protein were analysed together with two dilutions of TN72_SR_pal-HA whole cell extract on the same gel and membrane in 
western blot analyses with anti-HA antibodies and IRDye® secondary antibodies (A, C). Standard curves of quantities of the standard protein against the IR fluorescence 
signal of the Odyssey® Infrared Imaging System were used for the quantification of Pal, taking the lower molecular weight of Pal into account (B, C). 
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3.3 Conclusion and future work 
 
The study described in this chapter investigated the synthesis of the endolysin Pal, a 
potential candidate for use as a novel antibiotic against S. pneumoniae, in the C. 
reinhardtti chloroplast to evaluate its suitability as a novel expression platform.  
 
Transgenic lines with a transgene encoding Pal inserted in the plastome were created, 
both with and without a HA-tag and under the control of two different 
promoters/5’UTRs. Subsequently the expression of pal was confirmed with anti-HA 
antibodies and specific anti-Pal antibodies. Furthermore these western blot analyses 
showed that no degradation products accumulate to detectable levels in the C. 
reinhardtii chloroplast, whereas an analysis of E. coli DH5α expressing pal showed 
that degradation products accumulate to even higher levels than full-length Pal protein 
in the bacterium. The choice of promoter/5’UTR element was found to have a marked 
effect on pal expression and a comparison of two elements (those from atpA and psaA 
exon 1) that had shown high levels of recombinant protein in previous studies (Purton 
et al. 2013; Michelet et al. 2011) revealed that the expression of pal is three to ten 
times higher under the influence of the psaA exon 1 compared to the atpA 
promoter/5’UTR.  
 
Growth studies showed that the accumulation of Pal in the chloroplast does not have a 
negative impact on the growth of C. reinhardtii proving that the endolysin does not 
have a toxic effect on C. reinhardtii. In contrast, a toxic effect of Pal for E. coli was 
reported by Oey et al. (2009b) and is further discussed in chapter 6.  
 
The synthesis of Pal was subsequently investigated during mixotrophic growth in 
acetate containing medium, since the highest growth rates and cell densities can be 
reached under these conditions in batch cultivation (Harris 2009) and these conditions 
consequently also result in the highest yields of recombinant protein per culture 
volume (Braun Galleani 2014). The study showed that the yield of Pal protein per cell 
is highest in the logarithmic phase under these conditions and that production, dilution 
and degradation of Pal are at equilibrium in this phase. Upon entry into the stationary 
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phase, the amount of Pal per cell decreases by about 60%. Transferring the culture 
into the dark can limit this decrease, indicating that the protein degradation in the 
stationary phase is partially light depended. Nevertheless, cultures that were grown in 
the dark from the start only reached approximately one third of the final OD750nm that 
mixotrophic cultures achieved, and had therefore 40 – 70% (depending on the growth 
stage) lower yields of Pal per culture volume, despite of the reduced protein 
degradation.  
 
These findings indicate that the best strategy for obtaining maximal yields of Pal 
protein per culture volume in batch cultivation is mixotrophic cultivation and 
harvesting of the cells at the end of the logarithmic phase. The start of the stationary 
phase and the final cell density of C. reinhardtii cultures is influenced by the quality 
of light penetration and can therefore vary with the culture volume, the speed of 
mixing and the light intensity, and therefore needs to be determined individually for 
every cultivation set up. An alternative for large-scale production is the cultivation of 
C. reinhardtii in continuous cultures, in which fresh media continuously replaces used 
media and cells. The previous results suggest a flow rate that keeps the culture in the 
late-logarithmic phase would result in the highest yields during continuous cultivation. 
Nevertheless, the optimal conditions for continuous cultivation and other specific set 
ups need to be individually determined.   
 
The cultivation of C. reinhardtii in the dark for the production of Pal is nevertheless 
an interesting option for large scale cultivation (Chen & Johns 1996a), since it makes 
it possible to use established fermentation vessels that are used for the growth of 
bacteria or yeast. Furthermore it makes the installation of growth lights dispensable 
and it is not necessary to use transparent materials and vessels with a small diameter 
to ensure sufficient light penetration of the culture. This might decrease the costs for 
the set up of the culture facilities and the costs of cultivation enough to compensate 
for the lower Pal yields gained during heterotrophic batch cultivation. Furthermore, 
continuous heterotrophic cultivation can increase the yield of biomass to up to 1.5 g 
per litre of culture volume (Chen & Johns 1996a). Alternatively, the biomass yields of 
heterotrophic cultures can be increased in fed-batch cultures or to a even higher 
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degree (up to 9 g per litre) in hollow-fibre cell-recycle systems (HFCRS), in which the 
media is replaced without cell removal (Chen & Johns 1996b).  
 
In this chapter, the stability and degradation of Pal in the chloroplast was investigated 
by inhibiting the protein synthesis by chloramphenicol. This experiment showed that 
Pal is able to withstand degradation processes for up to 122 h in both the light and the 
dark unlike the endogenous protein D1 or the human growth hormone proving that Pal 
exists as a remarkable stable protein in the C. reinhardtii chloroplast and indicates that 
Pal has a high degree of resistance to the proteolytic processes in the plastid.  
 
Furthermore it illustrated once more that the amount of Pal per cell stays at a higher 
level in cultures that are transferred to the dark. This observation indicates that the 
degradation of Pal is slowed down in the dark, this could be caused by a drop of 
stromal ATP levels, which decreases the activity of energy-dependent proteases 
(Preiss et al. 2001; Harris 2009). These results might help to narrow down which 
proteases in the C. reinhardtii chloroplast are involved in the degradation of Pal and 
other recombinant proteins. This knowledge could be useful for the identification of 
possible candidates for specific knockouts or knockdowns of nuclear genes encoding 
energy-dependent proteases with the aim of increasing the yields of recombinant 
protein. However, it is also conceivable that UV light has a negative impact on the 
stability of Pal (Teresa et al. 2012).  
 
To be able to compare quantitatively the levels of different recombinant proteins 
produced in the C. reinhardtii chloroplast, and to compare the production of Pal to 
that in conventional expression systems, a quantification was performed using two 
different HA-tagged standard proteins. This quantification revealed a maximal yield 
of recombinant Pal protein of about 10 mg per litre of culture volume, and that Pal 
accounts for about 13 mg per g of cell dry weight in the logarithmic phase, which is 
comparable to a recent study that produced bovine Milk Amyloid A (MAA) in the C. 
reinhardtii chloroplast at pilot greenhouse scale. The quantification in this study was 
performed with two different standard proteins to ensure no protein specific 
differences occurred in western blot analyses. However, the quantification should be 
further improved by using purified Pal as a standard, thus ensuring that the Pal protein 
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does not behave differently in western blot quantifications in comparison to the two 
standard proteins.  
 
Taken together, the results of this study suggest that the C. reinhardtii chloroplast can 
be used as a suitable production platform for the endolysin Pal, since reliable 
expression of predominantly full-length Pal, with a high stability was achieved. In 
contrast, expression in E. coli DH5α resulted in an accumulation of mainly 
degradation products compared to full-length protein. Nevertheless, it is of great 
importance that the recombinant Pal protein is fully active against the target bacterium 
Streptococcus pneumoniae. This is investigated, together with strategies for the 
purification of Pal, in chapter 4.  
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4 Purification of Chlamydomonas reinhardtii-produced Pal 
and analysis of its antimicrobial activity against 
Streptococcus pneumoniae 
 
4.1 Introduction 
 
4.1.1 Previous studies investigating the antimicrobial activity of the 
endolysin Pal 
 
Different research groups have studied the antimicrobial activity of E. coli-produced 
Pal. Loeffler et al. (2001) showed that Pal is effective in killing 15 different clinical 
isolates of S. pneumoniae including three penicillin resistant strains, while the 
endolysin does not affect the commensal Streptococcus strains S. gordonii, S. mutans, 
S. salvarius, S. intermedius, S. crista and S. parasanguis, even when they were 
challenged with 100 times higher dosages. Pal had also an effect on exponentially 
growing S. oralis and S. mitis strains, but at a significantly lower rate compared to S. 
pneumoniae. The study also showed that a capsule-deficient strain (R36A) and a 
mutant lacking a capsule and the major pneumococcal autolysin LytA (Lyt 4-4) have 
identical susceptibilities to Pal as the clinical isolates. Loeffler et al. concluded that 
the capsule of S. pneumoniae does not hinder Pal from accessing the cell wall and that 
LytA does not play a significant role in the lysis caused by Pal. Furthermore, Loeffler 
et al. (2001) performed electron microscopy with S. pneumoniae cells exposed to Pal. 
After one minute of exposure to Pal, protrusions of the cytoplasmic membrane and the 
cytoplasm were clearly visible and five minutes later only empty cell walls remained.  
 
Loeffler & Fischetti (2003), Jado et al. (2003) and Rodríguez-Cerrato et al. (2007) 
have described a synergistic effect of Pal in combination with another S. pneumoniae 
specific endolysin Cpl-1. In the latter study, the chequerboard technique (Lorian 2005) 
- a method in which combinations of substances are tested at different concentrations 
in microtiter plates - was used to analyse synergistic effects between Pal, Cpl-1, LytA 
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and the antibiotics cefotaxime and moxifloxacin. The study determined minimal 
inhibitory concentration (MIC) values for Pal of 32, 32, 128 and 256 mg/L for four 
different clinical isolates of S. pneumoniae. The chequerboard technique revealed 
synergy for Pal and Cpl-1 for three out of four strains and values very close to synergy 
for Pal and LytA for all strains, but no synergistic effect was observed for Pal and the 
two antibiotics and no antagonism for any of the substances. In time-kill assays, which 
analysed a decrease in colony forming units (cfu) over a time course in vitro, Pal and 
the combination of Pal with LytA decreased the cfu titres by more than two or 3 three 
log units, respectively.  
 
Another study indicated that Pal can kill bacteria within biofilms without affecting the 
structure of the biofilm (Domenech et al. 2011). Domenech et al. reported as well that 
the pH optimum of Pal is between 6.0 and 9.0. The optimum temperature for the 
enzyme activity of Pal is 37°C and the specific enzyme activity of Pal determined by 
Domenech et al. using an assay with radioactively labelled purified cell walls was 3.4 
x 104 units/mg1. 
 
The first study describing Pal isolated from S. pneumoniae cells infected by the 
bacteriophage Dp-1 showed that the activity of Pal is inhibited by temperatures of 
50°C and above, the pneumococcal Forssman antigen (1 µg/ml), cardiolipin (IC50 > 50 
µg/ml), 0.1% (w/v) deoxycholate, 0.1% (w/v) SDS, proteases such as trypsin, pronase 
E and proteinase K (50 µg/ml), as well as 10 mM CaCl2, FeSO4, CuSO4, ZnCl2, 
HgCl2, while 10 mM of LiCl, NaCl and KCl or 1% (w/v), whereas Triton X-100 did 
not affect the activity (Garcia et al. 1983a). This study observed also a strong 
stimulating effect of DTT (10 mM) on the activity of Pal. Nevertheless, this effect was 
only observed with Pal isolated from Dp-1 infected pneumococci, but not recombinant 
Pal produced in E. coli (Sheehan et al. 1997).  
 
Two animal studies have been conducted so far with E. coli-produced Pal. In the study 
by Loeffler et al. (2001), Pal was tested in a mouse model of nasopharyngeal 
                                                
1 Domenech et al. (2011) One unit of enzymatic activity is defined as the amount of enyzyme that catalyses the 
hydrolysis of 1 µg of pneumococcal cell walls in 10 min using cell walls that are radioactively labeled with 
[methyl-3H]choline. 
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colonization. Intranasally infected mice were treated by one nasal and pharyngeal 
wash 42 h after infection with 1400 units2 of Pal. The treatment with Pal decreased S. 
pneumoniae cfu to undetectable levels within 5 h, whereas high levels of cfu were 
found in the untreated controls. The same treatment with 700 units eliminated S. 
pneumoniae from five of eight mice and strongly decreased titers in the other three.  
 
Furthermore, pneumococci were exposed to low concentrations of Pal (<1 U) on agar 
plates for 16 rounds or to increasing concentrations in liquid cultures for three rounds 
in this study. The exposed cells did not shown any difference in the susceptibility to 
Pal in an in vitro assay compared to unexposed cells indicating that the occurrence of 
resistance against Pal is a rare event. Loeffler et al. (2001) explained these findings by 
the fact that Pal evolved to bind to choline in the pneumococcal cell wall and the 
presence of this molecule is critical for S. pneumoniae. The replacement of choline in 
the pneumococcal cell wall by ethanolamine results in marked changes of the cell 
physiology (López et al. 1997). Loeffler et al. concluded that S. pneumoniae cells on 
mucosal membranes are highly susceptible to the action of the lytic enzyme Pal. The 
mucosal membranes in the nasopharynx are seen as a major reservoir for S. 
pneumoniae in the population and the diminution of this reservoir would have a great 
impact on the incidence of S. pneumoniae infections. So far there are no treatments 
available to eliminate S. pneumoniae colonization on mucous membranes in humans 
without harming the beneficial bacterial flora. Loeffler et al. anticipate that Pal and 
similar endolysins are promising candidates to control nasopharyngeal carriage and 
thereby reduce the prevalence of S. pneumoniae infections.  
 
Jado et al. (2003) used a murine sepsis model, in which mice were injected 
intraperitoneally with a serotype 6B clinical isolate of S. pneumoniae with resistances 
to β-lactam, tetracycline, chloramphenicol and erythromycin antibiotics. Single doses 
of 40 µg of Pal 10 minutes after the bacterial challenge (5 x 107 cfu, a dose with a 
100% mortality rate) or 200 µg one hour after the bacterial challenge, resulted in the 
full recovery of all mice. The bacterial titres in the blood of the mice dropped by ≈4 
                                                
2 Loeffler et al. (2001) One unit of Pal is defined as the reciprocal of the highest dilution, which caused 50% 
decrease in absorbance after 15 minutes incubation at 37°C, as compared with the absorbance of the control, in a 
turbidity reduction assay (OD600nm 1.3) with equal volumes of S. pneumoniae suspension and Pal solution. 
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log units two hours after injection and were completely cleared after four to five days. 
No toxic effects were observed upon intraperitoneally administration of 200 µg of Pal. 
Heat-inactivated Pal did not rescue the mice challenged with S. pneumoniae proving 
that the observed effect is enzyme-specific. A dose of 10 µg was found to be the 
minimal effective dose, which rescued two to three out of four mice. The synergy of 
Pal and Cpl-1 was confirmed in vivo in this study, since 2.5 µg of Pal together with 
2.5 µg of Cpl-1 rescued 100% of the infected mice, whereas 5 µg of Pal or Cpl-1 
alone did not protect the mice (Jado et al. 2003).  
 
Furthermore, the immune response 10 days after the injection of Pal was analysed, 
and it was found that the titres of specific IgG antibodies to the S. pneumoniae 
serotype 6B polysaccharide were eight times higher in hyperimmune compared to 
preimmune serum. Additionally, the immune serum from the mice was shown to be 
active against Pal in western blot analyses. However, mice that got a second bacterial 
challenge and Pal treatment ten days after the first all recovered indicating that the 
immune response does not decrease the activity of Pal in vivo. Furthermore, no signs 
of anaphylaxis or adverse side effects were observed. Taken together, this makes the 
endolysin Pal a promising candidate for use as a novel, highly specific antibacterial 
agent against Streptococcus pneumoniae.  
 
 
4.1.2 Aims and Objectives 
 
The aim of the experiments presented in this chapter was to analyse the endolysin Pal 
produced in the C. reinhardtii chloroplast to see if it shows a specific lytic and 
bactericidal activity against S. pneumoniae, including clinical isolates. This was 
followed by a quantification and characterisation of the antimicrobial activity. 
Furthermore, different strategies for the purification of Pal were investigated to be 
able to analyse the antibacterial activity of C. reinhardtii-produced Pal without the 
interference of other cell components. During the performance of these experiments a 
strong antibacterial activity of C. reinhardtii extracts against S. pneumoniae was 
observed and partly characterised.   
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4.2 Results and discussion 
 
4.2.1 Production of Pal protein preparations for the performance of 
activity assays 
 
4.2.1.1 The cell wall less C. reinhardtii strain TN72 can be broken by simple 
mechanical methods 
 
For initial western blot analysis confirming and analysing the synthesis of Pal in the 
C. reinhardtii chloroplast, cells were broken by the addition of 2% SDS (w/v) and 
boiling. For the performance of activity assays, it was necessary to break the cells and 
recover Pal without denaturing the enzyme. The C. reinhardtii strain TN72 lacks an 
intact cell wall and is therefore more sensitive to mechanical and osmotic damage than 
walled strains. A cell wall-less background was specifically chosen for the recipient 
strain TN72 to enable transformation using the simple and quick glass bead method, 
which is very inefficient for the transformation of cell-wall containing strains. 
Accordingly, the lack of a cell wall should also be an advantage for cell breakage and 
the extraction of Pal using simple mechanical methods. For initial antimicrobial 
activity assays, algal extracts were applied onto nutrient agar plates followed by 
overnight incubation. Therefore it was desired to keep the extracts sterile during 
preparation. A few simple mechanical methods that do not risk the contamination of 
the extracts were therefore tested to determine whether they can lyse the cells and 
whether Pal can be recovered and separated from the cell debris afterwards. 
 
TN72_pal-HA cells were broken by freezing in liquid nitrogen, thawing at 30ºC and 
vortexing (ten seconds) for three or six cycles (F+T), in one case followed by grinding 
with a pestle. Alternatively, the cells were incubated in a sonication bath for 15 
minutes. Both methods (except for the pestle treatment) can be done in enclosed tubes 
preventing contamination, which can easily occur using cell breakage equipment such 
as a cell disrupter or French pressure cell press.  
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Figure 4.1: Western blot analysis showing the recovery of Pal in the supernatant after different 
methods of cell breakage and centrifugation 
Tn72_pal-HA cells were broken by freezing in liquid nitrogen, thawing at 30ºC and vortexing for 10 
sec (F+T) for three or six cycles, in one case followed by grinding with a pestle. Alternatively, the cells 
were put into a sonication bath for 15 min. Subsequently cells were centrifuged at 21,000 x g for 2 min. 
The presence of Pal in the supernatants and the pellets were determined by western blot analysis with 
anti-HA antibodies, IRDye® secondary antibodies and the Odyssey® Infrared Imaging system. A shows 
the western blot picture and B shows the corresponding Odyssey IR fluorescence signals.  
 
 
After breakage, the cells were centrifuged (21,000 x g, 2 min) to pellet cell debris. The 
presence of Pal in the supernatants and the pellets was determined by western blot 
analysis. Prior to that, the pellets were resuspended in the previous volume of fresh 
buffer and these samples were additionally treated with SDS and boiling to break 
leftover unbroken cells. All four methods (three cycles of F+T, three cycles of F+T 
plus pestle treatment, six cycles of F+T, sonication bath) were sufficient to recover the 
majority of Pal in the supernatant (70 to 83% (comparison between the amount of Pal 
in the supernatants and in the pellets regarding to the signal values of the Odyssey 
system)) showing that the cell-wall less strain TN72 can be easily broken by simple 
mechanical methods (Figure 4.1, Figure 4.16). The presence of Pal in the cell pellets 
is presumably caused by a portion of unbroken cells or an insoluble fraction of Pal. 
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The cells that had been broken by three cycles of freezing and thawing were 
additionally examined with a light microscope before and after breakage. Before 
breakage the vast majority of cells were clearly visible as round and intact cells, 
whereas the vast majority of cells were broken into pieces or showed an irregular 
shape after freezing and thawing indicating that the treatment was sufficient to break 
the cells (Figure 4.2). 
 
Three cycles of freezing and thawing was used routinely in the following assays in 
this chapter, since the western blot analysis indicated a recovery of approximately 
80% of Pal into the supernatant. Furthermore, it is a quick and easy method that 
prevents contamination of the protein preparations. The whole extracts were routinely 
frozen additionally in aliquots at -20ºC for storage and as a first step of breakage. The 
supernatant obtained after breakage and centrifugation is referred to as “crude extract” 
in the following sections. 
 
 
 
Figure 4.2: Microscopy of C. reinhardtii TN72_pal-HA cells before and after breakage by freezing 
and thawing 
Cells were frozen in liquid nitrogen, thawed in a 30ºC water bath and vortexed for 10 seconds for three 
cycles. The cells were analysed before and after treatment with an Olympus microscope at 400x 
magnification.  
C. reinhardtii TN72_pal-HA cells before 
freezing and thawing 
C. reinhardtii TN72_pal-HA cells after 3 
cycles of  freezing and thawing 
Round, intact cells 
Broken cells with irregular 
shapes and cell pieces 
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4.2.1.2 Production of protein preparations can be done at high cell densities 
 
For the performance of assays analysing the antimicrobial activity of Pal, it was of 
interest to produce protein preparations with a high concentration of Pal. However, a 
previous study had shown that the endolysin Cpl-1 precipitates and cannot be 
recovered in the supernatant when suspensions of TN72_(SR)_cpl-1-HA with high 
cell densities were used for cell breakage (Taunt 2013). Suspensions of whole cells 
that were concentrated more than 5x the culture volume resulted in lower amounts of 
Cpl-1 in the supernatant compared to less concentrated suspensions and 
concentrations of 100x the culture volume caused complete precipitation of Cpl-1 to 
the pellet after breakage (Taunt 2013). The recovery of Pal into the supernatant after 
the breakage of TN72_SR_pal-HA by freezing and thawing was therefore analysed at 
different cell densities.  
 
TN72_SR_pal-HA cultures were grown to an OD750nm of 2.0, harvested and 
concentrated to different cell densities (100x, 50x, 10x and 5x the culture volume). 
Subsequently the cells were broken by freezing and thawing (three cycles), followed 
by centrifugation at 21,000 x g for 5 min. The amount of Pal in the whole cell extracts 
before centrifugation and in the supernatants (= crude extracts) after breakage and 
centrifugation was determined by western blot analysis with anti-HA antibodies. The 
samples were additionally treated with SDS and boiling to ensure that all cells in the 
whole cell extract are broken. Just before the samples were loaded onto the western 
blot, all samples were diluted to the same cell density (to 5x the culture volume) to 
ensure that the samples are analysed within the linear range of the detection method 
and to make it easier to compare them afterwards. The western blot analyses showed 
similar amounts of Pal in the supernatants at all densities, indicating that the cell 
density within the analysed range does not have any influence on the solubility and 
therefore the recovery of Pal into the supernatant after cell breakage and 
centrifugation (Figure 4.3).  
 
Furthermore, the amount of Pal in the whole cell extracts before centrifugation (which 
were additionally broken by SDS and boiling) and in the supernatant fractions after 
centrifugation were found to be similar. These results confirm that freezing and 
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thawing for three cycles is a suitable method for the cell breakage of C. reinhardtii 
TN72 and the recovery of Pal. These western blot analyses also indicated that the 
treatment with SDS and boiling does not improve the cell breakage and recovery of 
Pal. Only the supernatant of the 50x culture volume sample contained about 30% less 
Pal than the corresponding whole cell extract. 
 
 
 
Figure 4.3: Western blot analysis showing the recovery of Pal in the supernatant after cell 
breakage by freezing and thawing at different cell densities 
TN72_SR_pal-HA cultures were concentrated to different cell densities and broken by freezing in 
liquid nitrogen, thawing at 30ºC and vortexing for 10 sec for three cycles, followed by centrifugation at 
21,000 x g for 5 min. The presence of Pal in the whole cell extracts before centrifugation and in the 
supernatants after breakage and centrifugation was determined by western blot analysis with anti-HA 
antibodies, IRDye® secondary antibodies and the Odyssey® Infrared Imaging system was used for 
detection (A) and for quantification (B). The expected band size for Pal-HA is 35.6 kDa. The error bars 
show ± one standard deviation (n = 2). 
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4.2.2 Antimicrobial activity of Pal against S. pneumoniae  
 
Expression of a recombinant protein in a different expression system can result in 
changes or even abolishment of the activity, since for example reductant levels, 
availability of cofactors and the protein folding as well as the proteolytic machinery 
vary in different organisms. It was therefore of great importance to show that the Pal 
protein produced in the C. reinhardtii chloroplast exhibits full antimicrobial activity 
against the target bacterium Streptococcus pneumoniae. Therefore the bacteriolytic 
and bactericidal activity of Pal was analysed and quantified, and the findings are 
discussed in the following sections.  
 
 
4.2.2.1 Bacteriolytic activity of Pal-HA in crude extracts of C. reinhardtii  
 
Pal cleaves the peptidoglycan of the S. pneumoniae cell wall between the L-alanine of 
the peptide chain and the N-acetyl-muramic acid of the sugar strand, which results in a 
rapid cell lysis and subsequent death of the cell (Loeffler et al. 2001). As lysed cells 
make a significantly lower contribution to the light scattering (measured as ‘optical 
density’ = OD) of a suspension than do intact cells, the activity of a lytic enzyme can 
be measured as a decrease in OD. This type of assay is often referred to as turbidity 
reduction assay (TRA) and has been used in several studies to measure the lytic 
activity of endolysins (Schmelcher et al. 2012). The antimicrobial activity of Pal 
produced in the C. reinhardtii chloroplast was therefore analysed by measuring its 
lytic activity using TRAs. 
 
Cells of a S. pneumoniae culture were harvested and resuspended in NaPi-buffer, 
before the addition of crude algal extracts from either TN72_SR_pal-HA or 
TN72_SR_control. Subsequently, the OD was measured at 600 nm in 1 ml cuvettes or 
595 nm in 96-well plates using a plate reader over a time course. During the first 
performances of the TRAs, it was observed that the OD decreased over time without 
the addition of crude extracts or in the presence of the control extracts. S. pneumoniae 
produces autolysins, which lyse the cells in the stationary phase and play a role in the 
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virulence of S. pneumoniae (Berry et al. 1989; Mellroth et al. 2012). The observed 
decrease of the OD was therefore most likely caused by the autolysis of the cells. It 
was found that cells from overnight cultures, where a high proportion of cells had 
already reached the stationary phase, lysed much faster than cells in the logarithmic 
phase (data not shown). S. pneumoniae cells were therefore grown in overnight 
cultures, sub-cultured the following morning and grown for six hours before the 
performance of the TRAs, to ensure that the cells are in the logarithmic phase. The 
TRAs performed with the TN72_SR_pal-HA crude extracts showed a more rapid 
decrease of the OD compared to the negative controls, confirming the lytic activity of 
C. reinhardtii-produced Pal in crude extracts against S. pneumoniae (Figure 4.4).  
 
The decrease in OD plateaued in all TRAs after a certain amount of time and never 
decreased to an OD value close to zero (Figure 4.6 A). Looking at figure 2 in Loeffler 
et al. (2001), it is not surprising that the OD did not decrease completely to zero, since 
empty cell walls remain after the lysis of S. pneumoniae by Pal, which still contribute 
to the optical density of the solution. To be able to determine if the residual OD is 
caused by empty cell walls or by residual intact cells, the bile salt detergent 
deoxycholate (0.05% w/v) was used as a positive control and to determine the 
maximal possible decrease in OD of a S. pneumoniae suspension. Deoxycholate 
induces the rapid autolysis of S. pneumoniae cultures already in the stationary phase 
(Mellroth et al. 2012). The activation of the autolysis by deoxycholate is specific to S. 
pneumoniae and is used in the diagnostic to distinguish it from other alpha-hemolytic 
Streptococcus strains (Neufeld 1900; Avery & Cullen 1920). A concentration of 
0.05% (w/v) deoxycholate was chosen, because it was effectively used in other studies 
for the lysis of S. pneumoniae (Park et al. 2007). However, an analysis of S. 
pneumoniae lysis by deoxycholate at three different concentrations (0.0125%, 0.025% 
and 0.05% w/v) during this study did not show a difference in the speed or efficiency 
of the lysis (data not shown). 
 
The described assays were performed with crude extracts that had been prepared from 
cell suspensions concentrated to 100x of the culture volume. The assay shown in 
Figure 4.4 was performed with 20 µl of crude extract, which contained approximately 
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5 µg of Pal protein, in a 200 µl reaction. This amount of Pal was sufficient to decrease 
the OD to nearly the same extent as the addition of deoxycholate (0.05% w/v). 
 
 
 
 
Figure 4.4: Turbidity reduction assay showing the lytic activity of Pal-HA in crude extract of C. 
reinhardtii against Streptococcus pneumoniae  
S. pneumoniae cells were resuspended in NaPi-buffer to an optical density (OD595nm) of 0.45 in a 96-
well plate. C. reinhardtii TN72_SR_pal-HA or TN72_SR_control crude extract (= supernatant after cell 
breakage and centrifugation at 21,000 x g for 5 min) was added (20 µl with approximately 5 µg Pal 
protein) to the cell suspension in a 200 µl reaction and the OD595nm was measured over a time course of 
90 min. Deoxycholate (0.05% w/v) was used as a positive control. The assays were performed at 37ºC. 
The error bars show ± one standard deviation (n = 3). 
 
 
4.2.2.2 Bacteriolytic activity of untagged Pal against S. pneumoniae  
 
The addition of N- or C-terminal tags can reduce or eliminate the activity of enzymes 
in some cases e.g. by hampering the correct folding (Economou, unpublished; Rehm 
2006). It was therefore important to analyse the activity of untagged Pal compared to 
HA-tagged Pal. For this purpose the strain TN72_SR_pal-x was created, which 
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synthesizes Pal without the addition of a tag. Western blot analysis with anti-Pal 
antibodies confirmed similar expression levels of Pal in TN72_SR_pal-x and 
TN72_SR_pal-HA (Figure 3.8). Subsequently TRAs were performed with C. 
reinhardtii crude extracts of TN72_SR_pal-HA, TN72_SR_pal-x and as a negative 
control Tn72_SR_control. In the assays with TN72_SR_pal-HA and the ones with 
TN72_SR_pal-x crude extract the OD595nm decreased at the same rates and to a similar 
extent during the time course (Figure 4.5). The assay was repeated five times with 
different preparations of crude extracts and different cultures of S. pneumoniae, but no 
difference between TN72_SR_pal-HA and TN72_SR_pal-x was observed indicating 
that the HA-tag does not interfere with the lytic activity of Pal. 
 
 
 
Figure 4.5: Turbidity reduction assay showing the lytic activity of C. reinhardtii-produced HA-
tagged Pal and untagged Pal 
S. pneumoniae cells were resuspended in NaPi-buffer to an optical density (OD595nm) of 0.1. C. 
reinhardtii TN72_SR_pal-HA, TN72_SR_pal-x or as a control Tn72_SR_control crude extract was 
added to the cell suspension (20 µl crude extract (prepared from whole cell extract that had been 
concentrated to 100x the culture volume) in a 200 µl reaction) and the OD595nm was measured. The 
error bars show ± one standard deviation (n = 2).  
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4.2.2.3 Specificity of C. reinhardtii-produced Pal  
 
As discussed in the introduction, endolysins are generally very specific for the host 
species of the corresponding bacteriophage. In particular, endolysins targeting Gram-
positive bacteria are often only effective against one or a few species of bacteria or 
even specific only against certain sub-species (Fischetti 2005). Pal produced in E. coli 
has been shown to lyse 15 strains of S. pneumoniae, while it showed no activity 
against commensal Streptococcus strains including S. gordonii, S. mutans, S. 
salvarius, S. intermedius, S. crista and S. parasanguis. The study showed that it is 
able to lyse S. oralis and S. mitis, which contain choline in their cell walls, but at a lot 
lower rate than S. pneumoniae (Loeffler et al. 2001). Oey et al. showed that E. coli–
produced Pal does not have any effect on E. coli when it is applied from outside to the 
cells, even when it seemed to have a toxic effect on E. coli when expressed in high 
concentrations inside the cell (Oey et al. 2009b).  
 
To test the specificity of Pal produced in C. reinhardtii, TRAs were performed with 
Escherichia coli, Streptococcus pyogenes and Staphylococcus aureus. C. reinhardtii 
crude extract containing Pal, which caused a strong decrease in the OD600nm of a S. 
pneumoniae suspension, did not have any spectrophotometrically measurable effect 
on live E. coli and S. pyogenes cells nor on a heat-inactivated suspension of S. aureus 
(Figure 4.6). These results indicate that C. reinhardtii-produced Pal shows also a high 
specificity for S. pneumoniae when it is applied from outside to the cells.  
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Figure 4.6: Turbidity reduction assays showing the specific lytic activity of Pal-HA produced in C. reinhardtii against Streptococcus pneumoniae (A) compared to 
Escherichia coli (B), Streptococcus pyogenes (C) and Staphylococcus aureus (D) 
All strains were resuspended in NaPi-buffer to an optical density (OD600nm) of 0.8. to 1.0. C. reinhardtii TN72_SR_pal-HA or TN72_SR_control crude extract (50 µl) (prepared 
from whole cell extract that had been concentrated to 100x the culture volume) was added to the cell suspension in a 1 ml reaction and the OD600nm was measured over a time 
course of 150 min at room temperature. S. aureus cells had been heat inactivated at 80ºC for 10 min before the assay, the other species were used alive just after harvest. The 
error bars show ± one standard deviation (n = 2). 
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4.2.2.4 Quantification of the bacteriolytic activity of C. reinhardtii-produced Pal 
 
After it had been demonstrated that Pal produced in the C. reinhardtii chloroplast 
shows lytic activity against S. pneumoniae, it was of interest to quantify the activity 
and to determine specific enzyme activities. It was important to compare the 
enzymatic activity of C. reinhardtii-produced Pal to E. coli- or tobacco-produced Pal 
to show that the algal-produced endolysin is fully active. Furthermore, quantification 
and standardisation facilitates the comparison of different conditions, different 
preparations of Pal and the comparison to other enzymes.  
 
 
4.2.2.4.1 Determination of specific enzyme activities  
 
Some of the previous studies that produced Pal in E. coli determined enzyme activities 
for the endolysin. However, most of these studies used different methods to analyse 
the antimicrobial activity of Pal and defined all their own units to quantify the activity 
(4.1.1), which makes it difficult to compare the enzyme activities in these studies with 
each other. In a review by Schmelcher et al. (2012) about bacteriophage endolysins, 
the authors raise the criticism that different labs use different assays and unit 
definitions, and emphasize the need for a standardization of assays and units. 
Schmelcher et al. cite Briers et al. (2007) as a good approach to standardize the 
quantification of murein hydrolase activity. The method of Briers et al. was therefore 
used in this study to quantify the activity of C. reinhardtii-produced Pal.  
 
This method involves spectrophotometric turbidity reduction assays (TRA) with 
isolated peptidoglycan, whole cells or outer membrane-permeabilized Gram-negative 
cells as substrate. After the addition of the enzyme, in TRAs with an excess of 
substrate, an initial linear decrease of optical density occurs that gradually decelerates 
when the enzyme and/or the substrate becomes limited. The slope of the linear part of 
the decrease in turbidity is usually used as direct measure for the activity of an 
enzyme. Briers et al. criticize that there are often no specifications in the literature 
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how to define the linear region. Therefore they define the linear region in their method 
as the region with the data points that result in the highest determination coefficient 
(R2) of a linear regression. The value of R2 increases the more data points are included 
and decreases outside the linear region. Maximizing R2 ensures therefore that the most 
reliable data set is used for the determination of the enzyme activity. The activity is 
then calculated using the corresponding slope of the linear regression and is expressed 
as a decrease in optical density per minute (ΔOD600nm/min). The method takes into 
account the reaction volume and expresses the activity in units/mg enzyme. The 
formula is shown in Figure 4.7 A. The calculation of activity should be performed 
with different quantities of the enzyme, since in the presence of high amounts of 
enzyme a gradual saturation occurs and eventually the maximal activity of an enzyme 
is reached.  
 
In this study, TRAs using S. pneumoniae cells from logarithmic phase cultures as 
described in 4.2.2.1 were performed to determine specific enzyme activities for Pal. 
The amount of enzyme used in the assays was determined in western blot analyses 
with the HA-tagged standard protein CARHSP1 as described in 3.2.4 and two 
dilutions of the analysed crude extract (Figure 4.7 C). Subsequently, the enzyme 
activities were calculated using the formula shown in Figure 4.7 A.  
 
When the assays were performed with three different concentrations of 
TN72_SR_pal-HA crude extract (undiluted, 1:2, 1:10 corresponding to 5.2, 2.6 and 
0.52 µg Pal in the reaction), a dosage dependency of the lysis reaction was observed 
(Figure 4.8). Furthermore, the different concentrations of crude extract containing Pal 
analysed in the same TRA resulted in comparable enzymatic activities with 
overlapping standard errors indicating that the amounts of enzyme used in the assay 
are within the dosage dependent and therefore linear range of the method (Table 4.2).  
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Figure 4.7: Determination of specific enzyme activities of Pal  
The method described by Briers et al. (2006) was used to determine specific enzyme activities for Pal produced in C. reinhardtii. Briers at al. describe a standardized 
approach for accurate quantification of murein hydrolase activity (A). The method is based on turbidity reduction assays, in which the slope of the linear region of the drop in 
turbidity after the addition of the enzyme is used to determine the enzyme activity. The linear region is defined as the data set that results in the maximal determination 
coefficient (R2 = max.) of a linear regression (B). The activity is then calculated using the corresponding slope of the linear regression and is expressed as a decrease in optical 
density per minute (ΔOD600nm/min) and takes into account the reaction volume (µl) and the amount of enzyme in mg. (A). The amount of Pal (or Cpl-1) used in the assays 
was determined in western blot analyses with the HA-tagged standard protein CARHSP1 (C).  
Activity (units/mg) =  
ΔOD595nm / (min * mg enzyme)                reaction volume (µl) 
                    0.001                                                1000 µl 
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Table 4.1: Specific enzyme activities of C. reinhardtii-produced Pal determined with different 
amounts of crude extract containing Pal 
The specific enzyme activities were determined using turbidity reduction assays with suspension of S. 
pneumoniae logarithmic phase cells at an OD595nm of 0.15 and the method by Briers et al. (2006). The 
amount of Pal was determined by western blot analyses with HA-tagged CARHSP1 protein as a 
standard. 100x CE = crude extract prepared by freezing and thawing from whole cell extract that had 
been concentrated to 100x the culture volume. The standard deviations (±) are stated (n = 4).  
 
Start OD595nm of the             
S. pneumoniae suspension 
Concentration of Pal 
 (100x CE with ≈ 5 µg Pal) 
Specific enzyme activities of Pal 
(Units/mg protein) 
OD595nm 0.15 
Undiluted 
(≈ 5 µg Pal) 
37.4 ± 3.7 
1:2 
(≈ 2.5 µg Pal) 
41.5 ± 6.9 
1:10 
(≈ 0.5 µg Pal) 
38.9 ± 5.1 
 
 
Figure 4.8: Turbidity reduction assay showing the lytic activity of Pal against Streptococcus 
pneumoniae using different amounts of Pal containing crude extract of C. reinhardtii  
S. pneumoniae cells were resuspended in NaPi-buffer to an optical density (OD595nm) of 0.15 in a 96-
well plate. C. reinhardtii TN72_SR_pal-HA or TN72_SR_control crude extract (= supernatant after cell 
breakage and centrifugation at 21,000 x g for 5 min) was added (UD = 20 µl containing ≈ 5 µg Pal) to 
the cell suspension in a 200 µl reaction and the OD595nm was measured over a time course. The assays 
were performed at 37ºC; UD = undiluted. The error bars show ± one standard deviation (n = 4). 
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However, during several performances of the experiment it was observed that the 
OD595nm of the S. pneumoniae suspension used in the assay has a strong effect on the 
calculated enzyme activities of Pal (Table 4.2). The performance of the TRA with 
cells from the same S. pneumoniae culture at an OD595nm of 0.1 compared to 0.5 
resulted in ten times higher activity values. Interestingly, the increase in activity 
plotted against the start OD595nm of the S. pneumoniae suspension showed a clear 
linear correlation (Figure 4.9).  
 
It is conceivable that this was because the substrate (here the S. pneumoniae cells) was 
not in excess and represented the limiting factor. However, experiments with smaller 
concentrations of Pal resulted in comparable activity values and resulted in an earlier 
plateauing of the final OD750nm (Table 4.1, Figure 4.8, Figure 4.23), which both 
indicates that the substrate was not the limiting factor in the reactions. Furthermore, it 
was demonstrated in a dilution series with S. pneumoniae cells that OD595nm 0.1 to 0.5 
is within the linear range of the spectrophotometer. 
 
The same assays performed with C. reinhardtii crude extract containing the endolysin 
Cpl-1 (TN72_SR_cpl-1-HA), showed also a slight increase in the enzyme activities of 
Cpl-1 in correlation to an increase of the start OD595nm of the S. pneumoniae 
suspension, but the increase was much less pronounced (Table 4.2, an increase of the 
OD595nm from 0.1 to 0.5 resulted in doubling of the activities). Rodríguez-Cerrato et 
al. (2007) analysed the interactions of Pal and Cpl-1 with the major autolysin of S. 
pneumoniae LytA in a chequerboard technique assay. The analyses resulted in values 
very close to synergy for Pal and LytA and showed a clear additive effect of the two 
enzymes for all four S. pneumoniae strains tested. The same analyses showed for Cpl-
1 and LytA only an additive effect for two out of four strains and the values were not 
close to synergy. When Garcia et al. (1983a,b) described the endolysin Pal isolated 
from Dp-1-infected S. pneumoniae cells for the first time, they observed an apparent 
involvement of the host autolysis activity in the release of Dp-1 phage particles. 
Autolysis-defective pneumococcal mutants for example showed an increased 
resistance to Dp-1 infection, which could be reversed by coating the cells with LytA 
or Pal (Garcia et al. 1983a; Garcia et al. 1983b). It is therefore conceivable that a 
release of LytA or other autolysins combined with an additive interaction of these 
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enzymes with Pal causes the observed increase in the speed of the cell lysis by Pal 
when the cell density of S. pneumoniae in the assay is increased.  
 
On the other hand, Loeffler et al. (2001) showed that the antimicrobial activity of a 
LytA deficient strain is comparable to wild-type strains and concluded that LytA does 
not contribute to the lysis by Pal. However, this study analysed only a LytA deficient 
strain and not if there is an involvement of any other S. pneumoniae autolysins. 
Furthermore, a decrease in cfu was used to analyse the enzyme activities in this study, 
which does not monitor the speed of the reaction as closely as TRAs.  
 
Additionally, the speed of lysis of S. pneumoniae by deoxycholate, increased when the 
cell densities in the TRAs were increased. The drop in ΔOD595nm/min induced by 
deoxycholate increased by 18 fold when the start OD595nm was changed from 0.1 to 
0.5 (OD595nm 0.1: -0.0048 ΔOD595nm/min; OD595nm 0.1: -0.0860 ΔOD595nm/min) and 
the increase in activity showed a linear correlation to the start OD595nm as well. 
Furthermore, it took 18 minutes to reach 90% of the maximal drop in OD595nm in the 
assay with a start OD595nm of 0.1 and only eight minutes in the one with a start 
OD595nm of 0.5 (not shown). The lysis of S. pneumoniae by deoxycholate is a result of 
the induction of autolysins and is LytA-dependent (ΔlytA mutants are not susceptible 
to lysis by deoxycholate) (Mellroth et al. 2012). This study showed as well that 
deoxycholate causes a strong release of intracellular LytA to the surroundings. 
Therefore it seems to be logical that a higher cell density causes a faster lysis of even 
more cells when lysis is triggered by deoxycholate. Since the lysis caused by Pal also 
showed a response to increasing cell densities, it is conceivable that this could be due 
to a release of autolysins after the S. pneumoniae cells have been lysed by Pal. 
Nevertheless, to confirm this hypothesis more experiments need to be performed.  
 
Furthermore, the calculated activities varied between assays performed with different 
cultures of S. pneumoniae, even when Pal preparations from the same C. reinhardtii 
culture were used (Table 4.2, Table 4.3). This might have been also due to slightly 
different growth stages of the S. pneumoniae cultures and therefore different amounts 
of accumulated autolysins.  
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Table 4.2: Specific enzyme activities of Pal and Cpl-1 determined at different S. pneumoniae cell 
densities 
The specific enzyme activities were determined using turbidity reduction assays with suspensions of S. 
pneumoniae logarithmic phase cells at different OD595nm in 96 well plates and the method by Briers et 
al. (2006). The amounts of Pal and Cpl-1 used in the assays were determined by western blot analyses 
with HA-tagged CARHSP1 protein as a standard. The standard deviations (±) are stated (n = 3).  
 
Start OD595nm of the S. pneumoniae 
suspension 
Specific enzyme activities (Units/mg protein) 
Pal Cpl-1 
OD595nm 0.5 146.1 ± 8.7 22.4 ± 1.6 
OD595nm 0.3 73.0 ± 2.9 16.6 ± 2.2 
OD595nm 0.2 44.6 ± 2.9 16.9 ± 0.4 
OD595nm 0.1 14.7 ± 0.8 9.8 ± 0.6 
 
 
 
Figure 4.9: Correlation between the start OD595nm of the S. pneumoniae suspension used in 
TRAs and the calculated specific enzyme activity of Pal 
The specific enzyme activities were determined using turbidity reduction assays with suspension of 
S. pneumoniae logarithmic phase cells and different start OD595nm in 96 well plates and the method by 
Briers et al. (2006). The amounts of Pal used in the assays were determined by western blot analyses 
with HA-tagged CARHSP1 protein as a standard. The error bars show ± one standard deviation (n = 
R² = 0.99614 
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3).  
The Cpl-1 protein preparations were prepared in the same way as described for Pal in 
4.2.1.2 and the specific enzyme activities were calculated as described above. The 
activities (per mg of protein) measured for Cpl-1 using crude extracts were in all 
performed assays lower compared to those of Pal. This was surprising, since purified 
Cpl-1 showed an even higher antibacterial activity than purified Pal (4.2.4.5) and 
previous studies described higher enzyme activities for Cpl-1 compared to Pal when 
both enzymes were produced in E. coli (Rodríguez-Cerrato et al. 2007; Domenech et 
al. 2011). The experiments analysing the activity of Cpl-1 using crude extracts shown 
in this study were all performed with TN72_SR_cpl-1 cells prepared from one culture. 
To accurately determine the specific enzyme activities of Cpl-1 and to conclude if 
Cpl-1 in crude extracts has a decreased activity, the experiments need to be repeated 
with cells from different cultures.  
 
 
4.2.2.4.2 Evaluation of the determined enzyme activities and the bacteriolytic 
activity of C. reinhardtii-produced Pal 
 
The specific enzyme activities determined in the previous section showed strong 
variations depending on the cell densities and growth stages of the S. pneumoniae 
cells. It is therefore difficult to use these activities for comparisons to Pal produced in 
other expression systems or between assays performed with different S. pneumoniae 
cultures. However, the assay described here allows the comparison of different 
preparations of Pal, and of Pal to other enzymes, in TRAs with S. pneumoniae cells 
from the same culture diluted to the same OD595nm.  
 
To decrease fluctuations of the specific enzyme activities an alternative would be to 
use isolated cell walls radioactively labelled with [methyl-3H]choline as used in a few 
studies for the analysis of E. coli-produced Pal (Sheehan et al. 1997; Domenech et al. 
2011; Jado et al. 2003). To avoid the use of assays involving radioactivity, it might be 
possible to just use isolated S. pneumoniae cell walls and measure their degradation 
spectrophotometrically as described for other bacterial species, for example 
CHAPTER 4 
 
 174 
Staphylococcus aureus (Navarre et al. 1999). Alternatively, a mutant deficient for 
LytA and other autolysins could be used for TRAs. Additionally, experiments with 
autolysin deficient mutants would help to further understand the possible involvement 
of autolysis in the lysis of S. pneumoniae by Pal.  
 
Nevertheless, some of the previously described studies used TRAs with live S. 
pneumoniae cells (Oey et al. 2009b; Loeffler et al. 2001). Oey et al. state that 100 µg 
of total soluble protein from tobacco leaves expressing Pal in a one millilitre reaction 
was sufficient to decrease the OD600nm in a TRA until only residual optical density of 
the bacterial lysate was left. In the assay shown in the publication, the OD600nm 
dropped from around 0.6 to 0.25 within one hour (Oey et al. 2009b). They state that 
Pal accounts for 30% of the total soluble protein in the tobacco leaves, which means 
the assays were performed with approximately 30 µg of Pal protein per millilitre. In 
the assay shown in Figure 4.4 the OD595nm decreased also by 0.35 from 0.5 to 0.15 in a 
200 µl reaction within one hour and was performed with approximately 25 µg/ml Pal 
protein. This indicates that the bacteriolytic activity of Pal produced in C. reinhardtii 
is comparable to the activity of tobacco-produced Pal.  
 
Loeffler et al. (2001) used TRAs only to define units for the performance of in vivo 
studies and assays analysing the bactericidal effect of E. coli-produced Pal. Most other 
studies analysed either the degradation of radioactively labelled cell walls or the 
bactericidal effect of Pal. To be able to compare the C. reinhardtii-produced Pal to E. 
coli-produced Pal while avoiding experiments involving radioactivity, assays 
analysing the bactericidal activity, for example by measuring a decrease in colony 
forming units after a treatment with Pal, need to be performed.  
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4.2.2.5 Antibacterial activity against clinical isolates of S. pneumoniae 
 
It was of particular interest to test whether Pal produced in C. reinhardtii shows 
activity against clinical isolates, including antibiotic-resistant strains, since effective 
killing of these strains would highlight the potential of Pal as a treatment when 
traditional antibiotics fail. TRAs were therefore performed with five clinical isolates 
of S. pneumoniae: Serotype 6A strain H08212 0259, serotype 6B strain H08052 0052, 
serotype 6C strain H05252 0075, serotype 27 strain H08432 0293, serotype 6B strain 
35 NP1. The strain 35 NP1 shows intermediate resistant against penicillin (Minimal 
inhibitory concentration (MIC): 0.125 µg/ml) and co-trimoxazole (MIC: 6 µg/ml).  
 
The OD595nm of all five strains decreased significantly during the time course of the 
assays in the presence of Pal when compared to the controls, which indicates that C. 
reinhardti-produced Pal has antibacterial activity against all five clinical isolates and 
shows that Pal is effective against a range of S. pneumoniae serotypes (Table 4.3, 
Figure 4.10, Figure 4.11). To determine specific enzyme activities of Pal against the 
clinical isolates, TRAs with four of the five strains and the reference strain were 
performed. The starting ODs were kept at 0.5 for all strains (except 35 NP1) to make 
the assays more comparable. As shown in Figure 4.10, the specific enzyme activities 
and also the speed of the reaction in comparison to the lysis caused by deoxycholate 
varied between the different strains. Rodríguez-Cerrato et al. also observed varying 
minimal inhibitory concentrations (MIC) when they analysed the effect of E. coli-
produced Pal against four different S. pneumoniae clinical isolates. Their study 
determined MIC values ranging from 32 to 256 µg/ml (Rodríguez-Cerrato et al. 
2007). Pal produced in C. reinhardtii showed (in all repetitions of the experiment) 
higher activities against the two serotype 6B strains and the reference strain with the 
serotype 19F, compared to the serotypes 6A and 6C. The OD595nm of suspensions of 
serotype 6A and 6C also decreased in the presence of Pal eventually until only 
residual optical density of the bacterial lysate was left when the TRAs were performed 
for a longer period of 600 min. In contrast, the enzyme activities of Cpl-1 showed 
smaller differences between different strains, but need to be confirmed in more 
repetitions of the experiment as already mentioned in 4.2.2.4.1.  
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Figure 4.10: Turbidity reduction assays showing the lytic activity of C. reinhardtii-produced Pal against four clinical isolates of S. pneumoniae 
The S. pneumoniae clinical isolates were resuspended in NaPi-buffer to an optical density (OD595nm) of around 0.5, with the exception of NP1 with an OD595nm of around 0.15. C. 
reinhardtii TN72_SR_pal-HA or TN72_SR_control crude extract (20 µl containing around 5 µg Pal protein) was added to the cell suspension in a 200 µl reaction and the 
OD595nm was measured over a time course of 100 min at 37ºC. Clinical isolates of S. pneumoniae : A = Serotype 6A H08212 0259; B =  Serotype 6B H08052 0052; C= Serotype 
6C H05252 0075; D = 35 NP1 serotype 6B. The error bars show ± one standard deviation (n = 3). 
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Table 4.3: Specific enzyme activities of Pal and Cpl-1 against different clinical isolates of S. 
pneumoniae  
The specific enzyme activities were determined using turbidity reduction assays with suspensions of S. 
pneumoniae at a start optical density (OD595nm) of 0.5, for NP1 of 0.15, and the method by Briers et al. 
(2006). The amounts of Pal and Cpl-1 used in the assays were determined by western blot analyses with 
HA-tagged CARHSP1 protein as a standard. The standard deviations (±) are stated (n = 3).  
 
S. pneumoniae 
strain 
Serotype Strain number 
Specific enzyme activities  
(Units/mg protein) 
Pal Cpl-1 
Reference strain 19F 16 NP3 462.8 ± 20.4 53.6 ± 1.5 
Clinical 
isolates 
6A H08212 0259 53.8 ± 8.2 30.4 ± 2.1 
6B H08052 0052 400.6 ± 14.0 34.5 ± 2.8 
6C H05252 0075 99.0 ± 11.9 62.0 ± 0.7 
6B 35 NP1 190.2 ± 18.5 85.8 ± 2.9 
 
 
Figure 4.11: Turbidity reduction assay showing the lytic activity of C. reinhardtii-produced Pal 
against a clinical isolates of S. pneumoniae serotype 27 strain H08432 0293 
The S. pneumoniae strain was resuspended in NaPi-buffer to an optical density (OD595nm) of around 
0.35. C. reinhardtii TN72_SR_pal-HA or TN72_SR_control crude was added to the cell suspension 
and the OD595nm was measured over a time course. The error bars show ± one standard deviation (n = 3 
for TN72_SR_pal-HA and n = 2 for TN72_SR_control). 
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4.2.2.6 Activity assays analysing the bactericidal activity of Pal 
 
The TRAs described in the previous sections proved that the recombinant Pal protein 
produced in the C. reinhardtii chloroplast is able to lyse S. pneumoniae cells, 
including clinical isolates and different serotypes. Subsequently, it was desired to have 
a direct demonstration that the endolysin efficiently kills the target bacterium and to 
compare the activity of Pal produced in this study to studies that only assayed the 
bactericidal activity of E. coli-produced Pal. Therefore, the following experiments 
analysing the bactericidal activity of Pal in crude extracts against S. pneumoniae were 
performed. In spot tests, crude extracts of TN72_pal-HA and TN72_control were 
spotted onto a lawn of S. pneumoniae cells, which had been plated onto Columbia 
blood agar plates. After incubation overnight, the plates were analysed for inhibition 
zones in the area of the spots. Alternatively, the crude extracts were mixed with a 
suspension of S. pneumoniae cells, and spotted in different dilutions onto agar plates. 
On the next day, the numbers of colony forming units (cfu) were determined and the 
cfu/ml calculated. However, it was found that both assays were hampered by an 
endogenous activity in the C. reinhardtii crude extracts, including the control extracts, 
that had a growth-inhibiting or bactericidal effect against S. pneumoniae. This is 
despite the observations above that the control extract does not induce lysis of the 
bacterial cells. 
 
Ghasemi et al. (2007) already described antimicrobial activity of C. reinhardtii culture 
supernatant and methanolic extracts against different bacterial species including 
Staphylococcus aureus and Staphylococcus epidermis. Furthermore, earlier studies 
had shown that C. reinhardtii solvent extracts had antibacterial activity against B. 
subtilis (Cannell et al. 1988; Jørgensen 1962). The next section (4.2.3) discusses the 
antimicrobial activity of C. reinhardtii in more detail. However, in order to analyse 
the bactericidal activity of Pal produced in C. reinhardtii, different strategies for the 
purification of Pal were examined to separate the recombinant endolysin from the 
endogenous antimicrobial substance in the algal crude extracts and are described in 
4.2.4. 
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4.2.3 Endogenous antimicrobial activity of C. reinhardtii crude extracts 
 
As mentioned in 4.2.2.6, an inhibitory effect against S. pneumoniae growth was 
observed for C. reinhardtii crude extracts, both with and without Pal. Crude extract 
(prepared from whole cell extract concentrated to 100x the culture volume) caused 
clear inhibition zones in lawns of S. pneumoniae platted on blood agar plates (Figure 
4.12 A). In further experiments, the crude extract was mixed in a ratio of 1:1 with S. 
pneumoniae suspensions from an overnight culture. The mixture was spotted in 
different dilutions onto blood agar plates and on the next day the colony forming units 
(cfu) were counted. In the spots treated with crude extract, no S. pneumoniae colonies 
grew at all, whereas the control with buffer contained 695,833 ± 153,922! cfu/ml 
(Figure 4.12 B). The same experiment performed with Streptococcus pyogenes, which 
is the causative agent of group A streptococcal infections like skin infections or 
pharyngitis, showed a growth inhibiting effect of the algal extracts against this species 
as well. The control contained 330 million cfu/ml, whereas the samples treated with 
C. reinhardtii crude extract contained between 0.9 and 6.6 million cfu/ml (Figure 4.12 
C).  
 
To analyse whether the crude extract just inhibits the growth of S. pneumoniae or 
actually kills the cells, the following experiment was performed. Crude extract was 
mixed with S. pneumoniae suspensions or NaPi-buffer as described above and 
incubated for one hour. Subsequently, one part of cells that had been incubated with 
crude extract and the cells incubated with NaPi-buffer were washed three times with 
buffer and spotted in different dilutions on blood agar plates. After overnight 
incubation the plates were inspected for colony forming units. The controls that were 
incubated with buffer showed strong, uncountable growth at all dilutions, whereas the 
spots with S. pneumoniae cells that had been incubated with C. reinhardtii crude 
extract did not contain any cfu, independent of whether the cells had been washed 
after the treatment or not (Figure 4.12 D). These results suggest that the crude extract 
not just inhibits the growth, but rather that it contains a substance that kills S. 
pneumoniae cells, albeit without lysis as demonstrated by the TRAs. 
  
!
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Figure 4.12: Antimicrobial activity of C. reinhardtii TN72_x crude extract against Streptococcus 
pneumoniae (A, B, D) and Streptococcus pyogenes (C) 
S. pneumoniae cells were spread onto Colombia blood agar plates, subsequently crude extract of 
TN72_pal-HA and TN72_control were spotted onto the lawn before the plates were incubated 
overnight at 35ºC (A). S. pneumoniae or S. pyogenes cells were mixed with crude extract or NaPi-
buffer, incubated and spotted at different dilutions onto blood agar plates. After overnight incubation 
the colony forming units (cfu) were counted and the cfu per ml calculated (B, C). After incubation with 
crude extract or buffer, cells were washed three times with NaPi-buffer before spotting; the figure 
shows the 1:100 dilution (D). The error bars in B and C show ± one standard deviation (n = 4).  
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The antimicrobial effect of C. reinhardtii crude extract was also tested against 
Propionibacterium acnes, Agrobacterium tumefaciens and Escherichia coli by either 
mixing suspensions of the bacteria with crude extract and spotting the mixture on 
appropriate growth medium or spotting crude extract on a lawn of the bacterium. In 
none of the experiments was an antimicrobial effect against any of the three species 
observed (Figure 4.13).  
 
Subsequently, experiments to further characterize the unknown antimicrobial 
substance were performed. Preliminary experiments indicated that the substance is or 
binds to something that is larger in size than 30 kDa, because when crude extract was 
separated with centrifugal concentrators with a MWCO of 30,000, the antimicrobial 
substance did not pass the selective membrane (not shown). The antibacterial activity 
precipitated during ultracentrifugation at 100,000 x g for one hour, which suggests 
that the substance is not soluble in aqueous solution, since soluble molecules are 
expected to stay in the supernatant during ultracentrifugation (Figure 4.14 B). Another 
preliminary experiment did not show an effect of proteinase K or pronase E (0.2 
mg/ml) on the unknown antimicrobial activity against S. pneumoniae suggesting that 
the substance is not a protein (not shown). To investigate the thermostability of the 
substance, crude extracts of TN72_pal-HA and TN72_control were heated to different 
temperatures for three minutes. Subsequently, the extracts were spotted on lawns of S. 
pneumoniae incubated overnight and inspected for inhibition zones. Above 
temperatures of 50ºC TN72_control did not cause inhibition zones anymore, whereas 
TN72_pal-HA still caused an inhibition of S. pneumoniae, although the effect was 
reduced, after incubation at 65ºC (Figure 4.14 A). The results were confirmed in two 
repetitions of the experiment. Endolysins are described as remarkably heat stable in 
the literature (up to 60°C) (Fischetti 2005) and Schmelcher et al. observed residual 
activity after incubating a Listeria bacteriophage endolysin at 90°C (Schmelcher et al. 
2011). It is therefore conceivable that Pal survived the heat treatments at 55ºC and 
65ºC, whereas the unknown endogenous substance lost its activity above 50ºC. On the 
other hand, Garcia et al. state that temperatures above 50ºC destroy the activity of Pal 
purified from Dp-1-infected S. pneumoniae cells (Garcia et al. 1983a), but they heated 
the samples for five minutes and Pal in crude extract might exhibit a higher stability 
than in purified form. Taken together, the results suggest that the endogenous 
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substance losses its antibacterial effect above temperatures of 50ºC and that Pal has 
bactericidal activity against S. pneumoniae. Nevertheless, the bactericidal activity of 
Pal needs to be confirmed with purified Pal to avoid any interference of the unknown 
antibacterial substance in the C. reinhardtii crude extract. 
 
 
 
Figure 4.13: Effect of C. reinhardtii TN72_x crude extract against Propionibacterium acnes, 
Agrobacterium tumefaciens and Escherichia coli 
P. acnes and A. tumefaciens cell suspensions were mixed with C. reinhardtii crude extract TN72_x in a 
ratio of 1:1 and incubated for 1.5 h (P.acnes) or 0.5 h (A. tumefaciens) at room temperature. 
Subsequently the mixture was spotted onto agar plates and incubated for 5 days (P.acnes) or overnight 
(A. tumefaciens). The mixture with A. tumefaciens was spotted in different dilutions onto the agar plates 
(undiluted, 1:10, 1:100, 1:1000), the undiluted spot is shown. E. coli was spread onto an agar plate and 
C. reinhardtii crude extract TN72_x (100x culture volume) was spotted onto the lawn before incubation 
overnight. C. reinhardtii crude extract did not show antibacterial activity against the three tested 
species under the used experimental conditions. 
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Figure 4.14: Effect of different temperature (A) and ultracentrifugation (B) on the antibacterial 
activity of C. reinhardtii crude extract against Streptococcus pneumoniae 
Crude extracts of C. reinhardtii TN72_pal-HA and TN72_control were heated to different temperatures 
for 3 minutes (A). Crude extract of TN72_control was separated by ultracentrifugation at 100,000 x g 
for 1 h and the pellet was resuspended in the previous volume (B). Subsequently, the samples were 
spotted on S. pneumoniae cells plated on Colombia blood agar plates. After incubation overnight the 
plates were inspected for inhibition zones. Control in A = unheated extract. 
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A few studies have already described antimicrobial activities of Chlamydomonas 
species. Ghasemi et al. described an antimicrobial activity found in the culture 
supernatant of C. reinhardtii and in methanolic extracts that was effective against 
Bacillus subtilis, Escherichia coli, Salmonella typhi, Pseudomonas aeruginosa, 
Staphylococcus aureus and Staphylococcus epidermis (Ghasemi et al. 2007). In the 
here described study, no antibacterial effect against E. coli was observed with the used 
experimental procedure and algal extracts prepared as described in 4.2.1.1. The crude 
extracts of TN72_x showed in a few assays an effect against Staphylococcus aureus, 
but the results were not consistent and therefore not seen as conclusive.  
 
Furthermore, Ghasemi et al. (2007) found an antifungal activity in C. reinhardtii 
culture supernatants against Candida kefyr, Aspergillus niger and Aspergillus 
fumigatus. The study analysed 60 strains of microalgae and found that 21 showed 
antibacterial and 17 antifungal activity. Most of them were Chlorella, Chroococcus, 
Nostoc or Anacystis species. Kellam & Walker (1989) had previously shown that a 
hexane extract of Chlamydomonas vectensis has antibacterial activity against S. 
aureus and B. subtilis, whereas the extract did not have any effect against Escherichia 
coli and P. aeruginosa. Cannell et al. (1988) observed antibacterial activity of C. 
reinhardtii methanolic extracts against B. subtilis, but stated that the extracts did not 
show activity against E. coli or S. aureus. In this study, 300 eukaryotic microalgae 
were analysed and 36 showed antimicrobial activity. Furthermore, the study showed 
that the growth medium has an influence on the production of the antimicrobial 
compounds (Cannell et al. 1988). Jørgensen (1962) first described the antibacterial 
activity of C. reinhardtii ether and ethanol extracts as well as culture supernatant 
against B. subtilis and is the only study that further characterized the antimicrobial 
substances. This study used paper chromatography and analyses of absorption spectra 
to show that chlorophyllides and other derivatives of chlorophyll cause the observed 
antimicrobial activity. The activity described in this study was dependent on 
illumination during the experiment and Jørgensen concluded that a substance formed 
by chlorophyllides during illumination probably by photo-oxidation is responsible for 
the antibacterial activity against B. subtilis.  
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The ability of chlorophylls to strongly absorb visible and near-infrared light and to 
store the energy in long-lived excited states, which is beneficial for photosynthesis, 
also render them highly phototoxic. Whenever the energy in the chlorophylls excited 
states cannot be used productively, triplet states can be formed, which can react with 
oxygen to form reactive oxygen species, which belong to the most aggressive agents 
found in nature (Scheer 2012). Several previous studies have shown that chlorophyll 
derivatives have antimicrobial activity and these substances were even used as 
antimicrobial treatments for wound healing and against infected ulcerative lesions in 
the 1940s and 1950s (Smith 1955). One conspicuous observation from the 
experiments described in this chapter is that the endogenous antimicrobial substance 
in the crude extracts was always found in the ‘green fraction’ after purification steps 
such as ultracentrifugation, ammonium sulphate precipitation, and separation with 
centrifugal concentrators (MWCO 30,000). The ‘green fraction’ contains presumably 
chlorophyll derivatives in addition to the bulk chlorophyll. This suggests that the 
antimicrobial activity that was observed in C. reinhardtii TN72_x extracts during this 
study could have also been caused by chlorophyll derivatives.  
 
Several examples of eukaryotic microalgae that use free fatty acids as defense 
mechanism against other microorganisms have been described. The free fatty acids 
are mainly part of the cell membranes and storage structures and are released after cell 
breakage and the action of lipolytic enzymes (Desbois & Smith 2010; Smith et al. 
2010). Ohta et al. showed that linolenic acid (18:3) from the green algae 
Chlorococcum HS-101 shows antibacterial activity against S. aureus, including 
MRSA strains (Ohta et al. 1994). The diatom Phaeodactylum tricornutum releases 
eicosapentaenoic acid (EPA, 20:5 (5, 8, 11, 14, 17)) after cell breakage through lipase 
activity, and EPA has antibacterial activity against a wide range of Gram-positive and 
Gram-negative bacteria (Desbois et al. 2009). Furthermore, it has been shown that 
butanoic acid (4:0) from the green alga Haematococcus pluvialis has an effect against 
E. coli and S. aureus (Amaro et al. 2011; Santoyo et al. 2009). Moreover, it has been 
shown that numerous other free fatty acids have antibacterial, antifungal and antiviral 
activity (Smith et al. 2010; Desbois & Smith 2010).  
 
 
CHAPTER 4 
 
 186 
Table 4.4 shows a comparison between the fatty acids found in C. reinhardtii 
according to Giroud et al. (1988) and fatty acids that have been shown to exhibit 
antibacterial activity. The table shows that several fatty acids that are found in C. 
reinhardtii have antibacterial properties. Some of these fatty acids (16:0, 16:1 (Δ 7), 
18:2 (Δ 9,12), 18:3 (Δ 9, 12, 15)) have even been shown to be effective against S. 
pneumoniae and other Streptococcus species (Kabara et al. 1972). Palmitic acid (16:0) 
represents about 22% of the total lipids, and the fatty acids stated in the table that have 
been shown to have antibacterial activity represent together about 80% of the total 
lipids in C. reinhardtii.  
 
It is therefore conceivable that the observed antibacterial activity against S. 
pneumoniae and S. pyogenes of C. reinhardtii TN72_x is at least partly caused by 
antibacterial fatty acids. The previously mentioned observation that the antibacterial 
activity was found in the ‘green fraction’ (the chlorophyll containing fraction) after 
purification steps such as ultracentrifugation, ammonium sulphate precipitation and 
separation using centrifugal concentrators (MWCO 30,000) does not contradict this. 
The chlorophyll is connected to membrane proteins and to the cell membranes. 
Furthermore, membrane lipids and chlorophyll have similar polarities. It would be 
therefore not surprising that membrane lipids and chlorophyll react in similar ways in 
these purification steps. Membrane lipids are, for example, known to precipitate 
during ultracentrifugation. On the other hand, the observed temperature sensitivity of 
the substance is contradictory, since free fatty should be able to withstand 
temperatures of 55 to 60ºC. In contrast, it is conceivable that chlorophyll is sensitive 
to temperature within this range. 
 
It is conceivable that a combination of different substances including chlorophyll 
derivatives and certain fatty acids are responsible for the antibacterial activity of C. 
reinhardtii TN72_x against Streptococcus species observed in this study. 
Nevertheless, more experiments need to be performed to identify and characterize the 
substances that cause this activity.  
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Table 4.4: Comparison between fatty acid composition of Chlamydomonas reinhardtii and fatty 
acids that have been show to have antibacterial properties 
Column one shows the fatty acid composition of total lipids from C. reinhardtii 137c regarding to 
Giroud et al. (1988), in bold are fatty acids that represent more than 10% of the total lipids, the other 
columns show antibacterial fatty acids, the organisms they were effectively tested on and the reference. 
The fatty acids are named with their lipid numbers (C:D) and the Δx nomenclature, which counts the 
double bonds starting from the carboxyl acid end, the fatty acids are cis unless stated, t = trans.   
 
Fatty-acids in 
C. reinhardtii 
(Giroud et al. 1988) 
Antibacterial  
fatty acids 
Susceptible test 
organisms Reference 
16:0 16:0 Palmitic acid 
Several Gram- marine 
pathogens Benkendorff et al. (2005) 
Several Gram+ Galbraith et al. (1971) 
Several Gram+, 
 incl. S. pneumoniae Kabara et al. (1972) 
16:1 (7) 16:1 (7) 
16:1 (9) 
Palmitoleic acid 
16:1 (9t) 
Palmitelaidic acid 
Neisseria gonorrhoeae Bergsson et al. (1999) 
16:1 (9) 
Bacillus larvae Feldlaufer et al. (1993) 
Several Gram+, 
incl. S. pneumoniae Kabara et al. (1972) 
16:1 (3t) - - - 
16:2 (7, 10) - - - 
16:3 (4, 7, 10) - - - 
16:3 (7, 10, 13) - - - 
16:4 (4, 7, 10, 13) - - - 
18:0 18:0 Stearic acid 
Several Gram- marine 
pathogens Benkendorff et al. (2005) 
Several Gram+ Galbraith et al. (1971) 
18:1 (9) 
18:1 
18:1 (9) 
18:1 (11) 
18:1 (cis) 
18:1 (trans) 
Several Gram- marine 
pathogens Benkendorff et al. (2005) 
18:1 (11) 
Several Gram+ Galbraith et al. (1971) 
Streptococcus group A Kabara et al. (1972) 
Bacillus larvae Feldlaufer et al. (1993) 
18:2 (9,12) 
18:2 (9, 12) 
18:2 
Linoleic acid 
Several Gram+ Galbraith et al. (1971) 
Several Gram+,  
incl. S. pneumoniae Kabara et al. (1972) 
Bacillus larvae Feldlaufer et al. (1993) 
18:3 (5, 9, 12) 18:3 
18:3 (9, 12, 15) 
18:3 (6, 9, 12) 
Linolenic acid 
Several Gram+ Galbraith et al. (1971) 
18:3 (9, 12, 15) 
Several Gram+,  
incl. S. pneumoniae Kabara et al. (1972) 
Bacillus larvae Feldlaufer et al. (1993) 
18:4 (5, 9, 12, 15) 18:4 Several Gram- marine pathogens Benkendorff et al. (2005) 
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4.2.4 Purification of Pal 
 
The purification of Pal is essential in order to study the activity of C. reinhardtii-
produced Pal without the interference of other cell components, especially the 
endogenous antibacterial substance present in the alga. Furthermore, for the 
performance of in vivo studies, Pal needs to be purified to remove transgenic DNA 
and immunogenic compounds. The long-term goal is to use C. reinhardtii-produced 
Pal as a therapeutic agent. Therefore an efficient and economical method for the 
purification of Pal needs to be developed. Different purification and enrichment 
steps/methods were performed during this study and are discussed in this chapter.  
 
 
4.2.4.1 Ultracentrifugation as a first step for the purification of C. reinhardtii-
produced Pal 
 
Previous studies described ultracentrifugation as a first step for the purification of 
Escherichia coli-produced Pal (Jado et al. 2003) (Loeffler et al. 2001). 
Ultracentrifugation can be used to remove cell debris, membrane pieces and non-
soluble proteins, whereas most soluble proteins stay in solution. 
 
Cells were broken by freezing and thawing and major cell debris was removed by 
centrifugation at 5,000 x g for 15 min (= low speed centrifugation), before 
ultracentrifugation at 100,000 x g for one hour. The majority of Pal (about 80% 
regarding to the IRF 3  signals) remained in the supernatant during low speed 
centrifugation. The amount of Pal that was detected in the pellet is presumably caused 
by a portion of unbroken cells or Pal that got trapped in or bound to major cell debris 
(Figure 4.15). As shown in Figure 4.15, the vast majority of Pal also remained in the 
supernatant during ultracentrifugation (98% (comparison between UC↵ supernatant 
and pellet), 82% (comparison between 5K↵ and UC↵ supernatant)) suggesting that 
the majority of Pal exists as a soluble protein in the chloroplast of C. reinhardtii.  
                                                
3 IRF = The Infrared fluorescence signals measured by the Odyssey® Infrared Imaging system were used to 
estimate the amount of Pal present in samples that were analysed in western blots. 
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An analysis of the protein extracts before (5K↵ supernatant) and after 
ultracentrifugation (UC↵ supernatant) on a Coomassie stained SDS-PAGE showed 
that ultracentrifugation can be used as an effective first step to remove a high 
proportion of cell debris and non-soluble proteins. It also removes the membrane-
associated chlorophyll, which interferes with western blot detection systems by 
increasing the background of blots detected by the Odyssey infrared (IR) fluorescence 
system. Furthermore, chlorophyll increases the background in SDS-PAGE analyses 
(Figure 4.15 C) and photometric turbidity reduction assays. 
 
 
 
 
Figure 4.15: Western blot analysis (A, B) and SDS-PAGE (C) showing ultracentrifugation as a 
first step for the purification of C. reinhardtii TN72_SR_pal-HA  
C. reinhardtii cells (whole cell extract that had been concentrated to 100x the culture volume, grown to 
an OD750nm of 2) were broken by freezing and thawing and major cell debris was removed by low speed 
centrifugation (5,000 x g for 15 min). Ultracentrifugation was performed at 100,000 x g for 1 h. 
Samples were collected after each centrifugation step and analysed by western blot analysis with anti-
HA antibodies and IRDye® secondary antibodies. The Odyssey® Infrared Imaging system was used for 
detection (A) and for quantification (B). Samples were also analysed on a Coomassie stained SDS-
PAGE (C). The error bars in B show ± one standard deviation (n = 2). 
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4.2.4.2 Enrichment of Pal using ammonium sulphate precipitation  
 
Ammonium sulphate precipitation is an inexpensive purification method, which can 
be used in large-scale protein purifications (Burgess & Jendrisak 1975; Lohman et al. 
1986). Proteins differ markedly in their solubility at different concentrations of 
ammonium sulphate and therefore can be easily separated by this method.  
 
The ammonium sulphate concentration of UC↵ supernatant was increased stepwise 
and the extract was centrifuged (3,000 x g for 15 - 30 minutes) at the end of each step. 
The pellet of precipitated proteins was resuspended in fresh buffer (with 10% of the 
previous volume), whereas the supernatant was treated with a higher concentration of 
ammonium sulphate (Deutscher, 1990). The majority of Pal (approximately 85% 
suggested by the IRF signals) precipitated between 25% and 30% saturation (= 30% 
AS). Smaller amounts of Pal precipitated at an ammonium sulphate concentration of 
20%, 25% and 35% saturation (Figure 4.16 A, B). The findings were confirmed in 
two repetitions of the experiment.  
 
An analysis of the UC↵ supernatant and the 30% AS fraction on a Coomassie stained 
SDS-PAGE showed that ammonium sulphate precipitation is a further useful step for 
the enrichment of Pal, since it separates Pal from a high number of other proteins 
(Figure 4.16 D). Furthermore, it easily allows the concentration of the protein extract. 
In the experiments shown the protein extract was concentrated by a factor of 10 
(Figure 4.16 A, B; Figure 4.17 A, B), but the concentration factor could be further 
increased.  
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Figure 4.16: Western blot analysis (A, B, C) and Coomassie stained SDS-PAGE (D) showing the enrichment of Pal using ammonium sulphate precipitation 
The ammonium sulphate concentration of ultracentrifugation supernatant (gained at 100,000 x g for 1h (= UC↵ supernatant)) of C. reinhardtii TN72_SR_pal-HA was increased 
stepwise, stirred on ice for 15 min and centrifuged (3,000 x g, 15 min) at the end of each step. The pellet was resuspended in fresh buffer with 10% of the previous volume. 
Samples from resuspended pellets (20%, 25% etc. ammonium sulphate concentration (% saturation)) were analysed by western blot with anti-HA antibodies, IRDye® secondary 
antibodies and the Odyssey® Infrared Imaging system. A shows the western blot picture, B the corresponding Odyssey IR fluorescence signals. C and D show the UC supernatant 
before the ammonium sulphate precipitation and the precipitated fraction (30% AS) with the highest amount of Pal. D shows the total protein content on a Coomassie stained 
SDS-PAGE and C the corresponding anti-HA western blot. The expected band size for Pal is 35.6 kDa.  
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4.2.4.3 Immunoprecipitation with monoclonal anti-HA agarose conjugate resin 
for the purification of Pal 
 
Anti-HA antibody conjugated agarose resin (Sigma-Aldrich) can be used for the 
purification of HA-tagged proteins. The antibodies bind with high specificity to HA-
tagged proteins, and the proteins can be eluted by a pH shift to 2.5 or by using high 
concentrations of HA peptide.  
 
The fraction of proteins that precipitated between 25% and 30% ammonium sulphate 
concentration (30% AS) was incubated with anti-HA agarose (volume ratio of sample 
to resin: 3-5:1) for 4 – 16 h at 4ºC. After five washes with NaPi-buffer, Pal was eluted 
by Glycine-HCl buffer (pH 2.5) with a volume equal to the volume of the loaded 
sample, followed by neutralisation (pH 7). Alternatively, Pal was eluted with 100 
µg/ml of HA peptide to exclude inactivation of the protein by the low pH. In both 
cases a second elution at pH 2.5 was performed to ensure complete elution of Pal from 
the resin.  
 
As shown in Figure 4.17 (A, B) the resin was able to bind Pal and it was possible to 
elute the majority of bound Pal in one step when using Glycine-HCl (pH 2.5) as 
eluent. However, the flow through still contained a high amount of Pal (approximately 
35% of the applied sample in the shown experiment). Extension of the incubation time 
to 16 h did not improve the binding capacity (not shown). A decrease of the sample to 
resin ratio from 5:1 to 3:1 decreased the loss of Pal into the flow only to about 20% 
(not shown). Nevertheless, it was possible to detect a faint band in the lane of the first 
elution on the Coomassie stained gel at the size of Pal (36.5 kDa) and to remove the 
majority of other proteins (Figure 4.17 C), which were still present in the 30% AS 
fraction (Figure 4.16 D). HA peptide could also be used to elute Pal (Figure 4.17 D, 
E), however, this procedure was not as effective, since the following elution at pH 2.5 
still contained about 70% of the amount of Pal eluted with the HA peptide (Figure 
4.18 D, E).  
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Figure 4.17: Purification of C. reinhardtii-produced Pal protein with monoclonal anti-HA agarose 
conjugate resin 
Ultracentrifugation supernatant of TN72_SR_pal-HA was precipitated with ammonium sulphate. Anti-
HA agarose was incubated with the suspension of proteins that precipitated between 25% and 30% 
ammonium sulphate concentration (= 30% AS) for 5 h at 4ºC. After 5 washes with NaPi-buffer, Pal 
was eluted in the same volume of Glycine-HCl buffer (pH 2.5) as the loaded sample, followed by pH 
neutralisation. Samples taken before and after this purification step were analysed by western blot with 
anti-HA antibodies and IRDye® secondary antibodies. The Odyssey® Infrared Imaging system was used 
for detection (A, D) and quantification of the bands (B, E). The elution samples were additionally 
analysed on a Coomassie stained SDS-PAGE protein gel (C). In a second experiment Pal was first 
eluted with HA peptide (100 µg/ml), followed by a second elution at pH 2.5 (D, E). UC↵ supernatant 
= supernatant after ultracentrifugation at 100,000 x g for 1h.  
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In a combination of ultracentrifugation, ammonium sulphate precipitation and 
immunoprecipitation with monoclonal anti-HA agarose conjugate resin, Pal could be 
sufficiently purified and enriched that it could be visualized as a faint band on a 
Coomassie stained SDS-PAGE. However, the binding capacity of the resin for Pal 
was exceeded in all repetitions of the experiment. Anti-HA agarose is relatively 
expensive (£160-300/ml with a binding capacity of 30-50 nmol/mL (SIGMA July 
2014)) and therefore not feasible for large-scale purifications. Furthermore, in spite of 
the high specificity of the antibody-conjugated resin, there were still other proteins 
present in the elution from the anti-HA resin (Figure 4.17 C). 
 
 
4.2.4.4 Purification with diethylaminoethanol (DEAE) cellulose and choline as 
specific eluent 
 
Diethylaminoethanol (DEAE) cellulose was used in previous studies for the 
purification of Escherichia coli-produced Pal with choline as the specific eluent 
(Loeffler et al. 2001; Jado et al. 2003). The method used in these study is based on the 
methods reported by Sanchez-Puelles et al. (1992) and Sanz et al. (1988). Pal and 
other S. pneumoniae cell wall hydrolases (e.g Cpl-1, LytA) bind specifically to 
choline residues of the teichoic acids in the pneumococcal cell wall. The binding is 
required for the hydrolytic activity of these enzymes. DEAE is a choline analogue 
(Figure 4.18) and can bind these hydrolases as well (Sanchez-Puelles et al. 1992). The 
binding is strong enough to withstand a high salt wash at 1.0 or 1.5 M NaCl, which 
removes a high number of contaminant proteins, while choline-binding hydrolases can 
be specifically eluted with a buffer containing choline (2 to 6.5%). Henry Taunt 
(Taunt 2013) established the method for the purification of the S. pneumoniae 
endolysin Cpl-1 produced in C. reinhardtii. The purification with DEAE cellulose and 
choline described in this section is based on his findings and the previously mentioned 
studies.  
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Figure 4.18: Comparison of the structural formulae of choline and the choline analogue 
diethylaminoethanol (DEAE). (Source: www.wikipedia.com) 
 
 
Cells of TN72_SR_pal-HA and TN72_SR_control were concentrated to 100x the 
culture volume, broken by freezing and thawing followed by low speed centrifugation 
and ultracentrifugation. The UC↵ supernatants were loaded onto a column with 
DEAE cellulose with a sample to column volume ratio of 1:1 or 1.5:1. The loading 
was repeated three to four times. Subsequently, the column was washed with six 
column volumes of NaPi-buffer (pH 6.9), followed by washes with eight column 
volumes of NaPi-buffer containing 1.5 M NaCl and four column volumes of NaPi-
buffer plus 0.1 M NaCl. The elution was performed with NaPi-buffer containing 0.1 
M NaCl and 6.5% (w/v) choline and collected in 1 or 1.5 ml samples.  
 
The elution samples were analysed together with samples from previous steps in 
protein microarrays on nitrocellulose membrane with anti-HA antibodies and the 
Odyssey® Infrared Imaging system. Protein microarrays allow the simultaneous 
analysis of high numbers of samples. However, since chlorophyll fluorescence causes 
a strong background signal, this type of protein microarray is only suitable for 
samples containing hardly any chlorophyll (e.g. after ultracentrifugation). Cells of the 
corresponding negative control strain were processed in the same way and samples 
were analysed in the same protein microarray. The IR fluorescence signals that were 
detected in the protein microarray of the negative control, were subtracted from the 
corresponding samples with Pal before the analyses to account for background 
fluorescence.  
The DEAE cellulose columns were able to bind the vast majority of the C. reinhardtii-
produced Pal using the described experimental procedure, since the signals of the 
Choline Diethylaminoethanol (DEAE)  
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protein microarrays detected in the flow through were only around 5% 4 of the signals 
detected in the UC↵ supernatants that were applied to the columns (Figure 4.19 A, 
B). Furthermore, a western blot analysis with anti-HA antibodies of the flow through 
did not show any band at the size of Pal-HA, whereas the applied UC↵ supernatant 
showed a strong band (Figure 4.21 B). 
 
In all purification attempts, it was possible to elute the majority of Pal in three to five 
elution fractions (Figure 4.19 A, B). During the first attempt with one litre cultures 
and a sample column ratio of 1:1, the concentration of Pal could be doubled in the 
elution fractions with the highest amount of Pal (E7 and E8) compared to the UC↵ 
supernatant that was applied to the column (5.62 (UC↵) : 11.06 (E8), Figure 4.19 A) 
as indicted by the IR fluorescence signal values of the protein microarray. An analyses 
of the IR fluorescence signal values of the protein microarray suggested that 
approximately 72% 5 of the amount of Pal applied to the column could be recovered 
into the elution fractions in the experiment shown in Figure 4.19.  
 
  
                                                
4 Percentage of Pal in flow through compared to amount applied to the DEAE column: Performance 1: 100% / (IR 
fluorescence signal (IRF) of the UC↵ supernatant minus the IRF of the corresponding control sample (6.92 – 1.3)) 
= 5.62 x IRF of flow through (0.33 – 0.07) = 4.6%; Performance 2: (100% / 818653) * 40149 = 4.9%. 
 
5 Percentage of Pal recovered in the elution fractions: IRF of the applied UC↵ supernatant (6.92 – 1.3) = 5.62 x 9 
ml (volume applied to the column) = 50.58; IRF’s of 1 ml elution fractions with Pal: 10.24 + 11.05 + 7.95 + 3.99 + 
1.75 + 1.04 + 0.52 = 36.54; percentage recovered: 100% / 50.58 x 36.54 = 72%.  
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Figure 4.19: Protein microarray showing the enrichment of C. reinhardtii-produced Pal protein 
with diethylaminoethanol (DEAE) cellulose and choline as specific eluent 
Ultracentrifugation supernatant (= UC extract) of C. reinhardtii TN72_SR_pal-HA (A, B) and of 
TN72_SR_control (C, D) were applied to DEAE cellulose columns (total volume 9 ml). After high salt 
washes, Pal was specifically eluted with choline (1 ml elution fractions). Samples of the different steps 
of the purification were spotted onto a nitrocellulose membrane, which was incubated with anti-HA 
antibodies and IRDye® secondary antibodies. The Odyssey® Infrared Imaging system was used for 
detection (A, C) and quantification (B, C). Flow = flow through; W1.1, 1.2 = Wash with NaPi-buffer 
(pH 6.9); W2.x = wash with NaPi-buffer + 1.5 M NaCl; W3.x = wash with NaPi-buffer + 0.1M NaCl. 
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The binding to choline in the cell wall is essential for the function of Pal and therefore 
free choline bound to the binding sites of Pal inhibits its activity (Domenech et al. 
2011). For this reason, the eluted fractions with the highest amounts of Pal were 
combined and dialysed against NaPi-buffer to remove the choline. The dialysis caused 
no marked loss of Pal, since western blot analysis and Coomassie stained SDS-PAGE 
gels showed similar signals for the samples before and after dialysis (Figure 4.20 A, 
B; Figure 4.21 C). 
 
Centrifugal concentrators (MWCO 30,000) were used as a next step to concentrate the 
amount of Pal in the combined and dialysed elution fractions. In the experiment here 
reported the previous volume was reduced to a quarter. However, the amount of Pal 
measured by western blot analysis suggested only an increase by a factor of two 
(76.61 / 37.43 = 2.05) (Figure 4.21 A, B). The use of centrifugal concentrators 
resulted in losses of a similar extent in repetitions of this experiment and in other 
experiments. Additionally, the concentrated elution fractions and the UC↵ 
supernatant (that was applied to the column) were analysed on a Coomassie stained 
SDS-PAGE for their total protein content. A faint band was visible for the 
concentrated elution fraction and it was possible to remove most other proteins beside 
traces of a 55 kDa protein, presumably the large subunit of the abundant Rubisco 
protein (Figure 4.20 C).  
 
To decrease losses during the last concentration step and to remove the traces of the 
55 kDa protein, further concentration/purification steps were considered. It has been 
shown in section 4.2.4.2 that ammonium sulphate precipitation is an efficient method 
for the concentration of Pal. Furthermore, it separates proteins depending on their 
solubility in the presence of different concentrations of ammonium sulphate. 
Therefore, Pal in the combined and dialysed elution fractions was precipitated in one 
step with an ammonium sulphate concentration of 35% saturation. A one step 
precipitation with a concentration of 35% saturation was chosen to minimize losses of 
Pal, since although the majority of Pal precipitates at 30%, smaller fractions of Pal 
precipitate in a range of 20% up to 35% saturation (4.2.4.2) and at 20% saturation and 
below hardly any proteins precipitated overall (not shown).  
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Figure 4.20: Western blot analysis showing the dialysis and concentration of Pal (A, B, D) and 
SDS-PAGE showing the purification of Pal with diethylaminoethanol (DEAE) cellulose and 
choline as specific eluent (C) 
Ultracentrifugation supernatant of C. reinhardtii TN72_SR_pal-HA was purified using DEAE cellulose 
and choline as specific eluent. The elution fractions containing Pal were combined and dialysed against 
NaPi-buffer to remove the bound choline and concentrated to a quarter of the previous volume using a 
centrifugal concentrator (MWCO 30,000) (A, B). The combined, dialysed and concentrated elution 
fractions as well as the UC supernatant before purification were compared on a Coomassie stained 
SDS-PAGE (C), the corresponding western blot analysis of the elution is shown in D. UC supernatant = 
ultracentrifugation supernatant before application to the column; E, Elu. = elution; dia. = dialysed; CC 
conc. = concentrated with centrifugal concentrator (MWCO 30,000). 
 
 
Figure 4.21 B, D shows a Coomassie stained SDS-PAGE and the corresponding 
western blot analysis of all previous purification steps and of the elution concentrated 
by ammonium sulphate (AS) precipitation. The AS precipitated elution revealed a 
strong band at the size of Pal-HA on the SDS-PAGE and at the same time there were 
no other bands visible in the same lane. The corresponding western blot analysis with 
anti-HA antibodies confirmed a strong band at the same size. 
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Figure 4.21: Western blot analysis (A) and Coomassie stained SDS-PAGE (B, C) showing the 
purification of Pal using ultracentrifugation, diethylaminoethanol (DEAE) cellulose with choline 
as specific eluent and ammonium sulphate precipitation 
Ultracentrifugation supernatant (= UC sup.) of C. reinhardtii TN72_SR_pal-HA was purified using 
DEAE cellulose and choline as specific eluent. Subsequently the elution fractions with the highest 
amount of Pal were combined, dialysed and precipitated with 35% ammonium sulphate (% w/v) (= AS 
conc.). Samples of the UC sup, flow through and elution fractions were analysed in a western blot with 
anti-HA antibodies and IRDye® secondary antibodies and the Odyssey® Infrared Imaging system (A) 
and on a Coomassie stained SDS-PAGE (B). The bands of Pal in the combined, the dialysed and the 
AS precipitated elution were quantified using the Odyssey® Infrared Imaging system (C), CE = crude 
extract, sup. = supernatant, elu. = elution, dia. = dialysed, flow = flow through. 
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In the experiment shown in Figure 4.22, the pellet of precipitated proteins obtained 
after AS precipitation and centrifugation was resuspended in NaPi-buffer with 10% of 
the previous volume. A quantitative analysis of the SDS-PAGE using the Odyssey® 
Infrared Imaging system showed an increase in the strength of the Pal band by 8.5 
times when the bands of the samples before and after AS precipitation were compared 
(Figure 4.21 C). The corresponding western blot analysis could not be used for 
quantification in this experiment, since the intensity of the bands exceeded the linear 
range of the Odyssey® Infrared Imaging system. In another performance of the 
purification the AS precipitated elution was resuspended in 20% of the previous 
volume and the signal of the western blot analysis increased by 3.6 times (not shown). 
This suggests that the losses during concentration of the elution samples using AS 
precipitation are less compared to losses of approximately 50% when centrifugal 
concentrators were used. The use of AS precipitation as a last step also allows the 
recovery of all the Pal protein from those fractions with lower concentrations of the 
enzyme (E11 - E13 in Figure 4.19 B). This can be done by pooling the fractions and 
concentrating the combined pool using AS precipitation. Furthermore, no bands of 
other proteins were detectable on the SDS-PAGE when AS precipitation was used as a 
last step. 
 
Overall, using a combination of ultracentrifugation, DEAE cellulose with choline as 
eluent and ammonium sulphate precipitation, it was possible to visualize Pal as a 
strong single band on a Coomassie stained SDS-PAGE in the absence of any with this 
method detectable contaminant proteins.  
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4.2.4.5 Antimicrobial activity of Pal purified with ultracentrifugation 
diethylaminoethanol (DEAE) cellulose and ammonium sulphate 
precipitation 
 
C. reinhardtii-produced Pal purified using ultracentrifugation, DEAE cellulose and 
choline, as well as ammonium sulphate precipitation was subsequently used to analyse 
the antibacterial activity of C. reinhardtii-produced Pal without the interference of 
other cell components. This was of particular interest, since it was now possible to 
analyse the bactericidal activity of Pal without the inference of the endogenous 
antimicrobial substance in C. reinhardtii.  
 
 
4.2.4.5.1 Bacteriolytic activity of purified Pal 
 
The first aim was to show that the purification procedure does not destroy the activity. 
The activity of Pal is reduced by 50% in the presence of 2 mM choline (IC50) 
(Domenech et al. 2011) and here Pal was eluted from the DEAE cellulose column 
with 625 mM choline. Therefore the presence of residual choline could inhibit the 
activity of Pal after purification. Additionally, proteases, oxidation processes or other 
conditions that Pal was exposed to during the purification process, could have 
destroyed its antimicrobial activity.  
 
For that reason, TRAs as described in 4.2.2.1 were performed with purified Pal and 
the control strain processed in the same way, as well as crude extracts of 
TN72_SR_pal-HA and TN72_SR_control. Figure 4.21 shows a western blot analysis 
and a Coomassie stained SDS-PAGE of the purified Pal (Elu. Dia. AS conc.) and the 
crude extract containing Pal (21K Sup., CE) used in this TRA in Figure 4.22. In the 
presence of purified Pal and TN72_SR_pal-HA extract, the OD of the S. pneumoniae 
suspension decreased significantly compared to the corresponding controls. The 
decrease in the presence of purified Pal was five times faster compared to the decrease 
in the presence of TN72_SR_pal-HA crude extract (ΔOD595nm/min: -0.0065 (purified 
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Pal), -0.0013 (CE)) in the shown experiment (Figure 4.22). This!shows that purified 
Pal retained its bacteriolytic activity during the purification and that the concentration 
of Pal protein during the purification resulted in a five fold concentration of the 
antibacterial activity of Pal.  
 
However, analyses of the bacteriolytic activity of samples from different steps of the 
purification showed opposite trends during different purifications and TRAs, and the 
results were therefore not seen as conclusive (not shown). For that reason, it was not 
possible to determine quantitatively whether stages of the purification cause losses of 
the enzymatic activity of Pal. Nevertheless, an analysis of the bacteriolytic activities 
of samples from every purification step combined with an analysis of the amount of 
Pal in the samples, would be very useful to determine whether certain purification 
steps result in a reduction of the enzymatic activity of Pal and would be of great help 
to improve the purification of Pal. Furthermore, it would make it possible to 
investigate whether the endogenous activity in crude extracts of C. reinhardtii has an 
additive effect on the lysis of S. pneumoniae by Pal. 
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Figure 4.22: Turbidity reduction assay showing the bacteriolytic activity of purified Pal and Pal 
in C. reinhardtii crude extract against S. pneumoniae  
Cultures of TN72_SR_pal-HA and TN72_SR_control were grown to an OD750nm of ≈2, harvested and 
concentrated to 100x the culture volume. Pal was purified with ultracentrifugation, diethylaminoethanol 
(DEAE) cellulose and choline as specific eluent, as well as ammonium sulphate precipitation. S. 
pneumoniae cells were resuspended in NaPi-buffer to an optical density (OD595nm) of 0.23. Crude 
extract of TN72_SR_control, TN72_SR_pal-HA, purified Pal or control extract treated in the same way 
were added to the cell suspension and the OD595nm was measured. The error bars show ± one standard 
deviation (n = 2). 
 
 
TRAs performed with purified Pal showed also a clear dosage dependent response 
(Figure 4.23). Furthermore, these TRAs showed (even clearer than in Figure 4.8) that 
lower amounts of Pal enzyme in the assay not only result in a lower speed of the lysis 
reaction, but also in a plateauing of the lysis before reaching the maximal decrease, 
which was defined by deoxycholate (Figure 4.23). Moreover, a second addition of Pal 
enzyme after the reaction had plateaued resulted in a further decrease of the OD595nm 
until the level of the deoxycholate lysis was reached. These results reflect the nature of 
Pal and other endolysins with cell binding domains. The cell binding domains bind 
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tightly to specific molecules within the cell envelope. The recognition and binding of 
specific molecules is on one hand responsible for the high specificity of these 
endolysins. On the other hand, it binds the endolysins to cell debris after cell lysis, 
which prevents that the enzymes lyse surrounding uninfected cells of the target 
bacterium. (Schmelcher et al. 2012). This mechanism means that single Pal molecules 
most likely are only able to cleave the peptidoglycan once unlike typical enzyme 
molecules that can carry out the same reaction multiple times.  
 
The occurrence of the plateauing of the lysis depending on the amount of Pal as 
shown in the TRAs in Figure 4.8 and Figure 4.23 supports the theory that once bound 
to the cell wall Pal cannot move on to cleave other S. pneumoniae cells. This 
mechanism decreases the efficiency of Pal. However, both domains are most likely 
required for the activity as the choline binding causes a conformational change that is 
transmitted to the catalytic domain (Varea et al. 2004). Furthermore, it has been 
shown for several endolysins that both domains are needed for full antimicrobial 
activity (Schmelcher et al. 2011; Sass & Bierbaum 2006). A truncation of the cell wall 
binding domain of Pal would therefore likely result in a loss or reduction of the 
enzymatic activity. However, it might be possible to modify the choline binding sites 
by site-directed mutagenesis in a way that weakens the binding without destroying it. 
This might result in a scenario, in which Pal can still bind to choline to induce the 
interaction between his two domains, but is released after the reaction and is able to 
cleave more S. pneumoniae cells. Overall, the changes would hopefully result in a 
higher efficiency and an extended lytic activity of a designer Pal.  
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Figure 4.23: Turbidity reduction assay showing the dosage dependent bacteriolytic activity of 
purified Pal against S. pneumoniae  
Pal was purified with ultracentrifugation, diethylaminoethanol (DEAE) cellulose and choline as 
specific eluent, as well as ammonium sulphate precipitation. S. pneumoniae cells were resuspended in 
NaPi-buffer to an optical density (OD595nm) of 0.19. Purified Pal or control extract treated in the same 
way was added in different dilutions to the cell suspension and the OD595nm was measured. After 150 
minutes, the Pal and control suspensions were added a second time. The assay was performed at 37°C. 
The error bars show ± one standard deviation (n = 2). 
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4.2.4.5.2 Effect of choline on the bacteriolytic activity of purified Pal 
 
It was of interest to examine whether free choline also inhibits C. reinhardtii-
produced Pal, as described for E. coli-produced Pal (Domenech et al. 2011, Sheehan 
et al. 1997). This was on the one hand of interest to further characterise the endolysin 
produced in this study and on the other hand to evaluate whether the dialysis is a 
necessary step during purification, since it is a step that takes 16 hours and adds a 
further day to the purification procedure.  
 
Therefore, TRAs were performed with preparations of Pal before and after dialysis. 
During the dialysis step, the Pal protein preparation was not concentrated and western 
blot analysis as well as Coomassie stained SDS-PAGEs did not show a marked loss of 
Pal protein during dialysis (Figure 4.20 A, B, Figure 4.21 C). However, the TRAs 
showed a strong decrease in the bacteriolytic activity of Pal in the presence of choline 
(6.5% v/w, 625 mM) before dialysis compared to the activity of Pal after dialysis 
(Figure 4.24) showing that the bacteriolytic activity of C. reinhardtii-produced Pal is 
also inhibited by free choline and that the dialysis is a necessary step during the 
purification of Pal. The concentration of choline used for the elution was performed 
with 625 mM, which is a lot higher concentration than the IC50 of 2 mM described by 
Domenech et al. (2011). To determine the IC50 for choline of C. reinhardtii-produced 
Pal, assays with a range of lower choline concentrations need to be performed.  
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Figure 4.24: Turbidity reduction assay showing the inhibition of Pal by choline before dialysis 
Pal was purified with ultracentrifugation, diethylaminoethanol (DEAE) cellulose and choline as 
specific eluent. S. pneumoniae cells were resuspended in NaPi-buffer to an optical density (OD595nm) of 
0.13. Samples of Pal preparations before and after dialysis were added to the suspension and the 
OD595nm was measured. The assay was performed at 37°C. The error bars show ± one standard 
deviation (n = 3). 
 
 
4.2.4.5.3 Bactericidal activity of purified Pal and Cpl-1 
 
The purification of Pal allowed now to analyse the bactericidal activity of Pal without 
the inference of the endogenous antimicrobial substance in C. reinhardtii (4.2.3). The 
bacteriolytic activity of the endolysin Cpl-1 had been shown previously for purified 
enzyme and crude extracts, however the bactericidal effect had not yet been analysed 
(Taunt 2013). Cpl-1 was purified in the same way as Pal using ultracentrifugation, a 
DEAE cellulose column with choline as eluent and ammonium sulphate precipitation. 
The only difference to the purification of Pal was that Cpl-1 was precipitated with 
50% ammonium sulphate instead of 35%. 
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Subsequently TRAs were performed with purified Pal, purified Cpl-1, deoxycholate 
and NaPi-buffer to follow the lysis of the S. pneumoniae cells (Figure 4.25 A). After 
the addition of further endolysins did not result in a further decrease of the OD595nm, 
samples of the TRAs were spotted in different dilutions onto blood agar plates to 
analyse the number of colony forming units that had survived. After incubation 
overnight the plates showed only a few colonies in the spots of the undiluted samples 
that had been treated by Pal, Cpl-1 or deoxycholate, whereas the buffer control needed 
to be diluted 1:10,000 to reach a countable level (Figure 4.25 C).  
 
Calculations of the cfu/ml showed that the samples treated with Pal contained 0.00047 
± 0.0005 million cfu/ml, the sample treated with Cpl-1 0.0003 ± 0.0001 million 
cfu/ml, whereas the control contained 2.5 ± 1 million cfu/ml. The sample treated with 
deoxycholate contained with 0.00122 ± 0.00025 million cfu/ml, more cfu than the 
samples treated with Pal or Cpl-1, despite that the OD595nm measured in the TRA 
decreased more in presence of deoxycholate (Figure 4.25 A). This indicates that the 
decrease in OD595nm is not directly related to the number of killed cells. Pal and Cpl-1 
cleave only one specific bond of the peptidoglycan, whereas deoxycholate might 
trigger several autolysins that cleave different bonds. The lysis by Pal and Cpl-1 might 
result in larger cell pieces compared to the lysis by deoxcholate. Loeffler et al. showed 
that empty cell envelopes remain after the lysis by Pal, which still contribute to an 
OD595nm measurement (Loeffler et al. 2001).  
 
Overall, the number of cfu/ml decreased in the presence of Pal and Cpl-1 compared to 
the control by close to 4 log units (Pal: 3.54 log units, Cpl-1: 3.83 log units), which 
shows that both endolysins have bactericidal activity against S. pneumoniae.  
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Figure 4.25: Bacteriolytic (A) and bactericidal (B, C) activity of purified Pal and Cpl-1 
A turbidity reduction assay with S. pneumoniae cells (start OD595nm 0.13) (A) was performed with purified Pal and Cpl-1, as well as deoxycholate (0.05% w/v) and buffer as 
positive and negative control, respectively. After the TRA, the samples were spotted onto blood agar plates in different dilutions to analyse the number of colony forming units 
(cfu) that had survived the treatments (C), subsequently the cfu/ml were calculated (B). The error bars in A and B show ± one standard deviation (n = 3).  
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4.2.4.5.4 Evaluation of the bactericidal activity of Pal and Cpl-1 
 
Having analysed the bactericidal activity of Pal and Cpl-1, it was now possible to 
evaluate the antimicrobial activity of the endolyins produced in C. reinhardtii in 
comparison to these endolysins produced in E. coli. 
 
Loeffler & Fischetti (2003) state that a freshly produced and purified batch of both 
endolysins is approximately 1 U/µg and found minimal inhibitory concentration 
(MIC) values of 50 to 200 U/ml for Pal and 25 to 50 U/ml for Cpl-1. A study by 
Rodríguez-Cerrato et al. (2007) states MIC values measured with four different strains 
of S. pneumoniae of 32, 32, 128 and 256 µg/ml for Pal and 8, 16, 16, 32 µg/ml for 
Cpl-1. The protein concentrations used in the experiment described in 4.2.4.5.3, were 
determined using a Bradford protein assay. The experiment was performed with 25 
µg/ml of Pal and 15 µg/ml of Cpl-1. The concentrations used were therefore within 
the same range as the MIC values determined by Rodríguez-Cerrato et al. and even 
lower than the MIC values determined by Loeffler & Fischetti (2003).  
 
Furthermore, Rodríguez-Cerrato et al. performed experiments similar to the one 
described in the last section with concentrations of 0.25x the MIC (in the case of Pal 
between 8 and 64 µg/ml, for Cpl-1 between 2 and 8 µg/ml). These experiments 
showed in average (of the four strains) a decrease in cfu of 2.71 log units after 5 h of 
incubation with Pal, and a decrease of 2.66 log units for Cpl-1, which is around one 
log (ten times) unit less compared to the results described in the last section of this 
chapter with only maximal three times (Pal) or 7.5 times (Cpl-1) less enzyme. In 
Loeffler & Fischetti, concentrations of 0.25x MIC (6.25 – 12.5 U/ml) decreased the 
cfu by 3 to 4 log units for Pal and 1 to 2 log units for Cpl-1. Loeffler et al. (2001) 
showed for 15 clinical isolates that the treatment with Pal (100 U/ml) (about 100 
µg/ml) results in a decrease of cfu by around 4 log units, a result that was nearly 
reached in this study as well with around 25 µg/ml. 
 
CHAPTER 4 
 
 212 
Taken together, these results suggest that Pal and Cpl-1 produced in the C. reinhardtii 
chloroplast have bactericidal activities, which are comparable to the activities of these 
endolysins produced in E. coli.  
 
Oey et al. (2009b) determined also the amount of cfu after the treatment with Pal 
produced in tobacco (Nicotiana tabacum). This study states that after incubation for 
one hour with 300 µg of protein extract (equal to about 90 µg of Pal) the number of 
cfu of a S. pneumoniae suspension decreased to 7%, which is only just over one log 
unit. The experiment is not described for Cpl-1 in this article. But the article describes 
TRAs with Cpl-1 and states that 20 µg of Cpl-1 was sufficient to decrease the OD595nm 
to a residual low OD600nm, which meant from about OD600nm 0.6 to 0.2, which was 
reached in TRAs performed during this study as well (not shown). This indicates that 
the C. reinhardtii-produced endolysins have antibacterial activities that are 
comparable to Pal and Cpl-1 produced in tobacco. 
 
Overall, these results indicate that Pal and Cpl-1 are produced and accumulate in the 
C. reinhardtii chloroplast as proteins that are as active as the E. coli or tobacco 
produced enzymes. Furthermore, the data suggest that the purification of Pal and Cpl-
1 did not cause major harm to the antibacterial activity of the endolysins.  
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4.2.4.6 Comparison of different purification/enrichment steps 
 
Ultracentrifugation, ammonium sulphate precipitation, immunoprecipitation with anti-
HA agarose and ion exchange chromatography with choline as specific eluent were all 
investigated for the purification of Pal. Ultracentrifugation removed the majority of 
cell debris, non-soluble proteins and the chlorophyll as well as most other pigments 
without a considerable loss of Pal, and proved to be a very effective first step for the 
purification of Pal. Ammonium sulphate precipitation can be used to separate Pal from 
numerous proteins, but still leaves a considerable number of contaminants when it is 
performed with ultracentrifugation supernatant. It is a very useful tool for the 
concentration of a protein suspension. Furthermore, ammonium sulphate precipitation 
is a purification method, which is used in large-scale protein purifications (Burgess & 
Jendrisak 1975, Lohman et al. 1986).  
 
In a combination of ultracentrifugation, ammonium sulphate precipitation and 
immunoprecipitation with anti-HA agarose, Pal could be purified and enriched to such 
a degree that it could be visualized as a faint band on a Coomassie stained SDS-
PAGE. However, the binding capacity of the resin for Pal under the assay conditions 
was exceeded in all repetitions of the experiment. Anti-HA agarose is expensive and 
therefore makes large-scale purifications uneconomical. Furthermore, in spite of the 
high specificity of antibody-conjugated resin, there were still contaminations with 
other proteins in the elution from the anti-HA resin. In another attempt, Pal was 
purified using ultracentrifugation and DEAE cellulose with choline as specific eluent. 
It was possible with this method to visualise a band for Pal on a Coomassie stained 
SDS-PAGE and to remove nearly all other proteins beside traces of a protein around 
55kDa. Furthermore, it could be shown that Pal had been purified in an active form. 
DEAE cellulose can be easily used for scaling up and is used in industrial scale 
purifications (Burnouf et al. 2011) (Zhang et al. 2000). The addition of ammonium 
sulphate precipitation as a last step allowed the concentration of Pal without major 
losses and resulted in the removal of the 55 kDa protein. These results show that Pal 
can be purified using a combination of ultracentrifugation, DEAE cellulose with 
choline as eluent and ammonium sulphate precipitation and indicate that this 
purification method does not decrease the antibacterial activity of the endolysin.  
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4.3 Conclusion and future work 
 
The experiments presented in this chapter analysed the antibacterial activity of the 
endolysin Pal synthesized in the C. reinhardtti chloroplast using crude extracts and 
purified enzyme. Furthermore, different purification methods for Pal were 
investigated and an antibacterial activity of C. reinhardtii extracts against two 
Streptococcus species was observed and further analysed.  
 
As a first step, it was established that the cell wall less strain of C. reinhardtii TN72_x 
can be easily disrupted under sterile conditions by freezing and thawing or 
alternatively in a sonication bath. After cell breakage by these methods, Pal could be 
separated from the cell debris by centrifugation even at high cell densities. The 
breakage of cell-wall containing algae or bacteria species can be difficult and requires 
specialised equipment such as a French pressure cell press or other cell disrupter at 
lab-scale. These methods often result in marked losses of the extract and it is difficult 
to perform the breakage under sterile conditions. For large-scale cell disruption high-
speed agitator bead mills or high-pressure homogenization methods are used. These 
methods can generate small pieces of cell fragments that are often difficult to remove. 
In contrast, breakage by freezing and thawing resulted in larger pieces, often just burst 
whole cells (Figure 4.2) that could be more easily separated by centrifugation than cell 
debris from cells broken by a cell disrupter. The acquisition of specialised equipment 
causes major costs and the operation is energy- and time-consuming. A cell wall less 
strain that can be easily disrupted by simple methods and simplifies the extraction of 
the desired protein is therefore a major advantage for a recombinant protein 
production platform.  
 
As a next step, the bacteriolytic activity of C. reinhardtii-produced Pal against S. 
pneumoniae was demonstrated in turbidity reduction assays (TRAs). Moreover, the 
results suggest that the HA-tag does not hamper the antibacterial activity of the 
produced Pal. C. reinhardtii-produced Pal had no photometrically measurable effect 
on Escherichia coli, Streptococcus pyogenes or Staphylococcus aureus, which 
indicates that it has a high specificity for S. pneumoniae. On the other hand, it was 
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shown that Pal has bacteriolytic activity against not only the reference strain, but also 
five clinical isolates and five different serotypes of S. pneumoniae, including a strain 
with penicillin and co-trimoxazole resistance.  
 
Moreover, an attempt was made to determine specific enzyme activities for C. 
reinhardtii-produced Pal using TRAs with live S. pneumoniae cells in this study. This 
determination was complicated by an autolytic activity of the S. pneumoniae cells. 
Cells from overnight cultures showed lysis in the control assays and even before the 
start of the TRAs. However, the performance of the TRAs with mid-logarithmic phase 
cells allowed the investigation of the lysis by Pal without major lysis in the control 
assays. Nevertheless, a strong dependency of the calculated enzyme activities on the 
start OD595nm was observed. The more S. pneumoniae cells were added at the 
beginning to the TRA the quicker was the change in ΔOD595nm. The same 
phenomenon was observed to a more extreme extent for the lysis by deoxycholate and 
to a lesser extent for the lysis by Cpl-1. On the other hand, TRAs performed at the 
same OD595nm with different concentrations of Pal showed a clear dosage dependent 
response and identical specific enzyme activities per mg of Pal. It was considered 
whether the effect could be caused by an involvement of autolysins that might be 
released after lysis by Pal and have an additive bacteriolytic effect together with Pal. 
Nevertheless, more experiments, for example with mutants deficient for specific 
autolysins or autolysis inhibitors, need to performed before it can be concluded 
whether autolysins play a role in the cell lysis of S. pneumoniae by Pal. The results 
suggest that the determination of specific enzyme activities using such a complex 
substrate as live S. pneumoniae cells causes major variations in the resulting activities. 
To avoid major fluctuations of the activity values between different performances, an 
alternative would be to use isolated cell walls radioactively labelled with [methyl-
3H]choline as described in a few studies for the analysis of E. coli-produced Pal 
(Sheehan et al. 1997; Domenech et al. 2011; Jado et al. 2003) or non radioactive, 
purified and isolated S. pneumoniae cell walls for TRAs. Alternatively, it might be a 
solution to perform TRAs with mutants deficient for certain autolysins or heat-
inactivated S. pneumoniae cells. Nevertheless, the method described in this study can 
be still used to compare different preparations of Pal, samples from different 
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purification steps or for the comparison to other enzymes, when cells from the same S. 
pneumoniae culture and the same start OD595nm are used.   
During this study it was possible to purify Pal in active form using a combination of 
ultracentrifugation, DEAE cellulose with choline as specific eluent and ammonium 
sulphate precipitation. A subsequent analyses of the antibacterial activity indicated 
that the purification procedure did not cause major harm to the antibacterial activity of 
the endolysin. The different steps performed for the purification of Pal are discussed 
in 4.2.4.6. Subsequently, purified Pal and additionally purified Cpl-1 were used to 
demonstrate the bactericidal activity of these endolysins against S. pneumoniae.  
 
As a next step, TRAs with crude extracts and assays analysing the bactericidal activity 
with purified endolysins were used to demonstrate that the antibacterial activity of Pal 
and Cpl-1 produced in C. reinhardtii is at least as high as the bacteriolytic and 
bactericidal activities of the same endolysins produced in E. coli and tobacco. This 
was shown with two independent methods that used two different ways for the 
quantification of the amount of enzyme used in the assays. The amount of enzyme in 
the crude extracts was determined using western blots analysis with the HA-tagged 
standard protein CARHSP1 and the amounts of purified endolysins was analysed 
using Bradford protein assays and both resulted in values within the same range. This 
study did not determine minimal inhibitory concentrations (MIC) for Pal and Cpl-1. A 
careful determination of MIC values for Pal and Cpl-1 would enable a better 
comparison of the enzymatic activities of the two endolysins produced in C. 
reinhardtii to the enzymes from other production platforms and might even reveal 
higher activities for the algal produced ones. It is conceivable that Pal produced in C. 
reinhardtii has a higher enzymatic activity than the E. coli-produced one, since 
experiments described in 3.2.2.3 indicated that Pal is quickly degraded in E. coli and 
that more degradation products accumulate in the bacterium, which presumably have 
less or no activity, than full-length Pal.  
 
An important further step would be now to perform in vivo studies with C. reinhardtii-
produced Pal and Cpl-1 to investigate how the endolysins perform in mouse models in 
comparison to the E. coli-produced ones. The results of the quantification discussed in 
section 3.2.4 suggest that 10 mg of Pal are produced per litre of C. reinhardtii culture 
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volume (Cpl-1 accumulates to a similar level in the chloroplast (Taunt 2013)) and 
single doses of 40 – 200 µg Pal per mouse as used in Jado et al. (2003), with the 
created C. reinhardtii strains it is possible to produce 50 – 250 single doses for mice 
per litre of culture volume. Taken a loss of 50% during purification into account, this 
would be still 25 – 125 single dose per litre of C. reinhardtii culture. The facilities in 
the Purton lab allow the growth of 90 litres of culture at the same time. It seems 
therefore feasible to produce enough Pal and Cpl-1 with the created C. reinhardtii 
strains to conduct animal studies. 
 
During this study a strong bactericidal activity of C. reinhardtii crude extracts against 
S. pneumoniae and also S. pyogenes was observed. On one hand, this was masking the 
measurements of the bactericidal activity of Pal and made it necessary to purify Pal. 
On the other hand, it adds an interesting feature to C. reinhardtii as a production 
platform for an antibacterial protein against S. pneumoniae. It was not directly 
demonstrated in this study that the unknown antimicrobial substance and Pal have an 
additive effect in killing S. pneumoniae cells, but it is conceivable. It would be very 
interesting to investigate whether this is the case, for example by quantitatively 
comparing the bactericidal activities of crude extract of C. reinhardtii containing Pal 
and E coli or tobacco extract with the same concentration of Pal. Additionally, the 
activity of Pal in crude algal extract could be analysed quantitatively in comparison to 
purified Pal.  
 
The demonstration of an additive antibacterial effect would make the use of crude C. 
reinhardtii extracts containing Pal not only interesting from a commercial point of 
view (because it saves the costs for purification), but also because it would increase 
the therapeutic potency. C. reinhardtii is classified as GRAS (Generally recognised as 
safe) organism, which means that the alga is even safe for consumption. The use of 
crude extracts for topical and veterinary applications would therefore be conceivable. 
Another possibility would be to use C. reinhardtii crude extract containing Pal as a 
nasal wash for the elimination of S. pneumoniae in the nasopharynx. The nasopharynx 
is seen as the major reservoir for S. pneumoniae in the population and Loeffler et al 
(2001) propose that the diminution of this reservoir would have a great impact on the 
incidence of S. pneumoniae infections. 
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A literature research revealed two possible explanations about the nature of the 
endogenous antibacterial substance in C. reinhardtii. Jørgensen (1962) showed that 
chlorophyll derivatives from C. reinhardtii extracts have antibacterial activity against 
the Gram-positive bacterium Bacillus subtilis and this explanation agrees with the 
observation that the antibacterial activity was found in the ‘green fraction’ after all 
performed purification steps. A second explanation would be that certain fatty acids 
are responsible for the effect. It has been demonstrated that several microalgae contain 
fatty acids with antibacterial properties (Desbois & Smith 2010; Smith et al. 2010; 
Ohta et al. 1994). A comparison of the fatty acids found in C. reinhardtii and fatty 
acids that have been shown to possess antibacterial properties showed that a majority 
of fatty acids in the green microalgae do have antibacterial activity. Some studies 
demonstrated even an antimicrobial activity of some of the fatty acids against S. 
pneumoniae. It is therefore likely that fatty acids are at least partly responsible for the 
observed activity. A simple experiment to analyse whether chlorophyll derivatives or 
fatty acids are more likely to cause the antibacterial activity would be to nitrogen 
starve C. reinhardtii, which increases the amount of lipids and decreases the amount 
of pigments including chlorophylls. Followed by an analysis of the antibacterial 
activity of extracts from the starved and non-starved cells. 
 
The occurrence of fatty acids with antimicrobial properties in C. reinhardtii and other 
microalgae makes microalgae in general more interesting as production platforms 
specifically for antibacterial proteins and makes the use of crude algal extract for the 
administration more attractive. This can be especially interesting for the use of 
endolysins against Gram-negative bacteria. The outer membrane represents a barrier 
that most endolysins against Gram-negative bacteria cannot cross. The mechanism of 
the antibacterial action of fatty acids is not fully understood yet, but the cell 
membranes are most likely the main target (Desbois & Smith 2010). Free fatty acids 
have an amphipathic structure and therefore detergent properties. This enables them to 
interact or even insert into cell membranes, which can result in pores, a higher fluidity 
of the membranes or at higher concentration solubilisation of the membranes (Desbois 
& Smith 2010). An antibacterial activity against Gram-negative bacteria has been 
shown for several fatty acids and also for some extracts of C. reinhardtii (Ghasemi et 
al 2007; Benkendorff et al. 2005). In a combination of Gram-negative specific 
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endolysins and algae extract, the ability of certain fatty acids to disintegrate 
membranes could be of great help to open the way for the Gram-negative specific 
endolysins to cross the outer membrane to get to the peptidoglycan. Ghasemi et al. 
(2007) demonstrated an antibacterial effect of extracts of C. reinhardtii against three 
Gram-negative bacterial species after extraction with methanol. Using a different 
extraction method (e.g. with methanol or chloroform) might allow the extraction of 
the fatty acids against Gram-negative bacteria together with synthesised endolysins. 
Furthermore, a proceeding approach could be to increase the percentage of fatty acids 
with the desired properties or introduce new ones in C. reinhardtii by metabolic 
engineering. For example, capric acid (10:0) and lauric acid (12:0), which are not 
present in C. reinhardtii, have been shown to have considerable antibacterial activities 
against Chlamydia trachomatis and Neisseria gonorrhoeae (Bergsson et al. 1999).  
 
 
Overall, the results of this study strongly support the feasibility of the C. reinhardtii 
chloroplast as a platform for the synthesis of antimicrobial proteins, since reliable 
accumulation of predominantly full length Pal with a remarkable high stability was 
achieved. Moreover, it was possible to demonstrate a bacteriolytic and bactericidal 
activity against S. pneumoniae for C. reinhardtii-produced Pal and a second endolysin 
Cpl-1 and the results suggest that the enzymatic activities of both endolysins are 
comparable to the one of endolysins produced in E. coli or tobacco. Furthermore, the 
cell wall less C. reinhardtii strain TN72_x enables breakage by simple methods and 
easy extraction of the synthesised enzymes. The observation of an endogenous 
antibacterial activity of C. reinhardtii and the occurrence of several fatty acids with 
antibacterial properties in C. reinhardtii and other microalgae adds a very interesting 
argument for the use of microalgae as production platform for antimicrobial proteins 
and the use of crude algal extract for administration.  
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5 Synthesis of the Staphylococcus specific endolysin ϕ11 in 
the chloroplast of Chlamydomonas reinhardtii 
 
5.1 Introduction 
 
5.1.1 The Staphylococcus specific endolysin ϕ11 
 
The endolysin ϕ11 is encoded by the temperate bacteriophage ϕ11 of Staphylococcus 
aureus. The bacteriophage ϕ11 belongs, like Dp-1, to the family Siphoviridae, which 
is a member of the tailed bacteriophages of the order Caudovirales (Navarre et al. 
1999). The genome of ϕ11 consists of a 44 kb double-stranded DNA molecule and the 
bacteriophage infects phage lytic group III strains of S. aureus including many strains 
that are human and animal pathogens (Iandolo et al. 2002).  
 
The endolysin ϕ11 has a size of 54 kDa and two catalytic domains, an N-terminal D-
alanyl-glycyl endopeptidase and a central N-acetylmuramoyl-L-alanine amidase, 
which have high sequence similarity to the catalytic domains of endolysins from other 
S. aureus specific bacteriophages such as Twort, ϕPVL, ϕ187 and α80 (Figure 5.1) 
(Sass & Bierbaum 2006; Navarre et al. 1999). The N-terminal catalytic domain 
belongs to the group of CHAP (cysteine, histidine-dependent 
amidohydrolase/peptidase) domains and cleaves the peptidoglycan between the D-
alanine of the peptide chain and the first glycine of the glycine bridge and seems to be 
the more effective activity, whereas the second catalytic domain cleaves between the 
L-alanine of the peptide chain and the N-acetyl-muramic acid of the sugar strand 
(Figure 5.2) (Navarre et al. 1999). The C-terminal cell wall binding domain is 
homologous to the cell wall binding domain of the staphylolytic bacteriocin 
lysostaphin, which is produced by Staphylococcus simulans biovar staphylolyticus, 
and the protein ImlB, which occurs on the surface of Listeria monocytogenes (Figure 
5.1) (Navarre et al. 1999). The domain belongs to the SH3b_5 cell wall binding 
domains, which are found in a large subset of staphylococcal peptidoglycan 
hydrolases (Becker et al. 2009).  
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Figure 5.1: Modular organisation of the endolysin ϕ11 
The endolysin ϕ11 has a N-terminal catalytic domain with D-alanyl-glycyl endopeptidase activity and a 
second central catalytic domain with N-acetyl-muramoyl-L-alanine amidase activity, which both have a 
sequence similarity to the catalytic domains of other S. aureus specific bacteriophages like Twort, 
ϕPVL and ϕ187. The C-terminal cell wall binding domain is homologous to the staphylolytic 
bacteriocin lysostaphin. (Figure based on Navarre et al. 1999 and Sass & Bierbaum 2006).  
 
 
Figure 5.2: Cleaving sites of the S. aureus specific endolysin ϕ11 
The first catalytic domain has D-alanyl-glycyl endopeptidase activity and cleaves the peptidoglycan 
between the D-alanine of the peptide chain and the first glycine of glycine bridge, whereas the second 
catalytic domain with N-acetyl-muramoyl-L-alanine amidase activity cleaves between the L-alanine of 
the peptide chain and the N-acetyl-muramic acid of the sugar strand. The structure of S. aureus 
peptidoglycan shown. CCWP = carbohydrate cell wall polymer, LU = linkage unit, P = phosphate 
group, MurNAc = N-acetyl-muramic acid, GlcNAc = N-acetyl-glucosamine, Ala = alanine, Gln = 
glutamine, Lys = lysine, Gly = glycine. Reproduced from (Navarre et al. 1999). 
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It has been shown for some hydrolases, amongst others lysostaphin, that the SH3b 
domain is essential for correct species-specific targeting to the S. aureus cell wall 
(Becker et al. 2009; Baba & Schneewind 1996). Furthermore, it has been shown that 
this domain is necessary for full staphylolytic activity (Becker et al. 2009). 
 
Navarre et al. (1999) were the first to characterise the two different catalytic activities 
of ϕ11 and expressed a deletion mutant that lacks the amidase domain (Δ181 – 381) in 
Escherichia coli. The amidase deletion mutant still exhibited lytic activity against 
crude staphylococcal cell walls. The study found that the activity of the amidase 
deletion mutant is inhibited by p-hydroxymercuribenzoic acid, which is an organic 
mercurial that forms stable complexes with cysteine thiol residues. Furthermore, the 
enzyme was partly inhibited by EDTA (5 mM). Sequence alignments of the N-
terminal endopeptidase domain of ϕ11 with the catalytic domains of the S. aureus 
specific endolysins Twort, ϕPVL, ϕ187 and α80 revealed the presence of one 
conserved cysteine. Navarre et al. concluded that this conserved cysteine residue is 
essential for the alanyl-glycyl endopeptidase activity of ϕ11 (Navarre et al. 1999). 
 
Two further studies created a variety of deletion mutants to analyse the involvement 
of the three domains in the lytic activity of ϕ11. Sass & Bierbaum (2006) found that 
all three domains were essential for full lytic activity of ϕ11. Each of the catalytic 
domains together with the cell binding domain were able to lyse isolated cell walls of 
Staphylococcus simulans 22, but with a reduced enzymatic activity. Each catalytic 
domain on its own did not show any activity, whereas both catalytic domains together 
without the cell wall binding domain had nearly full activity against isolated cell 
walls. However, only the full-length ϕ11 and none of the truncations showed lytic 
activity against whole heat-killed staphylococcal strains or biofilms. Sass & Bierbaum 
(2006) concluded that both catalytic domains have to be combined and that substrate 
recognition of the cell-wall binding domain is necessary for the full function of ϕ11 
and its ability to cleave the cell wall of intact cells. It has also been shown for 
lysostaphin that the cell wall binding domain is essential for full lytic activity (Baba & 
Schneewind 1996). Furthermore, the study showed that a concentration of 20 µg/ml of 
full-length ϕ11 causes the lysis of the strains S. aureus NCTC8325, S. aureus Wood 
46, S. aureus Newman, S. epidermis O-47 and S. simulans 22 with a lytic activity that 
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was comparable to highly purified lysostaphin (5 µg/ml). Moreover, Sass & Bierbaum 
(2006) showed that ϕ11 can eradicate S. aureus NCTC8325 biofilms with an 
efficiency nearly equivalent to lysostaphin, which was the first report of a 
staphylococcal endolysin eliminating biofilms. The ability to disrupt staphylococcal 
biofilms makes ϕ11 particular interesting as an antibacterial agent, since biofilms 
represent a major problem for the treatment and management of staphylococcal 
infections, especially given that the build up of biofilms on catheters and other long-
term medical devices remains challenging (Donlan & Costerton 2002).  
 
A second study by Donovan et al. (2006) analysed truncation mutants of ϕ11 and 
found that both ϕ11(1-194) (endopeptidase domain with parts of the amidase domain) 
and ϕ11(1-389) (endopeptidase and full amidase domain without the cell binding 
domain) had lytic activity against whole untreated S. aureus cells, but the authors also 
state that the truncations had less activity than full-length ϕ11. The major aim of this 
study was to investigate the potential of ϕ11 as a treatment against bovine mastitis. 
This infection of the mammary gland of dairy cows is a problem worldwide and is the 
number one reason for antibiotic use in the dairy industry (Donovan et al. 2006; 
Erskine et al. 2002). The development of a pathogen-specific antimastitis treatment 
could reduce the use of broad-range antibiotics and at the same time the risk of 
antibiotic resistance development. Donovan et al. (2006) demonstrated that ϕ11 is able 
to lyse live staphylococcal mastitis pathogens such as S. aureus and coagulase-
negative staphylococci including S. chronogenes, S. epidermis, S. hyicus, S. simulans, 
S. warneri and S. xylosus. Together with the results of Sass & Bierbaum (2006), this 
shows that ϕ11 is effective against a broad range of staphylococcal species. 
Furthermore, the study showed that ϕ11 is active at a broad range of physiologically 
relevant pHs values (pH 5.5 – 8) including that of milk (pH 6.7) and that the endolysin 
is active at the calcium concentration of milk (3 mM). Both findings are important for 
the long-term goal of Donovan et al. to express ϕ11 in the mammary glands of 
transgenic cows to prevent the occurrence of mastitis.  
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David M. Donovan holds a patent on the “Specific lysis of staphylococcal pathogens 
by bacteriophage ϕ11 endolysin”, which was filed in July 2011 and published in 
January 2013 amongst others as US8361772 B2 and US20110318328 A1 patents. 
This patent covers the full-length endolysin as well as any ϕ11 truncations and the use 
as a treatment for any human and animal diseases caused by staphylococcal strains.  
 
A short communication by Donovan et al. (2008) addresses the problem that two 
different gene sequences of the ϕ11 endolysin are available in the databases. The gene 
sequences differ only in three bases, but the changes result in 41 different amino acids 
due to a frame shift. The study used DNA sequence alignments and matrix-assisted 
desorption/ionization-time-of-flight (MALDI-TOF) mass spectroscopy to identify the 
correct sequence of the endolysin ϕ11 and found that the sequence determined by 
Iandolo et al. (2002) with the protein accession number NP_803306 and the 
nucleotide accession number NC_004615 is the correct sequence. This protein 
sequence of ϕ11 was used in this study and the corresponding gene sequence was 
codon-optimised for the C. reinhardtii chloroplast. 
 
The endolysin ϕ11 is a promising candidate for the use as a novel antibacterial agent 
due to its efficiency against a variety of staphylococcal species including bovine 
mastitis pathogens and its ability to disrupt biofilms. S. aureus and other 
staphylococci species are major human and animal pathogens with a high percentage 
of antibiotic resistant strains including multi-drug resistances (1.3.2). As a treatment 
for bovine mastitis it would be possible to use ϕ11 in crude algal extracts as a topical 
treatment. The use of ϕ11 in a veterinary application would strongly facilitate the 
approval process compared to an application in human medicine. Nevertheless, S. 
aureus causes several skin infections in humans and a topical administration in human 
medicine would also be conceivable despite a protracted and more expensive approval 
process. 
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5.1.2 Aims and objectives 
 
The aim of the experiments in this chapter was the synthesis of the endolysin ϕ11, a 
promising candidate as a novel antibacterial agent against staphylococcal human and 
animal pathogens, in the C. reinhardtii chloroplast. Subsequently, the aim was to 
analyse the antibacterial activity of C. reinhardtii-produced ϕ11 against S. aureus 
including strains with antibiotic resistance and to compare the activity to ϕ11 
produced in Escherichia coli.  
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5.2 Results and discussion 
 
5.2.1 Creation of transgenic lines of C. reinhardtii carrying the ϕ11 gene 
in the plastome 
 
A transgenic line of C. reinhardtii carrying a synthetic ϕ11 gene in the plastome was 
created to study the synthesis of the ϕ11 protein in the algal chloroplast. The line uses 
as expression elements the atpA promoter/5’UTR and the rbcL 3’UTR, which are 
described in 3.2.1.2. The ϕ11 gene contains the coding sequence for a C-terminal HA-
tag (Figure 5.3). To enable a straightforward purification procedure for ϕ11 using 
commercially available Ni-NTA (nickel-nitrilotriacetic acid) columns, a second 
transgenic line was created carrying the ϕ11 gene with the coding sequence for a C-
terminal HA-tag followed by the sequence of a polyhistidine (His)-tag (Figure 5.3). 
The line carries the same expression cassette as TN72_ϕ11-HA. The HA-tag was 
included in addition to the His-tag to enable the detection of ϕ11 using anti-HA 
antibodies, which are more sensitive than antibodies against the His-tag. Finally, a line 
carrying the pal gene with coding sequences for both tags was created to test another 
purification strategy for Pal (Figure 5.3). The analysis of the transgene expression of 
both lines is discussed in this chapter.  
 
All lines were created using the C. reinhardtii chloroplast transformation system that 
consists of the cell wall-less recipient strain TN72 and the expression vector pASapI. 
For a detailed description of the transformation system see 2.3.8 and 3.2.1.  
 
 
5.2.1.1 Design and codon-optimisation of the synthetic ϕ11 gene 
 
The sequence of the ϕ11 protein was taken from the database UniProtKB/Swiss-Prot 
(Entry: Q8SDS7; Entry name: Q8SDS7_BPPHA; Protein name: Amidase; Protein 
accession number: NP_803306.2; Organism: Staphylococcus phage phi11 
(Taxonomic identifier: 12360)). The protein ϕ11 is comprised of 481 amino acids and 
has a mass of 54,030 Da. The corresponding gene was codon-optimised for the C. 
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reinhardtii chloroplast to a Codon Adaption Index (CAI) of 0.8 with respect to the 
codon usage table from Nakamura et al. (2000) (http://www.kazusa.or.jp/codon) and 
synthesised by GENEART (Regensburg, Germany) with the addition of a 5’ SapI and 
a 3’ SphI site for subsequent cloning, and sequence for a C-terminal human influenza 
haemagglutinin (HA) epitope tag for detection. The created ϕ11 gene has a length of 
1,443 bp and including the HA-tag coding sequence and two stop codons (TAA) a 
length of 1,476 bp. The codon-optimised DNA sequence of the ϕ11 gene is attached in 
the appendix. The HA-tagged ϕ11 protein has a predicted molecular mass of 55.1 
kDa. In TN72_ϕ11-HA-His and TN72_pal-HA-His the genes of interest contain 
additionally the coding sequence for a polyhistidine-tag, which consist of six 
histidines residues. The resulting recombinant proteins have a mass of 56.0 and 36.4 
kDa, respectively.  
 
 
 
 
Figure 5.3: Strains of C. reinhardtii TN72_x analysed in this chapter 
The diagram shows the differences in the gene of interest and tags of the C. reinhardtii TN72_x strains, 
which were created to study the expression of ϕ11 in the C. reinhardtii chloroplast or to facilitate the 
purification of ϕ11 and Pal. Endogenous chloroplast genes are indicated in green, expression elements 
in blue, the genes of interest in yellow and the tags in orange. 
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5.2.1.2 Creation of the transgenic lines 
 
5.2.1.2.1 TN72_ ϕ11-HA 
 
For the creation of TN72_ϕ11-HA the expression vector pASapI was used (Economou 
et al. 2014). The ϕ11-HA gene was cloned from the GENEART vector pMK_ϕ11-HA 
into pASapI using the SapI and SphI restriction sites. The successful cloning of ϕ11-
HA into pASapI was confirmed by sequencing. The resulting plasmid pASapI_ϕ11-
HA was transformed into C. reinhardtii TN72 using the glass bead method. Colonies 
obtained from transformation were restreaked three times to achieve homoplasmicity. 
Insertion of ϕ11-HA into the correct location in the chloroplast genome and 
homoplasmicity were confirmed by PCR with the primers FLANK1, atpA.R and 
rbcL.Fn (Figure 5.4) and by sequencing between the primers atpA.F and rbcL.R. Of 
six transformants analysed by PCR, five contained the expression cassette with ϕ11-
HA in the correct location. Figure 5.4 B shows transformant 1 and 2 after one round of 
restreaking in a heteroplasmic state and transformant 3 and 4 after three rounds of 
restreaking in a homoplasmic state.  
 
 
5.2.1.2.2 TN72_ϕ11-HA-His and TN72_pal-HA-His 
 
For the addition of the His-tag coding sequence, the pal-HA and ϕ11-HA genes were 
amplified in a PCR with primers that bind at both ends of the genes and contain the 
restriction sites SphI and SapI. The reverse primer used binds within the HA-tag 
sequence and contains the sequence for six histidines, which form the His-tag. The 
primers used for this PCR were Pal.F, ϕ11.F and for both genes Histag.R. Afterwards, 
the PCR products were digested with SphI and SapI and cloned into pASapI. 
Subsequently, the constructs were transformed into C. reinhardtii TN72 and the 
correct insertion of the genes was confirmed as described for TN72_ ϕ11-HA 
(5.2.1.2.1).  
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Figure 5.4: PCR screening for the successful transformation of the C. reinhardtii TN72 
chloroplast 
Schematic diagram showing the binding sites of the used set of primers and the expected fragment sizes 
for the recipient strain TN72 and successful TN72_ϕ11-HA, TN72_ϕ11-HA-His and TN72_pal-HA-His 
transformants (A). PCR screening for putative transformants with the recipient strain TN72 as control 
(B). The primer FLANK1 binds to the plastome outside of the insertion area. RbcL.Fn binds within the 
aadA cassette of the untransformed recipient strain TN72 and results together with FLANK1 in a 
product of 0.85 kb. The third primer atpA.R binds to the promoter of the expression cassette, which 
results together with FLANK1 in a product of 1.2 kb. Homoplasmic transformants show only a band at 
1.2 kb. Heteroplasmic transformants show additionally a 0.85kb band. (A) Grey arrows = primers, blue 
boxes = expression elements, green boxes = plastome genes. (B) 1 = Transformant 1, R1/3 = First/third 
restreak. 
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Both TN72_pal-HA-His transformants analysed by PCR contained the expression 
cassette with pal-HA-His in the correct location and had achieved homoplasmicity 
(Figure 5.5). The PCR screening showed that of five TN72_ϕ11-HA-His 
transformants analysed, four had been successfully transformed and had reached 
homoplasmicity (Figure 5.5). 
 
 
5.2.1.2.3 TN72_control 
 
The corresponding control strain was created by transformation of the recipient strain 
TN72 with the corresponding transformation vector pASapI carrying an empty 
expression cassette with the atpA promoter/5’UTR and the rbcL 3’UTR to ensure the 
same genetic background (Figure 5.3) (Ninlayarn 2012). 
 
 
 
 
Figure 5.5: PCR screening for the successful transformation of the C. reinhardtii TN72 
chloroplast with pASapI_ϕ11-HA–His and pASapI_pal-HA–His 
In the PCR screening for putative TN72_ϕ11-HA-His and TN72_pal-HA-His transformants the primers 
FLANK1, atpA.R and rbcL.Fn were used. For binding regions of the primers see Figure 5.4 A. TN72 = 
Recipient strain; 1,2.. = Transformants; Expected band sizes are: TN72 = 0.85 kb; Homoplasmic 
transformant = 1.2 kb; Heteroplasmic transformant: 0.85 kb and 1.2 kb. 
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5.2.2 Expression of ϕ11 in the C. reinhardtii chloroplast 
5.2.2.1 Confirmation of ϕ11 expression using anti-HA antibodies 
 
The ϕ11 protein was synthesised with the addition of a C-terminal HA-tag to enable 
the detection of ϕ11 using commercially available anti-HA antibodies, which had been 
successfully used for the detection of Pal and Cpl-1 (this study, Taunt 2013). 
The transformant lines were therefore analysed for the presence of HA-tagged ϕ11 
protein, which has a predicted size of 55.1 kDa, by western blot analysis using anti-
HA antibodies together with IRDye® secondary antibodies and the Odyssey® Infrared 
(IR) Imaging System. Alternatively, horseradishperoxidase-linked secondary (ECL) 
antibodies were used and the resulting chemiluminescence was detected with 
photographic film. Both detection systems showed a band at approximately 55 kDa 
for samples of TN72_ϕ11-HA that was not present in samples of the TN72_control 
strain (Figure 5.6 A, Figure 5.15). These results confirm the successful synthesis of 
ϕ11 in the chloroplast of C. reinhardtii.  
 
The majority of western blot analyses with TN72_ϕ11-HA showed an additional band 
at approximately 38 kDa, which was not present in analyses of TN72_control (Figure 
5.6 A). It is conceivable that the additional band is a degradation product of ϕ11, and 
has lost approximately the first 150 N-terminal amino acids due to proteolytic 
degradation at a specific cleavage site. This would mean that the truncation had 
resulted in the loss of the majority of the first catalytic domain, which consists of 180 
amino acids (Figure 5.7). Another explanation could be that the truncated protein is a 
result of a cryptic ribosome-binding site within the ϕ11 mRNA. The protein sequence 
of ϕ11 contains in the region of the truncation start a methionine and a translation start 
at this position would result in a protein with a mass of 38.9 kDa. This explanation 
would be therefore feasible as well. Figure 5.7 shows the protein sequence of ϕ11 with 
the potential methionine start codon highlighted in red and the three domains of ϕ11.  
 
Transgenic lines that are created via the introduction of genes into the chloroplast 
genome by homologous recombination are genetically identical and are therefore 
expected to show identical expression levels for recombinant proteins. A western blot 
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analysis of two TN72_ϕ11-HA transformants harvested at the same growth stage 
showed similar ϕ11 protein levels for both transformants (Figure 5.6 B). This 
indicates that the proposed theory is right that genetically identical transformants have 
comparable recombinant protein production levels. Furthermore, it has been shown in 
a previous study that independent C. reinhardtii TN72_cpl-1-HA transformants 
produce similar levels of recombinant Cpl-1 protein (Taunt 2013). TN72_ϕ11-HA 
transformant 1 was chosen for further experiments. The synthesis of ϕ11 in 
TN72_ϕ11-HA-His is analysed together with the production of Pal in TN72_pal-HA-
His in section 5.2.5. 
 
 
 
Figure 5.6: Western blot analysis of crude extract (A) and whole cell extract of two TN72_ϕ11-
HA transformants showing the presence of HA-tagged ϕ11 protein 
The western blot was performed with samples of TN72_ ϕ11-HA and anti-HA antibodies, IRDye® 
secondary antibodies and the Odyssey® Infrared Imaging System for detection. TN72_control was used 
as a negative control. The expected band size is 55.1 kDa. Protein sizes were determined using the 
PageRulerTM Prestained Protein ladder (Thermo Scientific). 
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Figure 5.7: Protein sequence of ϕ11 showing the potential alternative methionine start codon that 
would result in a 38.9 kDa protein and the three domains of ϕ11  
The methionine highlighted in red could potentially function as an alternative translation start, which 
would be a possible explanation for the approximately 38 kDa ϕ11 truncation observed in western blot 
analyses with TN72_ϕ11-HA. The protein molecular mass was calculated using 
http://bioinformatics.org/sms/prot_mw.html. The HA-tag is highlighted in dark green. The first 
catalytic domain is indicated in light green, the second catalytic domain in yellow and the cell binding 
domain in light blue.  
 
 
5.2.2.2 Expression of ϕ11 in Escherichia coli DH5α  
 
As mentioned already in chapter 3, Escherichia coli is widely used as an established 
expression system for the production of recombinant proteins and it was therefore of 
interest to compare also ϕ11 synthesised in E. coli to the C. reinhardtii-produced 
endolysin. It has been shown in 3.2.2.3 and previous studies that the expression 
cassette of pASapI results also in the expression of the gene of interest (GOI) in 
Escherichia coli DH5α (Szaub 2012; Taunt 2013). This allows an easy qualitative 
analysis of the synthesis of ϕ11 in E. coli compared to C. reinhardti. Furthermore, it 
enables a comparison of the antibacterial activity of ϕ11 produced in both systems.  
 
The construct pASapI_ϕ11-HA was transformed into E. coli DH5α and a western blot 
analysis with anti-HA antibodies was performed using crude cell extracts. It was 
MQAKLTKNEFIEWLKTSEGKQFNVDLWYGFQCFDYANAGWKVLFGLLLKGLGAKDIPFANNF
DGLATVYQNTPDFLAQPGDMVVFGSNYGAGYGHAWVIEATLDYIIVYEQNWLGGGWTDGIEQ
PGWGWEKVTRRQHAYDFPMWFIRPNFKSETAPRSVQSPTQAPKKETAKPQPKAVELKIIKDV
VKGYDLPKRGSNPKGIVIHNDAGSKGATAEAYRNGLVNAPLSRLEAGIAHSYVSGNTVWQALD
ESQVGWHTANQIGNKYYYGIEVCQSMGADNATFLKNEQATFQECARLLKKWGLPANRNTIRL
HNEFTSTSCPHRSSVLHTGFDPVTRGLLPEDKRLQLKDYFIKQIRAYMDGKIPVATVSNESSAS
SNTVKPVASAWKRNKYGTYYMEESARFTNGNQPITVRKVGPFLSCPVGYQFQPGGYCDYTE
VMLQDGHVWVGYTWEGQRYYLPIRTWNGSAPPNQILGDLWGEISYPYDVPDYA 
 38.9 kDa 
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possible to detect a strong band at approximately 55 kDa. However, the negative 
control with DH5α_control also showed a band at approximately the same size 
(Figure 5.8, Figure 3.10), though the band in the control samples was always found 
weaker than the band in the samples of DH5α_ϕ11-HA (Figure 5.8). Furthermore, the 
extract of DH5α_ϕ11-HA showed bacteriolytic activity against Staphylococcus aureus 
in turbidity reduction assays (TRAs), which is discussed in section 5.2.4. Taken 
together, this suggests that ϕ11 is synthesised in E. coli DH5α_ϕ11-HA. Additionally, 
the western blot analyses with DH5α_ϕ11-HA showed a band at approximately 38 – 
39 kDa that was not present in the negative control (Figure 5.8). This indicates that the 
same truncation of ϕ11 occurs in C. reinhardtii and E. coli either by proteolytic 
activity or an alternative translation start site.  
 
 
 
 
Figure 5.8: Western blot analysis with crude extracts of Escherichia coli DH5α_ϕ11-HA for the 
presence of HA-tagged ϕ11 protein 
The western blot analysis was performed with 20 µl of crude extract prepared from E. coli overnight 
cultures that had been concentrated to 20 times of the culture volume and broken by passing the 
suspension through a French Pressure cell press. Anti-HA antibodies and IRDye® secondary antibodies 
and the Odyssey® Infrared Imaging System were used for detection. The expected band size is 55.1 
kDa. Protein size was determined using the PageRulerTM Prestained Protein ladder (Thermo Scientific). 
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5.2.2.3 Yield of ϕ11 at different growth stages 
 
As a next step the yield of recombinant ϕ11 protein in cells of TN72_ϕ11-HA was 
determined at different growth stages to analyse the expression and stability of the 
endolysin in the chloroplast. Additionally, it was of interest to further investigate the 
truncation of ϕ11 that had been observed in several western blot analyses.  
 
For this experiment, TN72_ϕ11-HA was grown under standard conditions, the culture 
growth was recorded by measuring the OD750nm and samples were taken at multiple 
time points during growth. After harvesting, the cell pellet was resuspended in a 
volume depending on the OD750nm of the culture at the time of sampling to obtain the 
same cell density in every sample. Subsequently, the samples were analysed by 
western blot with anti-HA antibodies and the Odyssey® Infrared Imaging System was 
used for quantification.  
 
This analysis showed that predominantly full-length ϕ11 was present in the cells until 
the mid-logarithmic phase, which explains the absence of the truncation in some 
western blot results. At the end of the logarithmic phase the amount of ϕ11 truncation 
increased. Similar amounts of truncation and full-length ϕ11, or even higher amounts 
of the truncation were detected at the end of the logarithmic phase and the beginning 
of the stationary phase. In contrast, the last sample, which was taken after the OD750nm 
started to decrease, contained again a higher proportion of full-length ϕ11. Overall, 
the yield of recombinant ϕ11 per cell increased slightly during culture growth. 
 
The metabolism of cells changes during the transition into the stationary phase to 
adapt to the changing conditions and to become more resistant to stress and nutrient 
limitation. The overall protein synthesis generally decreases, whereas the synthesis of 
proteases and peptidases increases (Navarro Llorens et al. 2010). The observation that 
more ϕ11 truncation is formed during the transition into the stationary phase 
compared to the logarithmic phase therefore supports the hypothesis that the 
truncation is formed by proteolytic activity.  
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Figure 5.9: Yield of ϕ11 synthesis at different growth stages  
Cultures of TN72_ϕ11-HA were grown under standard conditions and samples were taken at multiple time points during growth. After harvesting the samples were normalised 
to the OD750nm at the time of sampling (cells were resuspended in 1 ml of buffer per OD750nm of 2) and 20 µl of the samples were analysed in a western blot analysis with anti-HA 
antibodies, IRDye® secondary antibodies and the Odyssey® Infrared Imaging System for detection and quantification. A shows the western blot picture, B the Odyssey IR 
fluorescence signals of both bands and C the growth of the TN72_ϕ11-HA culture.  
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5.2.3 Production of ϕ11 protein preparations for activity assays 
 
For the performance of assays analysing the antibacterial activity of ϕ11 against S. 
aureus it was necessary to break the C. reinhardtii cells and to recover ϕ11 without 
denaturing the endolysin. It has been already shown in 4.2.1 that the cell wall-less 
strain TN72 can be easily broken by freezing and thawing and that the majority of Pal 
can be recovered in active form and subsequently separated from the cell debris 
afterwards. Nevertheless, it was still important to analyse whether ϕ11 would behave 
in the same way.  
 
TN72_ϕ11-HA cells were therefore broken by freezing and thawing for three cycles as 
described in 4.2.1. Subsequently, the amount of ϕ11 in the whole cell extracts and the 
supernatants after pelleting the cell debris by centrifugation was determined in 
western blot analyses. All samples were additionally treated with SDS and boiling to 
break leftover unbroken cells. These analyses showed that it was also possible to 
recover the majority of ϕ11 into the supernatant (= crude extract) after cell breakage 
by freezing and thawing (Figure 5.10 A). However, the supernatant contained about 
23% less ϕ11 compared to the whole cell extract in the experiment shown in Figure 
5.10 experiment. Similar or even higher losses were observed in different 
performances of the experiment.  
 
The green pigment chlorophyll can interfere with the spectrophotometric-based 
turbidity reduction assay (TRA) when highly concentrated crude extract is used in the 
assay. For the performance of TRAs with highly concentrated crude extracts of 
TN72_ϕ11-HA, it was therefore desired to remove the chlorophyll. Ultracentrifugation 
is a useful first purification step for soluble proteins, which removes cell membranes 
and the majority of the chlorophyll. Furthermore, ultracentrifugation can be used to 
analyse the solubility of a recombinant protein (Shih et al. 2002; Gutmann et al. 
2007). For that reason, crude extracts of TN72_ϕ11-HA prepared as described before 
were treated by ultracentrifugation (100,000 x g, 1h). Subsequently, the amount of 
ϕ11 in the crude extract before and the supernatant and pellet after ultracentrifugation 
were determined in western blot analyses. 
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The majority of full-length ϕ11 (71% in A, B; 76% in C, D of Figure 5.11) and nearly 
all of the 38 kDa ϕ11 truncation (90% in Figure 5.11 A, B) precipitated during 
ultracentrifugation. This suggests that a majority of full-length ϕ11 does not exist as a 
soluble protein in C. reinhardtii chloroplast and that especially the 38 kDa truncation 
is present as mainly insoluble protein. Furthermore, it demonstrates that 
ultracentrifugation cannot be used for the purification of ϕ11 without significant loss 
of the enzyme. The TRAs with S. aureus described in the next section were therefore 
mainly performed with TN72_ϕ11-HA crude extract despite the presence of the 
chlorophyll.  
 
 
 
Figure 5.10: Western blot analysis showing the recovery of ϕ11 in the supernatant after cell 
breakage by freezing and thawing  
TN72_ϕ11-HA cells were broken by freezing in liquid nitrogen, thawing at 30ºC and vortexing for 10 
sec for three cycles, followed by centrifugation at 21,000 x g for 5 min. The presence of ϕ11 in the 
whole cell extracts before centrifugation and the 21K↵ supernatant (crude extract) was determined by 
western blot analysis with anti-HA antibodies, IRDye® secondary antibodies and the Odyssey® Infrared 
Imaging system was used for detection (A) and for quantification (B). 
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Figure 5.11: Western blot analysis showing the precipitation of ϕ11 during ultracentrifugation  
TN72_ϕ11-HA cells were broken by freezing in liquid nitrogen, thawing at 30ºC and vortexing for 10 
sec for three cycles, followed by centrifugation at 21,000 x g for 5 min. Ultracentrifugation (UC↵) was 
performed with the 21K↵ supernatant at 100,000 x g for 1 h. The presence of ϕ11 in the 21K↵ 
supernatant (crude extract), the UC↵ supernatant and UC↵ pellet was determined by western blot 
analysis with anti-HA antibodies, IRDye® secondary antibodies and the Odyssey® Infrared Imaging 
system was used for detection (A, C) and for quantification (B, D). The data presented in A+B and 
C+D are from two different performances of the experiment. The error bars in D show ± one standard 
deviation (n = 2). 
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5.2.4  Investigation of the antibacterial activity of C. reinhardtii- and E. 
coli-produced ϕ11 against S. aureus  
 
As already mentioned in 4.2.2, it is of great importance to analyse the activity of a 
recombinant protein after its expression in a new system has been confirmed. 
Turbidity reduction assays (TRAs) had been used successfully to demonstrate the 
activity of the C. reinhardtii-produced endolysin Pal (4.2.2). Furthermore, previous 
studies by Sass & Bierbaum (2006) and Donovan et al. (2006) used TRAs with heat-
killed and live staphylococcal cells to demonstrate the lytic activity of E. coli-
produced ϕ11. Consequently, as a next step the antibacterial activity of ϕ11 produced 
in the C. reinhardtii chloroplast was analysed using TRAs with heat-killed S. aureus 
cells to investigate whether the endolysin has full enzymatic activity.  
 
Cells of a S. aureus culture were harvested and resuspended in NaPi-buffer before the 
suspension was heated to 80°C for 10 min. Subsequently, crude algal extracts from 
either TN72_ϕ11-HA or TN72_control were added to the cell suspensions to start the 
assays and the change in OD600nm was determined over a time course. In contrast to 
TRAs with S. pneumoniae cells, S. aureus cells did not show marked autolysis, since 
the OD600nm hardly decreased without the addition of enzyme or in the control assays 
even over long periods of time. However, the TRAs performed with the TN72_ϕ11-
HA crude extracts also did not show a decrease in OD600nm compared to the control 
assays (Figure 5.12 A) and therefore showed no detectable lytic activity.  
 
As a first attempt the ϕ11 concentration used in the assays was increased. This was 
done by enriching the ϕ11 concentration in the crude extracts using centrifugal 
concentrators (MWCO 30,000) or alternatively by an increase of the initial cell 
density of the whole cell extract before cell breakage. This resulted in a concentration 
of the chlorophyll and therefore strong green background of the assays. As already 
mentioned in 5.2.3, ultracentrifugation was investigated as a method to separate the 
chlorophyll from the extract with ϕ11, but was found to be unsuitable since the 
majority of ϕ11 moved into the pellet during the procedure together with the 
chlorophyll. Subsequently, lysostaphin was used as a positive control and to 
investigate whether the lysis of the S. aureus cells is still measurable as a decrease in 
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OD600nm in the presence of high chlorophyll concentrations. Lysostaphin is a zinc 
endopeptidase, which is produced by Staphylococcus staphylolyticus and cleaves the 
polyglycine bridge of the peptidoglycan of Staphylococcus aureus (Cui et al. 2010). 
After addition of lysostaphin (20 µg/ml) to S. aureus suspensions, which already 
contained crude algal extract, a fast decrease of the OD600nm was measurable (Figure 
5.12 A). This proves that the experimental design used is suitable to measure the 
enzymatic lysis of S. aureus cells and that the background caused by the green 
pigment chlorophyll does not interfere with the measurement. Nevertheless, higher 
concentrations of ϕ11 also did not result in a measurable decrease of the OD600nm of 
the S. aureus suspensions. Furthermore, proteinase inhibitors were added to the crude 
extract before cell breakage to prevent inactivation of ϕ11 by proteinases in the algal 
extract, but this procedure also did not result in measurable lytic activity of the algal-
produced ϕ11.  
 
Moreover, experiments analysing the bactericidal activity of ϕ11 against S. aureus 
were performed. In spot tests, crude extracts of TN72_ϕ11-HA and TN72_control 
were spotted onto a lawn of S. aureus cells, which had been plated onto agar plates. 
After incubation overnight, the plates were analysed for inhibition zones in the area of 
the spots. Alternatively, the crude extracts were mixed with a suspension of S. aureus 
cells, and spotted in different dilutions onto agar plates. On the next day, the numbers 
of colony forming units (cfu) were determined and the cfu/ml calculated. However, 
none of these experiments confirmed the antibacterial activity of ϕ11 produced in C. 
reinhardtii. 
 
To investigate whether the absence of observed activity is caused by insufficient 
concentrations of ϕ11 or whether the experimental design used is not suitable to 
measure the lytic activity of the endolysin, ϕ11 produced in E. coli was used as a 
positive control. E. coli DH5α_ϕ11-HA cells were broken using a French pressure cell 
press and the crude extract was analysed in TRAs with heat-killed S. aureus cells. In 
the TRAs with DH5α_ϕ11-HA, a marked decrease of the OD595nm compared to the 
control was measurable (Figure 5.12 B), which proved the lytic activity of ϕ11 
produced in DH5α_ϕ11-HA. 
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To compare ϕ11 produced in C. reinhardtii to the endolysin produced in E. coli, 
TRAs with different dilutions of TN72_ϕ11-HA and DH5α_ϕ11-HA crude extracts 
were performed. Subsequently, the amount of ϕ11 in the extracts was analysed and 
quantified in western blot analyses with anti-HA antibodies. These analyses showed 
that equivalent amounts of ϕ11 produced in C. reinhardtii had no measurable effect on 
S. aureus cells. In contrast, equal amounts of E. coli-produced ϕ11 caused a marked 
decrease in OD600nm of S. aureus suspensions. Figure 5.12 shows two representative 
TRAs with C. reinhardtii- and E. coli-produced ϕ11 and the corresponding western 
blot analysing the concentration of ϕ11 in the extracts. The western blot shows that 
similar amounts of full-length Pal were present in the algal and the bacterial extract, 
which were used in the shown TRAs (Figure 5.12, first and last lane). It can be 
assumed that the ϕ11 concentration in the E. coli extract is even lower, since the non-
specific band at the same size (which is also present in the negative control) most 
likely contributes to the IR fluorescence signal. The concentration of the ϕ11 
truncation is even higher in the algal extract. Furthermore, one in two dilutions of the 
E. coli extract containing ϕ11 still had a measurable effect on S. aureus (Figure 5.13). 
These results suggest that the activity of ϕ11 in the C. reinhardtii crude extract is 
strongly reduced or completely abolished.  
 
It was considered whether a substance or molecule within in the C. reinhardtii crude 
extract has an inhibitory effect on the activity of ϕ11. Therefore, crude extract of 
TN72_ϕ11-HA and DH5α_ϕ11-HA were mixed in a ratio of 1:1 and the lytic activity 
was analysed in a TRA. The mixture of both extracts caused a nearly identical 
decrease in OD595nm as the same amount of DH5α_ϕ11-HA extract on its own (Figure 
5.13). This indicates that the lytic activity of ϕ11 is not inhibited or destroyed by a 
substance contained in the crude extract of C. reinhardtii.  
 
 
 
 
CHAPTER 5 !
 244 
 
 
Figure 5.12: Turbidity reduction assays (A, B) and western blot analysis (C, D) showing the absence of lytic activity of C. reinhardtii-produced ϕ11 (A) and the lytic 
activity of E. coli DH5α-produced ϕ11 (B) against Staphylococcus aureus  
The S. aureus cells were resuspended in NaPi-buffer to an optical density (OD595nm) of 1.0. E. coli DH5α_ϕ11-HA, C. reinhardtii TN72_ϕ11-HA crude extract and the 
corresponding control extracts were added to the cell suspensions and the OD595nm was measured over a time course at 37ºC. The extracts were analysed for HA-tagged ϕ11 
protein in a western blot analysis with anti-HA antibodies, IRDye® secondary antibodies and the Odyssey® Infrared Imaging system, to compare the amount of ϕ11 in the 
different extracts. The error bars show ± one standard deviation (n = 3 (A), n = 2 (B)). 
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Overall, the results indicate that C. reinhardtii-produced ϕ11 is not active or has a 
markedly lower activity compared to the same endolysin produced in E. coli and is 
therefore not fully active. It is conceivable that differences in the protein folding 
machinery of E. coli and the C. reinhardtii chloroplast are responsible for the 
differences in the lytic activity of both versions of ϕ11. Navarre et al. (1999) found a 
conserved cysteine residue using sequence alignments of the N-terminal 
endopeptidase domain of ϕ11 with the catalytic domains of the S. aureus specific 
endolysins Twort, ϕPVL, ϕ187 and α80. Furthermore, the study showed that ϕ11 is 
inhibited by p-hydroxymercuribenzoic acid, which is an organic mercurial that forms 
stable complexes with cysteine thiol residues, and concluded therefore that the 
conserved cysteine residues is important for the activity of the endopeptidase domain. 
 
Figure 5.13: Turbidity reduction assay showing the lytic activity of E. coli DH5α_ϕ11-HA crude 
extract mixed with C. reinhardtii crude extract against Staphylococcus aureus 
The S. aureus cells were resuspended in NaPi-buffer to an optical density (OD595nm) of 0.9. E. coli 
DH5α_ϕ11-HA (undiluted and diluted 1:2), DH5α_ϕ11-HA mixed in a ratio of 1:1 with C. reinhardtii 
TN72_ϕ11-HA crude extract and the corresponding control extract were added to the cell suspension 
and the OD595nm was measured over a time course at 37ºC. 
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Differences in the reductant levels in both expression platforms could have an 
influence on the interactions of this cysteine residue, which could have resulted in a 
misfolding of ϕ11 in the C. reinhardtii chloroplast.  
 
 
5.2.4.1 Antibacterial activity of ϕ11 against clinical isolates of S. aureus 
 
Endolysins against Gram-positive bacteria are often highly specific and can even 
exhibit specificities for certain strains and serotypes within one species. It was 
observed in this study that the endolysin Pal lyses different strains of S. pneumoniae 
with varying rates. Furthermore, Rodríguez-Cerrato et al. (2007) reported minimal 
inhibitory concentrations for Pal varying from 32 to 256 µg/ml. Therefore the 
antibacterial activity of ϕ11 produced in C. reinhardtii was tested using another S. 
aureus strain to investigate whether the algal endolysin is able to lyse this strain with a 
measurable activity. It was of particular interest to analyse whether the produced 
endolysins have antibacterial activity against clinical isolates, including antibiotic-
resistant strains, since effective killing of these strains would highlight the potential as 
a form of treatment when traditional antibiotics fail. Therefore two clinical isolates of 
S. aureus (provided by Bambos Charalambous from the Royal Free Hospital) were 
used for further tests. The strain ATCC 25923 is methicillin-sensitive clinical isolate 
of S. aureus (MSSA strain), whereas the strain ATCC 43300 is a MRSA isolate of S. 
aureus (methicillin-resistant S. aureus) with resistances against methicillin and 
oxacillin.  
 
Spot tests and assays analysing a decrease in cfu (as described in 5.2.4) were 
performed with the S. aureus MSSA strain and crude extract of TN72_ϕ11-HA and 
the corresponding control extract, but none of the assays demonstrated any 
antibacterial activity of C. reinhardtii-produced ϕ11 against this S. aureus strain (not 
shown).  
 
However, preliminary TRAs performed with crude extract of E. coli DH5α_ϕ11-HA 
showed a marked decrease in OD595nm of suspensions of both S. aureus clinical 
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isolates. The assays were performed with wild type microalgal extract as control and 
need to be repeated with DH5α_control. Nevertheless, since DH5α_control did not 
cause any decrease in OD595nm against the reference S. aureus strain and the OD did 
not decrease in any of the performed control assays, the results suggest that E. coli-
produced ϕ11 has antibacterial activity against the two S. aureus clinical isolates, 
including a MRSA strain.  
 
This is another demonstration that ϕ11 has great potential to be used as an 
antibacterial agent against human and animal staphylococcal pathogens and that it is 
worth undertaking further attempts to produce the endolysin in active form in C. 
reinhardtii or in other microalgae.  
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Figure 5.14: Turbidity reduction assays indicating the lytic activity of E. coli DH5α-produced ϕ11 
against two clinical isolates of Staphylococcus aureus, a MSSA (A) and a MRSA strain (B) 
The S. aureus strains were resuspended in NaPi-buffer to an optical density (OD595nm) of 0.8. E. coli 
DH5α_ϕ11-HA crude extract was added to the cell suspensions and the OD595nm was measured over a 
time course at 37ºC. The control is Synechocystis PCC6803 wild type crude extract. Clinical isolates: A 
= Staphylococcus aureus ATCC 25923, B = Staphylococcus aureus ATCC 43300. MSSA = 
Methicillin-sensitive S. aureus, MRSA = Methicillin-resistant S. aureus. The error bars in B show ± 
one standard deviation (n = 2).  
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5.2.5 The addition of a His-tag to ϕ11 and Pal interferes with the 
production of the recombinant proteins 
 
The purification of C. reinhardtii-produced ϕ11 would enable the investigation of the 
antibacterial activity of the endolysin without the interference of other cell compounds 
in the alga that may inhibit the antibacterial activity of the endolysin. It would also 
allow a strong concentration of ϕ11 without the simultaneous concentration of the 
chlorophyll to investigate whether the antibacterial activity of C. reinhardtii-produced 
ϕ11 is reduced or completely abolished. Furthermore, it is possible in some cases to 
denature and subsequently correctly refold misfolded recombinant proteins in vitro 
after purification and restore the enzymatic activity (De Bernardez Clark 1998).  
 
The addition of polyhistidine-tags (His-tags) to recombinant proteins is widely used 
for the purification of proteins using commercially available and inexpensive 
sepharose or agarose columns with nickel bound to iminodiacetic acid (Ni-IDA) or 
nitrilotriacetic acid (Ni-NTA). Previous studies used the addition of a His-tag for the 
purification of ϕ11 produced in E. coli (Donovan et al. 2006, Sass & Bierbaum 2007) 
and no purification protocol specific for ϕ11 without the use of tags has been 
developed so far.  
 
Therefore the C. reinhardtii transgenic line TN72_ϕ11-HA-His, which carries the ϕ11 
gene attached to the sequence of a His-tag was created (5.2.1.2.2). The ϕ11 gene is 
additionally attached to the sequence of a HA-tag, which is located in between the 
gene and the His-tag sequence (Figure 5.3). This was done to enable an easy detection 
of the recombinant protein in western blot analyses, since anti-HA antibodies are 
known to be more sensitive than anti-His antibodies. At the same time the transgenic 
line TN72_pa1-HA-His, which carries the pal gene with both tags in the same 
arrangement was created. This was done to evaluate another method for the 
purification of Pal in addition to the purification methods discussed in 4.2.4.  
 
Whole cell extracts of TN72_ϕ11-HA-His and TN72_pa1-HA-His were analysed for 
the presence of HA- and His- tagged ϕ11 and Pal protein by western blot analysis 
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using anti-HA antibodies and horseradish peroxidase-linked secondary antibodies and 
the resulting chemiluminescence was detected with photographic film. In these 
analyses the strain TN72_control was used as a negative control and the strains 
TN72_ϕ11-HA and TN72_pa1-HA were used as positive controls. However, none of 
the performed western blot analyses showed bands that were not present in the 
negative control for any of the TN72_ϕ11-HA-His and TN72_pal-HA-His 
transformants, whereas samples of the positive controls with the same cell densities 
showed strong bands at the size of ϕ11-HA and Pal-HA (Figure 5.15) 
 
Subsequently, the gene sequences of the TN72_ϕ11-HA-His and TN72_pa1-HA-His 
transformants were analysed by sequencing to investigate whether the absence of 
detectable recombinant protein can be explained by erroneous mutations. However, 
the analyses confirmed that the transgenic lines have the correct sequences.  
 
 
 
 
Figure 5.15: Western blot analysis with whole cell extract of TN72_ϕ11-HA-His and TN72_pal-
HA-His transformants for the presence of HA- and His-tagged ϕ11 and Pal 
The western blot was performed with samples of TN72_ϕ11-HA, TN72_pal-HA and TN72_control as 
controls and anti-HA antibodies, horseradish peroxidase-linked secondary (ECL) antibodies and the 
resulting chemiluminescence was detected with photographic film. The cultures were harvested at an 
OD750nm of approximately 3 and normalised to the OD750nm at the time of sampling (cells were 
resuspended in 1 ml of buffer per OD750nm of 1). The expected band sizes are shown in the figure. 
Protein sizes were determined using the PageRulerTM Prestained Protein ladder (Thermo Scientific), L 
= ladder. 
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These results indicate that the addition of six histidine residues to the C-terminal end 
of ϕ11 and Pal interferes with either the synthesis or the stability of the recombinant 
endolysins, which results in protein levels that are reduced below the detection limit 
of the method used in this study. It is conceivable that the attachment of six further 
amino acids in addition to the nine amino acids of the HA-tag prevents the correct 
folding of the proteins and that the misfolded endolysins are quickly degraded by the 
proteolytic machinery in the chloroplast.  
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5.3 Conclusion and future work 
 
The study described in this chapter investigated the synthesis of the endolysin ϕ11, a 
potential candidate for use as a novel antibiotic against staphylococcal human and 
animal pathogens, in the C. reinhardtii chloroplast to evaluate the suitability of the 
microalga as a novel expression platform using another example. 
 
Two lines of C. reinhardtii were created with a transgene encoded HA-tagged ϕ11 
inserted in the plastome, in one case with the addition of a His-tag sequence. 
Subsequently the expression of ϕ11 in the algal chloroplast was confirmed with anti-
HA antibodies. Furthermore, the results suggested that genetically identical lines, 
created by homologous recombination in the chloroplast, produce comparable levels 
of recombinant protein.  
 
The western blot analyses confirming the synthesis of ϕ11 protein in the C. reinhardtii 
chloroplast also showed the presence of an approximately 38 kDa truncation of ϕ11 
missing the first 150 N-terminal amino acids. This truncation product was present in 
the majority of western blots performed with ϕ11 and its size did not vary between 
different analyses. The same truncation was also present when ϕ11 was produced 
using Escherichia coli DH5α. This is in contrast to the endolysin Pal, of which no 
truncations accumulate to detectable levels in the C. reinhardtii chloroplast, whereas 
in E. coli DH5α truncations of Pal accumulate to even higher levels than the full-
length Pal. The ϕ11 sequence contains a methionine in the predicted start region of the 
truncation and a translational start at this AUG codon would result in a 38.9 kDa 
protein. It is therefore conceivable that this AUG functions as part of a cryptic internal 
translation initiation region. Another explanation would be that the truncation is 
formed by proteolytic degradation. The observation that more ϕ11 truncated protein 
compared to full-length protein is formed at the transition from exponential to 
stationary phase supports this theory, because the production of proteases increases in 
the stationary phase. Furthermore, the proteases in the cytoplasm have more time to 
cleave ϕ11. Analysis using the ExPASy PeptideCutter showed that most proteases are 
predicted to cleave ϕ11 multiple times and did not reveal an obvious candidate. 
CHAPTER 5 
 
 253 
However, the amount of proteases in the database is very limited. Several proteases 
exist that have very specific cleavage sites consisting of sequence combinations of 
four and even more amino acids. It is conceivable that a protease with a specific 
cleavage site that appears only once in the sequence of ϕ11 and that exists in E. coli 
DH5α and the C. reinhardtii chloroplast is responsible for the ϕ11 truncation product. 
The vast majority of proteases in the chloroplast are homologues of bacterial proteases 
(Adam et al. 2006). It is therefore likely that homologue proteases are involved in the 
degradation of ϕ11 in both organisms. It would also be possible that the structure of 
ϕ11 allows easy access for proteases only in this region. Furthermore, it should be 
borne in mind that the western blot analysis with anti-HA antibodies shows only C-
terminal degradation products that still contain the HA-tag. A potential experiment to 
investigate whether the truncation is caused by an alternative translation initiation at 
the mentioned methionine (rather than proteolytic activity) would be to change the 
ATG codon of the methionine to another codon by site-specific mutagenesis. Provided 
this change does not abolish the expression of ϕ11 it would make it possible to 
confirm or exclude this theory.  
 
As a next step the isolation of ϕ11 in an active form was investigated. It was shown 
that, like Pal, ϕ11 can be easily recovered after breakage of the cell wall-less strain 
TN72_ϕ11-HA by freezing and thawing. However, the results indicated that some 
parts of the protein precipitated during the subsequent centrifugation together with the 
cell debris. An even higher percentage of full-length ϕ11 and the vast majority of the 
ϕ11 truncation were found to be located in the pellet following ultracentrifugation. 
These results suggest that a high percentage of ϕ11 does not exist as soluble protein in 
the C. reinhardtii chloroplast and might exist as aggregates instead (Shih et al. 2002). 
 
Subsequently, the antibacterial activity of ϕ11 produced in C. reinhardtii was 
analysed using TRAs, spot tests and assays analysing a decrease in cfu. None of these 
assays demonstrated any enzymatic activity for ϕ11 produced in C. reinhardtii. In 
contrast, TRAs using ϕ11 produced in E. coli DH5α showed marked bacteriolytic 
activity against S. aureus, whereas the same amount of ϕ11 produced in C. reinhardtii 
did not show any activity. These results suggest that C. reinhardtii-produced ϕ11 is 
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not active or has a significantly lower activity compared to the same endolysin 
produced in E. coli.  
 
A likely explanation for the absence or reduced activity is that ϕ11 is not folded 
correctly in the chloroplast of C. reinhardtii, which might result in aggregates. The 
observation that a high percentage of ϕ11 precipitates during ultracentrifugation, 
which suggest that ϕ11 does not exist as soluble protein in the chloroplast, supports 
this theory. The misfolding of ϕ11 might be the result of differences in the protein 
folding machinery in the two organisms. Furthermore, Navarre et al. (1999) found a 
conserved cysteine residue and concluded that it is important for the activity of the 
endopeptidase domain. Since the formation of disulphide bonds is influenced by the 
reductant levels, unfavourable levels in the chloroplast stroma could have been 
therefore responsible for a misfolding of the ϕ11 protein. Navarre et al. (1999) and 
Donovan et al. (2006) added dithiothreitol (DTT) to the TRA buffer or the protein 
purification buffer, respectively. DDT reduces disulphide bonds and prevents in this 
way the formation of intramolecular and intermolecular disulphide bonds between 
cysteine residues of proteins, which can result in misfolding or aggregation. Sass & 
Bierbaum (2006) demonstrated the enzymatic activity of ϕ11 produced in E. coli 
without the addition of DDT. In this study the lytic activity of ϕ11 produced in DH5α 
was also shown without the addition of DDT. Nevertheless, the addition of DDT to 
the lysis buffer might preserve (or restore) the antibacterial activity of ϕ11 produced 
in C. reinhardtii. 
 
The NCBI database predicts using sequence alignments that the N-acetylmuramoyl-L-
alanine amidase domain, which belongs to the PGRP (peptidoglycan recognition 
protein) superfamily, contains three zinc binding residues. Another explanation for the 
absence of lytic activity could be therefore that the availability of the cofactor zinc 
was insufficient in the C. reinhardtii chloroplast. During this study an attempt was 
made to perform TRAs with the addition of zinc ions (50, 500, 1000 µM ZnSO4, 
performed in 50 mM Tris-HCl buffer). However, the TRAs were hindered by 
precipitations in the presence of the zinc, which resulted in an increase of the OD750nm 
that masked any lytic activity. However, the performance of TRAs in different buffer 
conditions might allow the experiment. Provided that a lack of zinc in the chloroplast 
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does not result in irreversible damage of the endolysin, the addition of zinc after cell 
breakage might result in the restoration of the lytic activity. Another option would be 
the cultivation of TN72_ϕ11-HA in the presence of higher zinc concentrations in the 
medium. In this study 2.5 µM ZnSO4 were used for the cultivation, which is 
considered as zinc-replete growth for C. reinhardtii. The alga can tolerate up to 125 – 
250 µM chelated (EDTA) zinc ions and it is therefore possible to increase the zinc 
concentration in the medium (Malasarn et al. 2013). However, excess zinc within the 
cell is toxic, since it can compete for binding sites with other metal cofactors. The 
intracellular zinc concentration in microalgae and other organisms is therefore 
regulated (Malasarn et al. 2013). Provided that an increase of the zinc concentration in 
the medium, despite the regulation mechanisms, has an influence on the availability of 
zinc inside the chloroplast, this cultivation method might result in the production of 
fully active ϕ11. 
 
Another strategy to produce active ϕ11 in C. reinhardtii could be to grow the alga at a 
lower temperature. Shih et al. (2002) found that a number of proteins are soluble when 
the synthesising E. coli JM109 strain was grown at 20ºC, but not after cultivation at a 
temperature of 37ºC. The study concludes that a lower cultivation temperature and 
long induction periods facilitate correct protein folding. Furthermore, Pal and the 
human growth hormone show higher recombinant protein levels in the C. reinhardtii 
chloroplast during cultivation at 25ºC compared to 35ºC, which suggests an influence 
of temperature on the production of stable protein in the alga as well (R. Young, 
unpublished). It might therefore be conceivable that a cultivation of TN72_ϕ11-HA at 
an even lower temperature than 25ºC can facilitate the correct folding of ϕ11 and 
results in the production of active endolysin in the chloroplast.  
 
It has been shown in 3.2.2.4 that the levels of recombinant Pal are three to ten times 
higher when produced under the control of the psaA exon 1 promoter/5’UTR 
compared to the atpA promoter/5’UTR. Further studies showed also higher 
recombinant protein levels for Cpl-1 and VFP under the control of the psaA exon 1 
promoter/5’UTR in the C. reinhardtii chloroplast (Taunt 2013; Braun Galleani 2014). 
It was not attempted in this study to produce ϕ11 under the control of the psaA exon 1 
promoter/5’UTR, because of the absence of any detectable antibacterial activity. 
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However, it is likely that an expression of ϕ11 using this promoter would result also in 
higher levels of the endolysin. Provided that the activity of ϕ11 is reduced and not 
completely abolished, higher expression levels might make it possible to at least 
demonstrate the antibacterial activity against S. aureus and to further investigate what 
is reducing the activity.  
 
Another observation during the experiments described in this chapter was that the 
addition of a His-tag comprised of six histidine residues at the C-terminal end of Pal 
and ϕ11 resulted in undetectable protein levels. A possible explanation is that the 
additional residues, together with the nine amino acids of the HA-tag, interfere with 
the correct folding of endolysins, which could result in rapid degradation. This 
suggests that the correct folding of recombinant proteins in the chloroplast can be 
easily disturbed. The aim of the addition of a His-tag to ϕ11 was to enable the 
purification of the endolysin to be able to analyse its antibacterial activity without the 
inference of any potential inhibitory substances or conditions present in the crude 
algal extract. Furthermore, it might be possible to denature and subsequently correctly 
refold misfolded ϕ11 in vitro after purification and so to restore the enzymatic activity 
(De Bernardez Clark 1998; Lilie et al. 1998). It would therefore be worthwhile to 
attempt the purification of ϕ11 using different methods. One option would be to try 
the addition of a Strep-tag or the addition of a His-tag without the HA-tag, which 
might not interfere with the production the endolysin. The HA-tagged ϕ11 could be 
purified using immunoprecipitation with monoclonal anti-HA agarose conjugate resin. 
Furthermore, untagged ϕ11 could be purified using fast protein liquid chromatography 
(FPLC).  
 
As already mentioned in 4.2.2.2, the addition of N- or C-terminal tags can hamper the 
correct folding of proteins and reduce or eliminate in this way the activity of enzymes 
in some cases (C. Economou, unpublished; Rehm 2006). Nevertheless, this 
explanation is less likely, since HA-tagged ϕ11 produced in E. coli shows antibacterial 
activity. However, it is conceivable that in less favourable conditions the HA-tag 
hampers the folding, even it does not interfere with the activity when the protein is 
produced in E. coli.  
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Taken together, the results show that it is possible to synthesise the staphylococcal 
specific endolysin ϕ11 in the C. reinhardtii chloroplast. However, it was not possible 
so far to synthesize the enzyme in a fully active form. As discussed in this section 
there are still several strategies that can be tried to produce active ϕ11 in C. 
reinhardtii. It is too early to conclude that the C. reinhardtii chloroplast is not a 
suitable production platform for the endolysin ϕ11. 
 
The great potential of ϕ11 as an antibacterial agent against human and animal 
staphylococcal pathogens has been demonstrated by Donovan et al. (2006) and Sass & 
Bierbaum (2006). Furthermore, it has been shown in this study that ϕ11 exhibits 
antibacterial activity against two clinical isolates of S. aureus including a MRSA 
strain. Microalgae are believed to have the potential to be a cost-efficient production 
platform (Gimpel et al. 2014; Rasala et al. 2010) and the availability of several 
microalgae with GRAS status is of great advantage. Furthermore, the occurrence of 
antibacterial properties, amongst others against S. aureus, of C. reinhardtii and other 
microalgae adds a very interesting argument for the use of microalgae as production 
platform for antimicrobial proteins and the use of crude algal extract for 
administration. A conceivable application for algal crude extract containing ϕ11 could 
be a topical treatment for mastitis, which is externally applied to the udder of infected 
dairy cows. The use of a crude extract from a GRAS organism would be highly 
desirable in this case. The use of ϕ11 in crude extract as a topical treatment for 
mastitis seems to be more realistic in the close future than the idea of Donovan et al. 
(2006) to express ϕ11 in the udder of transgenic cows for the production of milk for 
human consumption. Moreover, a variety of topical treatments for human skin 
infections is conceivable as well. It is therefore worth undertaking additional attempts 
to produce the endolysin in active form in C. reinhardtii or other microalgae, which is 
further investigated in the following chapter.  
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6 Synthesis of bacteriophage endolysins in the 
cyanobacterium Synechocystis sp. PCC 6803 
 
6.1 Introduction 
 
6.1.1 Limitations of the C. reinhardtii chloroplast as an expression 
platform 
 
The results presented in chapter 3 and 4 strongly support the feasibility of the C. 
reinhardtii chloroplast as a platform for the synthesis of endolysins. Reliable 
expression of predominantly full-length Pal was achieved and the endolysin exhibited 
a high stability and full bacteriolytic and bactericidal activity against S. pneumoniae. 
Furthermore, Cpl-1, a second S. pneumoniae specific endolysin was successfully 
synthesised in active form in the C. reinhardtii chloroplast (Taunt 2013).  
 
However, it has been shown in chapter 5 that the staphylococci specific endolysin ϕ11 
was successfully synthesised in C. reinhardtii, but the endolysin was not active or had 
a markedly lower activity compared to E. coli-produced ϕ11. Another problem that 
was encountered was that the addition of a His-tag comprising of six histidines to the 
C-terminal end of already HA-tagged Pal and ϕ11 resulted in undetectable protein 
levels.  
 
The study by Taunt (2013) attempted to produce two further endolysins in the C. 
reinhardtii chloroplast: the S. aureus specific endolysin Lys16 and the P. acnes 
specific endolysin Gp20. The expression of Gp20 was even attempted with two 
differently codon-optimised versions of the gp20 gene and the expression of both 
proteins was attempted with two different promoters, and through translational fusions 
of these non-expressing endolysins to expressed proteins. Nevertheless, neither 
endolysin accumulated to detectable levels in the C. reinhardtii chloroplast. Table 6.1 
shows a summary of the endolysins, whose expression in the C. reinhardtii 
chloroplast has been investigated in this study and the study by Taunt (2013).  
CHAPTER 6 
 
 260 
Table 6.1: Summary of the endolysins, whose expression in the C. reinhardtii chloroplast has been 
investigated in this study and the study by Taunt (2013).  
All proteins mentioned in this table carry a HA-tag. NA = not analysed.  
 
Endolysin 
Expression in the 
 C. reinhardtii 
chloroplast 
Activity Study 
Pal Yes Active This study 
Cpl-1 Yes Active Taunt 2013 
ϕ11 Yes Not detectable with applied methods  This study 
ϕ11-His Not detectable with applied methods NA This study 
Pal-His Not detectable with applied methods NA This study 
Gp20 Not detectable with applied methods NA Taunt 2013 
Lys16 Not detectable with applied methods NA Taunt 2013 
 
 
These findings are in agreement with a study by Rasala et al. that found that out of 
seven human proteins they attempted to express in the C. reinhardtii chloroplast, three 
accumulated to detectable levels under the control of the atpA and psbA promoters, 
and a fourth one was only synthesised to detectable levels when fused to a well-
expressed serum amyloid protein. The other three did not accumulate to any 
detectable level (Rasala et al. 2010).  
 
The earliest studies on the production of recombinant therapeutic protein in the C. 
reinhardtii chloroplast were performed over a decade ago (Mayfield 2003) and several 
studies since then  have demonstrated the production of a variety of proteins such as 
antibodies, hormones and vaccines (He et al. 2007; Dreesen et al. 2010; Rasala et al. 
2010). However, C. reinhardtii is still a relatively new production platform for 
recombinant proteins compared to established platforms such as E. coli or the yeast 
Saccharomyces cerevisiae. Several investigations have already contributed to an 
improvement of the expression levels, including studies that investigated different 
promoters and UTRs as well as codon optimisation strategies (Purton et al. 2013; 
Michelet et al. 2011; Franklin et al. 2002). It is therefore likely that further research 
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will result in increased yields of recombinant protein in the C. reinhardtii chloroplast 
and will help to identify the reasons that lead to non-expression or inactivity of some 
proteins. Nevertheless, since several endolysins were not produced to detectable levels 
in C. reinhardtii or were found to be inactive, the use of an alternative microalgal 
protein production platform was considered.  
 
 
6.1.2 Cyanobacteria as production platform for endolysins 
 
Endolysins are naturally produced in bacteriophage-infected bacteria and have 
evolved over billions of years to be adapted to a prokaryotic environment. Therefore it 
can be assumed that these proteins have a high resistance against prokaryotic 
proteases, and that endolysins are adapted to the prokaryotic protein synthesis 
machinery and the conditions in the bacterial cytoplasm.  
 
Cyanobacteria, also called blue-green algae, are prokaryotic microorganisms that 
carry out oxygenic photosynthesis and have similar advantages for recombinant 
protein production as the C. reinhardtii chloroplast. These eubacteria have minimal 
nutrient requirements and are capable of photoautotrophic or mixotrophic growth, and 
their cultivation is inexpensive. Furthermore, several species of cyanobacteria have 
GRAS status. Species such as Arthrospira plantesis and Arthrospira maxima (better 
known as Spirulina) as well as Nostoc flagelliforme and Nostoc commune are even 
used as food supplements for vitamins, minerals and β-carotene. Moreover, several 
studies identified antimicrobial compounds in cyanobacteria. Ishida et al. (2007) for 
example identified Kawaguchipeptin B, an antibacterial cyclic undecapeptide that was 
isolated from the cyanobacterium Microcystis aeruginosa (Ishida et al. 1997). 
Furthermore, two highly halogenated aromatic compounds, Ambigol A and B, were 
isolated from Fischerella ambigua and characterized by Falch et al. (1993). An 
application is therefore conceivable, in which crude cyanobacterial extracts are used 
that contain endolysins and have potentially additive antibacterial properties, as was 
described for C. reinhardtii extracts.  
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Cyanobacteria are classified as Gram-negative bacteria, but their peptidoglycan is 
thicker and has a higher degree of cross-linking than that of most Gram-negative 
bacteria (Hoiczyk and Hansel 2000). However, the peptide chains that crosslink the 
polysaccharide strands have the typical Gram-negative composition and differ 
therefore from the peptidoglycan of S. pneumoniae, S. aureus and other Gram-positive 
bacteria. These cell walls lack for example the glycine bridge, which contains the 
bond that is cleaved by the endopeptidase domain of ϕ11, suggesting that synthesis of 
ϕ11 in cyanobacteria would be feasible. Furthermore, the cytoplasmic membrane 
would present a barrier, in the absence of holins that prevents the endolysins from 
reaching the peptidoglycan. Finally, the endolysins investigated in this study are 
highly specific and have been successfully produced in the Gram-negative bacterium 
E. coli. It can be therefore assumed that these proteins can be synthesised in the 
cyanobacterial cytoplasm without causing major harm to the cell.  
 
Cyanobacteria have been seldom considered as production platforms for recombinant 
proteins despite the fact that genetic engineering tools for the expression of foreign 
genes have been developed for several species (Zhou et al. 2014). In most cases the 
introduction of foreign genes is used for metabolic engineering and the creation of 
novel biosynthetic pathways. For example, Lan & Liao (2011) expressed a trans-
enoyl-CoA reductase gene for the production of butanol in Synechococcus elongatus 
PCC 7942, whereas Guerrero et al. (2012) produced an ethylene-forming enzyme 
(EFE) in Synechocystis sp. PCC 6803 for the production of ethylene. Furthermore, 
applications in which the cyanobacterium can be used as the production and 
delivering system have been investigated. A study by Zang et al. (2007) produced 
Paralichthys olivaceus (flounder) growth hormone (fGH) in Synechocystis sp. PCC 
6803. The group investigated also the effect of supplementing the feed of turbot 
(Scophthalmus maximus L.) with the transgenic Synechocystis cells producing fGH 
and found that it can be used as an efficient growth promoter without any observed 
side effects (Liu et al. 2007). These results indicated therefore that Synechocystis sp. 
PCC 6803 does not contain major amounts of endotoxins that harm turbot following 
oral administration. 
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Synechocystis sp. PCC 6803 is the cyanobacterial model organism and it was the first 
photosynthetic organisms whose genome was sequenced and annotated (Kaneko et al. 
1996; Ikeuchi & Tabata 2001). The bacterium is naturally transformable by 
exogenous DNA and several tools for the genetic manipulation are already available 
(Ikeuchi & Tabata 2001). Furthermore, it has been shown that Synechocystis species 
have antibacterial activity against Gram-positive bacteria (Martins et al. 2008).  
 
Synechocystis sp. PCC 6803 was therefore chosen to investigate the potential of 
cyanobacteria as a production platform for endolysins and other antibacterial proteins. 
The endolysin ϕ11, which did not show activity when produced in C. reinhardtii, and 
Pal as a positive control were used to analyse the endolysin synthesis in 
Synechocystis. Furthermore, Gp20, an endolysin from the study of Taunt (2013) was 
chosen to investigate the production of an endolysin in Synechocystis that did not 
accumulate to detectable levels in C. reinhardtii.  
 
 
6.1.3 The Propionibacterium acnes-specific endolysin Gp20 from 
bacteriophage PA6 
 
Farrar et al. (2007) were the first to sequence the genome of a bacteriophage that 
infects Propionibacterium acnes, a bacterium that is associated with inflammatory 
acnes vulgaris. The bacteriophage PA6 has a high genetically and morphologically 
similarity to several mycobacteriophages. Like Dp-1 and ϕ11, PA6 belongs to the 
family of the Siphoviridae. The genome of PA6 consists of double-stranded DNA and 
has a length of 29.7 kb. Farrar et al. (2007) showed that the bacteriophage could infect 
32 different isolates of P. acnes, including clinical isolates with antibiotic resistances 
to erythromycin and clindamycin. In contrast, PA6 showed a high specificity for P. 
acnes and did not infect other bacteria that are common commensals in the human 
skin microflora such as Propionibacterium granulosum, Propionibacterium avidum, 
Staphylococcus epidermis or Corynebacterium bovis. 
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Farrar et al. (2007) identified 48 ORFs in the genome of PA6 and predicted that 
ORF20 encodes a putative N-acetyl-muramoyl-L-alanine amidase and defined the 
encoded protein as Gp20. Gp20 was found to have homology to the amidases of the 
mycobcteriophages PG1 and Che8 and a high similarity (67% identity for amino acids 
2 to 145, N-terminal catalytic domain) to another N-acetyl-muramoyl-L-alanine 
amidase, which is an autolysin of P. acnes. Furthermore, the downstream ORF21 is 
predicted to encode the holin of the lytic system. The gene arrangement is typical for 
endolysin and holin genes in bacteriophage genomes.  
 
The study by Taunt (2013) confirmed using sequence alignments and database 
analysis, the prediction that ORF20 encodes an amidase at the N-terminus and 
therefore the endolysin of PA6. At the time Taunt started the investigation of the 
production of Gp20 in C. reinhardtii, PA6 was the only P. acnes bacteriophage that 
had been sequenced so far. Since then, several further P. acnes specific 
bacteriophages have been sequenced and further putative endolysins have been 
described by Lood & Collin (2011) and Marinelli et al. (2012). Marinelli et al. (2012) 
found that the genome sequence of all 11 bacteriophages they analysed exhibit a 
remarkably high nucleotide identity of more than 85%. Furthermore, the study found 
that ORF20 encodes the endolysin in all analysed P. acnes bacteriophages and that the 
N-terminal domains of these endolysins are predicted to be N-acetyl-muramoyl-L-
alanine amidases. The N-terminal domain and also the C-terminal domain, that is 
predicted to be responsible for cell binding, are highly conserved within different P. 
acnes bacteriophage endolysins and have sequence identities of 92 to 96%. Gp20 from 
phage PA6 can be therefore seen as a representative example for P. acnes 
bacteriophage endolysins in general. None of the mentioned studies has 
experimentally shown that the encoded putative endolysins are able to cleave 
peptidoglycan. A successful production followed by the demonstration of its lytic 
activity against P. acnes would therefore provide the experimental proof that ORF20 
encodes for the endolysin in P. acnes bacteriophages. However, the patent 
US_2012_0195872_A1 describes a fusion of gp20 from PA6 to an 18 amino acid long 
peptide sequence and showed the antimicrobial activity of the fusion protein against 
two strains P. acnes, which already indicates that gp20 encodes for an endolysin.  
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6.1.4 Aims and objectives 
 
The aim of the experiments in this chapter was the production in Synechocystis sp. 
PCC 6803 of several bacteriophage endolysins, including candidates that could not be 
produced as functional proteins in the C. reinhardtii chloroplast. Subsequently, the 
aim was to analyse the antibacterial activity of the produced endolysins against their 
target bacteria to investigate whether the proteins are functional. Overall, the aim was 
to investigate the suitability of the cyanobacterium Synechocystis sp. PCC 6803 as an 
alternative and novel production platform for endolysins and other therapeutic 
proteins. 
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6.2 Results and discussion 
 
6.2.1 Creation of transgenic lines of Synechocystis sp. PCC 6803 for the 
synthesis of bacteriophage endolysins 
 
Six different transgenic lines of Synechocystis sp. PCC 6803 carrying a synthetic 
endolysin gene in their genome were created to study the synthesis of endolysins in 
the cyanobacterium. The lines differ in regard to the promoters used for the expression 
of the genes and the endolysin genes they are carrying (Figure 6.1, Figure 6.2).  
 
All lines were created using one of the two Synechocystis transformation vectors 
pLAH.AII and the pLAH.nrsB that were created by Lamya Al-Haj (2014) and the 
Synechocystis sp. PCC 6803 wild type strain as recipient strain. The vectors carrying a 
Tn903 kanamycin resistance cassette and successful transformants can be therefore 
selected for kanamycin resistance. Both vectors insert the genes of interest into the 
locus of the psbAII gene. The psbAII encodes together with psbAI and psbAIII the D1 
subunit of the photosystem II (Vermaas 1998). It has been shown that a knockout of 
psbAII does not have an adverse effect on the growth of Synechocystis (Vermaas 
1998; Al-Haj 2014). 
 
 
6.2.1.1 Promoters and 5’/3’ untranslated regions (UTR) 
 
The vector pLAH.AII carries an expression cassette, which is flanked with upstream 
and downstream flanking regions of the psbAII gene that include the 5´UTR and 
3´UTR of the psbAII gene and the psbAII promoter (see vector map in appendix). 
These elements allow the expression of the gene of interest and the insertion into the 
psbAII locus by homologous recombination. The expression cassette of pLAH.nrsB is 
also flanked with upstream and downstream regions of the psbAII gene, but these 
elements exclude the psbAII promoter (see vector map in appendix).  
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Figure 6.1: Strains of Synechocystis sp. PCC 6803 expressing the endolysin genes using the 
constitutive promoter of the psbAII gene  
The diagram shows the Synechocystis sp. PCC 6803 strains that were created to study the expression of 
different endolysins in the cyanobacterium under the control of the psbAII promoter. Endogenous genes 
and expression elements are indicated in green, genes of interest in yellow, Tn903 kanamycin 
resistance cassette (KmR) in red and the HA-tag in orange. The strain Syn6803_AII_pal-HA whose 
production was attempted and is discussed in 6.2.1.3.3 is shown in faint colours. UE = upstream 
element, DE = downstream element.  
 
 
 
Figure 6.2: Strains of Synechocystis sp. PCC 6803 expressing the endolysin genes under the 
control the nickel-inducible promoter nrsB and the corresponding wild type strain 
The diagram shows the Synechocystis sp. PCC 6803 strains that were created to study the expression of 
different endolysins in the cyanobacterium under the control of the nrsB promoter and its nickel 
regulatory elements nrsRS. The wild type strain was used as the recipient strain and as a negative 
control. Endogenous genes and expression elements are indicated in green, nrsBRS system in purple, 
genes of interest in yellow, Tn903 kanamycin resistance cassette (KmR) in red and the HA-tag in 
orange. UE = upstream element, DE = downstream element. 
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The vector pLAH.nrsB lacks the psbAII promoter and carries instead the nickel 
inducible endogenous promoter from nrsB that is part of the nrsBACD operon. The 
four proteins encoded by nrsBACD are involved in the resistance of Synechocystis to 
nickel (Lopez-Maury et al. 2002). The nrsB promoter is controlled by a two-
component transduction system that is involved in nickel sensing and induces the 
promoter in the presence of nickel (Lopez-Maury et al. 2002). The transduction 
system is encoded by the genes nrsR and nrsS, which are located upstream of 
nrsBACD operon in the opposite orientation. The expression vector pLAH.nrsB 
carries beside the promoter nrsB also nrsR and nrsS.  
 
 
6.2.1.2 Design and codon-optimisation of the synthetic endolysin genes 
 
The gene sequences that were originally codon-optimised for the C. reinhardtii 
chloroplast were used in this study for a first investigation of Synechocystis sp. PCC 
6803 as a production platform for endolysins. An analysis of the codon usage tables 
from Nakamura et al. (2000) for both the C. reinhardtii chloroplast and Synechocystis 
sp. PCC 6803 shows that most codons that are used less frequently in Synechocystis, 
are less frequent in the C. reinhardtii chloroplast as well (Figure 6.3), which is not 
surprising given that the chloroplast evolved from a cyanobacterium. Overall, all 
codons are used in Synechocystis and the cyanobacterium shows less bias for 
particular codons for each amino acid, instead the codon usage is more evenly spread 
over the available codons for one amino acid compared to the C. reinhardtii 
chloroplast. The codons of the pal and ϕ11 genes used in this study are therefore 
mainly codons that are frequent in Synechocystis sp. PCC 6803 and should be 
therefore suitable for expression in the cyanobacterium. One exception is the UCA 
codon, which is less frequently used for serine in Synechocystis, but it is the most 
often used codon for serine in the C. reinhardtii chloroplast. This codon is present 16 
times in the pal gene and 13 times in the ϕ11 gene (Appendix 1). However, it was 
found 5,029 times in the coding sequences of Synechocystis sp. PCC 6803 that were 
analysed for the codon usage table. It can be therefore assumed that the corresponding 
tRNA for UCA is present in sufficient amounts in the cyanobacterium. For 
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comparison, the most frequently used codons for serine in Synechocystis, UCC and 
AGU, were found 18,364 and 17,502 times within this set of genes, which is 
approximately 3.5 times as often. The designs of the pal and ϕ11 genes are described 
in 3.2.1.1 and 5.2.1.1, respectively.  
 
The gp201 and gp202 genes were obtained from Henry Taunt. The sequence of the 
Gp20 protein is available in the database UniProtKB/Swiss-Prot (Entry: A4K487; 
Entry name: A4K487_9CAUD; Protein name: Gp20, EC=3.5.1.28; Organism: 
Propionibacterium phage PA6 (Taxonomic identifier: 376758)). Gp20 is comprised of 
286 amino acids and has a predicted mass of 31,237 Da. The gp201 gene was codon-
optimised for the C. reinhardtii chloroplast to a Codon Adaption Index (CAI) of 0.8 
with respect to the codon usage table from Nakamura et al. (2000) 
(http://www.kazusa.or.jp/codon), whereas the gp202 gene was designed using the 
CUO Moptomiser subroutine, which was developed by Henry Taunt and Khai Kong 
Jien. This program codon-optimises genes for the C. reinhardtii chloroplast not only 
in respect to the codon usage, but also takes into account codon-pairing and the usage 
of codons found in a subset of highly expressing C. reinhardtii chloroplast genes. The 
DNA sequences of the gp201 and gp202 gene are attached in the appendix. The 
previously mentioned UCA codon appears six times in gp201 and 13 times in gp202.  
 
Both gp20 genes were synthesised by GENEART (Regensburg, Germany) with a C-
terminal human influenza haemagglutinin (HA) epitope tag for detection. The created 
gp20 genes have a length of 858 bp and including the HA-tag coding sequence and 
two stop codons (TAA) a length of 891 bp. The HA-tagged Gp20 protein has a 
molecular mass of 32.3 kDa. 
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Synechocystis sp. PCC 6803 
 
UUU 29.4( 34201)  UCU  9.0( 10445)  UAU 17.4( 20257)  UGU  6.3(  7322) 
UUC 10.5( 12206)  UCC 15.8( 18364)  UAC 11.9( 13849)  UGC  3.9(  4482) 
UUA 26.4( 30619)  UCA  4.3(  5029)  UAA  1.4(  1607)  UGA  0.6(   747) 
UUG 28.9( 33614)  UCG  4.1(  4723)  UAG  1.1(  1269)  UGG 15.5( 17981)   
 
CUU 10.2( 11827)  CCU 10.0( 11628)  CAU 11.7( 13564)  CGU 10.3( 12025) 
CUC 13.9( 16178)  CCC 24.5( 28447)  CAC  7.2(  8310)  CGC 12.2( 14172) 
CUA 14.0( 16296)  CCA  8.1(  9434)  CAA 34.0( 39494)  CGA  5.4(  6267) 
CUG 20.0( 23264)  CCG  8.3(  9614)  CAG 21.2( 24630)  CGG 13.4( 15524)  
 
AUU 40.0( 46527)  ACU 13.9( 16157)  AAU 25.7( 29897)  AGU 15.1( 17502) 
AUC 17.8( 20730)  ACC 26.0( 30223)  AAC 15.0( 17423)  AGC 10.3( 11939) 
AUA  4.9(  5744)  ACA  7.0(  8150)  AAA 30.1( 34968)  AGA  4.6(  5315) 
AUG 19.3( 22456)  ACG  7.8(  9038)  AAG 12.8( 14924)  AGG  4.8(  5602)   
 
GUU 16.8( 19493)  GCU 20.0( 23248)  GAU 32.5( 37772)  GGU 19.8( 23048) 
GUC 11.2( 12973)  GCC 37.5( 43610)  GAC 17.8( 20706)  GGC 22.3( 25904) 
GUA 10.5( 12223)  GCA 10.9( 12646)  GAA 44.7( 51919)  GGA 12.9( 15026) 
GUG 28.0( 32580)  GCG 15.2( 17647)  GAG 16.1( 18664)  GGG 17.6( 20506) 
 
 
 
Chlamydomonas reinhardtii chloroplast 
 
UUU 33.4(   894)  UCU 17.0(   455)  UAU 24.6(   657)  UGU  7.6(   203) 
UUC 17.1(   456)  UCC  2.8(    74)  UAC 10.0(   266)  UGC  1.5(    39) 
UUA 77.7(  2078)  UCA 22.0(   588)  UAA  2.9(    78)  UGA  0.1(     3) 
UUG  4.3(   114)  UCG  4.0(   107)  UAG  0.4(    12)  UGG 13.5(   361) 
 
CUU 14.3(   383)  CCU 15.5(   414)  CAU 10.1(   270)  CGU 32.4(   866) 
CUC  1.0(    28)  CCC  3.4(    90)  CAC  8.8(   235)  CGC  4.1(   110) 
CUA  6.4(   170)  CCA 23.6(   630)  CAA 38.4(  1026)  CGA  3.4(    90) 
CUG  3.7(    99)  CCG  2.4(    63)  CAG  4.1(   110)  CGG  0.5(    14) 
 
AUU 51.4(  1374)  ACU 24.4(   651)  AAU 42.1(  1126)  AGU 16.0(   428) 
AUC  8.2(   219)  ACC  5.1(   135)  AAC 17.7(   472)  AGC  5.4(   144) 
AUA  6.9(   184)  ACA 32.4(   865)  AAA 69.1(  1847)  AGA  5.3(   143) 
AUG 22.3(   596)  ACG  3.9(   103)  AAG  6.2(   167)  AGG  0.9(    23) 
 
GUU 29.3(   783)  GCU 34.0(   908)  GAU 25.3(   676)  GGU 44.0(  1177) 
GUC  2.5(    68)  GCC  5.9(   159)  GAC  9.8(   263)  GGC  6.4(   172) 
GUA 26.0(   696)  GCA 20.7(   554)  GAA 41.1(  1098)  GGA  8.6(   229) 
GUG  5.6(   149)  GCG  3.3(    88)  GAG  5.7(   152)  GGG  3.7(    99) 
 
Figure 6.3: Codon usage tables from Nakamura et al. (2000) for Synechocystis sp. PCC 6803 and 
the C. reinhardtii chloroplast 
The tables show in the first row the codon triplet, in the second the frequency of the codon per thousand 
codons and in brackets the number of times the codon was found in the analysed coding sequences 
(CDS). In the C. reinhardtii chloroplast 93 CDS with 26,731 codons and in Synechocystis sp. PCC 
6803 3623 CDS with 1,161,949 codons were analysed. Codons with a frequency of 5.0 and below are 
highlighted in red, stop codons in green. The tables were taken from http://www.kazusa.or.jp/codon. 
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6.2.1.3 Creation of the transgenic lines 
 
6.2.1.3.1 Syn6803_AII_ϕ11-HA and Syn6803_AII_gp201-HA 
 
The vector pLAH.AII (Al-Haj 2014) was used for the creation of Syn6803_AII_ϕ11-
HA and Syn6803_AII_gp201-HA. The expression cassette of pLAH.AII carries the 
restriction sites NdeI and BamHI for the insertion of the gene of interest. 
 
The ϕ11-HA gene was amplified in a PCR reaction with the primers Syn6803ϕ11.F 
and Syn6803ϕ11.R, which bind at the ends of the gene and contain the restriction sites 
for AseI and BamHI, respectively. Since the ϕ11 gene contains an NdeI site, an AseI 
site was attached to prevent cleavage of the ϕ11 gene during subsequent cloning. The 
restriction of DNA by AseI results in the same overhang as the restriction by NdeI and 
the fragment can be therefore ligated with the pLAH.AII plasmid cut with NdeI. The 
gp201-HA gene was amplified in a PCR with the primers Syn6803gp20.F and 
Syn6803gp201.R, which bind at the ends of the gene and contain the restriction sites 
of AseI and BamHI respectively, since the gp20 gene also contains an NdeI site. The 
PCR products were digested with AseI and BamHI followed by ligation with 
pLAH.AII, which was cut by NdeI and BamHI. Subsequently, the construct was 
transformed into Synechocystis sp. PCC 6803. The colonies obtained were restreaked 
two times to achieve homoplasmicity. The correct insertion of the genes into the 
genome of Synechocystis was confirmed by PCR analysis with the primers psbAII.F 
and psbAII.R (Figure 6.4) and by sequencing. The PCR screening showed that all 
analysed colonies had been successfully transformed (Figure 6.5).  
 
 
6.2.1.3.2 Syn6803_nrsB_pal-HA, Syn6803_nrsB_ϕ11-HA, Syn6803_nrsB_gp201-
HA and Syn6803_nrsB_gp202-HA 
 
The vector pLAH.nrsB (Al-Haj 2014) was used for the creation of 
Syn6803_nrsB_pal-HA, Syn6803_nrsB_ϕ11-HA, Syn6803_nrsB_gp201-HA and 
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Syn6803_nrsB_gp202-HA. The expression cassette of pLAH.nrsB carries also the 
restriction sites NdeI and BamHI for the insertion of the gene of interest. 
 
The creation of the lines was performed as described in 6.2.1.3.1, except that the 
primers Syn6803pal.F and Syn6803pal.R, which contain the restriction sites NdeI and 
BamHI were used for the amplification of the pal-HA gene. For the amplification of 
gp202-HA the primers Syn6803gp20.F and Syn6803gp202.R were used. The 
successful transformation was confirmed as described in 6.2.1.3.1. The PCR screening 
confirmed once more that all analysed colonies had been successfully transformed 
(Figure 6.5).  
 
 
 
 
Figure 6.4: Schematic diagram showing the binding sites of the used sets of primers and the 
expected fragment sizes for the different transformants 
The primer psbAII.F binds to the 5´UTR of psbAII, whereas psbAII.R binds just outside of the 
insertion site of the gene of interest. Together these primers result in fragments sizes of 0.3 kb + the 
size of  the gene of interest (kb) for Syn6803_AII_x transformants and 1.1 kb kb + the size of  the gene 
of interest (kb) for Syn6803_nrsB_x transformants. Primers are shown as grey arrows, endogenous 
genes and expression elements are indicated in green, nrsBRS system in purple, genes of interest in 
yellow, Tn903 kanamycin resistance cassette (KmR) in red and the HA-tag in orange. 
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Figure 6.5: PCR screening for the successful transformation of Synechocystis sp. PCC 6803 with 
the expression vectors pLAH.AII and pLAH.nrsB 
In the PCR screening for putative Syn6803_AII_x and Syn6803_nrsB_x transformants the primers 
psbAII.F and psbAII.R were used. For the binding sites of the primers see Figure 6.4. Expected band 
sizes are as follows: (A) Syn6803_nrsB_ ϕ11-HA: 2.5 kb; (B) Syn6803_AII_gp201-HA: 1.2 kb; 
Syn6803_AII_ϕ11-HA: 1.8 kb; Syn6803_nrsB_pal-HA: 2.0 kb; Syn6803_nrsB_ gp20-HA:2.0 kb. 
 
 
6.2.1.3.3 The transformation plasmid pLAH.AII_pal-HA could not be produced 
in Escherichia coli DH5α 
 
The pal-HA gene was amplified as described in 6.2.1.3.2, cut with NdeI and BamHI 
and subsequently ligated into pLAH.AII, which had been cut with the same restriction 
enzymes. Alternatively, the PCR product was first cloned into pJet before restriction 
digestion. The ligated plasmids pLAH.AII_pal-HA were then transformed into 
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competent Escherichia coli DH5α cells using the kanamycin resistance cassette as the 
selectable marker.  
 
In total 15 ligations of pal-HA into pLAH.AII with different preparations and different 
concentrations of the insert and the vector followed by transformation into E. coli 
were performed, but none resulted in E. coli colonies carrying the desired plasmid. 
After transformation into E. coli DH5α either no colonies appeared or only very few 
colonies appeared, which contained the empty vector. In one case an E. coli colony 
appeared that carried pLAH.AII with only one half of the pal gene. In contrast, the 
pal-HA insert could be successfully cloned into the plasmid pLAH.nrsB, which carries 
a promoter that induces expression only in the presence of nickel. Furthermore, the 
genes of ϕ11-HA and gp201-HA were successfully cloned into the same preparations 
of the pLAH.AII plasmid. Therefore it can be excluded that the insert or the vector 
were unsuitable for ligation.  
 
It has been shown in a previous study that the promoter and expression elements of 
the psbAII gene result in the expression of the gene of interest in E. coli DH5α using 
two different antibiotic resistance cassettes (ble (zeocin resistance) and aadA 
(spectinomycin resistance)) as well as gfp (Mackrow 2012). It can be therefore 
assumed that the endolysin genes are also expressed under the control of the psbAII 
promoter in E. coli DH5α. As mentioned already in 3.1.1, a study by Oey et al. 
reported that the genes of pal and cpl-1 could not be cloned into a tobacco chloroplast 
expression vector in E. coli and concluded therefore that their chloroplast vectors 
reach production levels of Pal and Cpl-1, which become toxic to E. coli (Oey et al. 
2009b). It is therefore conceivable that the transformation of E. coli DH5α with 
pLAH.AII_pal-HA results in a level of pal expression that becomes harmful for E. 
coli. All studies that produced Pal or Cpl-1 in E. coli used inducible promoter systems, 
which enables the production of moderately toxic proteins (Jado et al. 2003; Loeffler 
& Fischetti 2003).  
 
Furthermore, the creation of pLAH.AII_gp202-HA in E. coli failed as well, whereas 
the gp202-HA gene could be cloned into pLAH.nrsB. Gp20 is predicted to have, like 
Pal, N-acetylmuramoyl-L-alanine amidase activity. In contrast, it was possible to 
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clone ϕ11-HA into pLAH.AII using E. coli. However, the D-alanyl-glycyl 
endopeptidase domain of ϕ11, which seems to be the more active domain, cleaves the 
peptidoglycan between the D-alanine of the peptide chain and the first glycine of the 
glycine bridge (Navarre et al. 1999). The peptidoglycan of the Gram-negative 
bacterium E. coli does not contain a glycine bridge. Sass & Bierbaum (2006) found 
that both catalytic domains have to be combined and that substrate recognition of the 
cell-wall binding domain is necessary for the full function of ϕ11 and the ability to 
cleave the cell wall of intact cells. It is therefore likely that ϕ11 cannot interact with 
the peptidoglycan of E. coli.  
 
These results therefore support the conclusion of Oey et al. (2009b) that the endolysin 
Pal, when it is synthesised inside the cell in high concentrations is harmful for E. coli. 
This observation is surprising, since the endolysin Pal is described to be highly 
specific for S. pneumoniae (Loeffler et al. 2001). However, it is conceivable that 
higher Pal concentrations inside the cell have a negative effect caused either by 
interaction with the peptidoglycan through the cleaving of specific bonds or binding to 
cell wall structures, or in a completely different unknown way.  
 
In contrast, it has been shown in 3.2.3.1 that the production of Pal in the C. reinhardtii 
chloroplast does not have any negative impact on the growth of the alga. It should be 
therefore possible to produce the endolysin Pal in C. reinhardtii in continuous 
cultivation, which is likely not possible in E. coli. This would highlight an advantage 
of C. reinhardtii as an expression platform over the conventional platform E. coli.  
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6.2.2 Confirmation of the production of the endolysins in Synechocystis 
sp. PCC 6803 
 
After the successful creation of the transgenic Synechocystis sp. PCC 6803 lines 
carrying the genes of three different endolysins under the control of two different 
promoters, the next stage was to analyse whether the endolysins were accumulating to 
detectable levels in the cyanobacterium. Of particular interest was the investigation of 
the gp20 expression, where the gene product did not accumulate to detectable levels in 
the C. reinhardtii chloroplast (Taunt 2013).  
 
 
6.2.2.1 Expression of pal in Syn6803_nrsB_pal-HA 
 
To investigate the expression of pal in Syn6803_nrsB_pal-HA, the strain was grown 
under standard conditions to an OD750nm of 0.5 before expression was induced with 
6.4 µM of NiCl2. Samples were taken before induction, as well as at four, seven and 
24 hours after the start of the induction. Subsequently, the samples were equalised to 
the same concentration of cells and analysed for the presence of the Pal protein by 
western blot using antibodies against the HA-tag and the Odyssey® Infrared (IR) 
Imaging System. 
 
The western blot analysis confirmed the successful production and accumulation of 
Pal in Syn6803_nrsB_pal-HA (Figure 6.6). Furthermore, the analysis showed that 
only trace amounts of Pal (about 160 times less compared to seven hours after 
induction) are detectable before induction proving that the nrsB promoter is tightly 
regulated in the absence of nickel (Figure 6.6, Figure 6.7). The analysis showed as 
well that Pal steadily accumulates in the Synechocystis cells following induction, since 
more Pal was present per cell after seven hours compared to four hours after 
induction. However, 24 hours after the induction by nickel the Pal levels per cell had 
dropped again (Figure 6.6). These results were confirmed in a repetition of the 
experiment with induction times of three, seven and 24 hours. 
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Figure 6.6: Western blot analysis of whole cell extracts of Syn6803_nrsB_pal-HA transformants 
showing the presence of HA-tagged Pal after induction for 0, 4, 7 and 24 h  
The gene expression was induced with 6.4 µM of NiCl2 and samples were taken at different time points 
before and after induction, normalised to the OD750nm at the time of sampling (cells were resuspended in 
1 ml of buffer per OD750nm of 1) and 20 µl of each sample (= suspension of whole cells that were 
broken by the addition of SDS (2% w/v) and boiling) were analysed in a western blot with anti-HA 
antibodies, IRDye® secondary antibodies and the Odyssey® Infrared Imaging System for detection (A) 
and quantification (B). Synechocystis sp. PCC 6803 wild type was used as a negative control. The 
expected band size is 35.6 kDa. Protein sizes were determined using the PageRulerTM Prestained 
Protein ladder (Thermo Scientific). 
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induction, since the amount of Pal protein in the transgenic Synechocystis line had 
already decreased 24 h after induction. Syn6803_AII_ϕ11-HA, which carries a 
constitutive promoter, was grown to an OD750nm of 0.9 and subsequently harvested. 
All samples were analysed for the presence of the ϕ11 protein by western blot analysis 
with anti-HA antibodies and the Odyssey® Infrared (IR) Imaging System. 
Alternatively, horseradish peroxidase-linked secondary (ECL) antibodies were used 
and the resulting chemiluminescence was detected with photographic film. Both 
detection systems were used to confirm the successful accumulation of ϕ11 in 
Syn6803_nrsB_ϕ11-HA and the Odyssey® Infrared (IR) Imaging System to confirm 
the production of ϕ11 in Syn6803_AII_ϕ11-HA. 
 
This analysis of the Syn6803_nrsB_ϕ11-HA samples showed again that the endolysin 
ϕ11 accumulated in the Synechocystis cells within the first hours after induction, since 
more ϕ11 was present per cell after five hours compared to three hours after induction. 
However, already 9.5 hours after the induction by nickel the amount of ϕ11 was lower 
than five hours after induction. A repeat of the experiment showed a decrease between 
six hours and 18 hours after induction. The study by Al-Haj (2014) showed as well 
that the highest concentration of α-farnesene synthase was achieved 7.5 hours after 
induction and found that nine hours after induction the yields had decreased and after 
24 hours the enzyme was no longer detectable.  
 
The results indicate therefore that the induction time that results in the highest 
endolysin yields is between five and seven hours when the induction is performed 
with 6.4 µM Ni2+. However, the experiments need to be repeated and samples need to 
be taken at more time points to determine the exact induction time for the highest Pal 
and ϕ11 yields. 
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Figure 6.7: Western blot analysis of whole cell extracts of Syn6803_nrsB_ϕ11-HA transformants 
showing the presence of HA-tagged ϕ11 protein after induction for 0, 3, 5 and 9.5 h  
The gene expression was induced with 6.4 µM of NiCl2 and samples were taken at different time points 
before and after induction, normalised to the OD750nm at the time of sampling (cells were resuspended in 
1 ml of buffer per OD750nm of 1) and 20 µl of each sample (= suspension of whole cells that were 
broken by the addition of SDS (2% w/v) and boiling) were analysed in a western blot with anti-HA 
antibodies, IRDye® secondary antibodies and the Odyssey® Infrared Imaging System for detection (A) 
and quantification (B). Synechocystis sp. PCC 6803 wild type was used as a negative control. The 
expected band size for full-length ϕ11 is 55.1 kDa. Protein sizes were determined using the 
PageRulerTM Prestained Protein ladder (Thermo Scientific). The black box indicates that all samples 
were analysed on the same gel and membrane and the white lines indicate that lanes were cut out 
between the samples for the preparation of the figure. 
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has a negative effect on the growth and health of Synechocystis during longer 
induction periods, which then results in a decrease of the recombinant protein yield 
after induction for 9.5 hours or longer.  
 
The concentration of 6.4 µM NiCl2 was chosen in this study and the study by Al-Haj 
(2014), because a study that used the nrsB promoter for the expression of the reporter 
gene luxAB found that an induction with 6.4 µM Ni2+ results in the highest level of 
bioluminescence (Peca et al. 2008). The study created a whole-cell bioluminescent 
reporter that quantitatively responds to Ni2+ and other metal ions and showed that 
increasing concentrations of Ni2+ result in a dose dependent bioluminescence signal, 
but concentrations above 6.4 µM resulted in a reduced bioluminescence. These results 
suggest that higher concentrations of Ni2+ have a negative impact on either the activity 
or production of the luminescent protein or the health of the cells. However, the study 
performed the induction for only three hours. It is therefore conceivable that extending 
the induction time to 9.5 hours or more has a negative impact on Synechocystis cells 
already at a concentration of 6.4 µM.  
 
Another study showed that nrs mRNA can be already detected after induction by 0.45 
µM Ni2+ for one hour, but the mRNA levels were higher after induction with 17 µM 
Ni2+. Higher concentrations of Ni2+ did not increase the mRNA levels any further 
(García-Domínguez et al. 2000). In contrast, the study by Al-Haj (2014) and a second 
study (Y. Lui, unpublished) did not observe a difference in recombinant protein yields 
after induction with Ni2+ concentrations between 0.8 and 6.4 µM.  
 
It is therefore conceivable that an induction with lower Ni2+ concentrations results in 
the same rate of protein accumulation, but might have less impact on the health of the 
Synechocystis cells and enable an induction over a longer period, which might result 
in the accumulation of higher final yields of the endolysins. This might be therefore a 
strategy to maximise the yield of endolysin protein under the control of the nrsBRS 
system in Synechocystis. 
 
Another observation during this analysis was that between three and six (depending 
on the overall intensity of the signal) additional bands were detectable in the samples 
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of the transgenic lines expressing ϕ11, which were not present in the wild type 
samples. This shows that multiple truncated protein products of ϕ11 are formed in 
Synechocystis sp. PCC 6803. The truncated ϕ11 products seen in each repeat of the 
analysis appeared to be the same size, but their relative intensities varied between 
experiments. In the western blot analysis shown in Figure 6.8, predominately full-
length ϕ11 was detected. The truncation products are further discussed in 6.2.2.4. 
 
 
 
 
 
Figure 6.8: Western blot analysis of whole cell extracts of Syn6803_AII_ϕ11-HA transformants 
showing the presence of HA-tagged ϕ11 protein  
Samples were normalised to the OD750nm at the time of sampling (cells were resuspended in 1 ml of 
buffer per OD750nm of 1) and 20 µl of each sample (= suspension of whole cells that were broken by the 
addition of SDS (2% w/v) and boiling) were analysed in a western blot with anti-HA antibodies, 
IRDye® secondary antibodies and the Odyssey® Infrared Imaging System for detection (A) and 
quantification (B).Synechocystis sp. PCC 6803 wild type was used as a negative control. The expected 
band size for full-length ϕ11 is 55.1 kDa. Protein sizes were determined using the PageRulerTM 
Prestained Protein ladder (Thermo Scientific). 
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6.2.2.3 Expression of gp20 in Syn6803_nrsB_gp201-HA, Syn6803_nrsB_gp202-
HA and Syn6803_AII_ gp201-HA 
 
As a next step it was of particular interest to investigate the production of the Gp20 
endolysin in Synechocystis. Therefore the three transgenic lines carrying the gp20 
genes were analysed for HA-tagged protein in a western blot analysis. The strains 
were cultured as described in 6.2.2.1 and 6.2.2.2. The induction of 
Syn6803_nrsB_gp201-HA and Syn6803_nrsB_gp202-HA was performed at an OD750nm 
of 0.8 and the cultures were harvested 5.5 hours after the start of the induction, 
whereas Syn6803_AII_gp201-HA was harvested at an OD750nm of 0.9. After harvest 
the samples were concentrated 100 times.  
 
Western blot analysis with anti-HA antibodies and the Odyssey® Infrared (IR) 
Imaging System, confirmed the successful production of the Gp20 protein in 
Syn6803_nrsB_gp201-HA (Figure 6.9, Figure 6.10), an endolysin that was not 
produced to detectable levels in either the C. reinhardtii chloroplast. Furthermore, the 
production of Gp20 on its own as a recombinant protein has not been described so far.  
 
However, the analysis did not show any band in the sample of Syn6803_AII_gp201-
HA and only a very weak band in the samples of Syn6803_nrsB_gp202-HA after the 
sample was analysed at two-fold concentration (Figure 6.9). Syn6803_AII_gp201-HA 
carries the same gp20 gene as Syn6803_nrsB_gp201-HA and the AII promoter has 
been shown to work for the expression of ϕ11. It is therefore surprising that no Gp20 
protein was detected in samples of Syn6803_AII_gp201-HA. One explanation would 
be that a mutation that prevents the expression appeared at some point during cloning 
or transformation. The correct sequence of gp20 in the plasmid was confirmed by 
sequencing. However, the sequence of the expression elements was not fully analysed 
and could have therefore contained a mutation. As already discussed in 6.2.1.3.3 the 
cloning of the pal gene failed in E. coli despite several attempts and the fact that the 
insert could be cloned into the vector pLAH.nrsB with the inducible expression 
system, and the preparation of the pLAH.AII vector could be used for the successful 
cloning of ϕ11. Furthermore, the cloning of the gp202 gene into pLAH.AII did not 
result in transformants. Since Oey et al. (2009b) describe a similar phenomenon when 
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creating expression vectors for the synthesis of Pal and Cpl-1 in tobacco, it is 
conceivable that the pLAH.AII vector results in protein production levels that are, in 
the case of certain endolysins, harmful for the cloning host. However, more 
experiments need to be performed to further investigate this hypothesis. 
 
Furthermore, the western blot analysis suggested that the codon optimised version 
gp201 results in higher expression levels than the gp202 gene (Figure 6.9). The genes 
have a shared sequence identity of 85.7%. The gp201 contains the UCA codon six 
times, which is less frequently used for serine in Synechocystis, whereas gp202 
contains it 13 times. This could be therefore an explanation for the lower protein 
levels. Though, the western blot analysis needs to be performed with a higher number 
of transformants and different induction times before it can be concluded that the gene 
sequence of gp201 results in higher protein yields compared to gp202. 
 
It is important to note that the levels of Gp20 produced in Synechocystis are 
significantly lower than the amounts of Pal and ϕ11 and that approximately ten–fold 
more concentrated samples were used compared to the western blot analysis showing 
the accumulation of Pal and ϕ11 in the previous sections. Figure 6.10 shows a 
comparison of samples from Syn6803_nrsB_gp201-HA with samples from 
Syn6803_nrsB_pal-HA and Syn6803_nrsB_ϕ11-HA, which were cultured, induced 
and prepared in the same way. This western blot analysis showed that under these 
conditions approximately 50 times more full-length ϕ11 and 60 times more Pal 
accumulated in Synechocystis using the same expression system. These results 
suggest, together with the fact that Gp20 could not be produced in the C. reinhardtii 
chloroplast or Escherichia coli DH5α, that either the synthesis of the protein is less 
efficient or that it is less stable than the endolysins Pal, Cpl-1 and ϕ11.  
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Figure 6.9: Western blot analysis of whole cell extracts of Syn6803_nrsB_gp201, 
Syn6803_nrsB_gp202 and Syn6803_AII_ gp201 transformants showing the presence or absence of 
HA-tagged Gp20 protein  
The gene expression in Syn6803_nrsB_gp201 and Syn6803_nrsB_gp202 was induced with 6.4 µM of 
NiCl2, samples were taken, concentrated to 100x the culture volume and 20 µl of each sample (= 
suspension of whole cells that were broken by the addition of SDS (2% w/v) and boiling) was analysed 
in a western blot with anti-HA antibodies, IRDye® secondary antibodies and the Odyssey® Infrared 
Imaging System for detection (A) and quantification (B). Synechocystis sp. PCC 6803 wild type (WT 
6803) was used as a negative control. The expected band size for Gp20 is 32.3 kDa. Protein sizes were 
determined using the PageRulerTM prestained protein ladder (Thermo Scientific). The black box 
indicates that all samples were analysed on the same gel and membrane and the white line indicates that 
lanes were cut out between the samples for the preparation of the figure. 
 
 
 
 
 
0.00 
0.19 
0.02 
0.01 0.00 0.01 
0 
0.05 
0.1 
0.15 
0.2 
0.25 
WT gp20_1 gp20_2 (2x 
conc.) 
gp20_2 WT AII_gp20_1 
S
ig
n
a
l 
(I
R
 f
lu
o
re
s
c
e
n
c
e
) 
M
il
li
o
n
s
 
WT 
6803 
gp201-HA 
Induced for 5.5 h  
Syn6803_nrsB_x 
(≈17 kDa) Unspecific band 
 
gp202-HA 
2x conc. 
gp202-HA 
WT 
6803 
Syn6803_AII_ 
gp201-HA 
170 
130 
100 
70 
55 
40 
35 
25 
 
 
 
 
 
15 
 
 
kDa 
Gp20-HA   
 (32.3 kDa)  
Not induced 
 
 
WT 
6803 
 
 
WT 
6803 
 
Syn6803_ 
AII_ 
gp201-HA 
gp201-HA gp202-HA 
2x conc. 
gp202-HA 
Induced for 5.5 h  
Syn6803_nrsB_x 
Not induced 
CHAPTER 6 
 
 285 
 
 
Figure 6.10: Western blot analysis of whole cell extracts of Syn6803_nrsB_pal-HA, 
Syn6803_nrsB_ϕ11-HA and Syn6803_nrsB_gp201 showing the relative amounts of Pal, ϕ11 and 
Gp20 protein 
The gene expression was induced with 6.4 µM of NiCl2 for 5.5 hours, harvested and concentrated to 
100x the culture volume. The western blot analysis was performed with whole cell extract (= 
suspension of whole cells that were broken by the addition of SDS (2% w/v) and boiling) and anti-HA 
antibodies, IRDye® secondary antibodies and the Odyssey® Infrared Imaging System for detection (A) 
and quantification (B). 
 
 
6.2.2.4 The occurrence of truncated protein products differs in the different 
expression platforms 
 
A striking observation during this study was that the production of Pal and ϕ11 in 
three different organisms resulted in different but, for each organism and endolysin, 
characteristic patterns of truncated protein products (Figure 6.11). These bands of 
lower molecular weight appeared in the samples from the transgenic lines, but not in 
the corresponding controls. The production of one endolysin in the same organism 
always resulted in the same pattern, however the intensity and the proportion between 
the additional bands and the full-length proteins varied.  
 
2.49 
1.87 
0.04 
0 
0.5 
1 
1.5 
2 
2.5 
3 
pal phi11 gp20 
Si
gn
al
 (I
R
 fl
uo
re
sc
en
ce
 
M
ill
io
ns
 
WT 
6803 
Syn6803_nrsB_ 
gp201-HA ϕ11-HA pal-HA 
(55.1 kDa) 
Φ11-HA   
Pal-HA  "
 (35.6 kDa)  
Gp20-HA  "
 (32.3 kDa)  
Syn6803_nrsB_ 
gp201-HA ϕ11-HA pal-HA 
B A 
CHAPTER 6 
 
 286 
It has been already discussed in previous chapters how the truncated proteins might be 
formed. It was mentioned in chapter 5 that a possible explanation for the 38 kDa 
product of ϕ11, which is formed in C. reinhardtii and E. coli, could be an alternative 
translation start, since the protein sequence contains a methionine in this region. 
Another explanation would be that the products are formed by specific proteolytic 
activity. Table 6.2 gives an overview of all N-terminal truncated protein products that 
could be formed by a translation start at an alternative AUG codon. Interestingly, 
several sizes match the observed truncated protein products on the western blot 
analysis – for example, the two bands just under the full-length Pal in Synechocystis 
and E. coli, which could match the 29.17, 31.43, 33.09 or 34.05 kDa alternative 
translation start proteins. In contrast the two additional Pal bands in Synechocystis and 
in E. coli between 15 kDa and 25 kDa do not match any of the predicted protein sizes. 
The ϕ11 protein produced in Synechocystis on the other hand results in several lower 
molecular weight products that approximately match the 45.87, 38.89, 24.44, 14.75 
and 10.76 predicted alternative translation start proteins. However the band around 17 
kDa does not fit to any predicted sizes. It is difficult to predict the exact size of a 
protein using western blot analysis, since even in SDS-PAGEs proteins of the same 
size do not necessarily run with exactly the same mobility. Some proteins run 
therefore a bit slower or faster compared to the proteins of the ladder. Furthermore, in 
prokaryotes and in chloroplasts in some cases the alternative start codons GUG and 
UUG are used (Blattner et al. 1997). Pal does not contain either of these codons, but 
ϕ11 contains additionally eight GUG codons, which could function as potential 
alternative translation start sites. Another explanation for the additional bands that do 
not fit any predicted size could be a combination of alternative translation start sites 
and proteolytic activity.  
 
However, taken the quantity of additional AUG codons in the pal and ϕ11 genes, the 
fact that some of the lower molecular weight bands of Pal and ϕ11 match the 
predicted sizes of the alternative translation start proteins could be just a coincidence, 
and the characteristic pattern of truncated protein products is the result of different 
proteolytic activities in each of the three organisms.  
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Independent of the cause for the formation of the truncated protein products, it is 
noticeable that the production in the C. reinhardtii chloroplast does not result in 
detectable level of truncated Pal products unlike the production in Synechocystis or E. 
coli and therefore results in the highest proportion of full-length Pal. The synthesis of 
ϕ11 in both the C. reinhardtii chloroplast and in E. coli results in only one additional 
band, whereas multiple additional bands can be detected in Synechocystis. Taken 
together, these observations suggest either that the control of the true translational 
start is more tightly controlled in the C. reinhardtii chloroplast, compared to the two 
prokaryotic systems, or that the endolysins are less exposed to specific proteolytic 
activity in C. reinhardtii. 
 
 
Table 6.2: Molecular weight of protein products that could be formed by alternative translation 
start sites  
The molecular weight of the N-terminal truncated Pal and ϕ11 products resulting from a start at 
alternative AUG codons were calculated using: http://bioinformatics.org/sms/prot_mw.html. 
 
Endolysin Molecular weight of alternative translation start protein products (kDa) 
Pal 5.46 8.2 10.64 13.45 24.55 29.17 31.43 33.09 34.05 
ϕ11 6.09 10.76 14.75 24.44 38.89 45.87    
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Figure 6.11: Western blot analyses showing the appearance of truncated Pal and ϕ11 protein 
products that were formed during production in three different systems 
The western blot analysis was performed with whole cell extract (= suspension of whole cells that were 
broken by the addition of SDS (2% w/v) and boiling) and anti-HA antibodies, IRDye® secondary 
antibodies and the Odyssey® Infrared Imaging System. 
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6.2.2.5 Influence of endolysin synthesis on the growth of Synechocystis sp. PCC 
6803  
 
Beside the fact that the synthesis of a recombinant protein is generally a metabolic 
burden for a cell, it is conceivable that the production of endolysins could have a 
negative impact on Synechocystis, since the Gram-negative bacterium has a cell wall 
composed of the endolysin substrate peptidoglycan. Therefore, it was important to 
ensure that the production of the endolysins does not have any toxic effect on the 
cyanobacterium. This was analysed by following the growth of the transgenic line 
Syn6803_AII_ϕ11-HA in comparison to the wild type. 
 
Syn6803_AII_ϕ11-HA and the Synechocystis sp. PCC 6803 wild type were grown 
under standard conditions in the Algem photobioreactor and the OD750nm was 
automatically recorded every 30 min. The wild type was found to grow slightly faster 
than Syn6803_AII_ϕ11-HA, which had a slightly longer lag phase. However the 
growth rates of both strains were similar and the strains reached the same final 
OD750nm (Figure 6.12). The results show therefore that the production of ϕ11 does not 
have any major impact on the growth of Synechocystis. 
 
It was also of interest to analyse whether the production of the endolysin Pal has any 
negative impact on the growth of Synechocystis, especially since observations during 
this study and by Oey et al. (2009b) suggested a harmful effect against the Gram-
negative bacterium E. coli. However, since a transgenic line was available only with 
the pal gene under the control of the nrsB promoter and the addition of Ni2+ on its own 
had already an impact on the growth of the cyanobacterium, it was not possible to 
evaluate the impact of the Pal production on Synechocystis using growth studies. The 
same was the case for Gp20, which was also only produced to detectable levels under 
the control of the nrsB promoter.  
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Figure 6.12: Growth of Synechocystis Syn6803_AII_ϕ11-HA in comparison to the Synechocystis 
sp. PCC6803 wild type 
The strains were grown under continuous shaking at 120 rpm, at 30ºC and 200 µmol/m2/s in BG11 
medium in the Algem photobioreactor (Algenuity, Stewartby (UK)), the OD750nm was automatically 
recorded every 0.5 h. The error bars show ± one standard deviation (n = 2). 
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6.2.3 Cell breakage of Synechocystis sp. PCC 6803 and production of 
endolysin protein preparations  
 
In order to perform assays analysing the antibacterial activity of the three endolysins 
against the target bacteria, it was necessary to break the Synechocystis cells and to 
recover the endolysins without denaturing the proteins. Previous protocols have used 
vortexing in the presence of glass beads to break Synechocystis cells (Al´Haj 2014). 
This method was therefore used for cell breakage and it was evaluated whether the 
endolysins can be recovered and separated from the cell debris afterwards. 
 
The three transgenic lines were broken by vortexing with glass beads (212 - 300 µm) 
for 2 min followed by 2 min on ice for five cycles. Subsequently the supernatant was 
separated from the cell debris by centrifugation (21,000 x g for 5 min). The whole cell 
extract before centrifugation and the supernatants (crude extract) were analysed by 
western blot analysis for the HA-tagged endolysins. All samples were additionally 
treated with SDS and boiling to break leftover unbroken cells.  
 
These analyses showed that all three endolysins could be recovered into the 
supernatant after cell breakage using glass beads (Figure 6.13). However, the 
supernatants contained less protein compared to the whole cell extracts. Figure 6.13 
shows a comparison of the whole cell extracts and the supernatants for Pal and Gp20. 
It is likely that the method does not result in the breakage of all cells, which then 
causes a loss of endolysin protein during centrifugation. Another explanation could be 
that a fraction of Pal and Gp20 is insoluble or aggregated and precipitates during 
centrifugation.  
 
Nevertheless, vortexing in the presence of glass beads is an easy and quick method 
and it was possible to recover all three endolysins into the crude extract after cell 
breakage. Furthermore, the procedure can be easily performed under sterile 
conditions. This method was therefore used to break the Synechocystis cells for the 
performance of activity assays. 
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Figure 6.13: Western blot analysis showing the recovery of Pal, Gp20 and ϕ11 in the supernatant 
after cell breakage by vortexing in the presence of glass beads  
The cells were broken by vortexing in the presence of glass beads (212 - 300 µm) for 2 min followed 
by 2 min on ice for five cycles, followed by centrifugation at 21,000 x g for 5 min. The presence of the 
endolysins in the whole cell extracts before centrifugation and the 21K↵ supernatant (crude extract) 
was determined by western blot analysis with anti-HA antibodies, IRDye® secondary antibodies and the 
Odyssey® Infrared Imaging system was used for detection (A) and for quantification (B). 
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6.2.4 Investigation of the antibacterial activity of Synechocystis-produced 
endolysins  
 
It has been shown in 5.2.4 that ϕ11 produced in C. reinhardtii is not active or has a 
markedly lower activity compared to the same endolysin produced in E. coli. This 
demonstrates the importance of analysing the activity of recombinant proteins after 
expression in a new production system. Furthermore it was of interest to investigate 
whether ϕ11 produced in Synechocystis has detectable enzymatic activity and to 
analyse the antibacterial activity of Gp20. Turbidity reduction assays (TRAs) had 
been used successfully to demonstrate the activity of the C. reinhardtii-produced 
endolysin Pal (4.2.2) and E. coli-produced ϕ11 (5.2.4). Therefore as a next step the 
bacteriolytic activities of Pal, ϕ11 and Gp20 produced in Synechocystis were analysed 
using TRAs with cells of S. pneumoniae, S. aureus and P. acnes, respectively.  
 
 
6.2.4.1 Synechocystis-produced Pal 
 
TRAs were performed with crude extract of Syn6803_nrsB_pal-HA that had been 
prepared as described in 6.2.3. Cells of a S. pneumoniae culture were harvested and 
resuspended in NaPi-buffer before the addition of crude extracts from either the 
transgenic line producing Pal or the wild type. Subsequently, the OD was measured at 
600 nm over a time course. 
 
The TRAs were performed with S. pneumoniae cells from an overnight culture and 
had already reached the stationary phase, which caused an observable autolysis of the 
cells already in the control samples (4.2.2.1). However, all performances (three 
performances in duplicate) of the TRA showed a more rapid decrease of the OD600nm 
in the presence of the cyanobacterial extract containing Pal compared to the wild type 
extract, confirming the lytic activity of Synechocystis-produced Pal against S. 
pneumoniae.  
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Figure 6.14: Turbidity reduction assay showing the lytic activity of Syn6803_nrsB_pal-HA crude 
extract against Streptococcus pneumoniae 
The S. pneumoniae cells were resuspended in NaPi-buffer to an OD600nm of 0.7. Crude extract of 
Synechocystis sp. PCC 6803 wild type was used as a negative control. The crude extracts were prepared 
from whole cell extract, the cells were harvested and resuspended in 1 ml of Na-Pi-buffer per OD750nm 
of 0.5 and broken by vortexing in the presence of glass beads The Syn6803_nrsB_pal-HA and the 
control extract were added to the cell suspension and the OD600nm was measured over a time course at 
room temperature. The error bars show ± one standard deviation (n = 2). 
 
 
6.2.4.2 Synechocystis-produced ϕ11  
 
As a next step, TRAs were performed to investigate the antibacterial activity of 
Synechocystis-produced ϕ11 against S. aureus. The TRAs were performed as 
described in 5.2.4 with heat inactivated S. aureus cells and crude extract of 
Syn6803_AII_ϕ11-HA, wild type extract as a negative control and extract of 
DH5α_ϕ11-HA as a positive control. These TRAs (two performances in duplicate) 
showed a clear decrease in OD595nm of the S. aureus suspension after the addition of 
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Syn6803_AII_ϕ11-HA crude extract in comparison to the negative control, indicating 
that ϕ11 produced in Synechocystis has bacteriolytic activity against its target 
bacterium Staphylococcus aureus (Figure 6.15). 
 
 
 
 
Figure 6.15: Turbidity reduction assay showing the lytic activity of Syn6803_AII_ϕ11-HA crude 
extract against Staphylococcus aureus 
The S. aureus cells were resuspended in NaPi-buffer to an optical density (OD595nm) of 0.4. Crude 
extracts of E. coli DH5α_ϕ11-HA and the Synechocystis sp. PCC 6803 wild type (WT) were used as a 
positive and negative control, respectively. The crude extracts were prepared from whole cell extract 
that was concentrated to 100x the culture volume and broken by vortexing in the presence of glass 
beads (Synechocystis) or using a French pressure cell press (E.coli). The extracts were added to the S. 
pneumoniae cell suspension and the OD595nm was measured over a time course at 37ºC. The error bars 
show ± one standard deviation (n = 2). 
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The TRA in Figure 6.15 shows a faster decrease in OD595nm for the positive control 
with DH5α_ϕ11-HA. However, a subsequent western blot analysis confirmed that the 
crude extract of Syn6803_AII_ϕ11-HA that was used for the assays contained less ϕ11 
than the DH5α_ϕ11-HA extract (the IR fluorescence signal was approximately 40% 
lower). It can be therefore assumed that the slower lysis of the S. aureus cells by the 
Synechocystis-produced ϕ11 is due to lower concentrations of the endolysin and not 
due lower enzymatic activity. Nevertheless, the TRAs with crude extracts from both 
organisms need to be repeated to quantitatively analyse the enzymatic activities of ϕ11 
produced in both systems. 
 
Taken together, these results show that it is possible to produce ϕ11, a promising 
candidate for the use as an antibacterial agent against staphylococcal caused 
infections, in Synechocystis in active form. The results suggest that the enzymatic 
activity is comparable to E. coli-produced ϕ11, unlike ϕ11 produced in the C. 
reinhardtii chloroplast.  
 
 
6.2.4.3 Synechocystis-produced Gp20 
 
A study by Farrar et al. (2007) sequenced the genome of the bacteriophage PA6 that 
infects Propionibacterium acnes and predicted that ORF20 encodes an endolysin, 
given it has homology to the amidases of the mycobacteriophages PG1 and Che8 and 
a high similarity (67% identity for amino acids 2 to 145, N-terminal catalytic domain) 
to another N-acetyl-muramoyl-L-alanine amidase, which is an autolysin of P. acnes. 
Further studies found that other P. acnes phages have a high sequence similarity to 
PA6 and predicted as well that ORF20 encodes in all cases the endolysin, and 
predicted as well that it has most likely N-acetyl-muramoyl-L-alanine amidase 
activity. However, none of these studies produced Gp20 as a recombinant protein and 
confirmed experimentally that the protein cleaves the peptidoglycan of P. acnes. A 
demonstration of the lytic activity of Synechocystis-produced Gp20 would not only 
demonstrate that it can be produced as an active enzyme in the cyanobacterium, but 
would also show that Gp20 on its own has antibacterial activity against P. acnes. 
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Figure 6.16: Turbidity reduction assay showing the absence of lytic activity of 
Syn6803_nrsB_gp201-HA crude extract against Propionibacterium acnes 
The P. acnes cells were resuspended in NaPi-buffer to an optical density (OD595nm) of 0.2. Crude 
extract of the Synechocystis sp. PCC 6803 wild type (WT) and Na-Pi-buffer were used as a negative 
control and lysozyme (1 mg/ml) as a positive control. The crude extracts of Syn6803_nrsB_gp201-HA 
and the WT were prepared from whole cell extract that was concentrated to 100x the culture volume 
and broken by vortexing in the presence of glass beads. The extracts were added to the S. pneumoniae 
cell suspension and the OD595nm was measured over a time course at 37ºC. The error bars show ± one 
standard deviation (n = 2). 
 
 
Therefore TRAs with a suspension of P. acnes cells and Syn6803_nrsB_gp201-HA 
crude extract as well as wild type extract and buffer as negative controls and lysozyme 
(1 mg/ml) as a positive control. However, the performed TRAs showed a decrease in 
the OD595nm for the positive control, which proved that the lysis of P. acnes can be 
measured photometrically, but did not show a decrease in the presence of crude 
extract containing Gp20 (Figure 6.16). 
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It has been shown in figure 6.10 that the yield of Gp20 achieved after production in 
Synechocystis is a lot lower (50 – 60 times) than the Pal and ϕ11 yields. It is therefore 
likely that the amount used in the TRA is not sufficient to cause detectable lytic 
activity. It was therefore attempted to further concentrate the amount of Gp20 in the 
crude extracts. However, cyanobacteria contain phycobiliproteins, which have 
absorption maxima between 500 and 650 nm and therefore an intense blue colour. 
This interferes strongly with the TRAs, which are performed at 595 nm. 
Phycobiliproteins are water soluble, unlike chlorophyll, and it was therefore not 
possible to remove these proteins using ultracentrifugation. The protein-pigment 
complexes phycoerythrin and phycocyanin have masses of approximately 240 kDa, 
whereas allophycocyanin has a mass of 105 kDa. Therefore the removal was also 
attempted using centrifugal concentrator with a MWCO of 100,000. However, the 
proteins causing the intense “blue colour” were able to pass the membrane of the 
centrifugal concentrator, most likely because phycobilliproteins consist of several 
subunits, which easily fall apart outside the cell. So far it was therefore not possible to 
concentrate Gp20 enough to show its antibacterial activity in crude extract. However, 
further attempts should be made to gain the experimentally proof that it is an 
endolysin and to investigate whether it is produced in Synechocystis as an active 
enzyme. Gp20 can be seen as a potential candidate for an antibacterial treatment 
against acnes vulgaris and the production of Gp20 in a microalgae and the use of 
crude extract with the endolysin as a topical cosmetic treatment would be a 
commercially viable option.  
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6.3 Conclusion and future work 
 
The study described in this chapter investigated the production of three endolysins, the 
S. pneumoniae-specific Pal, the S. aureus-specific ϕ11 and the P. acnes-specific 
Gp20, in Synechocystis sp. PCC 6803, in order to evaluate the cyanobacterium as an 
alternative production platform for endolysins.  
 
For this purpose six transgenic lines of Synechocystis carrying one of three synthetic 
endolysin genes in their genome under the control of either the constitutive psbAII 
promoter or the nickel inducible promoter system nrsBRS were created to study the 
synthesis of the endolysins in the cyanobacterium.  
 
One observation during the creation of the transgenic lines was that the cloning of the 
pal gene into the vector pLAH.AII that carries the constitutive expression system 
failed despite multiple attempts. As already mentioned, a study by Oey et. al. (2009b) 
described a similar observation. The study found that it was not possible to clone pal 
into a high expression tobacco vector and concluded that the Pal protein has a toxic 
effect on E. coli at higher expression rates (3.1). Figure 6.11 shows that the production 
of Pal in DH5α_pal-HA is possible, but results in hardly detectable levels of full-
length Pal and mainly truncated protein products of Pal. This suggests that Pal is 
rapidly degraded in E. coli, and might be another hint that the protein is harmful to the 
bacterium. This makes it conceivable that the expression elements of pLAH.AII result 
in protein production levels that are, in the case of certain endolysins harmful for the 
cloning host. However, more experiments need to be performed to further investigate 
this hypothesis.  
 
One possible approach could be to perform growth experiments with DH5α_pal-HA, 
DH5α_SR_pal-HA and the corresponding controls to investigate whether the 
expression levels of Pal under the control of the atpA and psaA exon 1 promoter, even 
if the levels do not completely kill E. coli, have a negative impact on the growth of the 
bacterium. Alternatively, growth studies with E. coli carrying the pLAH.nrsB_pal-HA 
plasmid with the addition of nickel could be performed to investigate whether this 
CHAPTER 6 
 
 300 
results in Pal production levels that have a negative impact on the growth of E. coli. 
Another option would be to clone the endolysin genes into an inducible high 
expression system tailored to E. coli and subsequently to analyse whether, after 
induction, high expression rates of any of the endolysins have adverse effects on the 
bacterium.  
 
To be able to transform Synechocystis with pal under the constitutive promoter 
psbAII, an attempt could be made to transform the ligated plasmid immediately into 
Synechocystis. Alternatively, transformation of Synechocystis with a PCR product 
consisting of the pal gene and 50 bp at each end of homologous regions can be 
performed as demonstrated in the study by Al-Haj (2014). Expression of pal and also 
gp20 under the control of the psbAII promoter is of interest, since it allows a longer 
accumulation time for the endolysins and might result in higher recombinant protein 
yields. Furthermore, it would enable an investigation of whether pal or gp20 
expression have a negative impact on Synechocystis without the interference of nickel. 
 
The experiments described in this chapter showed that all three endolysins accumulate 
in Synechocystis to detectable levels. This is especially of great interest in the case of 
Gp20, since this endolysin was not produced to detectable levels in either the C. 
reinhardtii chloroplast or E. coli DH5α and has not been produced as a recombinant 
protein before. However, the yields of Gp20 that accumulate in Synechocystis are 
significantly lower compared to the yields of Pal and ϕ11 protein. This indicates 
together with the fact that the protein could not be produced in the two other 
expression systems that the production of Gp20 is less efficient or the protein is more 
susceptible to degradation in comparison to the other two endolysins.  
 
Several strategies could be tried to increase the yield of Gp20 as well as the yields of 
Pal and ϕ11 during production in Synechocystis. One possibility would be to codon-
optimise the genes for Synechocystis. It was discussed in 6.2.1.2 that Synechocystis 
has less preferences for certain codons compared to the C. reinhardtii chloroplast and 
that the less frequently used codons are similar in both organisms. Furthermore, the 
successful expression of three genes in Synechocystis that were originally codon-
optimised for the chloroplast of the alga suggests that the codon preferences of both 
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organisms are not extremely different. However, preliminary results suggested that the 
sequence of gp201 results in higher production levels compared to the sequence of 
gp202, which indicates that the codons used do have an effect on the protein levels. 
Therefore it would be worthwhile to try different codon optimisation strategies to 
increase the recombinant protein production levels in Synechocystis, for example by 
either using the standard codon usage table of Nakamura et al (2000) or taking into 
account codon pairing preferences and the codon usage of highly expressed 
endogenous Synechocystis genes. Furthermore, the secondary structure of the mRNA 
transcript can have an influence on the translation efficiency and should be also 
consider for codon optimisation strategies. A further approach could be to take the 
predicted secondary structure of the protein into account. The introduction of rare 
codons, for example in the linker region, might slow down the translation at critical 
points and facilitates so the correct folding of the protein.  
 
Beside the expression of Gp20 and Pal under the control of the constitutive promoter 
psbAII, a careful study of the optimal length of induction, as well as nickel 
concentration and the OD750nm of the culture at the induction could help to increase the 
endolysin levels when produced under the control of the nrsBSR promoter system. 
 
Another option to further increase the endolysin yields in Synechocystis would be to 
investigate the use of different promoters and expression elements. A recent study 
showed that by using the Pcpc560 promoter for the expression of foreign genes, protein 
levels of up to 15% of total soluble protein can be achieved in Synechocystis sp. PCC 
6803 (Zhou et al 2014). These levels are comparable to expression levels of 
recombinant proteins in E. coli. The promoter system Pcpc560 regulates the expression 
of the cpcB gene and consists of two predicted promoters and 14 predicted 
transcription factor binding sites (TFBSs) and the study showed that the presence of 
multiple TFBSs is important to reach these high expression levels. It is likely that the 
expression of the endolysin genes using the Pcpc560 promoter system would result in 
significantly higher expression levels. Furthermore, these result encourage the search 
for more strongly expressing promoter and expression elements that would increase 
the recombinant protein yields that can be gained in Synechocystis and other 
cyanobacteria and help to develop them into a viable alternative expression platform 
CHAPTER 6 
 
 302 
compared to established bacterial expression systems. A possible tool for this could be 
the RBSDesigner, a software that helps to design synthetic ribosome binding sites and 
to predict endogenous expression elements that result in high translation efficiency 
(Na & Lee 2010). The results of this study suggest that the stability of Gp20 might be 
lower compared to the endolysins Pal and ϕ11, which would explain the lower protein 
yields using the same expression elements. An attempt to decrease the degradation of 
Gp20 and other recombinant proteins in Synechocystis could be to knock out specific 
proteases in Synechocystis as it has been done for other bacterial expression systems 
such as the knock out of the proteases rpoH and degP in E. coli (Meerman & 
Georgiou 1994). 
 
For the performance of activity assays, it was necessary to break the Synechocystis 
cells and recover the endolysins without denaturing the protein. It was shown in this 
study that Pal, ϕ11 and Gp20 can be recovered and separated from the cell debris after 
the cells have been broken by vortexing in the presence of glass beads. However, this 
method resulted in up to 50% losses of the recombinant proteins. It would be therefore 
worthwhile to investigate other cell breakage methods such as using a cell disrupter, a 
French Pressure cell press or sonication to minimize the losses of endolysin proteins. 
Alternatively, the cells could be broken enzymatically or in a combination of 
mechanical and enzymatic breakage. 
 
However, it was possible to show that Pal and ϕ11 are produced as functional proteins 
in Synechocystis and that both have antibacterial activity against their target bacteria 
S. pneumoniae and S. aureus, respectively. This is especially of interest in the case of 
ϕ11, which did not show any detectable antibacterial activity after the production in 
the C. reinhardtii chloroplast. The results suggest that the enzymatic activity of ϕ11 
produced in Synechocystis is comparable to E. coli-produced ϕ11, but more 
quantitative studies need to be performed with both versions of ϕ11 to finally 
conclude this. As a next step it would be desirable to analyse the activity of 
Synechocystis–produced ϕ11 against clinical isolates of S. aureus and other 
staphylococcal species to further characterise the endolysin produced in the 
cyanobacterium. Furthermore, it would be of interest to perform assays demonstrating 
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the bactericidal activity of the endolysin against S. aureus by analysing a decrease in 
cfu after incubation in the presence of ϕ11. 
 
So far it has not been possible to demonstrate the antibacterial activity of Gp20 
against P. acnes. This was mainly hampered by the low accumulation levels of Gp20 
in Synechocystis. An increase of the production using approaches as describe above 
would therefore most likely enable a straightforward demonstration of the enzymatic 
activity of the endolysin in crude cyanobacterial extracts. Another attempt would be to 
purify Gp20 using either a FPLC or by developing an ion exchange column protocol. 
Alternatively, the sequence for a His-tag or Strep-tag could be attached to the gene 
and commercial available columns could be used for the purification. In this way it 
would be possible to separate Gp20 from the phycobilliproteins that strongly interfere 
with the TRA and to concentrate the protein to levels that result in detectable activity. 
Another experiment that should be attempted is to mix crude extract containing Gp20 
with P. acnes cells and analyse a decrease in cfu after incubation on agar plates. 
However, this experiment is complicated by the fact that the growth of P. acnes is 
very slow and results only in very faint lawns with hardly visible colonies on either 
Columbia blood or brain heart infusion medium agar plates.  
 
Taken together, the experiments of this chapter demonstrated that Synechocystis can 
be used as an alternative expression platform for endolysins, since the successful 
production of three endolysins was achieved and the enzymatic activity was 
demonstrated for two of them. The results suggest that Synechocystis offers 
advantages for the production of certain endolysins over the C. reinhardtii chloroplast, 
since Gp20 that could not be produced in the C. reinhardtii chloroplast accumulated 
to detectable levels and ϕ11 was synthesized in active form, whereas C. reinhardtii-
produced ϕ11 had no detectable enzymatic activity. To investigate whether 
Synechocystis or the C. reinhardtii chloroplast are advantageous for the production of 
Pal, quantifications of the protein yields and the enzymatic activities of the endolysin 
produced in Synechocystis need to be performed. Furthermore, it needs to be 
investigated whether the Pal production has any harmful effect on Synechocystis, 
which could prevent the continuous cultivation of the cyanobacterium for the 
production of this endolysin at industrial scale.  
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Overall, this study demonstrated as well that Synechocystis sp. PCC 6803, which has 
been seldom considered to-date purely for the production of recombinant proteins, is a 
viable alternative expression platform. Especially, since it has been shown recently 
that with the use of other promoter systems, such as Pcpc560, recombinant protein yields 
can be reached that are comparable to yields achieved in E. coli (Zhou et al. 2014). An 
interesting aspect of photosynthetic organisms such as cyanobacteria and eukaryotic 
microalgae as expression platforms over heterotrophic organisms is that these 
organisms can produce heterogeneous proteins purely from CO2 and inorganic 
nutrients using sunlight. This offers the advantage that the cultivation of these 
organisms can help to decrease the carbon footprint caused by other steps during the 
production process of recombinant proteins.   
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7 Final discussion & future prospects 
 
7.1 Summary of findings 
 
The research presented in chapter 3 demonstrated the successful production of Pal, a 
bacteriophage endolysin with antibacterial activity against Streptococcus pneumoniae, 
in the C. reinhardtii chloroplast. It was shown that predominately full-length Pal 
accumulates in the microalga and experiments indicated that Pal accumulates as a 
stable protein in the chloroplast. The stability of Pal seems to be even further 
increased under dark conditions. Growth studies showed that the accumulation of Pal 
in the chloroplast does not interfere with the cultivation of the alga indicating that the 
endolysin does not have any negative impact on the viability of C. reinhardtii. 
Furthermore, this suggests that Pal production in C. reinhardtii could be performed 
using continuous cultivation systems. The accumulation of Pal was analysed under the 
control of two different promoters/5’UTR elements and at different growth stages 
before the yields of Pal protein were quantified using two HA-tagged standard 
proteins. These analyses suggested that approximately 10 mg Pal per litre of culture 
volume or 13 mg Pal per gram of cell dry weight can be achieved under the control of 
the psaA exon 1 promoter/5’UTR during mixotrophic cultivation. However, these 
results should be verified with purified Pal as a standard. 
 
In chapter 4 the bacteriolytic activity of Pal was demonstrated using a reference strain 
and five clinical isolates of S. pneumoniae, which belong to five different serotypes 
and included one strain with resistance to penicillin and co-trimoxazole. Furthermore, 
the results indicated that the HA-tag does not have a major impact on the enzymatic 
activity of Pal and further analyses suggested that the endolysin has specificity for S. 
pneumoniae. As the next step different purification methods were investigated and Pal 
was purified in active form using a serial process of ultracentrifugation, DEAE 
cellulose with choline as specific eluent and ammonium sulphate precipitation. 
Subsequently, purified Pal was used to analyse the bactericidal activity against S. 
pneumoniae. These analyses suggested that the enzymatic activities of Pal and a 
second S. pneumoniae-specific endolysin, Cpl-1, are comparable to the activities of 
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the same endolysins produced in E. coli. Moreover, experiments presented in chapter 
4 showed that crude extracts of C. reinhardtii have a growth inhibiting effect against 
S. pneumoniae and S. pyogenes. Further analyses indicated that the effect against S. 
pneumoniae is bactericidal rather than bacteriostatic. A literature research suggested 
that chlorophyll derivatives or fatty acids with antibacterial properties could be 
responsible for this endogenous antibacterial activity.   
 
The experiments described in chapter 5 demonstrated the detectable accumulation of 
ϕ11, a Staphylococcus aureus-specific endolysin, in the C. reinhardtii chloroplast. 
However, to-date, it has not been possible to synthesize the enzyme in the chloroplast 
in a form that has detectable enzymatic activity against S. aureus. Possible reasons for 
the inactivity of the protein together with strategies that could be attempted to produce 
enzymatically active ϕ11 in the C. reinhardtii chloroplast are discussed in the chapter. 
Furthermore, it was shown that the addition of a His-tag sequence to the genes of pal-
HA and ϕ11-HA results in non-detectable protein levels, which shows that the 
successful accumulation of recombinant protein in C. reinhardtii chloroplast can be 
easily disrupted through such seemingly minor alterations to the protein. 
 
The results of chapter 5 together with findings from other studies that observed that 
certain proteins, including two endolysins did not accumulate to detectable levels in 
the C. reinhardtii chloroplast (Rasala et al. 2010; Taunt 2013) led to the investigation 
of Synechocystis sp. PCC 6803 as an alternative endolysin production platform. The 
experiments described in chapter 6 demonstrated the successful production of three 
different endolysins in Synechocystis, including the Propionibacterium acnes-specific 
endolysin Gp20, which did not accumulate to detectable levels in the C. reinhardtii 
chloroplast. Growth studies showed that the accumulation of ϕ11 inside the cell does 
not have a marked negative impact on the viability of Synechocystis. In addition, it 
was possible to demonstrate the enzymatic activity of Synechocystis-produced ϕ11 
against S. aureus.  
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7.2 Evaluation of microalgae as a production platform for 
bacteriophage endolysins  
 
Taken together, the results of this study show that it is possible to use the C. 
reinhardtii chloroplast for the production of active Pal endolysin. Furthermore, it has 
been previously shown that active Cpl-1 can also be produced in the chloroplast of the 
microalga (Taunt 2013). Moreover, it was shown in this study that the cyanobacterium 
Synechocystis can be used for the production of active Pal and ϕ11 and that the 
endolysin Gp20 accumulates to detectable levels, which suggests that the success rate 
for the accumulation of active endolysins could be higher in the prokaryote. 
 
However, to establish the use of C. reinhardtii, Synechocystis or another microalga as 
commercially viable protein production platforms for endolysins, the production in 
these organism needs to be either cost-efficient or offer clear advantages over 
conventional production platforms such as yeast and bacterial systems, transgenic 
plants and mammalian cell cultures.  
 
Recombinant protein production in yeast systems results usually in the glycosylation 
of the produced protein, which is not desired for endolysins that are naturally 
produced in bacteria and do not require glycosylation (Gellissen 2000). Mammalian 
cell cultures are the most expensive production platform and therefore mainly used for 
the production of complex mammalian proteins that cannot be produced in other 
systems (Dove 2002). It has been shown that endolysins can be produced in the 
tobacco chloroplast and that the proteins accumulate to levels of up to 70% of TSP 
(Oey et al. 2009a). Furthermore, the study by Dove (2002) suggests that transgenic 
plants for the production of recombinant proteins are the most cost-efficient platform. 
However, one big concern regarding the use of transgenic plants is the release of 
transgenes into the environment during open or semi-enclosed cultivation. In contrast, 
microalgae can be easily cultivated in closed containment to prevent the release of 
transgenic algae, but also to avoid contamination of the production system and the 
therapeutic protein. PBRs for the cultivation of transgenic plants, such as plant cell 
suspension cultures and temporary immersion bioreactors have been developed as 
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well, but have not reach the same scale as PBRs for microalgae. In addition, for the 
cultivation of microalgae outdoor PBRs can be used that can be build on wasteland 
(such as deserts or salt land) that is not fertile enough for the cultivation of crop 
plants.  
 
Many bacterial production platforms contain endotoxins, for example the bacterium 
Escherichia coli, which makes it necessary to purify therapeutic proteins and 
significantly contributes to the production costs (Jonasson et al. 2002). In contrast, C. 
reinhardtii and several other microalgae such as Chlorella species have GRAS status, 
which could make protein purification steps dispensable in certain cases, for example, 
for topical or veterinary applications. It should be noted, however, that the transgenic 
DNA would need to be removed or degraded. 
 
There are several bacterial systems, such as lactic acid and coryneform bacteria that 
also have GRAS status (Ferrer-Miralles & Villaverde 2013). A recent study showed 
that in Lactococcus lactis, which has been used in food production for hundreds of 
years and has GRAS status, yields of 2.5 g recombinant protein per litre of culture 
volume can be reached (Jørgensen et al. 2014). This is 250 times more than what was 
reached for the production of Pal in the C. reinhardtii chloroplast (10 mg Pal per litre 
of culture volume). However, the nutrient requirements of microalgae are simple and 
inexpensive, which is believed to reduce the costs for cultivation and potentially the 
production costs for recombinant proteins (Gimpel et al. 2014). However, the higher 
recombinant protein yields and higher cell densities that can be achieved in bacterial 
systems might compensate higher media or cultivation costs. To analyse whether the 
C. reinhardtii chloroplast as a recombinant protein production platform is competitive 
in comparison to equivalent bacterial or transgenic plant systems that offer similar 
advantages (e.g. GRAS status or containment), an accurate costing for the production 
of recombinant Pal in the C. reinhardtii chloroplast needs to be generated. This 
costing should take cultivation costs, as well as harvesting and downstream processing 
costs into account into, and compare the overall costs of the different production 
systems.  
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Should the use of microalgae not prove cost-efficient for the production of 
recombinant proteins in comparison to conventional systems, their use as production 
platforms could be justified by other clear advantages. It was shown in chapter 4 that 
C. reinhardtii crude extracts possess antibacterial activity against S. pneumoniae and 
S. pyogenes. It would therefore be highly desirable to perform studies that investigate 
what this substance could be and whether this activity has an additive antibacterial 
effect in combination with Pal, since an additive or even synergistic effect would be a 
clear advantage for using C. reinhardtii for the production of the endolysin and add 
another argument for the use of crude algal extracts.  
 
Furthermore, observations during this study and the study by Oey et al. (2009b) 
suggest that high accumulation levels of the endolysin Pal inside bacterial cells might 
have a negative impact on the production host. This might be an even greater problem 
for the production of endolysins targeting Gram-negative bacteria, since these 
endolysins have often a broader spectrum and are not specific to the target bacterium 
(Schmelcher et al. 2012). The production of high levels of these endolysins might be 
therefore problematic in bacterial systems and the C. reinhardtii chloroplast, which 
has a prokaryotic origin but does not contain peptidoglycan, could be of great 
advantage.  
 
However, to finally conclude whether C. reinhardtii or other microalgae as protein 
production platforms are competitive or have certain advantages in comparison to 
conventional systems, as mentioned above a commercial evaluation of the production 
costs needs to be generated and further experiments need to be performed. 
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7.3 Future prospects 
 
7.3.1 The C. reinhardtii chloroplast as a production platform for 
endolysins specific to Gram-negative bacteria  
 
The treatment of infections arising from multi-drug resistant Gram-negative bacteria 
is a major concern. The outer membrane of Gram-negative bacteria represents a 
barrier that several mainstream antibiotics cannot cross and the availability of 
antibiotics against Gram-negative bacteria is therefore more limited. The WHO report 
mentions five Gram-negative and only two Gram-positive bacteria, in their list of 
bacteria of international concern with a high rate of antibiotic resistance (WHO report 
2014). The Gram-negative bacteria listed in the report are E. coli, Klebsiella 
pneumoniae, Salmonella and Shigella species, and Neisseria gonorrhoeae. 
 
It has been mentioned in the last section that the C. reinhardtii chloroplast as a 
production platform might be advantageous for the production of endolysins specific 
to Gram-negative bacteria, since these endolysins are less specific and might have 
toxic effects on bacterial production systems containing peptidoglycan (Schmelcher et 
al. 2012). It was generally believed that endolysins could not be used as a treatment 
against Gram-negative bacteria, since the outer membrane represents a barrier for the 
enzymes. However, a few studies recently have demonstrated the successful 
application in vitro of endolysins against Gram-negative bacteria (Lai et al. 2011; 
Lukacik et al. 2012). Table 7.1 gives a summary of such studies. Lukacik et al. (2012) 
choose a very interesting approach by combining an endolysin with the FyuA binding 
domain of pesticin, which enables the endolysin to cross the outer membrane. Such 
approaches could be used to engineer further endolysins that can cross the outer 
membrane and are effective against Gram-negative bacteria. An interesting target 
bacterium would be N. gonorrhoeae, since the bacterium has developed many multi-
drug resistant strains and most diseases caused by N. gonorrhoeae could be treated 
with topical or mucosal membrane applications. 
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The successful production in the C. reinhardtii chloroplast of an endolysin targeting 
Gram-negative bacteria that cannot be produced in bacterial systems would 
demonstrate a clear advantage of the eukaryotic microalga as a production system and 
would therefore make an interesting further study.  
 
 
Table 7.1: Studies that demonstrated the efficacy of endolysins against Gram-negative bacteria 
Endolysin 
phage 
Target bacteria Strategies Reference 
SPN9CC 
Phage SPN9CC 
Escherichia coli,  
Salmonella enterica 
+/- EDTA treatment Lim et al. 
(2014) 
LysAB2  
Phage ΦAB2  
Acinetobacter baumannii 
Escherichia coli 
Citrobacter freundii 
Salmonella enterica 
Study speculates that the C-
terminal domain enhances 
membrane permeability 
Lai et al. 
(2011) 
T4 
lysozyme/pesticin 
hybrid 
Escherichia coli  
Yersinia pestis 
Hybrid of T4 lysozyme and 
FyuA binding domain of pesticin 
Lukacik et 
al. (2012) 
EL188 
Phage EL 
Pseudomonas aeruginosa Tested different permeabilizer:  
EDTA most effective 
Briers et al. 
(2011) 
 
 
 
 
7.3.2 Further endolysin research 
 
The use of endolysins as antibacterial agents is a relatively new, but immense field. It 
is estimated that, in total, 1031 bacteriophages exists globally, so there is a huge 
untapped resource of endolysins that could be investigated for their potential use as 
antimicrobials for a wide range of applications. Additionally, several research groups 
have started to create designer endolyins by removing cell wall binding domains, 
adding additional catalytic domains, or combining of domains from different 
endolysins. Several of these studies reported promising effects such as enhanced lytic 
activity or broader host ranges for the engineered endolysins (Schmelcher et al. 2012). 
Furthermore, it might be possible to improve certain endolyins by random 
mutagenesis or by site-directed mutagenesis of key residues as was already discussed 
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for the choline binding sites of Pal in 4.2.4.5.1. Overall, this opens a huge research 
field for the development of designer endolysins that are adapted to specific clinical 
needs.  
 
It was discussed in the introduction that diagnostic methods need to be further 
improved before narrow-spectrum antibiotics can be used on an everyday basis. One 
approach would therefore be to combine different endolysins specific to those bacteria 
that are associated with the same disease, to decrease the diagnostic requirements 
before the application of narrow-spectrum endolysins. The skin disease impetigo, for 
example, is, in most cases, caused by either S. aureus or S. pyogenes. A combinational 
product consisting of different endolysins against both bacteria could be used to treat 
impetigo without having to determine which of the two pathogens is present, or 
needing to verify antibiotic susceptibility before administering treatment. 
Furthermore, the combination of endolysins targeting different bonds of the 
peptidoglycan might have a synergistic effect and might decrease the risk of resistance 
development.  
 
 
7.3.3 The use of other microalgae as recombinant protein production 
systems 
 
As already mentioned in 1.4.3, microalgae species other than C. reinhardtii or 
Synechocystis might offer advantages for the production of certain proteins. Higher 
growth rates and maximal cell densities, which can be reached, for example, by 
Chlorella sorokiniana, might result in faster production or in higher recombinant 
protein yields per litre of medium. Furthermore, the production of endolysins in 
microalgae with advantageous secondary metabolites would be an option as well. For 
example, an endolysin targeting a major fish pathogen could be synthesised in 
astaxanthin-producing H. pluvialis cells and the alga could be used to deliver the 
endolysin as the same time as the astaxanthin, as it has been previously suggested for 
vaccines (Gutiérrez et al. 2012). 
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Appendix A1: Gene sequences 
 
Sequence of pal including HA-tag (921 bp) 
 
ATGGGTGTTGATATTGAAAAAGGTGTTGCTTGGATGCAAGCTCGTAAAGGTCGTGTTTCATATTCAATG
GATTTCCGTGATGGTCCAGATTCATACGATTGTTCATCATCAATGTACTACGCTTTACGTTCAGCTGGT
GCTTCATCAGCTGGTTGGGCTGTTAATACAGAATATATGCACGCTTGGTTAATTGAAAACGGTTACGAA
TTAATTTCAGAAAACGCTCCATGGGATGCTAAACGTGGTGATATTTTCATTTGGGGTCGTAAAGGTGCT
TCTGCTGGTGCTGGAGGTCATACAGGTATGTTTATTGATTCAGATAACATTATTCACTGTAACTACGCT
TACGATGGTATTTCAGTTAATGATCACGATGAACGTTGGTATTATGCTGGTCAACCATATTACTACGTT
TACCGTTTAACAAACGCTAATGCTCAACCTGCTGAAAAAAAATTAGGTTGGCAAAAAGATGCTACAGGT
TTTTGGTATGCTCGTGCTAATGGTACATACCCAAAAGATGAATTTGAATACATTGAAGAAAACAAATCA
TGGTTCTACTTCGATGATCAAGGTTACATGTTAGCTGAAAAATGGTTAAAACACACAGATGGTAACTGG
TATTGGTTCGATCGTGATGGTTATATGGCTACATCATGGAAACGTATTGGTGAATCTTGGTACTATTTC
AACCGTGATGGTTCAATGGTTACAGGTTGGATTAAATACTACGATAACTGGTACTACTGTGATGCTACA
AACGGTGATATGAAATCAAACGCTTTCATTCGTTATAATGATGGTTGGTACTTATTATTACCAGATGGT
CGTTTAGCTGATAAACCACAATTCACAGTTGAACCTGATGGTTTAATTACAGCTAAAGTTTACCCATAC
GATGTTCCAGATTACGCTTAATAA 
 
 
Frequency of each codon triplet in the pal gene sequence 
 
UUU  9.8(     3)  UCU  6.5(     2)  UAU 32.6(    10)  UGU  9.8(     3) 
UUC 26.1(     8)  UCC  0.0(     0)  UAC 71.7(    22)  UGC  0.0(     0) 
UUA 39.1(    12)  UCA 52.1(    16)  UAA  6.5(     2)  UGA  0.0(     0) 
UUG  0.0(     0)  UCG  0.0(     0)  UAG  0.0(     0)  UGG 55.4(    17) 
 
CUU  0.0(     0)  CCU  6.5(     2)  CAU  3.3(     1)  CGU 45.6(    14) 
CUC  0.0(     0)  CCC  0.0(     0)  CAC 13.0(     4)  CGC  0.0(     0) 
CUA  0.0(     0)  CCA 26.1(     8)  CAA 19.5(     6)  CGA  0.0(     0) 
CUG  0.0(     0)  CCG  0.0(     0)  CAG  0.0(     0)  CGG  0.0(     0) 
 
AUU 45.6(    14)  ACU  0.0(     0)  AAU 16.3(     5)  AGU  0.0(     0) 
AUC  0.0(     0)  ACC  0.0(     0)  AAC 35.8(    11)  AGC  0.0(     0) 
AUA  0.0(     0)  ACA 35.8(    11)  AAA 52.1(    16)  AGA  0.0(     0) 
AUG 32.6(    10)  ACG  0.0(     0)  AAG  0.0(     0)  AGG  0.0(     0) 
 
GUU 32.6(    10)  GCU 91.2(    28)  GAU 94.5(    29)  GGU 91.2(    28) 
GUC  0.0(     0)  GCC  0.0(     0)  GAC  0.0(     0)  GGC  0.0(     0) 
GUA  0.0(     0)  GCA  0.0(     0)  GAA 45.6(    14)  GGA  3.3(     1) 
GUG  0.0(     0)  GCG  0.0(     0)  GAG  0.0(     0)  GGG  0.0(     0) 
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Sequence of ϕ11 including HA-tag (1,476 bp) 
 
ATGCAAGCTAAATTAACAAAAAACGAATTTATTGAATGGTTAAAAACATCTGAAGGTAAACAATTCAAC
GTAGATTTATGGTACGGTTTCCAATGTTTCGATTATGCTAACGCTGGTTGGAAAGTGTTATTCGGTTTA
CTTTTAAAAGGTTTAGGTGCTAAAGACATTCCATTCGCTAACAATTTCGACGGTTTAGCTACAGTTTAC
CAAAACACACCAGATTTTTTAGCTCAACCAGGTGATATGGTTGTTTTCGGTTCTAATTATGGTGCTGGT
TATGGTCATGTTGCTTGGGTTATTGAAGCTACATTAGACTACATTATTGTGTACGAACAAAACTGGTTA
GGTGGTGGTTGGACAGATGGTATTGAACAACCAGGATGGGGTTGGGAAAAAGTTACACGTCGTCAACAT
GCTTACGATTTCCCAATGTGGTTCATTCGTCCAAACTTCAAATCAGAAACAGCTCCACGTTCAGTTCAA
TCACCAACACAAGCTCCAAAAAAAGAAACTGCTAAACCACAACCAAAAGCTGTGGAGCTTAAAATCATT
AAAGACGTGGTAAAAGGATACGACTTACCTAAACGTGGTAGCAATCCAAAAGGTATTGTTATTCACAAC
GACGCTGGTAGTAAAGGTGCTACAGCTGAAGCTTATCGTAATGGTTTAGTTAACGCTCCATTATCTCGT
TTAGAAGCTGGTATTGCTCACTCATATGTTTCAGGTAATACAGTTTGGCAAGCTTTAGACGAATCACAA
GTTGGTTGGCACACAGCTAATCAAATTGGAAACAAATACTACTACGGAATTGAAGTGTGTCAATCAATG
GGTGCTGACAACGCTACATTCTTAAAAAACGAACAAGCTACATTCCAAGAATGTGCTCGTTTACTTAAA
AAATGGGGTTTACCAGCTAACCGTAACACTATTCGTTTACACAACGAATTTACAAGCACATCATGTCCA
CACCGTTCATCAGTTTTACATACAGGTTTTGATCCAGTGACACGTGGATTATTACCAGAAGATAAAAGA
CTTCAACTTAAAGACTACTTCATTAAACAAATTCGTGCTTACATGGACGGTAAAATTCCAGTTGCTACA
GTATCAAACGAATCATCAGCTAGCAGCAACACAGTTAAACCAGTAGCTTCTGCTTGGAAACGTAACAAA
TACGGTACATACTACATGGAAGAAAGCGCTCGTTTCACAAATGGTAACCAACCAATTACAGTTCGTAAA
GTGGGTCCATTCTTATCTTGTCCAGTGGGTTATCAATTCCAACCTGGTGGTTATTGTGACTACACTGAA
GTAATGTTACAAGATGGTCACGTTTGGGTAGGTTATACATGGGAAGGTCAACGTTACTACTTACCAATT
CGTACTTGGAATGGTTCTGCTCCACCAAACCAAATTTTAGGTGACTTATGGGGTGAAATTAGCTATCCA
TACGATGTTCCAGACTACGCTTAATAA 
 
 
 
Frequency of each codon triplet in the ϕ11 gene sequence 
 
UUU  8.1(     4)  UCU 12.2(     6)  UAU 18.3(     9)  UGU 12.2(     6) 
UUC 32.5(    16)  UCC  0.0(     0)  UAC 38.6(    19)  UGC  0.0(     0) 
UUA 56.9(    28)  UCA 26.4(    13)  UAA  4.1(     2)  UGA  0.0(     0) 
UUG  0.0(     0)  UCG  0.0(     0)  UAG  0.0(     0)  UGG 34.6(    17) 
 
CUU 10.2(     5)  CCU  4.1(     2)  CAU  6.1(     3)  CGU 36.6(    18) 
CUC  0.0(     0)  CCC  0.0(     0)  CAC 12.2(     6)  CGC  0.0(     0) 
CUA  0.0(     0)  CCA 54.9(    27)  CAA 50.8(    25)  CGA  0.0(     0) 
CUG  0.0(     0)  CCG  0.0(     0)  CAG  0.0(     0)  CGG  0.0(     0) 
 
AUU 42.7(    21)  ACU  8.1(     4)  AAU 16.3(     8)  AGU  2.0(     1) 
AUC  2.0(     1)  ACC  0.0(     0)  AAC 40.7(    20)  AGC 12.2(     6) 
AUA  0.0(     0)  ACA 48.8(    24)  AAA 63.0(    31)  AGA  2.0(     1) 
AUG 14.2(     7)  ACG  0.0(     0)  AAG  0.0(     0)  AGG  0.0(     0) 
 
GUU 36.6(    18)  GCU 75.2(    37)  GAU 20.3(    10)  GGU 83.3(    41) 
GUC  0.0(     0)  GCC  0.0(     0)  GAC 26.4(    13)  GGC  0.0(     0) 
GUA 12.2(     6)  GCA  0.0(     0)  GAA 46.7(    23)  GGA 10.2(     5) 
GUG 16.3(     8)  GCG  0.0(     0)  GAG  2.0(     1)  GGG  0.0(     0) 
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Sequence of gp201 including HA-tag (891 bp) 
 
ATGGTTCGTTATATTCCAGCTGCTCATCACTCAGCAGGTTCTAACAATCCTGTTAATCGTGTAGTAATT
CATGCAACATGTCCAGATGTAGGATTTCCTAGTGCTAGCCGTAAAGGTCGTGCTGTTTCAACTGCTAAT
TACTTCGCATCACCATCTAGTGGTGGTAGCGCTCACTATGTGTGTGACATTGGAGAAACAGTACAATGT
TTATCTGAAAGTACTATTGGATGGCACGCACCACCAAACCCTCATTCATTAGGTATTGAAATTTGTGCT
GATGGTGGTTCTCATGCTAGCTTTCGTGTGCCTGGTCACGCATATACACGTGAACAATGGTTAGATCCA
CAAGTTTGGCCAGCTGTTGAACGTGCTGCAGTATTATGTCGTCGTTTATGTGACAAATACAATGTACCT
AAACGTAAATTATCAGCTGCTGACTTAAAAGCAGGTCGTCGTGGTGTTTGTGGTCATGTTGATGTAACT
GACGCTTGGCACCAAAGCGATCATGATGATCCAGGACCATGGTTTCCTTGGGACAAATTCATGGCTGTT
GTAAACGGTGGTAGCGGTGACAGCGGAGAATTAACAGTTGCAGATGTAAAAGCTTTACACGATCAAATT
AAACAATTATCAGCACAATTAACTGGTAGCGTGAACAAATTACATCACGATGTTGGTGTTGTACAAGTG
CAAAACGGTGACTTAGGAAAACGTGTAGACGCTTTAAGCTGGGTGAAAAATCCAGTGACTGGAAAATTA
TGGCGTACAAAAGATGCTTTATGGTCTGTTTGGTATTATGTATTAGAATGTCGTAGCCGTTTAGATCGT
TTAGAAAGCGCTGTAAATGACTTAAAAAAATACCCATATGATGTACCTGACTATGCTTAATAA 
 
 
Frequency of each codon triplet in the gp201 gene sequence 
 
UUU 10.1(     3)  UCU 16.8(     5)  UAU 23.6(     7)  UGU 26.9(     8) 
UUC  6.7(     2)  UCC  0.0(     0)  UAC 10.1(     3)  UGC  0.0(     0) 
UUA 67.3(    20)  UCA 20.2(     6)  UAA  6.7(     2)  UGA  0.0(     0) 
UUG  0.0(     0)  UCG  0.0(     0)  UAG  0.0(     0)  UGG 33.7(    10) 
 
CUU  0.0(     0)  CCU 23.6(     7)  CAU 23.6(     7)  CGU 57.2(    17) 
CUC  0.0(     0)  CCC  0.0(     0)  CAC 23.6(     7)  CGC  0.0(     0) 
CUA  0.0(     0)  CCA 37.0(    11)  CAA 30.3(     9)  CGA  0.0(     0) 
CUG  0.0(     0)  CCG  0.0(     0)  CAG  0.0(     0)  CGG  0.0(     0) 
 
AUU 23.6(     7)  ACU 16.8(     5)  AAU 20.2(     6)  AGU 10.1(     3) 
AUC  0.0(     0)  ACC  0.0(     0)  AAC 16.8(     5)  AGC 33.7(    10) 
AUA  0.0(     0)  ACA 16.8(     5)  AAA 50.5(    15)  AGA  0.0(     0) 
AUG  6.7(     2)  ACG  0.0(     0)  AAG  0.0(     0)  AGG  0.0(     0) 
 
GUU 40.4(    12)  GCU 64.0(    19)  GAU 43.8(    13)  GGU 57.2(    17) 
GUC  0.0(     0)  GCC  0.0(     0)  GAC 33.7(    10)  GGC  0.0(     0) 
GUA 47.1(    14)  GCA 30.3(     9)  GAA 26.9(     8)  GGA 23.6(     7) 
GUG 20.2(     6)  GCG  0.0(     0)  GAG  0.0(     0)  GGG  0.0(     0) 
 
 
 
 
 
 
 
 
 334 
Sequence of gp202 including HA-tag (891 bp) 
 
ATGGTTCGTTATATTCCAGCTGCTCACCACTCTGCTGGTTCAAACAACCCAGTTAACCGTGTAGTTATT
CACGCTACTTGTCCAGATGTTGGTTTCCCTTCTGCTTCACGTAAAGGTCGTGCTGTTTCTACTGCTAAC
TACTTTGCTTCTCCATCTTCTGGTGGTTCAGCTCACTACGTATGTGACATCGGTGAAACAGTACAATGT
TTATCAGAATCAACTATTGGTTGGCACGCTCCACCAAACCCACACTCTTTAGGTATTGAAATTTGTGCT
GATGGTGGTTCACACGCTTCTTTCCGTGTTCCAGGTCACGCTTACACACGTGAACAATGGTTAGATCCA
CAAGTTTGGCCTGCTGTTGAACGTGCTGCTGTTTTATGTCGTCGTTTATGTGACAAATACAACGTTCCA
AAACGTAAATTATCAGCTGCTGATTTAAAAGCTGGTCGTCGTGGTGTTTGTGGTCACGTAGACGTAACT
GATGCTTGGCACCAATCTGATCACGACGACCCAGGTCCATGGTTCCCTTGGGATAAATTCATGGCTGTT
GTAAACGGTGGTTCAGGTGATTCTGGTGAATTAACAGTAGCTGATGTTAAAGCTTTACACGACCAAATT
AAACAATTATCAGCTCAATTAACAGGTTCAGTAAACAAATTACACCACGACGTAGGTGTTGTACAAGTA
CAAAACGGTGATTTAGGTAAACGTGTAGATGCTTTATCTTGGGTTAAAAACCCAGTTACAGGTAAATTA
TGGCGTACTAAAGATGCTTTATGGTCAGTATGGTACTACGTTTTAGAATGTCGTTCACGTTTAGACCGT
TTAGAATCAGCTGTAAACGATTTAAAAAAATACCCATACGATGTTCCAGATTACGCTTAATAA 
 
 
Frequency of each codon triplet in the gp202 gene sequence 
 
UUU  3.4(     1)  UCU 37.0(    11)  UAU  3.4(     1)  UGU 26.9(     8) 
UUC 13.5(     4)  UCC  0.0(     0)  UAC 30.3(     9)  UGC  0.0(     0) 
UUA 67.3(    20)  UCA 43.8(    13)  UAA  6.7(     2)  UGA  0.0(     0) 
UUG  0.0(     0)  UCG  0.0(     0)  UAG  0.0(     0)  UGG 33.7(    10) 
 
CUU  0.0(     0)  CCU 10.1(     3)  CAU  0.0(     0)  CGU 57.2(    17) 
CUC  0.0(     0)  CCC  0.0(     0)  CAC 47.1(    14)  CGC  0.0(     0) 
CUA  0.0(     0)  CCA 50.5(    15)  CAA 30.3(     9)  CGA  0.0(     0) 
CUG  0.0(     0)  CCG  0.0(     0)  CAG  0.0(     0)  CGG  0.0(     0) 
 
AUU 20.2(     6)  ACU 16.8(     5)  AAU  0.0(     0)  AGU  0.0(     0) 
AUC  3.4(     1)  ACC  0.0(     0)  AAC 37.0(    11)  AGC  0.0(     0) 
AUA  0.0(     0)  ACA 16.8(     5)  AAA 50.5(    15)  AGA  0.0(     0) 
AUG  6.7(     2)  ACG  0.0(     0)  AAG  0.0(     0)  AGG  0.0(     0) 
 
GUU 60.6(    18)  GCU 94.3(    28)  GAU 50.5(    15)  GGU 80.8(    24) 
GUC  0.0(     0)  GCC  0.0(     0)  GAC 26.9(     8)  GGC  0.0(     0) 
GUA 47.1(    14)  GCA  0.0(     0)  GAA 26.9(     8)  GGA  0.0(     0) 
GUG  0.0(     0)  GCG  0.0(     0)  GAG  0.0(     0)  GGG  0.0(     0) 
 
 
 
 
 
!
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Appendix A2: Vectors used in this study 
 
Figure 1: Vector maps of the plasmids pLAH.AII and pLAH.nrsB used for the transformation of 
Synechocystis sp. PCC 6803 
The transformation vectors were created by Lamya Al’Haj. Reproduced from Al-Haj (2014).   
 
 
 
 
 
 
Figure 2:  Vector maps of the plasmids pASapI and pSRSapI used for the transformation of 
Chlamydomonas reinhardtii 
The transformation vector pASapI was created by Economou et al. (2014) and pSRSapI by (Young & 
Purton 2014).   
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8 Commercial evaluation of Chlamydomonas reinhardtii as 
a production platform for bacteriophage endolysins 
 
8.1 Introduction 
 
The aim of the above-presented PhD thesis was to investigate the suitability of 
microalgae as a novel production platform for recombinant bacteriophage endolysins, 
a class of promising antibacterial proteins (for an introduction to endolysins, the 
rationale of this study and details of the microalga used, see chapter 1). During this 
study, it was shown that the two platforms used, the chloroplast of the eukaryotic 
green microalga Chlamydomonas reinhardtii and the cyanobacterium Synechocystis 
sp. PCC6803, are able to produce certain endolysins in an active form.  
 
Microalgae have emerged in the last ten years as an alternative production platform 
and are believed to offer several advantages over conventional systems (1.4 and 7.2), 
including the potential to lower the costs of recombinant protein production due to 
low cost cultivation requirements (Gimpel et al. 2014). However, the maximal cell 
densities of microalgae cultivated in bioreactor systems and the yields of recombinant 
proteins from microalgae are often considerably lower compared to conventional 
systems with comparable advantages (7.2) (Jørgensen et al. 2014; Oey et al. 2009). 
Together this could outweigh lower cultivation costs and result overall in higher 
production costs per mg of recombinant protein. To further evaluate microalgae as a 
production platform for bacteriophage endolysins, it is therefore important to attempt 
a cost analysis for the cultivation and harvesting of the transgenic algae strains. This 
can be then used to further investigate whether the production of recombinant 
endolysins in microalgae is competitive in comparison to bacterial or transgenic plant 
systems that offer similar advantages.  
 
Since the synthesis of the S. pneumoniae-specific endolysin Pal in the C. reinhardtii 
chloroplast showed the most promising results and had been most investigated during 
the research for this PhD thesis, it was used as a model to estimate the costs for the 
production of endolysins in microalgae. 
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8.1.1 Aims and objects of this study 
 
The objective of this study is to investigate the feasibility of microalgae as a 
production platform for recombinant bacteriophage endolysins and other antimicrobial 
proteins from a financial perspective by using production of the S. pneumoniae-
specific endolysin Pal in the chloroplast of C. reinhardtii as the model system. With 
this aim, the following studies were performed: 
 
• Designing of a model facility for the cultivation of C. reinhardtii and 
production of the endolysin Pal  
 
• Calculation of the costs for the production of Pal in C. reinhardtii,  
 
• Comparison the costs of recombinant protein production in C. reinhardtii to 
conventional expression platforms with similar advantages 
 
• Summary of the current market for antibiotics, particularly in endolysins, and 
the patent landscape 
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8.2 Methods 
 
8.2.1 Algal strains and quantification of recombinant endolysin 
production  
 
During this study, several transgenic lines of C. reinhardtii were created that produce 
the S. pneumoniae-specific endolysin Pal (chapter 3) in their chloroplast. Furthermore, 
it was shown that C. reinhardtii-produced Pal has specific antimicrobial activity 
against S. pneumoniae including clinical isolates with antibiotic resistances (4.2.2). 
Subsequently, the production of Pal was analysed under two different promoter 
systems and at different growth stages to optimise the yield of recombinant protein 
(3.2.2.4 and 3.2.3.2). Furthermore, the yield of Pal produced in the C. reinhardtii 
chloroplast was quantified using two standard proteins and the Odyssey® Infrared 
Imaging System. The quantification was performed at two growth stages that yield the 
highest amount of Pal per cell and per culture volume, respectively (3.2.4) (Table 8.1).  
 
 
Table 8.1: Quantification of Pal at two different growth stages using CARHSP1 and a multiple 
tag fusion protein as standards 
Cultures of TN72_SR_pal-HA were grown under standard conditions to an OD750nm of 2 and 3.8; the 
cells were broken by the addition of SDS (2% w/v) and boiling. Dilution series of CARHSP1 or the 
multiple tag fusion protein were analysed together with two dilutions of TN72_SR_pal-HA whole cell 
extract on the same gel and membrane in western blot analyses with anti-HA antibodies and IRDye® 
secondary antibodies. Standard curves of quantities of the standard protein against the IR fluorescence 
signal of the Odyssey® Infrared Imaging System were used for the quantification of Pal, taking the 
lower molecular weight of Pal into account. The standard deviations (±) are stated (n = x). 
 
Standard protein OD750nm of 
culture 
Pal (mg) / L culture 
volume 
Pal (mg) / g of cell dry 
weight 
CARSHP1 as 
standard 
2 
6.5 ± 0.8 
(n = 4) 
12.6 ± 0.7 
3.8 
9.6 ± 1.6 
 (n = 4) 
NA 
Multiple tag 
fusion protein as 
standard 
2 7.2 ± 0.8 
(n = 4) 
14.0 ± 0.7 
3.8 10.6 ± 5.0 
(n = 4) 
NA 
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8.2.2 Modelling of large-scale cultivation system 
 
The company Supreme Biotechnologies Ltd, which partly funded this study, cultivates 
Haematococcus pluvialis for the production of astaxanthin in Nelson, New Zealand. 
The cultivation of H. pluvialis for the production of astaxanthin is performed in two 
stages. In the first stage (the green phase), H. pluvialis is cultivated as continuous 
culture under optimal growth conditions. In the second phase (the red phase), the 
cultures are transferred to a batch cultivation and grown under high light and with 
limited nutrients to induce the formation of cysts with a high astaxanthin content. The 
culturing requirements of C. reinhardtii are comparable to the H. pluvialis green 
phase cultivation (similar nutrient, CO2, mixing and temperature requirements). The 
green phase cultivation of H. pluvialis can be therefore used as a model for the 
cultivation of C. reinhardtii. Supreme Biotechnologies Ltd produces astaxanthin as a 
dietary supplement for human consumption. H. pluvialis is therefore grown in closed 
containment and under tightly controlled conditions in an indoor facility, which would 
also be required for the production of endolysins for human use in C. reinhardtii. 
 
Supreme Biotechnologies Ltd uses a “hanging bag” system (Figure 8.1) for the 
cultivation of H. pluvialis in the green and red phases. This system consists of single 
independent 40-litre bags, which are connected to nutrient drippers and transfer lines 
for the continuous cultivation in the green phase, as well as CO2/air lines. The 
cultivation conditions can be first tested in single bags and subsequently easily scaled 
up to high numbers of bags. The cell-wall deficient C. reinhardtii strains producing 
Pal were successfully cultivated in single bags under conditions comparable to the 
ones in the facility of Supreme Biotechnologies Ltd during this study (Figure 8.3). 
This cultivation system is therefore used as a model system for the large-scale 
cultivation of C. reinhardtii producing Pal. Supreme Biotechnologies Ltd has 
provided a figure for their production costs in the green phase.  
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Figure 8.1: Green phase cultivation of Haematococcus pluvialis in the “hanging bag” system at 
Supreme Biotechnologies Ltd in Nelson, New Zealand. 
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8.2.3 Process of recombinant protein production in microalgae  
 
The first step of the process is the cultivation of the transgenic microalga strain in the 
above described “hanging bag system”. This process requires water (previously 
sterilized by filtration/ozonisation), as well as nutrients, CO2 and power for lighting, 
pumping and temperature control. The next step is the harvesting, which requires an 
input of power and creates wastewater. The last step involves breakage of the cells 
and the recovery of an algal crude extract containing the recombinant protein. This 
requires additional energy input. The remaining algal biomass could be used for 
further applications, such as animal feed or for energy generation by anaerobic 
digestion (Figure 8.3).  
 
Figure 8.2: Cultivation (left) of C. reinhardtii TN72_pal at the University College London (UCL) 
(UK) using the “hanging bag system” of Supreme Biotechnologies Ltd, and harvesting of the cells 
at UCL (right) 
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Figure 8.3: Process diagram for the production of recombinant proteins in microalgae 
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8.2.4 Cost evaluation 
 
The cost evaluation was calculated based on figures for the cost of the green phase 
cultivation of H. pluvialis at the astaxanthin production facility of Supreme 
Biotechnologies Ltd; a study by Acién et al. (2012) that describes the operation of a 
30 m3 facility for the cultivation of Scenedesmus almeriensis in Almería (Spain), as 
well as further literature evaluating commercially the production of biodiesel in 
microalgae. The total capital is a combination of construction costs as well as 
operational and maintenance costs.  
 
 
8.2.5 Market and patent landscape analysis 
 
The analysis of the market and patent landscape was mainly performed using the 
patent database www.lens.org, and general internet searches.   
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8.3 Results 
 
8.3.1.1 Modelling a facility for the cultivation of C. reinhardtii and the 
production of Pal: defining the scenario 
 
The facility is assumed to be located in New Zealand, to have a size of 300 m2 and to 
use the “hanging bag” system described in 8.2.2 for the cultivation of C. reinhardtii 
(Figure 8.4). The cultivation operates under steady state conditions in continuous flow 
with a total culture volume of 19,680 litres, which corresponds to 492 40-litre bags 
(Table 8.2). In the facility, the bags are attached in rows of 7 to both sides of a metal 
frame system, which contains the light systems, consisting of 12 horizontal 
fluorescent light tubes (58W, 152.4 cm) (Figure 8.1, Figure 8.4). The cultivation 
operates on 350 days per year with a 5-day shutdown every four months for cleaning 
and maintenance. The growth bags are single-use, whereas the silicone tubing is 
reused after cleaning and autoclaving. The facility includes a small laboratory for 
quality control and preparation of starter cultures.  
 
The water for the preparation of the culture medium is sterilized by 
filtration/ozonisation, before nutrients and water are mixed using a medium 
preparation unit (Acién et al. 2012). The bags are connected to CO2/air lines, which 
enable a constant bubbling of the bags for mixing of the culture and CO2 supply. 
Culture medium is continuously pumped into the bags and the outflow containing 
cells flows automatically into harvest tanks. The microalgae biomass is harvested by 
centrifugation, since this method is not disruptive even to fragile cells and has a very 
high harvesting efficiency of more than 95% (Leite et al. 2013; Rawat et al. 2013). 
This is especially important, since the C. reinhardtii strains are cell-wall deficient and 
broken cells can easily release the soluble endolysin proteins into the culture medium. 
Harvesting by centrifugation is performed during the day with a continuous decanter 
(solid-liquid centrifugation unit) from Flotweg (Germany) at 9500 rpm, which results 
in a sludge with a 15% dry matter content (Acién et al. 2012). Subsequently, the 
sludge is frozen in a freezer room at -20ºC to prevent degradation of the endolysins.  
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The advantage of the cell-wall deficient C. reinhardtii strains is that the cells can be 
easily broken by simple mechanical methods (4.2.1). The freezing process (-20ºC) 
already breaks a high percentage of the cells and can be easily completed by mild and 
simple methods. Subsequently, a crude extract containing Pal can be obtained by 
centrifugation (21,000 x g, 5 min). C. reinhardtii is classified as a GRAS organism 
(Generally Recognized as Safe), which means this organism is even safe for human 
consumption. Crude extract containing an endolysin could be therefore used for 
certain applications, such as topical or non-medical applications, without expensive 
purification steps. However, the transgenic nature of the organism might necessitate 
for certain applications the removal or destruction of the DNA component. 
Alternatively, C. reinhardtii-produced Pal can be purified using DEAE cellulose with 
choline as specific eluent and ammonium sulphate precipitation (4.2.4).  
 
The costs of the production process in this study are only analysed up to the 
harvesting and freezing step to simplify the analysis and to make the costing easier 
comparable to other production platforms, since extraction/purification costs vary 
depending on the protein and intended application.  
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Table 8.2: Main parameters defining the process and comparison of the growth parameters for C. 
reinhardtii and H. pluvialis  
Parameter Value Source/Comment 
Number of bags 492 Volume per bag: 40 litres 
Total culture volume (litres) 19,680  Calculated from the outflow and daily renewal rate 
Operation time 
(days/annum) 350  
Every 4 months 5 days shut down for 
cleaning/renewal 
Operation time  
(cultivation) (h/day) 
24  
 H. pluvialis  
Cells per ml 150,000 Supreme Biotechnologies Ltd 
Litres per minute (outflow) 4.1 Supreme Biotechnologies Ltd 
Litres per month (outflow) 179,580 Supreme Biotechnologies Ltd 
Litres per day (outflow) 5,904 Supreme Biotechnologies Ltd 
Cells per month 26,937,000,000,000 Supreme Biotechnologies Ltd 
Daily renewal rate 30% Fábregas et al. (2001) 
Growth rate 0.023 h-1 Katsuda et al. (2004) 
 0.024 h-1 García-Malea et al. (2005) 
 C. reinhardtii  
Growth rate 0.064 – 0.10 h-1 
Determined in this study for the C. reinhardtii 
strains producing Pal at 200 µmol m-2 s-1, 
approximately 3.5 times higher than H. pluvialis 
Litres per minute (outflow) 12.3 
Assumption:  
Higher growth rate results in at least three times 
higher outflow  
Litres per month (outflow) 538,740 
Litres per day (outflow) 17,712 
Daily renewal rate 90% 
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Figure 8.4: Model facility for the cultivation of Chlamydomonas reinhardtii for the production of recombinant endolysins 
Green circles represent the “hanging bag” cultivation system, green squares harvest storage tanks. 
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8.3.2  Costing for the production of the endolysin Pal in C. 
reinhardtii  
 
8.3.2.1 Capital costs  
 
The total capital costs consist of the costs for construction and installation of the metal 
frame system and the major equipment, as well as a yearly lease for the premises 
(Tables 8.3 and 8.4). The costs of the facility are based on a lifespan of ten years. The 
depreciation for most items is therefore 10 years, except for items with a predicted 
shorter life span such as light tubes (15,000 h = 1.7 years) and silicone tubing (2 
years). The costs for construction and installation, as well as contingency and 
insurance costs were estimated by multiplying the costs for major equipment by the 
corresponding Lang factors, which were taken from Acién et al. (2012) and Richmond 
(2008). The construction costs consist of onsite installation costs including piping and 
electrical installations, as well as labour costs. The estimated construction/installation 
time would be approximately six months.  
 
 
Table 8.3: Summary of fixed capital estimated for the study analysed 
Item NZ$ Source/comments 
Total costs for major equipment (MEC) 160,834 See table 8.4 
Total costs for construction and installation 157,618 See table 8.4 
Depreciation (per annum) in NZ$ 33,851 10 years, unless otherwise stated 
Contingency 0.08 x depreciation 2,708 Acién et al. (2012), Richmond (2008) 
Insurance 0.006 x depreciation 203 Acién et al. (2012), Richmond (2008) 
Purchase tax 0.15 (NZ $) 5,078 www.newzealandnow.govt.nz 
Premises (300 m2 in 
Nelson, New Zealand) 
Lease/year (NZ$) 28,000 
Colliers International New Zealand - 
Commercial Real Estate Agency - 
http://www.colliers.co.nz 
Total fix capital per annum  (NZ$) 69,840  
Total fix capital per month (NZ$) 5,820  
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Table 8.4: Detailed fixed capital costs estimated for the study analysed 
 
Item Units (max. capacity per unit) 
Costs (NZ$) Depreciation 
(DEP) Source Per item Total 
Major equipment for Metal frame work m3 (18 x 8.75 m3 = 158 m3) 97.50 15,400 10 www.alibaba.com 
- Cultivation Fluorescent light tubes 432 (= 12 x 4 x 9) 4.20 1,814 1.7 (15,000 h) www.lampshoponline.com 
 Silicone tubing 1000 m 2.80 2,800 2 www.polymax.co.uk 
 Air conditioning For 300 m2 1,120 1,120 10 www.alibaba.com 
 Medium preparation unit 1 (4 m3/h) 8,400 8,400 10 Acién et al. (2012) 
 Water sterilization unit 1 (2 m3/h) 21,000 21,000 10 Acién et al. (2012) 
 CO2 supply unit 1 (4 kg/h) 700 700 10 Acién et al. (2012) 
 Autoclave 250 litres 20,000 20,000 10 www.fisher.co.uk 
 Lab equipment Microscope, shaker 4,200 4,200 10 www.fisher.co.uk 
- Harvesting Continuous decanter 1 (4 m3/h) 63,000 63,000 10 Acién et al. (2012) 
 Harvest/medium pumps 3 (2 m3/h) 1,400 4,200 10 Acién et al. (2012) 
 Harvest storage tanks 14 (1 m3/h) 700 9,800 10 Acién et al. (2012) 
- Cell breakage/storage Freezer room 1 (2.5 x 2 x 2.5 m) 8,400 8,400 10 www.coldnet.co.uk 
 Total costs for major equipment (MEC) (NZ$) 160,834   
       
 Item Lang factor (x MEC) Total (NZ$) DEP Source 
Construction/  
installation costs 
Installation costs 0.2 32,167 10 Acién et al. (2012) 
Instrumentation and control 0.15 24,125 10 Acién et al. (2012), Richmond (2008) 
 Piping 0.2 32,167 10 Acién et al. (2012) 
 Electrical 0.1 16,083 10 Acién et al. (2012), Richmond (2008) 
 Engineering and supervision 0.3 48,250 10 Acién et al. (2012), Richmond (2008) 
 Contractor's fee 0.03 4,825 10 Acién et al. (2012) 
 Total costs for construction and installation (NZ$) 157,618 
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Table 8.5: Direct monthly production/operational costs estimated for the case study analysed. Power costs are: 1 kWh is 0.1 NZ$ (http://www.electricityinfo.co.nz/) 
 Item H. pluvialis  Costs (NZ$)  
C. reinhardtii  
Costs (NZ$)  Comments Source 
Cultivation Power  705 2,040 C. reinhardtii: Higher light intensity Supreme Biotechnologies Ltd 
 Water/wastewater 538 1,614 C. reinhardtii: 3 x higher flow rate Supreme Biotechnologies Ltd 
 Bags 37 37 - Supreme Biotechnologies Ltd 
 Nutrients 2,168 6,504 C. reinhardtii: 3 x higher flow rate Supreme Biotechnologies Ltd 
 Incidentals 100 100 - Supreme Biotechnologies Ltd 
 Filters 150 150 - Supreme Biotechnologies Ltd 
 CO2 345 345 - Supreme Biotechnologies Ltd 
Harvest Power (Continuous decanter, pumps) 114 Usage: 5h/day, 7.5 kWh  Acién et al. 2012  
Storage Power (freezer room) 109 Usage: 24h/day, 1.5 kWh www.mellcon.com 
Labour Wages (4 Shifts) 12,480 
2 shifts for cultivation and 2 shifts for 
harvesting (6,240 each) 
Supreme Biotechnologies Ltd 
 Supervision (0.2 labour) 2,496 Acién et al. 2012 
 Payroll charges (0.25 labour + supervision) 3,120 Acién et al. 2012 
Others Maintenance (0.04 x MEC) 724 0.04 x 18,089 (depreciation MEC) Acién et al. 2012 
 Contingency (0.05 x production costs) 1,492 0.05 x 29,833 Acién et al. 2012 
 Tax (0.15) 4,699 0.15 x 31,324 www.newzealandnow.govt.nz 
Total raw materials (nutrients, CO2) and consumables 7,136   
Total utilities (water, power) 3,877   
Total labour and others 25,010   
Total monthly production costs (NZ$) 36,023   
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8.3.2.2 Production/operational costs 
 
The production/operational costs are estimated based on the costs for the cultivation 
of H. pluvialis in the green phase at the facility of Supreme Biotechnologies assuming 
a three-fold higher flow rate, since C. reinhardtii has a higher growth rate than H. 
pluvialis (Table 8.2). This results in three times higher costs for water/waste water and 
nutrients. The optimal light intensity for the cultivation of C. reinhardtii (200 µmol m-
2 s-1) is higher compared to H. pluvialis (50 µmol m-2 s-1 (Harker et al. 1996)), which 
results in higher power costs for lighting (58W x 432 x 24h/day = 601 kWh/day x 30.4 
days = 18,280 kWh/month x 0.1 NZ$ = 1828) + (30% of NZ$ 704 for other power 
costs) = NZ$ 2040). Furthermore, the production/operational costs include labour 
costs, comprising supervision and payroll charges, as well as maintenance and 
contingency. For details see table 8.5.  
 
 
8.3.2.3 Total costs for the production of Pal produced in C. reinhardtii 
 
The total fixed capital costs per month and the monthly production/operational costs 
were added, and divided by the amount of Pal that can be produced in the described 
facility per month (amount of Pal produced in the transgenic C. reinhardtii strain 
during exponential phase x total culture outflow per month) taking the annual 
operation time and harvesting efficiency into account. This resulted in estimated 
production costs of 13 NZ$ per gram of Pal, which are approximately 10 US$ per 
gram of recombinant Pal protein (Table 8.6).  
 
It needs to be mentioned that these calculations strongly rely on the determination of 
the amount of Pal that is produced in the transgenic lines. This quantification was 
performed with two different standard proteins, which gave comparable results, 
during this study (3.2.4 and 8.1.2). However, to confirm the result, the quantification 
ideally needs to be repeated with purified Pal as the standard, to exclude protein-
specific differences.  
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Table 8.6: Estimated total costs per g of Pal produced in C. reinhardtii  
Total fix capital per month 5,820 
Total production costs per month 36,023 
Total monthly costs (NZ$) 41,843 
Litres per month (outflow)  538,740 
- Reduction due to Operation time (350 days/year) 517,190 
 Harvesting efficiency (90%) 465,471 
Pal (mg) / litre culture volume in the exponential phase 6.9 
Pal (mg) per month 3,211,752 
Costs (NZ$) per mg Pal 0.013 
Costs (NZ$) per g Pal 13.03 
Costs (US$) per g Pal 9.89 
 
 
This calculation represents a first attempt to estimate the costs for the production of 
endolysins in the green microalga C. reinhardtii. Subsequently, it may be possible to 
further optimise the production system to decrease the production costs. Janssen et al. 
(1999) and Janssen et al. (2000), for example, describe growth rates of up to µ = 
0.16/h-1, which is more than double the growth rate that was used for this calculation. 
Optimisation of the light and mixing conditions in the cultivation system might 
therefore improve growth rates and subsequently decrease the production costs. 
Labour costs represent, as in many production processes, a major part of the costs 
(approximately 50%). Further automation of the process would therefore most likely 
reduce labour costs and resulting production costs. Furthermore, the remaining algae 
biomass could be separately sold, for example as lifestock feed or as substrate for the 
anaerobic digestion for the production of biogas, which would further reduce the 
production costs and reduce waste material.  Moreover, a scale-up of the production 
facility would likely result in a reduction of the production costs per gram. On the 
other hand, it needs to be borne in mind that values such as the required work force, 
the monthly productivity and installation costs represents estimates and discrepancy 
could result in much higher production costs in reality. 
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8.3.3 Market and patent landscape 
 
8.3.3.1 The market for antibiotics and antibacterial agents 
 
The antibiotic market had a total value of US$42 billion globally in 2009 (Hamad 
2010). It has an annual growth of around 4% and represents 5% of the global 
pharmaceutical market (Hamad 2010). As mentioned earlier, the development of new 
antibiotics has declined in recent decades, mainly owing to the lower profitability of 
antibiotics compared to other drugs (1.1). Nevertheless, the resulting decline in the 
approval of new antibiotics and the increase in resistant bacteria has now caused a 
pressing need for the development of new antibiotics, as emphasized by several 
institutions and experts such as the British Society for Antimicrobial Chemotherapy 
(BSAC), the World Health Organization (WHO), the Infectious Disease Society of 
America (IDSA) and the Chief Medical Officer for England, Professor Dame Sally 
Davies (1.1). New proposed strategies for the economic feasible research and 
development of new antibiotics involve collaborations between academia and 
pharmaceutical companies, combined with public funding (So et al. 2011).  
 
Currently, the recommendation in many countries is to use antibiotics only when 
really necessary to limit the spread of resistances. However, the development of more 
specific antibiotics, which have less impact on the commensal bacterial flora (a 
reservoir for antibiotic resistance genes) and are more robust to resistance 
development, could make it safe again to use antibiotics for minor infections and as 
long-term treatment for recurring infections (1.1.2). 
 
Furthermore there are significant markets for antibacterials in livestock farming (e.g. 
staphylococcal mastitis), agriculture (treatment of plant pathogens) and the 
conservation of food. As mentioned earlier, there is a potential application for the 
endolysin Gp20 in a cosmetic product for the treatment of acne vulgaris, which has a 
market that generates revenue of nearly $3 billion annually (1.3.3). These markets are 
more easily accessible and require less investment then the pharmaceutical market, 
which requires major investment for clinical trials.  
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8.3.4 The current market and patent landscape for bacteriophage 
endolysins 
 
Bacteriophage endolysins are promising novel antibacterial agents due to their high 
specificity for the target bacteria, which enables the efficient elimination of the 
causative agent of an infection without affecting the beneficial commensal flora 
(1.2.3). Furthermore, the development of resistance against endolysins is very rare, 
because these enzymes evolved to target molecules in the cell wall that are essential 
for bacterial viability (1.2.4.1). Endolysins have been extensively investigated in vitro 
and several pre-clinical trials with a variety of endolysins specific to Gram-positive 
human pathogens showed a significant decrease of the bacterial loads and an increase 
of the survival rates of infected animals after treatment with endolysins (1.2.4, Table 
1.1). In recent years, several companies have started to perform clinical trials, to file 
patents and to sign licencing deals to bring endolysins as novel antibiotics to market.  
 
In November 2014, the Dutch company MICREOS (Bilthoven, Netherlands) was the 
first (and is still the only) company to sell products for human use that contain an 
endolysin. The company sells the pharmaceutical StaphefektTM for the topical 
treatment of Staphylococcus aureus infections. Furthermore, the product range 
comprises the series Gladskin with creams and gels for the treatment of acne, eczema, 
rosacea and skin irritations, which often have an S. aureus infection component. 
Furthermore, the US company GangaGen (Palo Alto, CA, USA) is working on the 
development of an S. aureus-specific human treatment based on the effect of an 
endolysin. Their product StaphTAME, containing the endolysin P128, is currently 
being evaluated as a treatment for the nasal decolonisation of S. aureus in a Phase 2 
clinical trial. Whereas, the UK-based company Sarum Biosciences (Salisbury, UK) is 
working on the development of a bacteriophage endolysin technology for the 
treatment and the diagnosis of Clostridium difficile infections.  
 
The Lysando AG (Triesenberg, Liechtenstein) holds several patents that relate to 
fusion proteins of endolysins and additional peptide sequences (which are often added 
for the extraction and purification of commercially produced proteins) and covers with 
these patents a wide range of endolysins against Gram-positive as well as Gram-
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negative bacteria and a variety of commercial applications. In August 2014, the 
company licenced the rights for its inventions as Artilysin® technology to Boehringer 
Ingelheim Vetmedica (a devision of Boehringer Ingelheim GmbH, Ingelheim, 
Germany), which is the 6th largest animal health company in the world.  
 
As well as applications in the treatment of human and animal infections, endolysins 
can be used for a variety of other applications, such as the control of bacterial 
contamination in food, feed and cosmetic products, as well as the abolishment of 
bacterial pathogens in crop plants. Several endolysins are also suitable for the 
eradication of biofilms on food processing equipment and medical devices, as well as 
surfaces in hospitals, surgeries and food producing factories. Furthermore, endolysins 
can be applied for the diagnosis of diseases and the detection of food spoilage.   
 
The company BioMérieux (Craponne, France) that markets clinical diagnostic 
products, as well as environmental and industrial microbial monitoring services and 
products, holds several patents relating to endolysins for the diagnosis and eradication 
of the bacterium Listeria (a common cause of food spoilage and poisoning). 
Furthermore, the company holds patents that relate to the use of the cell wall binding 
domains of endolysins for the diagnosis, detection and removal of a wide range of 
Gram-positive bacteria. Another example is the company DSM (Heerlen, 
Netherlands) that produces food, beverage and dietary supplements, including 
enzymes for the preservation of food, and holds several patents relating to endolysins 
for the control of Listeria contamination in food products.  
 
Taken together, this shows that there is a growing commercial interest in endolysins 
for medical as well as non-medical applications. And as for other recombinant protein 
therapeutics and agents, there is the need for a safe, reliable and commercially viable 
host organism for their production. Microalgal production platforms have not yet been 
exploited for the production of endolysins, and there are no patents relating to the 
production of non-mammalian recombinant proteins in C. reinhardtii, which could 
restrict the utilisation of this system.   
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Table 8.7: Summary of patents relating to endolysin inventions  
(Source: www.lens.org) 
Patent title Patent holder Patent number 
Method Of Reducing Biofilms Lysando Holding Ag 
WO 2011/134998 A8 
Patent Application 
Antimicrobial Agents Lysando Holding Ag 
US 8906365 B2 
Granted patent 
Antimicrobial Agents Lysando Holding Ag 
WO 2010/149795 A1  
Patent application 
Endolysin Obpgplys Lysando Holding Ag 
US 8846865 B2 
Granted patent 
New Endolysin Obpgplys Lysando Holding Ag 
WO 2011/023702 A1 
Patent application 
Composition For Use In Mycobacteria 
Therapy 
Lysando Holding Ag 
WO 2014/001572 A1 
Patent application 
New Endolysin Plyp40 BioMérieux Sa 
EP 2321409 B1  
Granted patent 
Modified Endolysin Ply511 BioMérieux Sa 
WO 2009/138475 A1 
Patent application 
Method and Means For Concentrating, 
Removing, And Detection of Gram-
positive Bacteria 
BioMérieux Sa 
EP 2121765 B1 
Granted patent 
Method and Means For Enrichment 
Removal And Detection of Listeria 
BioMérieux Sa 
US 8350005 B2 
Granted patent 
Endolysins For Controlling Listeria In 
Pasta Filata Cheese And Related Food 
Products 
Dsm lp Assets Bv 
WO 2012/159773 A1 
Patent Application 
Novel Listeria Bacteriophage P825 And 
Uses Thereof 
Dsm lp Assets Bv 
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8.4 Discussion and conclusion 
 
At the moment, the majority of recombinant proteins are commercially produced in 
mammalian cell cultures (mainly Chinese hamster ovary (CHO) cells) (45%), in yeast 
(15%) or in bacterial systems (40%) (Huang & McDonald 2009). Furthermore, a 
variety of other host expression systems have been brought to the market or are under 
development, including insect cells (baculovirus systems), transgenic plant cell 
cultures and whole plants, as well as transgenic mammal milk or chicken eggs (Huang 
& McDonald 2009; Dove 2002). 
 
It has already been discussed in 1.4 and 7.2 that the C. reinhardtii chloroplast has the 
potential to offer advantages for the synthesis of endolysins over certain conventional 
recombinant protein production platforms, including the absence of glycosylation 
(which is unwanted for the production of these proteins that are naturally produced in 
a prokaryotic environment, and often happens in yeast systems or during nuclear 
expression in eukaryotic systems), the possibility to be grown in closed containment 
(in contrast to the open cultivation of transgenic plants) as well as the GRAS status, 
which means C. reinhardtii is free of toxins or infectious agents (in contrast to, for 
example the bacterial platform Escherichia coli), whose removal can result in high 
purification costs. However, there are other host systems that offer similar advantages, 
for example plant cell cultures or bacterial systems with GRAS status. Therefore it is 
desirable to be investigated whether microalgae would be competitive from a financial 
point of view.  
 
The estimated production costs of US$ 10 per gram of the endolysin Pal produced in 
the C. reinhardtii chloroplast (without purification) are lower compared to estimates 
for the production of recombinant proteins in mammalian cell cultures. Dove (2002) 
and Hood et al. (2002) estimate raw material costs of US$100 – 600 per gram for the 
production of recombinant proteins in Chinese hamster ovary (CHO) cells. Farid 
(2007), Huang & McDonald (2009) and Boehm (2007) even describe production costs 
that range from US$ 300 to up to US$ 10,000 per gram of recombinant protein 
produced in mammalian cell cultures, due to expensive infrastructure and media 
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components, as well as the necessity of preventative measures against viral and 
oncogenic contamination.  
 
However, the later figures include most likely purification costs. Evangelista et al. 
(1998) state that 88% of the costs for the production of recombinant β-Glucoronidase 
in transgenic corn are caused by protein extraction (40%) and purification (48%), 
which is about US$ 38 per gram with total production costs of US$ 42 per gram. The 
purification is done with DEAE resin, which can be used for the purification of Pal as 
well (4.2.4). Nfor et al. (2013) analysed different recombinant protein purification 
methods and state that purification by ion exchange chromatography (such as DEAE 
cellulose) produces costs of approximately US$ 8 per gram of product or in 
combination with other methods US$ 30. The purification of C. reinhardtii-produced 
Pal would therefore likely increase the overall production costs by two-fold or even up 
to ten-fold. 
 
Furthermore, the capital investment costs for the installation of a facility for the 
cultivation of mammalian cell cultures are a lot higher than for the facility described 
here, that uses the relatively simple “hanging bag system”. Farid (2007) describes 
capital investment costs of US$ 50 million for bioreactor capacities of 30,000 litres 
and up to US$ 600 million for total capacities of 200,000 litres.  
 
However, other production platforms cause significantly less costs compared to 
mammalian cell cultures. Hood et al. (2002) estimates that the raw material 
production costs for recombinant proteins in transgenic plants is about US$ 0.1 to $1 
per gram, and Dove (2002) describe production costs as low as US$ 0.05 per gram of 
recombinant protein. However, these figures are for the open cultivation of plants, 
which harbours the risk of gene flow to surrounding crop plants. Protein production in 
enclosed plant systems such as plant cell cultures costs US$ 50 – 100 per gram 
(Huang & McDonald 2009). The figures for the production costs of recombinant 
proteins per gram in bacterial systems range from US$ 1 (Hood et al. 2002) to US$ 20 
– 100 (Huang & McDonald 2009). Other novel production platforms, which promise a 
reduction of the costs, are transgenic mammal milk and transgenic chicken eggs with 
estimated production costs of US$ 1 – 2 per gram of recombinant protein (Dove 2002; 
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Hood et al. 2002). However, these systems can contain agents such as viruses and 
prions, which might be able to infect humans, unlike algae or plants (Dove 2002). The 
use of yeast systems are described to cause production costs between US$ 20 and 100 
per gram of recombinant protein, whereas the production in insect cell cultures is 
estimated at US$ 50 – 200 per gram of recombinant protein (Huang & McDonald 
2009). 
 
Overall, the stated costs for recombinant protein production in the same systems vary 
in the literature (see above), most likely due to protein-specific differences in 
production efficiencies and purification costs, as well as differences in the cultivation 
systems. Comparing the result of the here presented costing with the studies described 
above, the costs for the production of Pal in the C. reinhardtii chloroplast would most 
likely be lower compared to mammalian cell cultures (even with a ten-fold increase 
due to purification costs) and within the same range as several other systems (e.g. 
plant cell or insect cell cultures). Whilst for example, the production of Pal in openly 
cultivated transgenic plants would be most likely cheaper.  
 
The calculation described here represents a first attempt to estimate the costs for the 
production of endolysins in the green microalga C. reinhardtii. The estimated costs of 
US$ 10 per gram of Pal produced in the C. reinhardtii chloroplast should be therefore 
verified by determining the amount of produced recombinant protein with purified Pal 
as a standard and ideally by running a pilot plant for the production of Pal in C. 
reinhardtii.  
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